<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>WS-1664 Keppra - EN PI clean</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EFPPNA+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	line-height:13.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
h3
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{margin:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:16.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-name:"Body Text\,Body Text Char\,Body Text Char Char Char Char Char Char9\,Body Text Char Char Char Char9\,Body Text Char Char9\,Body Text Char2 Char Char Char Char Char Char9\,Body Text Char2 Char Char Char Char9\,Body Text Char2 Char Char9\,Body Text Char3";
	mso-style-link:"Body Text Char1\,Body Text Char Char\,Body Text Char Char Char Char Char Char9 Char\,Body Text Char Char Char Char9 Char\,Body Text Char Char9 Char\,Body Text Char2 Char Char Char Char9 Char\,Body Text Char2 Char Char9 Char\,Body Text Char3 Char";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:13.0pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{mso-style-link:"Block Text Char";
	margin-top:0in;
	margin-right:57.2pt;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	line-height:13.0pt;
	background:navy;
	font-size:10.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.bulletlist, li.bulletlist, div.bulletlist
	{mso-style-name:"bullet list";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:12.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.BodyTextChar1
	{mso-style-name:"Body Text Char1\,Body Text Char Char\,Body Text Char Char Char Char Char Char9 Char\,Body Text Char Char Char Char9 Char\,Body Text Char Char9 Char\,Body Text Char2 Char Char Char Char9 Char\,Body Text Char2 Char Char9 Char\,Body Text Char3 Char";
	mso-style-link:"Body Text\,Body Text Char\,Body Text Char Char Char Char Char Char9\,Body Text Char Char Char Char9\,Body Text Char Char9\,Body Text Char2 Char Char Char Char Char Char9\,Body Text Char2 Char Char Char Char9\,Body Text Char2 Char Char9\,Body Text Char3";}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.msoins0
	{mso-style-name:msoins;}
p.Paragraph, li.Paragraph, div.Paragraph
	{mso-style-name:Paragraph;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.BlockTextChar
	{mso-style-name:"Block Text Char";
	mso-style-link:"Block Text";
	font-weight:bold;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.ColorfulShading-Accent11, li.ColorfulShading-Accent11, div.ColorfulShading-Accent11
	{mso-style-name:"Colorful Shading - Accent 11";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Arial",sans-serif;}
span.st
	{mso-style-name:st;}
p.C-BodyText, li.C-BodyText, div.C-BodyText
	{mso-style-name:"C-Body Text";
	mso-style-link:"C-Body Text Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";}
span.C-BodyTextChar
	{mso-style-name:"C-Body Text Char";
	mso-style-link:"C-Body Text";}
p.C-TableFootnote, li.C-TableFootnote, div.C-TableFootnote
	{mso-style-name:"C-Table Footnote";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.1in;
	text-indent:-.1in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX I</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keppra
250&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each film-coated
tablet contains 250&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3. PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Film-coated
tablet.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Blue, 13mm oblong, scored and debossed with the code
ucb and 250 on one side.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The score line
is only to facilitate breaking for ease of swallowing and not to divide into
equal doses. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4. CLINICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra is indicated as monotherapy in the
treatment of partial onset seizures with or without secondary generalisation in
adults and adolescents from 16 years of age with newly diagnosed epilepsy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra is indicated as adjunctive therapy</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the treatment of partial onset seizures with
or without secondary generalisation in adults, adolescents, children and
infants from 1 month of age with epilepsy.</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the treatment of </span>myoclonic seizures in
adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.</p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the treatment of primary generalised
tonic-clonic seizures in adults and adolescents from 12 years of age with
Idiopathic Generalised Epilepsy.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.2 Posology and method of administration</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Partial onset seizures</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dosing for monotherapy
(from 16 years of age) and adjunctive therapy is the same; as outlined below.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>All indications</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adults (&#8805;18 years) and adolescents
(12 to 17 years) weighing 50 kg or more</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=BodytextAgency><span lang=X-NONE style='font-size:11.0pt;font-family:
"Times New Roman",serif'>The initial therapeutic dose is 500&nbsp;mg twice
daily. This dose can be started on the first day of treatment. <span
style='color:black'>However, a lower initial dose of 250</span></span><span
lang=X-NONE>&nbsp;</span><span lang=X-NONE style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:black'>mg twice daily may be given based on
physician assessment of seizure reduction versus potential side effects. This
can be increased to 500</span><span lang=X-NONE>&nbsp;</span><span lang=X-NONE
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>mg
twice daily after </span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>two</span><span lang=X-NONE style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:black'> weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Depending upon the clinical response and
tolerability, the daily dose can be increased up to 1,500&nbsp;mg twice daily.
Dose changes can be made in 250 mg or 500&nbsp;mg twice daily increases<a
name="OLE_LINK8"> or decreas</a>es every two to four weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adolescents (12 to 17 years) weighing
below 50 kg and children from 1 month of age</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The physician should prescribe the most
appropriate pharmaceutical form, presentation and strength according to weight,
age and dose. Refer to <i>Paediatric population</i> section for dosing
adjustments based on weight.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Discontinuation</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If
levetiracetam has to be discontinued it is recommended to withdraw it gradually
(<i>e.g</i>. in adults and adolescents weighing more than 50&nbsp;kg:
500&nbsp;mg decreases twice daily every two to four weeks; in infants older
than 6 months, children and adolescents weighing less than 50&nbsp;kg: dose
decrease should not exceed 10&nbsp;mg/kg twice daily every two weeks; in
infants (less than 6 months): dose decrease should not exceed 7&nbsp;mg/kg twice
daily every two weeks). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly
(65 years and older)</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Adjustment
of the dose is recommended in elderly patients with compromised renal function
(see Renal impairment below).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The daily dose must be individualised
according to renal function. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For adult patients, refer to the following
table and adjust the dose as indicated. To use this dosing table, an estimate
of the patient's creatinine clearance (CL<sub>cr</sub>) in ml/min is needed.
The CL<sub>cr</sub> in ml/min may be estimated from serum creatinine (mg/dl)
determination, for adults and adolescents weighing 50 kg or more, the following
formula:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB> [140-age
(years)] x weight (kg)</span></p>

<p class=MsoNormal><span lang=EN-GB>CL<sub>cr</sub> </span>(ml/min)<span
lang=EN-GB> = ----------------------------------------- (x 0.85 for women)</span></p>

<p class=MsoNormal><span lang=EN-GB> 72 x serum
creatinine (mg/dl)</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Then <span lang=EN-GB>CL<sub>cr</sub></span> is adjusted for
body surface area (BSA) as follows:</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>  <span
lang=FR-BE>CL<sub>cr</sub></span><span lang=DE> (ml/min)</span></p>

<p class=MsoNormal><span lang=DE>CL<sub>cr</sub> (ml/min/1.73 m<sup>2</sup>) =
---------------------------- x 1.73 </span></p>

<p class=MsoNormal><span lang=DE>  </span><span
lang=FR-BE>BSA subject (m<sup>2</sup>)</span></p>

<p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Dosing adjustment for adult and adolescent
patients weighing more than 50&nbsp;kg with impaired renal function:</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Group</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Creatinine clearance (ml/min</span>/1.73m<sup>2</sup><span
  lang=EN-GB>)</span></p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Dose and frequency</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Normal</span></p>
  <p class=MsoNormal><span lang=EN-GB>Mild</span></p>
  <p class=MsoNormal><span lang=EN-GB>Moderate</span></p>
  <p class=MsoNormal><span lang=EN-GB>Severe</span></p>
  <p class=MsoNormal><span lang=EN-GB>End-stage renal disease patients</span></p>
  <p class=MsoNormal><span lang=EN-GB>undergoing dialysis <sup>(1)</sup></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;</span><span lang=EN-GB>&nbsp;80</span></p>
  <p class=MsoNormal><span lang=EN-GB>50-79</span></p>
  <p class=MsoNormal><span lang=EN-GB>30-49</span></p>
  <p class=MsoNormal><span lang=EN-GB>&lt;&nbsp;30</span></p>
  <p class=MsoNormal><span lang=EN-GB>-</span></p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>500 to 1,500&nbsp;mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>500 to 1,000 mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>250 to 750&nbsp;mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>250 to 500&nbsp;mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>500 to 1,000&nbsp;mg once daily <sup>(2)</sup></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><sup><span lang=EN-GB>(1)</span></sup><span lang=EN-GB> A
750&nbsp;mg loading dose is recommended on the first day of treatment with
levetiracetam.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(2)</span></sup><span lang=EN-GB>
Following dialysis, a 250 to 500&nbsp;mg supplemental dose is recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For children with renal impairment,
levetiracetam dose needs to be adjusted based on the renal function as
levetiracetam clearance is related to renal function. This recommendation is
based on a study in adult renally impaired patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The CL<sub>cr</sub> in ml/min/1.73&nbsp;m<sup>2</sup>
may be estimated from serum creatinine (mg/dl) determination, for young
adolescents, children and infants, using the following formula (Schwartz
formula): </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>  Height (cm)
x ks</p>

<p class=MsoNormal><span lang=EN-GB>CL<sub>cr</sub></span> (ml/min/1.73<span
lang=EN-GB>&nbsp;</span>m<sup>2</sup>) = ------------------------------------</p>

<p class=MsoNormal>  Serum Creatinine
(mg/dl)</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>ks= 0.45 in Term infants to 1 year old; ks=
0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in
adolescent male</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Dosing
adjustment for infants, children and adolescent patients weighing less than 50
kg with impaired renal function:</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=621
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=130 rowspan=2 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Group</span></p>
  </td>
  <td width=123 rowspan=2 valign=top style='width:92.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Creatinine
  clearance (ml/min</span>/1.73<span lang=EN-GB>&nbsp;</span>m<sup>2</sup><span
  lang=EN-GB>)</span></p>
  </td>
  <td width=369 colspan=2 valign=top style='width:276.4pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Dose and frequency <sup>(1)</sup></span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infants 1
  to less than 6 months</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Infants 6 to 23 months,
  children and adolescents weighing less than 50<span lang=EN-GB>&nbsp;</span>kg
  </p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Normal</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&#8805;</span><span
  lang=EN-GB>&nbsp;80</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>7 to
  21&nbsp;mg/kg (0.07 to 0.21&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>10 to
  30&nbsp;mg/kg (0.10 to 0.30&nbsp;ml/kg) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Mild</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>50-79</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>7 to
  14&nbsp;mg/kg (0.07 to 0.14&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>10 to
  20&nbsp;mg/kg (0.10 to 0.20&nbsp;ml/kg) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Moderate</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>30-49</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>3.5 to
  10.5&nbsp;mg/kg (0.035 to 0.105&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>5 to
  15&nbsp;mg/kg (0.05 to 0.15&nbsp;ml/kg) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Severe</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&lt;&nbsp;30</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>3.5 to
  7&nbsp;mg/kg (0.035 to 0.07&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>5 to
  10&nbsp;mg/kg (0.05 to 0.10&nbsp;ml/kg) twice daily </span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>End-stage
  renal disease patients</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>undergoing
  dialysis</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>--</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>7 to
  14&nbsp;mg/kg (0.07 to 0.14&nbsp;ml/kg) once daily <sup>(2) (4)</sup></span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>10 to
  20&nbsp;mg/kg (0.10 to 0.20&nbsp;ml/kg) once daily <sup>(3) (5)</sup></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB>(1)</span></sup><span
lang=EN-GB> Keppra oral solution should be used for doses under 250 mg, for
doses not multiple of 250 mg when dosing recommendation is not achievable by
taking multiple tablets and for patients unable to swallow tablets. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB>(2) </span></sup><span
lang=EN-GB>A 10.5&nbsp;mg/kg (0.105&nbsp;ml/kg) loading dose is recommended on
the first day of treatment with levetiracetam. </span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(3)</span></sup><span lang=EN-GB> A
15&nbsp;mg/kg (0.15&nbsp;ml/kg) loading dose is recommended on the first day of
treatment with levetiracetam.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(4)</span></sup><span lang=EN-GB>
Following dialysis, a 3.5 to 7&nbsp;mg/kg (0.035 to 0.07&nbsp;ml/kg)
supplemental dose is recommended.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(5)</span></sup><span lang=EN-GB>
Following dialysis, a 5 to 10&nbsp;mg/kg (0.05 to 0.10&nbsp;ml/kg) supplemental
dose is recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No dose adjustment is needed in patients
with mild to moderate hepatic impairment. In patients with severe hepatic
impairment, the creatinine clearance may underestimate the renal insufficiency.
Therefore a 50&nbsp;% reduction of the daily maintenance dose is recommended
when the creatinine clearance is &lt;&nbsp;60&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><a name="OLE_LINK18"></a><a name="OLE_LINK19"><span
lang=EN-GB>&nbsp;</span></a></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The physician should prescribe the most appropriate pharmaceutical
form, presentation and strength according to age, weight and dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The tablet formulation is not adapted for
use in infants and children under the age of 6 years. Keppra oral solution is
the preferred formulation for use in this population. In addition, the
available dose strengths of the tablets are not appropriate for initial
treatment in children weighing less than 25 kg, for patients unable to swallow
tablets or for the administration of doses below 250 mg. In all of the above
cases Keppra oral solution should be used.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Monotherapy</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of Keppra in
children and adolescents below 16 years as monotherapy treatment have not been
established.</span></p>

<p class=MsoNormal>No data are available.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Adolescents (16 and 17 years of age) weighing 50 kg or
more with partial onset seizures with or without secondary generalisation with
newly diagnosed epilepsy.</i> </p>

<p class=MsoNormal>Please refer to the above section on <i>Adults (&#8805;18
years) and adolescents (12 to 17 years) weighing 50 kg or more</i>. </p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Add-on
therapy for infants aged from 6 to 23 months, children (2 to 11 years) and
adolescents (12 to 17 years) weighing less than 50 kg</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Keppra oral
solution is the preferred formulation for use in infants and children under the
age of 6 years. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For children
6 years and above, Keppra oral solution should be used for doses under 250 mg,
for doses not multiple of 250 mg when dosing recommendation is not achievable
by taking multiple tablets and for patients unable to swallow tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>The lowest effective dose should be used for
all indications. The starting dose for a child or adolescent of 25kg should be
250mg twice daily with a maximum dose of 750mg twice daily.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Dose in children 50&nbsp;kg or greater is
the same as in adults for all indications.</span></p>

<p class=MsoNormal>Please refer to <a name="_Hlk50451008">the above section on </a><i>Adults
(&#8805;18 years) and adolescents (12 to 17 years) weighing 50 kg or more </i>for
all indications.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Add-on therapy for infants aged from 1
month to less than 6 months</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The oral solution is the formulation to use in infants.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The film-coated tablets must be taken
orally, swallowed with a sufficient quantity of liquid and may be taken with or
without food. </span><span lang=EN-GB>After oral administration the bitter
taste of levetiracetam may be experienced. </span><span lang=EN-GB>The daily
dose is administered in two equally divided doses.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to the active substance or
other pyrrolidone derivatives or to any of the excipients</span><span
lang=EN-GB> listed in section 6.1</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.4 Special warnings and precautions for use</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Renal impairment</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The administration of levetiracetam to
patients with renal impairment may require dose adjustment. In patients with
severely impaired hepatic function, assessment of renal function is recommended
before dose selection (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Acute Kidney injury</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The use of levetiracetam has been very
rarely associated with acute kidney injury, with a time to onset ranging from a
few days to several months.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Blood cell counts</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rare cases of decreased blood cell counts
(neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia)
have been described in association with levetiracetam administration, generally
at the beginning of the treatment. Complete blood cell counts are advised in
patients experiencing important weakness, pyrexia, recurrent infections or
coagulation disorders (section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u>Suicide</u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Suicide,
suicide attempt, <span lang=EN-GB>suicidal ideation and behaviour have been
reported in patients treated with anti-epileptic agents (including levetiracetam.
A meta-analysis of randomized placebo-controlled trials of anti-epileptic
medicinal products has shown a small increased risk of suicidal thoughts and
behaviour. The mechanism of this risk is not known. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Therefore, patients should be monitored for
signs of depression and/or suicidal ideation and behaviours and appropriate
treatment should be considered. Patients (and caregivers of patients) should be
advised to seek medical advice should signs of depression and/or suicidal
ideation or behaviour emerge.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Abnormal and aggressive behaviours </span></u></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam may cause psychotic symptoms
and behavioural abnormalities including irritability and aggressiveness.
Patients treated with levetiracetam should be monitored for developing
psychiatric signs suggesting important mood and/or personality changes. If such
behaviours are noticed, treatment adaptation or gradual discontinuation should
be considered. If discontinuation is considered, please refer to section 4.2.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u>Worsening of seizures</u></p>

<p class=MsoNormal>As with other types of antiepileptic drugs, levetiracetam
may rarely exacerbate seizure frequency or severity. This paradoxical effect
was mostly reported within the first month after levetiracetam initiation or
increase of the dose, and was reversible upon drug discontinuation or dose
decrease. Patients should be advised to consult their physician immediately in
case of aggravation of epilepsy.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Electrocardiogram QT interval
prolongation</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rare cases of ECG QT interval prolongation
have been observed during the post-marketing surveillance. Levetiracetam should
be used with caution in patients with QTc-interval prolongation, in patients
concomitantly treated with drugs affecting the QTc-interval, or in patients
with relevant pre-existing cardiac disease or electrolyte disturbances.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><a name="OLE_LINK12"></a><a name="OLE_LINK13"><span
lang=EN-GB>The tablet formulation is not adapted for use in infants and
children under the age of 6 years. </span></a></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Available data in children did not suggest
impact on growth and puberty. However, long term effects on learning,
intelligence, growth, endocrine function, puberty and childbearing potential in
children remain unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.5 Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Antiepileptic medicinal products</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Pre-marketing data from clinical studies
conducted in adults indicate that levetiracetam did not influence the serum
concentrations of existing antiepileptic medicinal products (phenytoin,
carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and
primidone) and that these antiepileptic medicinal products did not influence
the pharmacokinetics of levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-AU style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>As in adults,
there is no evidence of clinically significant medicinal product interactions
in paediatric patients receiving up to 60</span><span lang=EN-GB>&nbsp;<span
style='layout-grid-mode:line'>mg/kg/day levetiracetam.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>A
retrospective assessment of pharmacokinetic interactions in children and
adolescents with epilepsy (4 to 17</span><span lang=EN-GB>&nbsp;<span
style='layout-grid-mode:line'>years) confirmed that adjunctive therapy with
orally administered levetiracetam did not influence the steady-state serum
concentrations of concomitantly administered carbamazepine and valproate.
However, data suggested </span></span><span lang=EN-GB>a 20</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% higher levetiracetam clearance in
children taking</span><span lang=EN-GB style='layout-grid-mode:line'>
enzyme-inducing antiepileptic medicinal products. Dose adjustment is not
required. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Probenecid</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Probenecid (500&nbsp;mg four times daily),
a renal tubular secretion blocking agent, has been shown to inhibit the renal
clearance of the primary metabolite, but not of levetiracetam. Nevertheless,
the concentration of this metabolite remains low. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Methotrexate </span></u></p>

<p class=MsoNormal><span lang=EN-GB>Concomitant administration of levetiracetam
and methotrexate has been reported to decrease methotrexate clearance,
resulting in increased/prolonged blood methotrexate concentration to
potentially toxic levels. Blood methotrexate and levetiracetam levels should be
carefully monitored in patients treated concomitantly with the two drugs.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-AU style='layout-grid-mode:line'>Oral
contraceptives and other pharmacokinetics interactions</span></u></p>

<p class=MsoNormal><span lang=EN-AU style='layout-grid-mode:line'>Levetiracetam
1,000&nbsp;mg daily did not influence the pharmacokinetics of oral
contraceptives </span><span lang=EN-GB style='layout-grid-mode:line'>(ethinyl-estradiol</span><span
lang=EN-AU style='layout-grid-mode:line'> and levonorgestrel); endocrine
parameters (luteinizing hormone and progesterone) were not modified.
-Levetiracetam 2,000&nbsp;mg daily did not influence the pharmacokinetics of
digoxin and warfarin; prothrombin times were not modified. Co-administration
with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics
of levetiracetam.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Laxatives</u></p>

<p class=MsoNormal><span lang=EN-GB>There have been isolated reports of
decreased levetiracetam efficacy when the osmotic laxative macrogol has been
concomitantly administered with oral levetiracetam. Therefore, macrogol should
not be taken orally for one hour before and for one hour after taking
levetiracetam.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Food and alcohol</u></p>

<p class=MsoNormal>The extent of absorption of levetiracetam was not altered by
food, but the rate of absorption was slightly reduced.</p>

<p class=MsoNormal style='line-height:normal'>No data on the interaction of
levetiracetam with alcohol are available.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6 Fertility, pregnancy
and lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Women of
child bearing potential </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Specialist
advice should be given to women who are of childbearing potential. Treatment
with levetiracetam should be reviewed when a woman is planning to become
pregnant. As with all antiepileptic medicines, sudden discontinuation of
levetiracetam should be avoided as this may lead to breakthrough seizures that
could have serious consequences for the woman and the unborn child. Monotherapy
should be preferred whenever possible because therapy with multiple
antiepileptic medicines AEDs could be associated with a higher risk of
congenital malformations than monotherapy, depending on the associated
antiepileptics.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><span lang=EN-GB>A large amount of postmarketing data on
pregnant women exposed to levetiracetam monotherapy (more than 1800, among
which in more than 1500 exposure occurred during the 1<sup>st</sup> trimester)
do not suggest an increase in the risk for major congenital malformations. Only
limited evidence is available on the neurodevelopment of children exposed to
Keppra monotherapy in utero. However, current epidemiological studies (on about
100 children) do not suggest an increased risk of neurodevelopmental disorders
or delays. </span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam can be used during pregnancy,
if after careful assessment it is considered clinically needed. In such case,
the lowest effective dose is recommended. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Physiological
changes during pregnancy may affect levetiracetam concentration. D</span>ecrease
in levetiracetam plasma concentrations has been observed during pregnancy. This
decrease is more pronounced during the third trimester (up to 60% of baseline
concentration before pregnancy). Appropriate clinical management of pregnant
women treated with levetiracetam should be ensured. </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Breastfeeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam is excreted in human breast
milk. Therefore, breast-feeding is not recommended. </span></p>

<p class=MsoNormal style='line-height:normal'>However, if levetiracetam
treatment is needed during breastfeeding, the benefit/risk of the treatment
should be weighed considering the importance of breastfeeding.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><u>Fertility</u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No impact on
fertility was detected in animal studies (see section 5.3). No clinical data
are available, potential risk for human is unknown.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.7 Effects on ability to drive and use
machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam has minor or moderate
influence on the ability to drive and use machines.</span><span lang=EN-GB> Due
to possible different individual sensitivity, some patients might experience
somnolence or other central nervous system related symptoms, </span><span
lang=EN-GB>especially</span><span lang=EN-GB> </span><span lang=EN-GB>at the
beginning of treatment or following a dose increase. Therefore, caution is
recommended in those patients when performing skilled tasks, <i>e.g</i>.
driving vehicles or operating machinery. Patients are advised not to drive or
use machines until it is established that </span><span lang=EN-GB>their</span><span
lang=EN-GB> ability to perform such activities is not affected.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Summary
of the safety profile</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The most
frequently reported adverse reactions were nasopharyngitis, somnolence,
headache, fatigue and dizziness. The adverse reaction profile presented below
is based on the analysis of pooled placebo-controlled clinical trials with all
indications studied, with a total of 3,416 patients treated with levetiracetam.
These data are supplemented with the use of levetiracetam in corresponding
open-label extension studies, as well as post-marketing experience. The safety
profile of levetiracetam is generally similar across age groups (adult and
paediatric patients) and across the approved epilepsy indications. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Tabulated list of adverse
reactions</u></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Adverse reactions reported in clinical
studies (adults, adolescents, children and infants &gt; 1&nbsp;month) and from
post-marketing experience are listed in the following table per System Organ
Class and per frequency. Adverse reactions are presented in the order of
decreasing seriousness and their frequency is defined as follows: very common
(&#8805;1/10); common (&#8805;1/100 to &lt;1/10); uncommon (&#8805;1/1,000 to
&lt;1/100); rare (&#8805;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="98%"
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="22%" rowspan=2 style='width:22.82%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
   style='font-size:10.0pt'>MedDRA SOC</span></u></p>
   </td>
   <td width="77%" colspan=4 valign=top style='width:77.18%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><u><span lang=EN-GB style='font-size:10.0pt'>Frequency category</span></u></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width="16%" valign=top style='width:16.96%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
   style='font-size:10.0pt'>Very common</span></u></p>
   </td>
   <td width="18%" valign=top style='width:18.54%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
   style='font-size:10.0pt'>Common</span></u></p>
   </td>
   <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
   style='font-size:10.0pt'>Uncommon </span></u></p>
   </td>
   <td width="21%" valign=top style='width:21.36%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
   style='font-size:10.0pt'>Rare</span></u></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
  style='font-size:10.0pt'>Infections and infestations</span></u></p>
  </td>
  <td width="16%" valign=top style='width:16.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Nasopharyngitis </span></p>
  </td>
  <td width="18%" valign=top style='width:18.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Infection</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
  style='font-size:10.0pt'>Blood and lymphatic system disorders</span></u></p>
  </td>
  <td width="16%" valign=top style='width:16.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-AU
  style='font-size:10.0pt'>Thrombocytopenia, leukopenia</span></p>
  </td>
  <td width="21%" valign=top style='width:21.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-AU
  style='font-size:10.0pt'>Pancytopenia,<sup> </sup>neutropenia,
  agranulocytosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
  style='font-size:10.0pt'>Immune system disorders</span></u></p>
  </td>
  <td width="16%" valign=top style='width:16.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-AU
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-AU
  style='font-size:10.0pt'>Drug reaction with eosinophilia and systemic
  symptoms (DRESS),</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-AU
  style='font-size:10.0pt'>Hypersensitivity (including angioedema and
  anaphylaxis)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Metabolism
  and nutrition disorders</span></u></p>
  </td>
  <td width="16%" valign=top style='width:16.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Anorexia</span></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Weight
  decreased, weight increase</span></p>
  </td>
  <td width="21%" valign=top style='width:21.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Hyponatraemia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Psychiatric
  disorders</span></u></p>
  </td>
  <td width="16%" valign=top style='width:16.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Depression,
  hostility/ aggression, anxiety, <br>
  insomnia, nervousness/irritability</span></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Suicide attempt,
  suicidal ideation</span><span lang=EN-AU style='font-size:10.0pt'>,<sup> </sup></span><span
  lang=EN-GB style='font-size:10.0pt'>psychotic disorder</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>abnormal behaviour, hallucination</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>anger, confusional state, panic attack, affect
  lability/mood swings, agitation</span></p>
  </td>
  <td width="21%" valign=top style='width:21.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Completed
  suicide</span><span lang=EN-AU style='font-size:10.0pt'>, </span><span
  lang=EN-GB style='font-size:10.0pt'>personality disorder, thinking abnormal,
  delirium</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Nervous
  system disorders</span></u></p>
  </td>
  <td width="16%" valign=top style='width:16.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Somnolence,
  headache</span></p>
  </td>
  <td width="18%" valign=top style='width:18.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Convulsion,
  balance disorder, dizziness, lethargy, tremor</span></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Amnesia, memory
  impairment, coordination abnormal/ataxia, paraesthesia</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>disturbance in attention</span></p>
  </td>
  <td width="21%" valign=top style='width:21.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Choreoathetosis,
  dyskinesia, hyperkinesia, gait disturbance, encephalopathy, seizures
  aggravated</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Eye disorders</span></u></p>
  </td>
  <td width="16%" valign=top style='width:16.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Diplopia, vision
  blurred</span></p>
  </td>
  <td width="21%" valign=top style='width:21.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Ear and
  labyrinth disorders</span></u></p>
  </td>
  <td width="16%" valign=top style='width:16.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Vertigo</span></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Cardiac
  disorders</span></u></p>
  </td>
  <td width="16%" valign=top style='width:16.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>Electrocardiogram
  QT prolonged</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Respiratory,
  thoracic and mediastinal disorders</span></u></p>
  </td>
  <td width="16%" valign=top style='width:16.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Cough</span></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Gastrointestinal
  disorders</span></u></p>
  </td>
  <td width="16%" valign=top style='width:16.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT style='font-size:10.0pt'>Abdominal pain,
  diarrhoea, dyspepsia, vomiting, nausea</span></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Pancreatitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-AU style='font-size:10.0pt'>Hepatobiliary
  disorders</span></u></p>
  </td>
  <td width="16%" valign=top style='width:16.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Liver function
  test abnormal</span></p>
  </td>
  <td width="21%" valign=top style='width:21.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Hepatic failure,
  hepatitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-AU style='font-size:10.0pt'>Renal and
  Urinary Disorders</span></u></p>
  </td>
  <td width="16%" valign=top style='width:16.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Acute Kidney
  injury</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Skin and
  subcutaneous tissue disorders</span></u></p>
  </td>
  <td width="16%" valign=top style='width:16.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Rash</span></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Alopecia</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>eczema, pruritus, </span></p>
  </td>
  <td width="21%" valign=top style='width:21.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Toxic epidermal
  necrolysis, Stevens-Johnson syndrome, erythema multiforme</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Musculoskeletal
  and connective tissue disorders</span></u></p>
  </td>
  <td width="16%" valign=top style='width:16.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Muscular
  weakness, myalgia</span></p>
  </td>
  <td width="21%" valign=top style='width:21.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Rhabdomyolysis
  and blood creatine phosphokinase increased*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>General
  disorders and administration site conditions</span></u></p>
  </td>
  <td width="16%" valign=top style='width:16.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Asthenia/</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>fatigue</span></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Injury,
  poisoning and procedural complications</span></u></p>
  </td>
  <td width="16%" valign=top style='width:16.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Injury</span></p>
  </td>
  <td width="21%" valign=top style='width:21.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>* Prevalence is significantly higher in
Japanese patients when compared to non-Japanese patients. </span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Description of selected adverse
reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU>The risk of
anorexia is higher when levetiracetam is coadministered with topiramate.</span></p>

<p class=MsoNormal><span lang=EN-AU>In several cases of alopecia, recovery was
observed when levetiracetam was discontinued.</span></p>

<p class=MsoNormal><span style='font-family:"TimesNewRomanPSMT",serif'>Bone
marrow suppression was identified in some of the cases of pancytopenia.</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>Cases of encephalopathy generally occurred
at the beginning of the treatment (few days to a few months) and were
reversible after treatment discontinuation.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>In patients aged 1 month to less than 4
years, a total of 190 patients have been treated with levetiracetam in
placebo-controlled and open label extension studies. Sixty of these patients
were treated with levetiracetam in placebo-controlled studies. In patients
aged 4-16 years, a total of 645 patients have been treated with levetiracetam
in placebo-controlled and open label extension studies. 233 of these patients
were treated with levetiracetam in placebo-controlled studies. In both these
paediatric age ranges, these data are supplemented with the post-marketing
experience of the use of levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In addition, 101 infants aged less than 12
months have been exposed in a post authorization safety study. No new safety
concerns for levetiracetam were identified for infants less than 12 months of
age with epilepsy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The adverse reaction profile of
levetiracetam is generally similar across age groups and across the approved
epilepsy indications. Safety results in paediatric patients in
placebo-controlled clinical studies were consistent with the safety profile of
levetiracetam in adults except for behavioural and psychiatric adverse
reactions which were more common in children than in adults. In children and
adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation
(common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%),
aggression (common, 8.2%), abnormal behaviour (common, 5.6%), and lethargy
(common, 3.9%) were reported more frequently than in other age ranges or in the
overall safety profile. In infants and children aged 1 month to less than 4
years, irritability (very common, 11.7%) and coordination abnormal (common,
3.3%) were reported more frequently than in other age groups or in the overall
safety profile. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>A double-blind,
placebo-controlled paediatric safety study with a non-inferiority design has
assessed the cognitive and neuropsychological effects of </span><span
lang=EN-GB>levetiracetam</span><span lang=EN-GB> in children 4 to 16 years of
age with partial onset seizures. It was concluded that Keppra was not different
(non inferior) from placebo with regard to the change from baseline of the
Leiter-R Attention and Memory, Memory Screen Composite score in the
per-protocol population. Results related to behavioural and emotional
functioning indicated a worsening in </span><span lang=EN-GB>levetiracetam</span><span
lang=EN-GB> treated patients on aggressive behaviour as measured in a
standardised and systematic way using a validated instrument (CBCL  Achenbach
Child Behavior Checklist). However, subjects, who took </span><span lang=EN-GB>levetiracetam</span><span
lang=EN-GB> in the long-term open label follow-up study, did not experience a
worsening, on average, in their behavioural and emotional functioning; in
particular measures of aggressive behaviour were not worse than baseline.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Reporting of
suspected adverse reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:silver'>the national reporting
system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a></span>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Symptoms</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Somnolence,
agitation, aggression, depressed level of consciousness, respiratory depression
and coma were observed with Keppra overdoses.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Management of overdose</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After an acute overdose, the stomach may be
emptied by gastric lavage or by induction of emesis. There is no specific
antidote for levetiracetam. Treatment of an overdose will be symptomatic and
may include haemodialysis. The dialyser extraction efficiency is 60&nbsp;% for
levetiracetam and 74&nbsp;% for the primary metabolite.</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>5. </span><span
lang=EN-GB>PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1 Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic group: antiepileptics,
other antiepileptics, ATC code: N03AX14.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The active substance, levetiracetam, is a
pyrrolidone derivative (S-enantiomer of </span><span lang=EN-GB
style='font-family:Symbol'>a</span><span lang=EN-GB>-ethyl-2-oxo-1-pyrrolidine
acetamide), chemically unrelated to existing antiepileptic active substances.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Mechanism of action</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The mechanism of action of levetiracetam
still remains to be fully elucidated. <i>In vitro</i> and <i>in vivo</i>
experiments suggest that levetiracetam does not alter basic cell
characteristics and normal neurotransmission. </span></p>

<p class=MsoNormal><i><span lang=EN-GB>In vitro</span></i><span lang=EN-GB>
studies show that levetiracetam affects intraneuronal Ca<sup>2+</sup> levels by
partial inhibition of N-type Ca<sup>2+</sup> currents and by reducing the
release of Ca<sup>2+</sup> from intraneuronal stores. In addition it partially
reverses the reductions in GABA- and glycine-gated currents induced by zinc and
</span><span lang=EN-GB style='font-family:Symbol'>b</span><span lang=EN-GB>-carbolines.
Furthermore, levetiracetam has been shown in <i>in vitro</i> studies to bind to
a specific site in rodent brain tissue. This binding site is the synaptic
vesicle protein 2A, believed to be involved in vesicle fusion and
neurotransmitter exocytosis. Levetiracetam and related analogs show a rank
order of affinity for binding to the synaptic vesicle protein 2A which
correlates with the potency of their anti-seizure protection in the mouse
audiogenic model of epilepsy. This finding suggests that the interaction
between levetiracetam and the synaptic vesicle protein 2A seems to contribute
to the antiepileptic mechanism of action of the medicinal product.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Pharmacodynamic effects</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam induces seizure protection in
a broad range of animal models of partial and primary generalised seizures
without having a pro-convulsant effect. The primary metabolite is inactive.</span></p>

<p class=MsoNormal><span lang=EN-GB>In man, an activity in both partial and
generalised epilepsy conditions (epileptiform discharge/photoparoxysmal
response) has confirmed the broad spectrum pharmacological profile of
levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adjunctive therapy in the treatment of
partial onset seizures with or without secondary generalisation in adults,
adolescents, children and infants from 1 month of age with epilepsy.</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In adults, levetiracetam efficacy has been
demonstrated in 3 double-blind, placebo-controlled studies at 1000</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg, 2000 mg, or 3000</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg/day, given in 2 divided doses, with
a treatment duration of up to 18 weeks. In a pooled analysis, the percentage of
patients who achieved 50</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>%
or greater reduction from baseline in the partial onset seizure frequency per
week at stable dose (12/14</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>weeks) was of 27.7</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>%, 31.6</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>% and
41.3</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>% for patients on
1000, 2000 or 3000</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg
levetiracetam respectively and of 12.6</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% for patients on placebo.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric</span></u><u> population</u></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal>In<span lang=EN-GB> paediatric</span> patients (4 to 16<span
lang=EN-GB>&nbsp;</span>years of age), levetiracetam efficacy was established
in a double-blind, placebo-controlled study, which included 198 patients and
had a treatment duration of 14 weeks. In this study, the patients received
levetiracetam as a fixed dose of 60<span lang=EN-GB>&nbsp;</span>mg/kg/day
(with twice a day dosing).</p>

<p class=MsoNormal><span lang=EN-GB>44.6</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% of the levetiracetam treated patients and 19.6</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% of the patients on placebo had a 50</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% or greater reduction from baseline
in the partial onset seizure frequency per week.</span><span lang=EN-GB> </span><span
lang=EN-GB>With continued long-term treatment, 11.4</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% of the patients were seizure-free for at least 6 months and 7.2</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% were seizure-free for at least 1
year.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In<span lang=EN-GB> paediatric</span> patients (1 month to
less than 4 years of age), levetiracetam efficacy was established in a
double-blind, placebo-controlled study, which included 116 patients and had a
treatment duration of 5<span lang=EN-GB>&nbsp;</span>days. In this study,
patients were prescribed 20<span lang=EN-GB>&nbsp;</span>mg/kg, 25<span
lang=EN-GB>&nbsp;</span>mg/kg, 40<span lang=EN-GB>&nbsp;</span>mg/kg or 50<span
lang=EN-GB>&nbsp;</span>mg/kg daily dose of oral solution based on their age
titration schedule. <span lang=EN-GB>A dose of 20</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>mg/kg/day titrating to 40</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>mg/kg/day for infants one month to less than six months and a dose
of 25</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg/kg/day titrating
to 50</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg/kg/day for
infants and children 6 months to less than 4 years old, was use in this study. </span>The
total daily dose was administered twice daily.</p>

<p class=MsoNormal><span lang=EN-GB>The primary measure of effectiveness was
the responder rate (percent of patients with &#8805; 50&nbsp;% reduction from
baseline in average daily partial onset seizure frequency) assessed by a
blinded central reader using a 48-hour video EEG.&nbsp; The efficacy analysis
consisted of 109 patients who had at least 24 hours of video EEG in both baseline
and evaluation periods. <span class=msoins0>43.6</span>&nbsp;<span
class=msoins0>% of the levetiracetam treated patients and 19.6</span>&nbsp;<span
class=msoins0>% of the patients on placebo were considered as responders. The
results are consistent across age group.</span></span><span lang=EN-GB> With
continued long-term treatment, 8.6</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% of the patients were seizure-free for at least 6 months and 7.8</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% were seizure-free for at least 1
year.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>35 infants aged
less than 1 year with partial onset seizures have been exposed in
placebo-control clinical studies of which only 13 were aged &lt; 6 months.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Monotherapy in the treatment of partial
onset seizures with or without secondary generalisation in patients from 16
years of age with newly diagnosed epilepsy. </span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Efficacy of levetiracetam as monotherapy was established in
a double-blind, parallel group, non-inferiority comparison to carbamazepine-controlled
release (CR) in 576 patients 16<span lang=EN-GB>&nbsp;</span>years of age or
older with newly or recently diagnosed epilepsy. The patients had to present
with unprovoked partial seizures or with generalized tonic-clonic seizures
only. The patients were randomized to carbamazepine CR 400  1200&nbsp;mg/day
or levetiracetam 1000 - 3000&nbsp;mg/day, the duration of the treatment was up
to 121 weeks depending on the response. </p>

<p class=MsoNormal>Six-month seizure freedom was achieved in 73.0<span
lang=EN-GB>&nbsp;</span>% of levetiracetam-treated patients and 72.8<span
lang=EN-GB>&nbsp;</span>% of carbamazepine-CR treated patients; the adjusted
absolute difference between treatments was 0.2<span lang=EN-GB>&nbsp;</span>%
(95<span lang=EN-GB>&nbsp;</span>% CI: -7.8 8.2). More than half of the
subjects remained seizure free for 12 months (56.6<span lang=EN-GB>&nbsp;</span>%
and 58.5<span lang=EN-GB>&nbsp;</span>% of subjects on levetiracetam and on
carbamazepine CR respectively).</p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>In a study
reflecting clinical practice, the concomitant antiepileptic medication could be
withdrawn in a limited number of patients who responded to levetiracetam
adjunctive therapy (36 adult patients out of 69). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adjunctive therapy in the treatment of
myoclonic seizures in adults and adolescents from 12 years of age with Juvenile
Myoclonic Epilepsy.</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Levetiracetam efficacy was established in a double-blind,
placebo-controlled study of 16 weeks duration, in patients 12 years of age and
older suffering from idiopathic generalized epilepsy with myoclonic seizures in
different syndromes. The majority of patients presented with juvenile myoclonic
epilepsy.</p>

<p class=MsoNormal>In this study, levetiracetam, dose was 3000<span lang=EN-GB>&nbsp;</span>mg/day
given in 2 divided doses. </p>

<p class=MsoNormal>58.3<span lang=EN-GB>&nbsp;</span>% of the levetiracetam
treated patients and 23.3<span lang=EN-GB>&nbsp;</span>% of the patients on
placebo had at least a 50<span lang=EN-GB>&nbsp;</span>% reduction in myoclonic
seizure days per week. With continued long-term treatment, 28.6<span
lang=EN-GB>&nbsp;</span>% of the patients were free of myoclonic seizures for
at least 6 months and 21.0<span lang=EN-GB>&nbsp;</span>% were free of
myoclonic seizures for at least 1 year.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Adjunctive
therapy in the treatment of primary generalised tonic-clonic seizures in adults
and adolescents from 12 years of age with idiopathic generalised epilepsy.</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>Levetiracetam efficacy was
established in a 24-week double-blind, placebo-controlled study which included
adults, adolescents and a limited number of children suffering from idiopathic
generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in
different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy,
childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening).
In this study, levetiracetam dose was 3000<span lang=EN-GB>&nbsp;</span>mg/day
for adults and adolescents or 60<span lang=EN-GB>&nbsp;</span>mg/kg/day for
children, given in 2 divided doses.</p>

<p class=MsoNormal>72.2<span lang=EN-GB>&nbsp;</span>% of the levetiracetam
treated patients and 45.2<span lang=EN-GB>&nbsp;</span>% of the patients on
placebo had a 50<span lang=EN-GB>&nbsp;</span>% or greater decrease in the
frequency of PGTC seizures per week. With continued long-term treatment, 47.4<span
lang=EN-GB>&nbsp;</span>% of the patients were free of tonic-clonic seizures
for at least 6 months and 31.5<span lang=EN-GB>&nbsp;</span>% were free of
tonic-clonic seizures for at least 1 year.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.2 Pharmacokinetic properties</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam is a highly soluble and
permeable compound. The pharmacokinetic profile is linear with low intra- and
inter-subject variability. There is no modification of the clearance after
repeated administration. There is no evidence for any relevant gender, race or
circadian variability. The pharmacokinetic profile is comparable in healthy
volunteers and in patients with epilepsy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Due to its complete and linear absorption,
plasma levels can be predicted from the oral dose of levetiracetam expressed as
mg/kg bodyweight. Therefore, there is no need for plasma level monitoring of
levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>A significant
correlation between saliva and plasma concentrations has been shown in adults
and children (ratio of saliva/plasma concentrations ranged from 1 to </span>1.7
for oral tablet formulation and after 4 hours post-dose for oral solution
formulation<span lang=EN-GB>).</span></p>

<p class=MsoEndnoteText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoEndnoteText><u><span lang=EN-GB>Adults and adolescents</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam is rapidly absorbed after
oral administration. Oral absolute bioavailability is close to 100&nbsp;%. </span></p>

<p class=MsoNormal><span lang=EN-GB>Peak plasma concentrations (C<sub>max</sub>)
are achieved at 1.3&nbsp;hours after dosing. Steady-state is achieved after two
days of a twice daily administration schedule.</span></p>

<p class=MsoNormal><span lang=EN-GB>Peak concentrations (C<sub>max</sub>) are
typically 31 and 43&nbsp;g/ml following a single 1,000&nbsp;mg dose and
repeated 1,000&nbsp;mg twice daily dose, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>The extent of absorption is
dose-independent and is not altered by food.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No tissue distribution data are available
in humans.</span></p>

<p class=MsoNormal><span lang=EN-GB>Neither levetiracetam nor its primary
metabolite are significantly bound to plasma proteins (</span><span lang=EN-GB
style='font-family:Symbol'>&lt;</span><span lang=EN-GB>&nbsp;10&nbsp;%).</span></p>

<p class=MsoNormal><span lang=EN-GB>The volume of distribution of levetiracetam
is approximately 0.5 to 0.7&nbsp;l/kg, a value close to the total body water
volume.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Levetiracetam
is not extensively metabolised in humans. The major metabolic pathway
(24&nbsp;% of the dose) is an enzymatic hydrolysis of the acetamide group.
Production of the primary metabolite, ucb&nbsp;L057, is not supported by liver
cytochrome P<sub>450</sub> isoforms. Hydrolysis of the acetamide group was
measurable in a large number of tissues including blood cells. The metabolite
ucb&nbsp;L057 is pharmacologically inactive.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Two minor metabolites were also identified.
One was obtained by hydroxylation of the pyrrolidone ring (1.6&nbsp;% of the
dose) and the other one by opening of the pyrrolidone ring (0.9&nbsp;% of the
dose). </span></p>

<p class=MsoNormal><span lang=EN-GB>Other unidentified components accounted
only for 0.6&nbsp;% of the dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No enantiomeric interconversion was
evidenced <i>in vivo</i> for either levetiracetam or its primary metabolite.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>In vitro</i><span lang=EN-GB>, levetiracetam and its
primary metabolite have been shown not to inhibit the major human liver
cytochrome P<sub>450</sub> isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2),
glucuronyl transferase<span style='text-transform:uppercase'> (UGT1A1 and
UGT1A6)</span> and epoxide hydroxylase activities. In addition, levetiracetam
does not affect the <i>in vitro</i> glucuronidation of valproic acid.</span></p>

<p class=MsoNormal><span lang=EN-GB>In human hepatocytes in culture,
levetiracetam had little or no effect on CYP1A2, SULT1E1 or UGT1A1.
Levetiracetam caused mild induction of CYP2B6 and CYP3A4. The in vitro data and
<i>in vivo</i> interaction data on oral contraceptives, digoxin and warfarin
indicate that no significant enzyme induction is expected <i>in vivo</i>.
Therefore, the interaction of Keppra with other substances, or <i>vice versa,</i>
is unlikely.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The plasma half-life in adults was 7</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>1&nbsp;hours and
did not vary either with dose, route of administration or repeated
administration. The mean total body clearance was 0.96&nbsp;ml/min/kg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The major route of excretion was via urine,
accounting for a mean 95&nbsp;% of the dose (approximately 93&nbsp;% of the
dose was excreted within 48&nbsp;hours). Excretion <i>via</i> faeces accounted
for only 0.3&nbsp;% of the dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>The cumulative urinary excretion of
levetiracetam and its primary metabolite accounted for 66&nbsp;% and 24&nbsp;%
of the dose, respectively during the first 48&nbsp;hours.</span></p>

<p class=MsoNormal><span lang=EN-GB>The renal clearance of levetiracetam and
ucb&nbsp;L057 is 0.6 and 4.2&nbsp;ml/min/kg respectively indicating that
levetiracetam is excreted by glomerular filtration with subsequent tubular
reabsorption and that the primary metabolite is also excreted by active tubular
secretion in addition to glomerular filtration. Levetiracetam elimination is
correlated to creatinine clearance.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Elderly</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the elderly, the half-life is increased
by about 40&nbsp;% (10 to 11&nbsp;hours). This is related to the decrease in
renal function in this population (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Renal impairment</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The apparent body clearance of both
levetiracetam and of its primary metabolite is correlated to the creatinine
clearance. It is therefore recommended to adjust the maintenance daily dose of
Keppra, based on creatinine clearance in patients with moderate and severe
renal impairment (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In anuric end-stage renal disease adult
subjects the half-life was approximately 25 and 3.1&nbsp;hours during
interdialytic and intradialytic periods, respectively. </span></p>

<p class=MsoNormal><span lang=EN-GB>The fractional removal of levetiracetam was
51&nbsp;% during a typical 4-hour dialysis session.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hepatic
impairment</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In subjects
with mild and moderate hepatic impairment, there was no relevant modification
of the clearance of levetiracetam. In most subjects with severe hepatic
impairment, the clearance of levetiracetam was reduced by more than 50&nbsp;%
due to a concomitant renal impairment (see section 4.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Children
(4 to 12 years)</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Following single oral dose administration
(20&nbsp;mg/kg) to epileptic children (6 to 12 years), the half-life of
levetiracetam was 6.0&nbsp;hours. The apparent body weight adjusted clearance
was approximately 30&nbsp;% higher than in epileptic adults.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Following repeated oral dose administration
(20 to 60</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg/kg/day) to
epileptic children (4 to 12</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>years), levetiracetam was rapidly absorbed. Peak plasma
concentration was observed 0.5 to 1.0</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>hour after dosing. Linear and dose proportional increases were
observed for peak plasma concentrations and area under the curve. The
elimination half-life was approximately 5</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>hours. The apparent body clearance was 1.1</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>ml/min/kg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Infants
and children (1 month to 4 years)</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Following
single dose administration (20</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>mg/kg) of a 100</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>mg/ml oral solution to epileptic children (1&nbsp;month to 4</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>years), levetiracetam was rapidly
absorbed and peak plasma concentrations were observed approximately 1 hour
after dosing. The pharmacokinetic results indicated that half-life was shorter
(5.3&nbsp;h) than for adults (7.2&nbsp;h) and apparent clearance was faster
(1.5&nbsp;ml/min/kg) than for adults (0.96&nbsp;ml/min/kg).</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>In the population pharmacokinetic
analysis conducted in patients from 1 month to 16<span lang=EN-GB>&nbsp;</span>years
of age, body weight was significantly correlated to apparent clearance
(clearance increased with an increase in body weight) and apparent volume of
distribution. Age also had an influence on both parameters. This effect was
pronounced for the younger infants, and subsided as age increased, to become
negligible around 4<span lang=EN-GB>&nbsp;</span>years of age.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>In both population
pharmacokinetic analyses, there was about a 20<span lang=EN-GB>&nbsp;</span>%
increase of apparent clearance of levetiracetam when it was co-administered
with an enzyme-inducing antiepileptic medicinal product.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.3 Preclinical safety data</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Non-clinical data reveal no special hazard
for humans based on conventional studies of safety pharmacology, genotoxicity
and carcinogenic potential. </span></p>

<p class=MsoNormal><span lang=EN-GB>Adverse effects not observed in clinical
studies but seen in the rat and to a lesser extent in the mouse at exposure
levels similar to human exposure levels and with possible relevance for
clinical use were liver changes, indicating an adaptive response such as
increased weight and centrilobular hypertrophy, fatty infiltration and
increased liver enzymes in plasma.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No adverse reactions on male or female
fertility or reproduction performance were observed in rats at doses up to 1800</span>&nbsp;mg/kg/day
(x 6 the MRHD on a mg/m2 or exposure basis) in parents and F1 generation.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>Two embryo&#8209;foetal
development (EFD) studies were performed in rats at 400, 1200 and
3600&nbsp;mg/kg/day. At 3600&nbsp;mg/kg/day, in only one of the 2 EFD studies,
there was a slight decrease in foetal weight associated with a marginal
increase in skeletal variations/minor anomalies. There was no effect on embryomortality
and no increased incidence of malformations. The NOAEL (No Observed Adverse
Effect Level) was 3600&nbsp;mg/kg/day for pregnant female rats (x 12 the MRHD
on a mg/m2 basis) and 1200&nbsp;mg/kg/day for fetuses. </p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'>Four embryo&#8209;foetal
development studies were performed in rabbits covering doses of 200, 600, 800,
1200 and 1800&nbsp;mg/kg/day. The dose level of 1800&nbsp;mg/kg/day induced a
marked maternal toxicity and a decrease in foetal weight associated with
increased incidence of foetuses with cardiovascular/skeletal anomalies. The
NOAEL was &lt;200&nbsp;mg/kg/day for the dams and 200&nbsp;mg/kg/day for the
fetuses (equal to the MRHD on a mg/m2 basis). </p>

<p class=MsoNormal>A peri- and post-natal development study was performed in
rats with levetiracetam doses of 70, 350 and 1800&nbsp;mg/kg/day. The NOAEL was
&#8805;&nbsp;1800&nbsp;mg/kg/day for the F0 females, and for the survival,
growth and development of the F1 offspring up to weaning (x 6 the MRHD on a
mg/m2 basis).</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Neonatal and
juvenile animal studies in rats and dogs demonstrated that there were no
adverse effects seen in any of the standard developmental or maturation
endpoints at doses up to 1800&nbsp;mg/kg/day </span>(x 6  17 the MRHD on a
mg/m2 basis)<span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>6. PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Tablet core</u></p>

<p class=MsoNormal>Croscarmellose sodium</p>

<p class=MsoNormal>Macrogol 6000</p>

<p class=MsoNormal>Silica colloidal anhydrous</p>

<p class=MsoNormal>Magnesium stearate</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoBodyText><u><span style='font-size:11.0pt'>Film-coating</span></u></p>

<p class=MsoNormal>Polyvinyl alcohol-part.hydrolyzed</p>

<p class=MsoNormal>Titanium dioxide (E171)</p>

<p class=MsoNormal>Macrogol 3350</p>

<p class=MsoNormal>Talc</p>

<p class=MsoNormal>Indigo carmine aluminium lake (E132)</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>3 years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.4 Special
precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product does not require any
special storage conditions</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.5 Nature and contents of container</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Aluminium/PVC blisters placed into
cardboard boxes containing 20, 30, 50, 60, 100 film-coated tablets and
multipacks containing 200 (2 packs of 100) film-coated tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aluminium/PVC
perforated unit dose blisters placed into cardboard boxes containing 100 x 1
film-coated tablet. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not all pack
sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.6 Special precautions for disposal </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="OLE_LINK3"><span lang=EN-GB>Any unused medicinal
product or waste material should be disposed of in accordance with local
requirements.</span></a></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=FR>7. MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR-BE>UCB Pharma SA </span></p>

<p class=MsoNormal><span lang=FR-BE>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=DE>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>8. MARKETING AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/001</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/002</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/003</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/004</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/005</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/00/146/029</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/00/146/034</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Date of first<span lang=EN-GB> authorisation</span>: 29
September 2000</p>

<p class=MsoNormal>Date of latest renewal: 20 August 2015</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10. DATE OF REVISION OF
THE TEXT</span></b></p>

<p class=Default style='line-height:13.0pt;page-break-after:avoid;text-autospace:
ideograph-numeric ideograph-other'><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency http://www.ema.europa.eu </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keppra
500&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each film-coated
tablet contains 500&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3. PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Film-coated
tablet.</span></p>

<p class=MsoNormal><span lang=EN-GB>Yellow, 16 mm oblong, scored and debossed
with the code ucb and 500 on one side.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The score line
is only to facilitate breaking for ease of swallowing and not to divide into
equal doses. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4. CLINICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra is indicated as monotherapy in the
treatment of partial onset seizures with or without secondary generalisation in
adults and adolescents from 16 years of age with newly diagnosed epilepsy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra is indicated as adjunctive therapy</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the treatment of partial onset seizures with
or without secondary generalisation in adults, adolescents, children and
infants from 1 month of age with epilepsy.</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the treatment of </span>myoclonic seizures in
adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.</p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the treatment of primary generalised
tonic-clonic seizures in adults and adolescents from 12 years of age with
Idiopathic Generalised Epilepsy.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.2 Posology and method of administration</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Partial onset seizures</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dosing for monotherapy
(from 16 years of age) and adjunctive therapy is the same; as outlined below.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>All indications</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adults (&#8805;18 years) and adolescents
(12 to 17 years) weighing 50 kg or more </span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The initial therapeutic dose is 500&nbsp;mg
twice daily. This dose can be started on the first day of treatment. <span
style='color:black'>However, a lower initial dose of 250</span>&nbsp;<span
style='color:black'>mg twice daily may be given based on physician assessment
of seizure reduction versus potential side effects. This can be increased to
500</span>&nbsp;<span style='color:black'>mg twice daily after two weeks.</span></span></p>

<p class=MsoNormal><span lang=EN-GB>Depending upon the clinical response and
tolerability, the daily dose can be increased up to 1,500&nbsp;mg twice daily.
Dose changes can be made in 250 mg or 500&nbsp;mg twice daily increases or
decreases every two to four weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adolescents (12 to 17 years) weighing
below 50 kg and children from 1 month of age</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The physician should prescribe the most
appropriate pharmaceutical form, presentation and strength according to weight,
age and dose. Refer to <i>Paediatric population</i> section for dosing
adjustments based on weight.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Discontinuation</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If
levetiracetam has to be discontinued it is recommended to withdraw it gradually
(<i>e.g</i>. in adults and adolescents weighing more than 50&nbsp;kg:
500&nbsp;mg decreases twice daily every two to four weeks; in infants older
than 6 months, children and adolescents weighing less than 50&nbsp;kg: dose
decrease should not exceed 10&nbsp;mg/kg twice daily every two weeks; in infants
(less than 6 months): dose decrease should not exceed 7&nbsp;mg/kg twice daily
every two weeks). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly
(65 years and older)</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Adjustment
of the dose is recommended in elderly patients with compromised renal function
(see Renal impairment below).</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i><span lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The daily dose must be individualised
according to renal function.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For adult patients, refer to the following
table and adjust the dose as indicated. To use this dosing table, an estimate
of the patient's creatinine clearance (CL<sub>cr</sub>) in ml/min is needed.
The CLcr in ml/min may be estimated from serum creatinine (mg/dl)
determination, for adults and adolescents weighing 50&nbsp;kg or more, the
following formula:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB> [140-age
(years)] x weight (kg)</span></p>

<p class=MsoNormal><span lang=EN-GB>CL<sub>cr</sub> </span>(ml/min)<span
lang=EN-GB> = ----------------------------------------- (x 0.85 for women)</span></p>

<p class=MsoNormal><span lang=EN-GB> 72 x serum
creatinine (mg/dl)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Then <span lang=EN-GB>CL<sub>cr</sub></span> is adjusted for
body surface area (BSA) as follows:</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>  <span
lang=DE>CL<sub>cr</sub> (ml/min)</span></p>

<p class=MsoNormal><span lang=DE>CL<sub>cr</sub> (ml/min/1.73 m<sup>2</sup>) =
---------------------------- x 1.73 </span></p>

<p class=MsoNormal><span lang=DE>  </span><span
lang=FR-BE>BSA subject (m<sup>2</sup>)</span></p>

<p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Dosing adjustment for adult and adolescent
patients weighing more than 50&nbsp;kg with impaired renal function:</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Group</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Creatinine clearance (ml/min</span>/1.73m<sup>2</sup><span
  lang=EN-GB>)</span></p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Dose and frequency</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Normal</span></p>
  <p class=MsoNormal><span lang=EN-GB>Mild</span></p>
  <p class=MsoNormal><span lang=EN-GB>Moderate</span></p>
  <p class=MsoNormal><span lang=EN-GB>Severe</span></p>
  <p class=MsoNormal><span lang=EN-GB>End-stage renal disease patients</span></p>
  <p class=MsoNormal><span lang=EN-GB>undergoing dialysis <sup>(1)</sup></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;</span><span lang=EN-GB>&nbsp;80</span></p>
  <p class=MsoNormal><span lang=EN-GB>50-79</span></p>
  <p class=MsoNormal><span lang=EN-GB>30-49</span></p>
  <p class=MsoNormal><span lang=EN-GB>&lt;&nbsp;30</span></p>
  <p class=MsoNormal><span lang=EN-GB>-</span></p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>500 to 1,500&nbsp;mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>500 to 1,000 mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>250 to 750&nbsp;mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>250 to 500&nbsp;mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>500 to 1,000&nbsp;mg once daily <sup>(2)</sup></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><sup><span lang=EN-GB>(1)</span></sup><span lang=EN-GB> A
750&nbsp;mg loading dose is recommended on the first day of treatment with
levetiracetam.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(2)</span></sup><span lang=EN-GB>
Following dialysis, a 250 to 500&nbsp;mg supplemental dose is recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For children with renal impairment,
levetiracetam dose needs to be adjusted based on the renal function as
levetiracetam clearance is related to renal function. This recommendation is
based on a study in adult renally impaired patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The CL<sub>cr</sub> in ml/min/1.73&nbsp;m<sup>2</sup>
may be estimated from serum creatinine (mg/dl) determination, for young
adolescents, children and infants, using the following formula (Schwartz
formula): </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>  Height (cm)
x ks</p>

<p class=MsoNormal><span lang=EN-GB>CL<sub>cr</sub></span> (ml/min/1.73 m<sup>2</sup>)
= -------------------------------------</p>

<p class=MsoNormal>  Serum Creatinine
(mg/dl)</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>ks= 0.45 in Term infants to 1 year old; ks=
0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in
adolescent male</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Dosing
adjustment for infants, children and adolescent patients weighing less than 50
kg with impaired renal function:</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=621
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=130 rowspan=2 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Group</span></p>
  </td>
  <td width=113 rowspan=2 valign=top style='width:85.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Creatinine
  clearance (ml/min</span>/1.73m<sup>2</sup><span lang=EN-GB>)</span></p>
  </td>
  <td width=378 colspan=2 valign=top style='width:283.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Dose and frequency <sup>(1)</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infants 1
  to less than 6 months</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Infants 6 to 23 months, children
  and adolescents weighing less than 50 kg </p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Normal</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span><span
  lang=EN-GB>&#8805;</span><span lang=EN-GB>80</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>7 to
  21&nbsp;mg/kg (0.07 to 0.21&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>10 to
  30&nbsp;mg/kg (0.10 to 0.30&nbsp;ml/kg) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Mild</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>50-79</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>7 to
  14&nbsp;mg/kg (0.07 to 0.14&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>10 to
  20&nbsp;mg/kg (0.10 to 0.20&nbsp;ml/kg) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Moderate</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>30-49</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>3.5 to
  10.5&nbsp;mg/kg (0.035 to 0.105&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>5 to
  15&nbsp;mg/kg (0.05 to 0.15&nbsp;ml/kg) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Severe</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&lt;&nbsp;30</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>3.5 to
  7&nbsp;mg/kg (0.035 to 0.07&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>5 to
  10&nbsp;mg/kg (0.05 to 0.10&nbsp;ml/kg) twice daily </span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>End-stage
  renal disease patients</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>undergoing
  dialysis </span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>--</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>7 to
  14&nbsp;mg/kg (0.07 to 0.14&nbsp;ml/kg) once daily <sup>(2) (4)</sup></span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>10 to
  20&nbsp;mg/kg (0.10 to 0.20&nbsp;ml/kg) once daily <sup>(3) (5)</sup></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB>(1)</span></sup><span
lang=EN-GB> Keppra oral solution should be used for doses under 250 mg, for
doses not multiple of 250 mg when dosing recommendation is not achievable by
taking multiple tablets and for patients unable to swallow tablets. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB>(2)</span></sup><span
lang=EN-GB> A 10.5&nbsp;mg/kg (0.105&nbsp;ml/kg) loading dose is recommended on
the first day of treatment with levetiracetam.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(3)</span></sup><span lang=EN-GB> A
15&nbsp;mg/kg (0.15&nbsp;ml/kg) loading dose is recommended on the first day of
treatment with levetiracetam.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(4)</span></sup><span lang=EN-GB>
Following dialysis, a 3.5 to 7&nbsp;mg/kg (0.035 to 0.07&nbsp;ml/kg)
supplemental dose is recommended.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(5)</span></sup><span lang=EN-GB>
Following dialysis, a 5 to 10&nbsp;mg/kg (0.05 to 0.10&nbsp;ml/kg) supplemental
dose is recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Hepatic impairment </span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No dose adjustment is needed in patients
with mild to moderate hepatic impairment. In patients with severe hepatic
impairment, the creatinine clearance may underestimate the renal insufficiency.
Therefore a 50&nbsp;% reduction of the daily maintenance dose is recommended
when the creatinine clearance is &lt;&nbsp;60&nbsp;ml/min/1.73 m<sup>2</sup>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The physician should prescribe the most appropriate pharmaceutical
form, presentation and strength according to age, weight and dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The tablet formulation is not adapted for
use in infants and children under the age of 6 years. Keppra oral solution is
the preferred formulation for use in this population. In addition, the
available dose strengths of the tablets are not appropriate for initial
treatment in children weighing less than 25 kg, for patients unable to swallow
tablets or for the administration of doses below 250 mg. In all of the above
cases Keppra oral solution should be used.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Monotherapy</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of Keppra in children
and adolescents below 16 years as monotherapy treatment have not been
established.</span></p>

<p class=MsoNormal>No data are available.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i>Adolescents (16 and 17 years of age) weighing 50 kg or
more with partial onset seizures with or without secondary generalisation </i>with
newly diagnosed epilepsy: Please refer to the above section on <i>Adults
(&#8805;18 years) and adolescents (12 to 17 years) weighing 50 kg or more</i>. </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Add-on
therapy for infants aged 6 to 23 months, children (2 to 11 years) and
adolescents (12 to 17 years) weighing less than 50&nbsp;kg</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Keppra oral
solution is the preferred formulation for use in infants and children under the
age of 6 years. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For children
6 years and above, Keppra oral solution should be used for doses under 250 mg,
for doses not multiple of 250 mg when dosing recommendation is not achievable
by taking multiple tablets and for patients unable to swallow tablets.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The lowest effective dose should be used
for all indications. The starting dose for a child or adolescent of 25kg should
be 250mg twice daily with a maximum dose of 750mg twice daily. Dose in children
50&nbsp;kg or greater is the same as in adults for all indications. </span></p>

<p class=MsoNormal>Please refer to the above section on <i>Adults (&#8805;18
years) and adolescents (12 to 17 years) weighing 50 kg or more </i>for all
indications.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Add-on therapy for infants aged from 1
month to less than 6 months</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The oral solution is the formulation to use in infants.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The film-coated tablets must be taken
orally, swallowed with a sufficient quantity of liquid and may be taken with or
without food. </span><span lang=EN-GB>After oral administration the bitter
taste of levetiracetam may be experienced. </span><span lang=EN-GB>The daily
dose is administered in two equally divided doses.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to the active substance or
other pyrrolidone derivatives or to any of the excipients</span><span
lang=EN-GB> listed in section 6.1</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.4 Special warnings and precautions
for use</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Renal impairment</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The administration of levetiracetam to
patients with renal impairment may require dose adjustment. In patients with
severely impaired hepatic function, assessment of renal function is recommended
before dose selection (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Acute Kidney injury</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The use of levetiracetam has been very
rarely associated with acute kidney injury, with a time to onset ranging from a
few days to several months.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Blood cell counts</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rare cases of decreased blood cell counts
(neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia)
have been described in association with levetiracetam administration, generally
at the beginning of the treatment. Complete blood cell counts are advised in
patients experiencing important weakness, pyrexia, recurrent infections or
coagulation disorders (section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u>Suicide</u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Suicide,
suicide attempt, <span lang=EN-GB>suicidal ideation and behaviour have been
reported in patients treated with anti-epileptic agents (including
levetiracetam. A meta-analysis of randomized placebo-controlled trials of
anti-epileptic medicinal products has shown a small increased risk of suicidal
thoughts and behaviour. The mechanism of this risk is not known. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Therefore, patients should be monitored for
signs of depression and/or suicidal ideation and behaviours and appropriate
treatment should be considered. Patients (and caregivers of patients) should be
advised to seek medical advice should signs of depression and/or suicidal
ideation or behaviour emerge.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Abnormal and aggressive behaviours </span></u></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam may cause psychotic symptoms
and behavioural abnormalities including irritability and aggressiveness.
Patients treated with levetiracetam should be monitored for developing
psychiatric signs suggesting important mood and/or personality changes. If such
behaviours are noticed, treatment adaptation or gradual discontinuation should
be considered. If discontinuation is considered, please refer to section 4.2.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk26862118"><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></a></p>

<p class=MsoNormal style='line-height:normal'><u>Worsening of seizures</u></p>

<p class=MsoNormal>As with other types of antiepileptic drugs, levetiracetam
may rarely exacerbate seizure frequency or severity. This paradoxical effect
was mostly reported within the first month after levetiracetam initiation or
increase of the dose, and was reversible upon drug discontinuation or dose
decrease. Patients should be advised to consult their physician immediately in
case of aggravation of epilepsy.</p>

<p class=MsoNormal><u><span style='font-size:12.0pt'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Electrocardiogram QT interval
prolongation</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rare cases of ECG QT interval prolongation
have been observed during the post-marketing surveillance. Levetiracetam should
be used with caution in patients with QTc-interval prolongation, in patients
concomitantly treated with drugs affecting the QTc-interval, or in patients
with relevant pre-existing cardiac disease or electrolyte disturbances.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The tablet
formulation is not adapted for use in infants and children under the age of 6
years. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="OLE_LINK14"></a><a name="OLE_LINK15"><span
lang=EN-GB>Available data in children did not suggest impact on growth and
puberty. However, long term effects on learning, intelligence, growth,
endocrine function, puberty and childbearing potential in children remain
unknown.</span></a></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.5 Interaction with other medicinal
products and other forms of interaction</span></b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Antiepileptic medicinal products</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Pre-marketing data from clinical studies
conducted in adults indicate that levetiracetam did not influence the serum
concentrations of existing antiepileptic medicinal products (phenytoin,
carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone)
and that these antiepileptic medicinal products did not influence the
pharmacokinetics of levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-AU style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>As in adults,
there is no evidence of clinically significant medicinal product interactions
in paediatric patients receiving up to 60 mg/kg/day levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>A
retrospective assessment of pharmacokinetic interactions in children and
adolescents with epilepsy (4 to 17</span><span lang=EN-GB>&nbsp;<span
style='layout-grid-mode:line'>years) confirmed that adjunctive therapy with
orally administered<u> </u>levetiracetam did not influence the steady-state
serum concentrations of concomitantly administered carbamazepine and valproate.
However, data suggested </span></span><span lang=EN-GB>a 20</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% higher levetiracetam clearance in
children taking</span><span lang=EN-GB style='layout-grid-mode:line'>
enzyme-inducing antiepileptic medicinal products. Dose adjustment is not
required. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Probenecid</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Probenecid (500&nbsp;mg four times daily),
a renal tubular secretion blocking agent, has been shown to inhibit the renal
clearance of the primary metabolite, but not of levetiracetam. Nevertheless,
the concentration of this metabolite remains low. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Methotrexate</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Concomitant administration of levetiracetam
and methotrexate has been reported to decrease methotrexate clearance,
resulting in increased/prolonged blood methotrexate concentration to
potentially toxic levels. Blood methotrexate and levetiracetam levels should be
carefully monitored in patients treated concomitantly with the two drugs.</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-AU style='layout-grid-mode:line'>Oral
contraceptives and other pharmacokinetics interactions</span></u></p>

<p class=MsoNormal><span lang=EN-AU style='layout-grid-mode:line'>Levetiracetam
1,000&nbsp;mg daily did not influence the pharmacokinetics of oral
contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters
(luteinizing hormone and progesterone) were not modified. Levetiracetam
2,000&nbsp;mg daily did not influence the pharmacokinetics of digoxin and
warfarin; prothrombin times were not modified. Co-administration with digoxin,
oral contraceptives and warfarin did not influence the pharmacokinetics of
levetiracetam.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Laxatives</u></p>

<p class=MsoNormal><span lang=EN-GB>There have been isolated reports of
decreased levetiracetam efficacy when the osmotic laxative macrogol has been
concomitantly administered with oral levetiracetam. Therefore, macrogol should
not be taken orally for one hour before and for one hour after taking
levetiracetam.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u>Food and alcohol</u></p>

<p class=MsoNormal>The extent of absorption of levetiracetam was not altered by
food, but the rate of absorption was slightly reduced.</p>

<p class=MsoNormal>No data on the interaction of levetiracetam with alcohol are
available.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.6 Fertility,
pregnancy and lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Women of
child bearing potential </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Specialist
advice should be given to women who are of childbearing potential. Treatment
with levetiracetam should be reviewed when a woman is planning to become
pregnant. As with all antiepileptic medicines, sudden discontinuation of
levetiracetam should be avoided as this may lead to breakthrough seizures that
could have serious consequences for the woman and the unborn child. Monotherapy
should be preferred whenever possible because therapy with multiple
antiepileptic medicines AEDs could be associated with a higher risk of
congenital malformations than monotherapy, depending on the associated
antiepileptics.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><span lang=EN-GB>A large amount of postmarketing data on
pregnant women exposed to levetiracetam monotherapy (more than 1800, among
which in more than 1500 exposure occurred during the 1<sup>st</sup> trimester)
do not suggest an increase in the risk for major congenital malformations. Only
limited evidence is available on the neurodevelopment of children exposed to
Keppra monotherapy in utero. However, current epidemiological studies (on about
100 children) do not suggest an increased risk of neurodevelopmental disorders
or delays. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Levetiracetam
can be used during pregnancy, if after careful assessment it is considered
clinically needed. In such case, the lowest effective dose is recommended.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Physiological
changes during pregnancy may affect levetiracetam concentration. D</span>ecrease
in levetiracetam plasma concentrations has been observed during pregnancy. This
decrease is more pronounced during the third trimester (up to 60% of baseline
concentration before pregnancy). Appropriate clinical management of pregnant
women treated with levetiracetam should be ensured. </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Breastfeeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam is excreted in human breast
milk. Therefore, breast-feeding is not recommended. </span></p>

<p class=MsoNormal style='line-height:normal'>However, if levetiracetam
treatment is needed during breastfeeding, the benefit/risk of the treatment
should be weighed considering the importance of breastfeeding.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><u>Fertility</u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No impact on
fertility was detected in animal studies (see section 5.3). No clinical data
are available, potential risk for human is unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.7 Effects on ability to drive and
use machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam has minor or moderate
influence on the ability to drive and use machines.</span><span lang=EN-GB> Due
to possible different individual sensitivity, some patients might experience
somnolence or other central nervous system related symptoms, </span><span
lang=EN-GB>especially</span><span lang=EN-GB> </span><span lang=EN-GB>at the
beginning of treatment or following a dose increase. Therefore, caution is
recommended in those patients when performing skilled tasks, <i>e.g</i>.
driving vehicles or operating machinery. Patients are advised not to drive or
use machines until it is established that </span><span lang=EN-GB>their</span><span
lang=EN-GB> ability to perform such activities is not affected.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.8 Undesirable
effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Summary
of the safety profile</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The most frequently reported adverse
reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness.
The adverse reaction profile presented below is based on the analysis of pooled
placebo-controlled clinical trials with all indications studied, with a total
of 3,416 patients treated with levetiracetam. These data are supplemented with
the use of levetiracetam in corresponding open-label extension studies, as well
as post-marketing experience. The safety profile of levetiracetam is generally
similar across age groups (adult and paediatric patients) and across the
approved epilepsy indications. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Tabulated list of adverse
reactions</u></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Adverse reactions reported in clinical
studies (adults, adolescents, children and infants &gt; 1&nbsp;month) and from
post-marketing experience are listed in the following table per System Organ
Class and per frequency. Adverse reactions are presented in the order of
decreasing seriousness and their frequency is defined as follows: very common
(&#8805;1/10); common (&#8805;1/100 to &lt;1/10); uncommon (&#8805;1/1,000 to
&lt;1/100); rare (&#8805;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="97%"
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="20%" rowspan=2 style='width:20.32%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
   style='font-size:10.0pt'>MedDRA SOC</span></u></p>
   </td>
   <td width="79%" colspan=4 valign=top style='width:79.68%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><u><span lang=EN-GB style='font-size:10.0pt'>Frequency category</span></u></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width="18%" valign=top style='width:18.74%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
   style='font-size:10.0pt'>Very common</span></u></p>
   </td>
   <td width="18%" valign=top style='width:18.76%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
   style='font-size:10.0pt'>Common</span></u></p>
   </td>
   <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
   style='font-size:10.0pt'>Uncommon </span></u></p>
   </td>
   <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
   style='font-size:10.0pt'>Rare</span></u></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
  style='font-size:10.0pt'>Infections and infestations</span></u></p>
  </td>
  <td width="18%" valign=top style='width:18.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Nasopharyngitis </span></p>
  </td>
  <td width="18%" valign=top style='width:18.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Infection</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
  style='font-size:10.0pt'>Blood and lymphatic system disorders</span></u></p>
  </td>
  <td width="18%" valign=top style='width:18.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-AU
  style='font-size:10.0pt'>Thrombocytopenia, leukopenia</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-AU
  style='font-size:10.0pt'>Pancytopenia, neutropenia, agranulocytosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
  style='font-size:10.0pt'>Immune system disorders</span></u></p>
  </td>
  <td width="18%" valign=top style='width:18.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-AU
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-AU
  style='font-size:10.0pt'>Drug reaction with eosinophilia and systemic symptoms
  (DRESS),</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-AU
  style='font-size:10.0pt'>Hypersensitivity (including angioedema and
  anaphylaxis)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
  style='font-size:10.0pt'>Metabolism and nutrition disorders</span></u></p>
  </td>
  <td width="18%" valign=top style='width:18.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Anorexia</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Weight decreased, weight increase</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Hyponatraemia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Psychiatric
  disorders</span></u></p>
  </td>
  <td width="18%" valign=top style='width:18.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Depression,
  hostility/ aggression, anxiety, <br>
  insomnia, nervousness/irritability</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Suicide attempt,
  suicidal ideation</span><span lang=EN-AU style='font-size:10.0pt'>,<sup> </sup></span><span
  lang=EN-GB style='font-size:10.0pt'>psychotic disorder</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>abnormal behaviour, hallucination</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>anger, confusional state, panic attack, affect
  lability/mood swings, agitation</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Completed
  suicide</span><span lang=EN-AU style='font-size:10.0pt'>, </span><span
  lang=EN-GB style='font-size:10.0pt'>personality disorder, thinking abnormal,
  delirium</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Nervous
  system disorders</span></u></p>
  </td>
  <td width="18%" valign=top style='width:18.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Somnolence,
  headache</span></p>
  </td>
  <td width="18%" valign=top style='width:18.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Convulsion,
  balance disorder, dizziness, lethargy, tremor</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Amnesia, memory
  impairment, coordination abnormal/ataxia, paraesthesia</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>disturbance in attention</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Choreoathetosis,
  dyskinesia, hyperkinesia, gait disturbance, encephalopathy, seizures
  aggravated</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Eye disorders</span></u></p>
  </td>
  <td width="18%" valign=top style='width:18.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Diplopia, vision
  blurred</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Ear and
  labyrinth disorders</span></u></p>
  </td>
  <td width="18%" valign=top style='width:18.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Vertigo</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Cardiac
  disorders</span></u></p>
  </td>
  <td width="18%" valign=top style='width:18.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>Electrocardiogram
  QT prolonged</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Respiratory,
  thoracic and mediastinal disorders</span></u></p>
  </td>
  <td width="18%" valign=top style='width:18.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Cough</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Gastrointestinal
  disorders</span></u></p>
  </td>
  <td width="18%" valign=top style='width:18.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT style='font-size:10.0pt'>Abdominal pain,
  diarrhoea, dyspepsia, vomiting, nausea</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Pancreatitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-AU style='font-size:10.0pt'>Hepatobiliary
  disorders</span></u></p>
  </td>
  <td width="18%" valign=top style='width:18.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Liver function
  test abnormal</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Hepatic failure,
  hepatitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Renal and
  Urinary Disorders</span></u></p>
  </td>
  <td width="18%" valign=top style='width:18.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Acute Kidney
  injury</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Skin and
  subcutaneous tissue disorders</span></u></p>
  </td>
  <td width="18%" valign=top style='width:18.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Rash</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Alopecia</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>eczema, pruritus, </span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Toxic epidermal
  necrolysis, Stevens-Johnson syndrome, erythema multiforme</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Musculoskeletal
  and connective tissue disorders</span></u></p>
  </td>
  <td width="18%" valign=top style='width:18.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Muscular
  weakness, myalgia</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Rhabdomyolysis
  and blood creatine phosphokinase increased*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>General disorders
  and administration site conditions</span></u></p>
  </td>
  <td width="18%" valign=top style='width:18.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Asthenia/fatigue</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Injury,
  poisoning and procedural complications</span></u></p>
  </td>
  <td width="18%" valign=top style='width:18.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Injury</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU>* Prevalence is
significantly higher in Japanese patients when compared to non-Japanese
patients. </span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Description of selected adverse reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU>The risk of
anorexia is higher when levetiracetam is coadministered with topiramate.</span></p>

<p class=MsoNormal><span lang=EN-AU>In several cases of alopecia, recovery was
observed when levetiracetam was discontinued.</span></p>

<p class=MsoNormal><span style='font-family:"TimesNewRomanPSMT",serif'>Bone
marrow suppression was identified in some of the cases of pancytopenia.</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU>Cases of
encephalopathy generally occurred at the beginning of the treatment (few days
to a few months) and were reversible after treatment discontinuation.</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients aged 1 month to less than 4
years, a total of 190 patients have been treated with levetiracetam in
placebo-controlled and open label extension studies. Sixty of these patients
were treated with levetiracetam in placebo-controlled studies. In patients
aged 4-16 years, a total of 645 patients have been treated with levetiracetam
in placebo-controlled and open label extension studies. 233 of these patients
were treated with levetiracetam in placebo-controlled studies. In both these
paediatric age ranges, these data are supplemented with the post-marketing
experience of the use of levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In addition, 101 infants aged less than 12
months have been exposed in a post authorization safety study. No new safety
concerns for levetiracetam were identified for infants less than 12 months of
age with epilepsy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The adverse reaction profile of
levetiracetam is generally similar across age groups and across the approved
epilepsy indications. Safety results in paediatric patients in
placebo-controlled clinical studies were consistent with the safety profile of
levetiracetam in adults except for behavioural and psychiatric adverse
reactions which were more common in children than in adults. In children and
adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation
(common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%),
aggression (common, 8.2%), abnormal behaviour (common, 5.6%), and lethargy
(common, 3.9%) were reported more frequently than in other age ranges or in the
overall safety profile. In infants and children aged 1 month to less than 4
years, irritability (very common, 11.7%) and coordination abnormal (common,
3.3%) were reported more frequently than in other age groups or in the overall
safety profile. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>A double-blind,
placebo-controlled paediatric safety study with a non-inferiority design has
assessed the cognitive and neuropsychological effects of </span><span
lang=EN-GB>levetiracetam</span><span lang=EN-GB> in children 4 to 16 years of
age with partial onset seizures. It was concluded that Keppra was not different
(non inferior) from placebo with regard to the change from baseline of the
Leiter-R Attention and Memory, Memory Screen Composite score in the
per-protocol population. Results related to behavioural and emotional
functioning indicated a worsening in </span><span lang=EN-GB>levetiracetam </span><span
lang=EN-GB>treated patients on aggressive behaviour as measured in a
standardised and systematic way using a validated instrument (CBCL  Achenbach
Child Behavior Checklist). However, subjects, who took </span><span lang=EN-GB>levetiracetam</span><span
lang=EN-GB> in the long-term open label follow-up study, did not experience a
worsening, on average, in their behavioural and emotional functioning; in
particular measures of aggressive behaviour were not worse than baseline.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Reporting of
suspected adverse reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:silver'>the national reporting
system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a></span>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Symptoms</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Somnolence,
agitation, aggression, depressed level of consciousness, respiratory depression
and coma were observed with Keppra overdoses.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Management
of overdose</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>After an
acute overdose, the stomach may be emptied by gastric lavage or by induction of
emesis. There is no specific antidote for levetiracetam. Treatment of an
overdose will be symptomatic and may include haemodialysis. The dialyser
extraction efficiency is 60&nbsp;% for levetiracetam and 74&nbsp;% for the
primary metabolite.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>5. </span><span
lang=EN-GB>PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1 Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic group: antiepileptics,
other antiepileptics, ATC code: N03AX14.</span></p>

<p class=MsoNormal><span lang=EN-GB>The active substance, levetiracetam, is a
pyrrolidone derivative (S-enantiomer of </span><span lang=EN-GB
style='font-family:Symbol'>a</span><span lang=EN-GB>-ethyl-2-oxo-1-pyrrolidine
acetamide), chemically unrelated to existing antiepileptic active substances.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Mechanism of action</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The mechanism of action of levetiracetam
still remains to be fully elucidated. <i>In vitro</i> and <i>in vivo</i>
experiments suggest that levetiracetam does not alter basic cell
characteristics and normal neurotransmission. </span></p>

<p class=MsoNormal><i><span lang=EN-GB>In vitro</span></i><span lang=EN-GB>
studies show that levetiracetam affects intraneuronal Ca<sup>2+</sup> levels by
partial inhibition of N-type Ca<sup>2+</sup> currents and by reducing the
release of Ca<sup>2+</sup> from intraneuronal stores. In addition, it partially
reverses the reductions in GABA- and glycine-gated currents induced by zinc and
</span><span lang=EN-GB style='font-family:Symbol'>b</span><span lang=EN-GB>-carbolines.
Furthermore, levetiracetam has been shown in <i>in vitro</i> studies to bind to
a specific site in rodent brain tissue. This binding site is the synaptic
vesicle protein 2A, believed to be involved in vesicle fusion and
neurotransmitter exocytosis. Levetiracetam and related analogs show a rank
order of affinity for binding to the synaptic vesicle protein 2A which
correlates with the potency of their anti-seizure protection in the mouse
audiogenic model of epilepsy. This finding suggests that the interaction
between levetiracetam and the synaptic vesicle protein 2A seems to contribute
to the antiepileptic mechanism of action of the medicinal product.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Pharmacodynamic effects</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam induces seizure protection in
a broad range of animal models of partial and primary generalised seizures
without having a pro-convulsant effect. The primary metabolite is inactive.</span></p>

<p class=MsoNormal><span lang=EN-GB>In man, an activity in both partial and
generalised epilepsy conditions (epileptiform discharge/photoparoxysmal
response) has confirmed the broad spectrum pharmacological profile of
levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adjunctive therapy in the treatment of
partial onset seizures with or without secondary generalisation in adults,
adolescents, children and infants from 1 month of age with epilepsy.</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In adults, levetiracetam efficacy has been
demonstrated in 3 double-blind, placebo-controlled studies at 1000</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg, 2000</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>mg, or 3000</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg/day,
given in 2 divided doses, with a treatment duration of up to 18</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>weeks. In a pooled analysis, the
percentage of patients who achieved 50</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% or greater reduction from baseline in the partial onset seizure
frequency per week at stable dose (12/14</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>weeks) was of 27.7</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>%, 31.6</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>% and
41.3</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>% for patients on
1000, 2000 or 3000</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg
levetiracetam respectively and of 12.6</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% for patients on placebo. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Paediatric population</u></p>

<p class=MsoNormal style='page-break-after:avoid'><b>&nbsp;</b></p>

<p class=MsoNormal style='page-break-after:avoid'>In paediatric patients (4 to
16<span lang=EN-GB>&nbsp;</span>years of age), levetiracetam efficacy was
established in a double-blind, placebo-controlled study, which included 198
patients and had a treatment duration of 14 weeks. In this study, the patients
received levetiracetam as a fixed dose of 60<span lang=EN-GB>&nbsp;</span>mg/kg/day
(with twice a day dosing).</p>

<p class=MsoNormal><span lang=EN-GB>44.6</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% of the levetiracetam treated patients and 19.6</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% of the patients on placebo had a 50</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% or greater reduction from baseline
in the partial onset seizure frequency per week.</span><span lang=EN-GB> </span><span
lang=EN-GB>With continued long-term treatment, 11.4</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% of the patients were seizure-free for at least 6 months and 7.2</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% were seizure-free for at least 1
year.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In paediatric patients (1 month to less than 4<span
lang=EN-GB>&nbsp;</span>years of age), levetiracetam efficacy was established
in a double-blind, placebo-controlled study, which included 116 patients and
had a treatment duration of 5<span lang=EN-GB>&nbsp;</span>days. In this study,
patients were prescribed 20<span lang=EN-GB>&nbsp;</span>mg/kg, 25<span
lang=EN-GB>&nbsp;</span>mg/kg, 40<span lang=EN-GB>&nbsp;</span>mg/kg or 50<span
lang=EN-GB>&nbsp;</span>mg/kg daily dose of oral solution based on their age
titration schedule. A dose of 20<span lang=EN-GB>&nbsp;</span>mg/kg/day
titrating to 40<span lang=EN-GB>&nbsp;</span>mg/kg/day for infants one month to
less than six months and a dose of 25<span lang=EN-GB>&nbsp;</span>mg/kg/day
titrating to 50<span lang=EN-GB>&nbsp;</span>mg/kg/day for infants and children
6 months to less than 4 years old, was use in this study. The total daily dose
was administered twice daily.</p>

<p class=MsoNormal><span lang=EN-GB>The primary measure of effectiveness was
the responder rate (percent of patients with &#8805; 50&nbsp;% reduction from
baseline in average daily partial onset seizure frequency) assessed by a
blinded central reader using a 48-hour video EEG. The efficacy analysis
consisted of 109 patients who had at least 24&nbsp;hours of video EEG in both
baseline and evaluation periods. <span class=msoins0>43.6</span>&nbsp;<span
class=msoins0>% of the levetiracetam treated patients and 19.6</span>&nbsp;<span
class=msoins0>% of the patients on placebo were considered as responders. The
results are consistent across age group.</span></span><span lang=EN-GB> With
continued long-term treatment, 8.6</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% of the patients were seizure-free for at least 6 months and 7.8</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% were seizure-free for at least 1
year.</span></p>

<p class=MsoNormal><span lang=EN-GB>35 infants aged less than 1 year with
partial onset seizures have been exposed in placebo-control clinical studies of
which only 13 were aged &lt; 6 months.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i><span lang=EN-GB>Monotherapy in the treatment of partial
onset seizures with or without secondary generalisation in patients from 16
years of age with newly diagnosed epilepsy. </span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Efficacy of levetiracetam as monotherapy was established in
a double-blind, parallel group, non-inferiority comparison to carbamazepine-controlled
release (CR) in 576 patients 16<span lang=EN-GB>&nbsp;</span>years of age or
older with newly or recently diagnosed epilepsy. The patients had to present
with unprovoked partial seizures or with generalized tonic-clonic seizures
only. The patients were randomized to carbamazepine CR 400  1200<span
lang=EN-GB>&nbsp;</span>mg/day or levetiracetam 1000  3000<span lang=EN-GB>&nbsp;</span>mg/day,
the duration of the treatment was up to 121 weeks depending on the response.</p>

<p class=MsoNormal>Six-month seizure freedom was achieved in 73.0<span
lang=EN-GB>&nbsp;</span>% of levetiracetam-treated patients and 72.8<span
lang=EN-GB>&nbsp;</span>% of carbamazepine-CR treated patients; the adjusted
absolute difference between treatments was 0.2<span lang=EN-GB>&nbsp;</span>%
(95<span lang=EN-GB>&nbsp;</span>% CI: -7.8 8.2). More than half of the
subjects remained seizure free for 12 months (56.6<span lang=EN-GB>&nbsp;</span>%
and 58.5<span lang=EN-GB>&nbsp;</span>% of subjects on levetiracetam and on
carbamazepine CR respectively).</p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>In a study
reflecting clinical practice, the concomitant antiepileptic medication could be
withdrawn in a limited number of patients who responded to levetiracetam
adjunctive therapy (36 adult patients out of 69). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adjunctive therapy in the treatment of
myoclonic seizures in adults and adolescents from 12 years of age with Juvenile
Myoclonic Epilepsy.</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Levetiracetam efficacy was established in a double-blind,
placebo-controlled study of 16 weeks duration, in patients 12 years of age and
older suffering from idiopathic generalized epilepsy with myoclonic seizures in
different syndromes. The majority of patients presented with juvenile myoclonic
epilepsy.</p>

<p class=MsoNormal>In this study, levetiracetam, dose was 3000<span lang=EN-GB>&nbsp;</span>mg/day
given in 2 divided doses. </p>

<p class=MsoNormal>58.3<span lang=EN-GB>&nbsp;</span>% of the levetiracetam
treated patients and 23.3<span lang=EN-GB>&nbsp;</span>% of the patients on
placebo had at least a 50<span lang=EN-GB>&nbsp;</span>% reduction in myoclonic
seizure days per week. With continued long-term treatment, 28.6<span
lang=EN-GB>&nbsp;</span>% of the patients were free of myoclonic seizures for
at least 6 months and 21.0<span lang=EN-GB>&nbsp;</span>% were free of
myoclonic seizures for at least 1 year.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adjunctive therapy in the treatment of
primary generalised tonic-clonic seizures in adults and adolescents from 12
years of age with idiopathic generalised epilepsy.</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Levetiracetam efficacy was established in a 24-week
double-blind, placebo-controlled study, which included adults, adolescents and
a limited number of children suffering from idiopathic generalized epilepsy
with primary generalized tonic-clonic (PGTC) seizures in different syndromes
(juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence
epilepsy, or epilepsy with Grand Mal seizures on awakening). In this study,
levetiracetam dose was 3000<span lang=EN-GB>&nbsp;</span>mg/day for adults and
adolescents or 60<span lang=EN-GB>&nbsp;</span>mg/kg/day for children, given in
2 divided doses.</p>

<p class=MsoNormal>72.2<span lang=EN-GB>&nbsp;</span>% of the levetiracetam
treated patients and 45.2<span lang=EN-GB>&nbsp;</span>% of the patients on
placebo had a 50<span lang=EN-GB>&nbsp;</span>% or greater decrease in the
frequency of PGTC seizures per week. With continued long-term treatment, 47.4<span
lang=EN-GB>&nbsp;</span>% of the patients were free of tonic-clonic seizures
for at least 6 months and 31.5<span lang=EN-GB>&nbsp;</span>% were free of
tonic-clonic seizures for at least 1 year.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.2 Pharmacokinetic properties</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam is a highly soluble and
permeable compound. The pharmacokinetic profile is linear with low intra- and
inter-subject variability. There is no modification of the clearance after
repeated administration. There is no evidence for any relevant gender, race or
circadian variability. The pharmacokinetic profile is comparable in healthy
volunteers and in patients with epilepsy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Due to its complete and linear absorption,
plasma levels can be predicted from the oral dose of levetiracetam expressed as
mg/kg bodyweight. Therefore, there is no need for plasma level monitoring of
levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>A significant
correlation between saliva and plasma concentrations has been shown in adults
and children (ratio of saliva/plasma concentrations ranged from 1 to </span>1.7
for oral tablet formulation and after 4 hours post-dose for oral solution
formulation<span lang=EN-GB>).</span></p>

<p class=MsoEndnoteText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoEndnoteText style='page-break-after:avoid'><u><span lang=EN-GB>Adults
and adolescents</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam is rapidly absorbed after
oral administration. Oral absolute bioavailability is close to 100&nbsp;%. </span></p>

<p class=MsoNormal><span lang=EN-GB>Peak plasma concentrations (C<sub>max</sub>)
are achieved at 1.3&nbsp;hours after dosing. Steady-state is achieved after two
days of a twice daily administration schedule.</span></p>

<p class=MsoNormal><span lang=EN-GB>Peak concentrations (C<sub>max</sub>) are
typically 31 and 43&nbsp;g/ml following a single 1,000&nbsp;mg dose and
repeated 1,000&nbsp;mg twice daily dose, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>The extent of absorption is
dose-independent and is not altered by food.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No tissue distribution data are available
in humans.</span></p>

<p class=MsoNormal><span lang=EN-GB>Neither levetiracetam nor its primary
metabolite are significantly bound to plasma proteins (</span><span lang=EN-GB
style='font-family:Symbol'>&lt;</span><span lang=EN-GB>&nbsp;10&nbsp;%).</span></p>

<p class=MsoNormal><span lang=EN-GB>The volume of distribution of levetiracetam
is approximately 0.5 to 0.7&nbsp;l/kg, a value close to the total body water
volume.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Levetiracetam
is not extensively metabolised in humans. The major metabolic pathway
(24&nbsp;% of the dose) is an enzymatic hydrolysis of the acetamide group.
Production of the primary metabolite, ucb&nbsp;L057, is not supported by liver
cytochrome P<sub>450</sub> isoforms. Hydrolysis of the acetamide group was
measurable in a large number of tissues including blood cells. The metabolite
ucb&nbsp;L057 is pharmacologically inactive.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Two minor metabolites were also identified.
One was obtained by hydroxylation of the pyrrolidone ring (1.6&nbsp;% of the
dose) and the other one by opening of the pyrrolidone ring (0.9&nbsp;% of the
dose). </span></p>

<p class=MsoNormal><span lang=EN-GB>Other unidentified components accounted
only for 0.6&nbsp;% of the dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No enantiomeric interconversion was
evidenced <i>in vivo</i> for either levetiracetam or its primary metabolite.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i>In vitro</i><span lang=EN-GB>, levetiracetam and its
primary metabolite have been shown not to inhibit the major human liver
cytochrome P<sub>450</sub> isoforms (CYP3A4, 2A6, </span>2C9<span lang=EN-GB>,
2C19, 2D6, 2E1 and 1A2), glucuronyl transferase<span style='text-transform:
uppercase'> (</span></span><span style='text-transform:uppercase'>UGT1A1 </span>and<span
style='text-transform:uppercase'> UGT1A6</span><span lang=EN-GB
style='text-transform:uppercase'>)</span><span lang=EN-GB> and epoxide
hydroxylase activities. In addition, levetiracetam does not affect the <i>in
vitro</i> glucuronidation of valproic acid.</span></p>

<p class=MsoNormal><span lang=EN-GB>In human hepatocytes in culture,
levetiracetam </span>had little or no effect on CYP1A2, SULT1E1 or UGT1A1.
Levetiracetam caused mild induction of CYP2B6 and CYP3A4. The in vitro data and
<i>in vivo</i> interaction data on oral contraceptives, digoxin and warfarin
indicate that no significant enzyme induction is expected <i>in vivo</i><span
lang=EN-GB>. Therefore, the interaction of Keppra with other substances, or <i>vice
versa,</i> is unlikely.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The plasma half-life in adults was 7</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>1&nbsp;hours and
did not vary either with dose, route of administration or repeated
administration. The mean total body clearance was 0.96&nbsp;ml/min/kg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The major route of excretion was via urine,
accounting for a mean 95&nbsp;% of the dose (approximately 93&nbsp;% of the
dose was excreted within 48&nbsp;hours). Excretion <i>via</i> faeces accounted
for only 0.3&nbsp;% of the dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>The cumulative urinary excretion of
levetiracetam and its primary metabolite accounted for 66&nbsp;% and 24&nbsp;%
of the dose, respectively during the first 48&nbsp;hours.</span></p>

<p class=MsoNormal><span lang=EN-GB>The renal clearance of levetiracetam and
ucb&nbsp;L057 is 0.6 and 4.2&nbsp;ml/min/kg respectively indicating that
levetiracetam is excreted by glomerular filtration with subsequent tubular
reabsorption and that the primary metabolite is also excreted by active tubular
secretion in addition to glomerular filtration. Levetiracetam elimination is
correlated to creatinine clearance.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Elderly</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In the
elderly, the half-life is increased by about 40&nbsp;% (10 to 11&nbsp;hours).
This is related to the decrease in renal function in this population (see
section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Renal
impairment</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The apparent body clearance of both
levetiracetam and of its primary metabolite is correlated to the creatinine
clearance. It is therefore recommended to adjust the maintenance daily dose of
Keppra, based on creatinine clearance in patients with moderate and severe
renal impairment (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In anuric end-stage renal disease adult
subjects the half-life was approximately 25 and 3.1&nbsp;hours during
interdialytic and intradialytic periods, respectively. </span></p>

<p class=MsoNormal><span lang=EN-GB>The fractional removal of levetiracetam was
51&nbsp;% during a typical 4-hour dialysis session.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hepatic
impairment</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In subjects
with mild and moderate hepatic impairment, there was no relevant modification
of the clearance of levetiracetam. In most subjects with severe hepatic
impairment, the clearance of levetiracetam was reduced by more than 50&nbsp;%
due to a concomitant renal impairment (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Children
(4 to 12 years)</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Following single oral dose administration
(20&nbsp;mg/kg) to epileptic children (6 to 12&nbsp;years), the half-life of
levetiracetam was 6.0&nbsp;hours. The apparent body weight adjusted clearance
was approximately 30&nbsp;% higher than in epileptic adults.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Following repeated oral dose administration
(20 to 60</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg/kg/day) to
epileptic children (4 to 12</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>years), levetiracetam was rapidly absorbed. Peak plasma
concentration was observed 0.5 to 1.0</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>hour after dosing. Linear and dose proportional increases were
observed for peak plasma concentrations and area under the curve. The
elimination half-life was approximately 5 hours. The apparent body clearance
was 1.1</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>ml/min/kg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Infants
and children (1 month to 4 years)</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Following
single dose administration (20</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>mg/kg) of a 100</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>mg/ml oral solution to epileptic children (1&nbsp;month to 4</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>years), levetiracetam was rapidly
absorbed and peak plasma concentrations were observed approximately 1 hour
after dosing. The pharmacokinetic results indicated that half-life was shorter
(5.3&nbsp;h) than for adults (7.2&nbsp;h) and apparent clearance was faster
(1.5&nbsp;ml/min/kg) than for adults (0.96&nbsp;ml/min/kg). </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>In the population pharmacokinetic
analysis conducted in patients from 1 month to 16 years of age, body weight was
significantly correlated to apparent clearance (clearance increased with an
increase in body weight) and apparent volume of distribution. Age also had an
influence on both parameters. This effect was pronounced for the younger infants,
and subsided as age increased, to become negligible around 4 years of age.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>In both population
pharmacokinetic analyses, there was about a 20<span lang=EN-GB>&nbsp;</span>%
increase of apparent clearance of levetiracetam when it was co-administered
with an enzyme-inducing antiepileptic medicinal product.</p>

<p class=MsoNormal><span style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.3 Preclinical
safety data</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Non-clinical
data reveal no special hazard for humans based on conventional studies of
safety pharmacology, genotoxicity and carcinogenic potential. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Adverse
effects not observed in clinical studies but seen in the rat and to a lesser
extent in the mouse at exposure levels similar to human exposure levels and
with possible relevance for clinical use were liver changes, indicating an
adaptive response such as increased weight and centrilobular hypertrophy, fatty
infiltration and increased liver enzymes in plasma.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No adverse reactions on male or female
fertility or reproduction performance were observed in rats at doses up to 1800</span>&nbsp;mg/kg/day
(x 6 the MRHD on a mg/m2 or exposure basis) in parents and F1 generation.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'>Two embryo&#8209;foetal
development (EFD) studies were performed in rats at 400, 1200 and
3600&nbsp;mg/kg/day. At 3600&nbsp;mg/kg/day, in only one of the 2 EFD studies,
there was a slight decrease in foetal weight associated with a marginal
increase in skeletal variations/minor anomalies. There was no effect on
embryomortality and no increased incidence of malformations. The NOAEL (No
Observed Adverse Effect Level) was 3600&nbsp;mg/kg/day for pregnant female rats
(x 12 the MRHD on a mg/m2 basis) and 1200&nbsp;mg/kg/day for fetuses. </p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'>Four embryo&#8209;foetal
development studies were performed in rabbits covering doses of 200, 600, 800,
1200 and 1800&nbsp;mg/kg/day. The dose level of 1800&nbsp;mg/kg/day induced a
marked maternal toxicity and a decrease in foetal weight associated with increased
incidence of fetuses with cardiovascular/skeletal anomalies. The NOAEL was
&lt;200&nbsp;mg/kg/day for the dams and 200&nbsp;mg/kg/day for the fetuses
(equal to the MRHD on a mg/m2 basis). </p>

<p class=MsoNormal>A peri- and post-natal development study was performed in
rats with levetiracetam doses of 70, 350 and 1800&nbsp;mg/kg/day. The NOAEL was
&#8805;&nbsp;1800&nbsp;mg/kg/day for the F0 females, and for the survival,
growth and development of the F1 offspring up to weaning (x 6 the MRHD on a
mg/m2 basis). </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Neonatal and
juvenile animal studies in rats and dogs demonstrated that there were no
adverse effects seen in any of the standard developmental or maturation
endpoints at doses up to 1800&nbsp;mg/kg/day </span>(x 6-17 the MRHD on a mg/m2
basis) </p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='text-transform:uppercase'>6. PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.1 List
of excipients</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'>Tablet core:</p>

<p class=MsoNormal>Croscarmellose sodium</p>

<p class=MsoNormal>Macrogol 6000</p>

<p class=MsoNormal>Silica colloidal anhydrous </p>

<p class=MsoNormal>Magnesium stearate</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoBodyText><span style='font-size:11.0pt'>Film-coating:</span></p>

<p class=MsoNormal><span lang=EN-GB>Polyvinyl alcohol-part. </span>hydrolyzed</p>

<p class=MsoNormal><span lang=EN-GB>Titanium dioxide (E171)</span></p>

<p class=MsoNormal><span lang=EN-GB>Macrogol 3350</span></p>

<p class=MsoNormal><span lang=EN-GB>Talc</span></p>

<p class=MsoNormal><span lang=EN-GB>Iron oxide yellow (E172)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.3 Shelf
life</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>3 years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.4 Special precautions for storage</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product does not require any
special storage conditions</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.5 Nature and contents of container</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Aluminium/PVC blisters placed into
cardboard boxes containing 10, 20, 30, 50, 60, 100, 120 film-coated tablets and
multipacks containing 200 (2 packs of 100) film-coated tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aluminium/PVC
perforated unit dose blisters placed into cardboard boxes containing 100 x 1
film-coated tablet. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.6 Special precautions for disposal
</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=FR>7. MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR-BE>UCB Pharma SA </span></p>

<p class=MsoNormal><span lang=FR-BE>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=DE>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>8. MARKETING AUTHORISATION
NUMBER(S)</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/006</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/007</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/008</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/009</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/010</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/00/146/011</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/00/146/012</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/00/146/013</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/00/146/035</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>9. DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Date of first<span lang=EN-GB> authorisation</span>: 29 September
2000</p>

<p class=MsoNormal>Date of latest renewal: 20 August 2015</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>10. DATE OF REVISION OF THE TEXT</span></b></p>

<p class=Default style='line-height:13.0pt;page-break-after:avoid;text-autospace:
ideograph-numeric ideograph-other'><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency http://www.ema.europa.eu </span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 750&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains
750&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipient with known effect</span></u><span
lang=EN-GB>: </span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains
0.19&nbsp;mg of sunset yellow FCF (E110).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see
section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>3. PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Film-coated tablet.</span></p>

<p class=MsoNormal><span lang=EN-GB>Orange, 18 mm oblong, scored and debossed
with the code ucb and 750 on one side.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The score line
is only to facilitate breaking for ease of swallowing and not to divide into
equal doses. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4. CLINICAL PARTICULARS</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra is indicated as monotherapy in the
treatment of partial onset seizures with or without secondary generalisation in
adults and adolescents from 16 years of age with newly diagnosed epilepsy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra is indicated as adjunctive therapy</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the treatment of partial onset seizures with
or without secondary generalisation in adults, adolescents, children and
infants from 1 month of age with epilepsy.</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the treatment of </span>myoclonic seizures in
adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.</p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the treatment of primary generalised
tonic-clonic seizures in adults and adolescents from 12 years of age with
Idiopathic Generalised Epilepsy.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.2 Posology and method of administration</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Partial onset seizures</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dosing for monotherapy
(from 16 years of age) and adjunctive therapy is the same; as outlined below.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>All indications</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Adults (&#8805;18 years) and adolescents
(12 to 17 years) weighing 50 kg or more</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The initial therapeutic dose is 500&nbsp;mg
twice daily. This dose can be started on the first day of treatment. <span
style='color:black'>However, a lower initial dose of 250</span>&nbsp;<span
style='color:black'>mg twice daily may be given based on physician assessment
of seizure reduction versus potential side effects. This can be increased to
500</span>&nbsp;<span style='color:black'>mg twice daily after two weeks.</span></span></p>

<p class=MsoNormal><span lang=EN-GB>Depending upon the clinical response and
tolerability, the daily dose can be increased up to 1,500&nbsp;mg twice daily.
Dose changes can be made in 250 mg or 500&nbsp;mg twice daily increases or decreases
every two to four weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adolescents (12 to 17 years) weighing
below 50 kg and children from 1 month of age</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The physician should prescribe the most
appropriate pharmaceutical form, presentation and strength according to weight,
age and dose. Refer to <i>Paediatric population</i> section for dosing
adjustments based on weight.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Discontinuation</span></u></p>

<p class=MsoNormal><span lang=EN-GB>If levetiracetam has to be discontinued it
is recommended to withdraw it gradually (<i>e.g</i>. in adults and adolescents
weighing more than 50&nbsp;kg: 500&nbsp;mg decreases twice daily every two to
four weeks; in infants older than 6 months, children and adolescents weighing
less than 50&nbsp;kg: dose decrease should not exceed 10&nbsp;mg/kg twice daily
every two weeks; in infants (less than 6 months): dose decrease should not exceed
7&nbsp;mg/kg twice daily every two weeks). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly
(65 years and older)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Adjustment of the dose is recommended in
elderly patients with compromised renal function (see Renal impairment
below).</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i><span lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The daily dose must be individualised
according to renal function. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For adult patients, refer to the following
table and adjust the dose as indicated. To use this dosing table, an estimate
of the patient's creatinine clearance (CL<sub>cr</sub>) in ml/min is needed.
The CL<sub>cr</sub> in ml/min may be estimated from serum creatinine (mg/dl)
determination, for adults and adolescents weighing 50 kg or more, the following
formula:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB> [140-age
(years)] x weight (kg)</span></p>

<p class=MsoNormal><span lang=EN-GB>CL<sub>cr</sub> </span>(ml/min)<span
lang=EN-GB> = ----------------------------------------- (x 0.85 for women)</span></p>

<p class=MsoNormal><span lang=EN-GB> 72 x serum creatinine
(mg/dl)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Then <span lang=EN-GB>CL<sub>cr</sub></span> is adjusted for
body surface area (BSA) as follows:</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>  <span
lang=DE>CL<sub>cr</sub> (ml/min)</span></p>

<p class=MsoNormal><span lang=DE>CL<sub>cr</sub> (ml/min/1.73 m<sup>2</sup>)
= ---------------------------- x 1.73 </span></p>

<p class=MsoNormal><span lang=DE> 
</span><span lang=FR-BE>BSA subject (m<sup>2</sup>)</span></p>

<p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Dosing adjustment for adult and adolescent
patients weighing more than 50&nbsp;kg with impaired renal function:</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Group</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Creatinine clearance (ml/min</span>/1.73m<sup>2</sup><span
  lang=EN-GB>)</span></p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Dose and frequency</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Normal</span></p>
  <p class=MsoNormal><span lang=EN-GB>Mild</span></p>
  <p class=MsoNormal><span lang=EN-GB>Moderate</span></p>
  <p class=MsoNormal><span lang=EN-GB>Severe</span></p>
  <p class=MsoNormal><span lang=EN-GB>End-stage renal disease patients</span></p>
  <p class=MsoNormal><span lang=EN-GB>undergoing dialysis <sup>(1)</sup></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;</span><span lang=EN-GB>&nbsp;80</span></p>
  <p class=MsoNormal><span lang=EN-GB>50-79</span></p>
  <p class=MsoNormal><span lang=EN-GB>30-49</span></p>
  <p class=MsoNormal><span lang=EN-GB>&lt;&nbsp;30</span></p>
  <p class=MsoNormal><span lang=EN-GB>-</span></p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>500 to 1,500&nbsp;mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>500 to 1,000 mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>250 to 750&nbsp;mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>250 to 500&nbsp;mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>500 to 1,000&nbsp;mg once daily <sup>(2)</sup></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><sup><span lang=EN-GB>(1)</span></sup><span lang=EN-GB> A
750&nbsp;mg loading dose is recommended on the first day of treatment with
levetiracetam.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(2)</span></sup><span lang=EN-GB>
Following dialysis, a 250 to 500&nbsp;mg supplemental dose is recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For children with renal impairment,
levetiracetam dose needs to be adjusted based on the renal function as
levetiracetam clearance is related to renal function. This recommendation is
based on a study in adult renally impaired patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The CL<sub>cr</sub> in ml/min/1.73 m<sup>2</sup>
may be estimated from serum creatinine (mg/dl) determination, for young
adolescents, children and infants, using the following formula (Schwartz
formula): </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'> 
Height (cm) x<span lang=EN-GB> ks</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>CL<sub>cr</sub></span>
(ml/min/1.73 m<sup>2</sup>) = ------------------------------------</p>

<p class=MsoNormal style='page-break-after:avoid'> 
Serum Creatinine (mg/dl)</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>ks= 0.45 in Term infants to 1 year old; ks=
0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in
adolescent male</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Dosing
adjustment for infants, children and adolescent patients weighing less than 50
kg with impaired renal function:</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=621
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=130 rowspan=2 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Group</span></p>
  </td>
  <td width=113 rowspan=2 valign=top style='width:85.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Creatinine
  clearance (ml/min</span>/1.73m<sup>2</sup><span lang=EN-GB>)</span></p>
  </td>
  <td width=378 colspan=2 valign=top style='width:283.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Dose and frequency <sup>(1)</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Infants 1 to less than 6 months</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Infants 6 to 23 months, children and adolescents weighing
  less than 50 kg </p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Normal</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;</span><span lang=EN-GB>&nbsp;80</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>7 to 21&nbsp;mg/kg (0.07 to
  0.21&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>10 to 30&nbsp;mg/kg (0.10 to
  0.30&nbsp;ml/kg) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Mild</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>50-79</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>7 to 14&nbsp;mg/kg (0.07 to
  0.14&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>10 to 20&nbsp;mg/kg (0.10 to
  0.20&nbsp;ml/kg) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Moderate</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>30-49</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>3.5 to 10.5&nbsp;mg/kg (0.035 to
  0.105&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>5 to 15&nbsp;mg/kg (0.05 to
  0.15&nbsp;ml/kg) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Severe</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&lt;&nbsp;30</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>3.5 to 7&nbsp;mg/kg (0.035 to
  0.07&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>5 to 10&nbsp;mg/kg (0.05 to
  0.10&nbsp;ml/kg) twice daily </span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>End-stage renal disease patients</span></p>
  <p class=MsoNormal><span lang=EN-GB>undergoing dialysis </span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>--</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>7 to 14&nbsp;mg/kg (0.07 to 0.14&nbsp;ml/kg)
  once daily <sup>(2) (4)</sup></span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>10 to 20&nbsp;mg/kg (0.10 to
  0.20&nbsp;ml/kg) once daily <sup>(3) (5)</sup></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB>(1)</span></sup><span
lang=EN-GB> Keppra oral solution should be used for doses under 250 mg, for
doses not multiple of 250 mg when dosing recommendation is not achievable by
taking multiple tablets and for patients unable to swallow tablets. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB>(2)</span></sup><span
lang=EN-GB> A 10.5&nbsp;mg/kg (0.105&nbsp;ml/kg) loading dose is recommended on
the first day of treatment with levetiracetam.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(3)</span></sup><span lang=EN-GB> A
15&nbsp;mg/kg (0.15&nbsp;ml/kg) loading dose is recommended on the first day of
treatment with levetiracetam.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(4)</span></sup><span lang=EN-GB>
Following dialysis, a 3.5 to 7&nbsp;mg/kg (0.035 to 0.07&nbsp;ml/kg)
supplemental dose is recommended.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(5)</span></sup><span lang=EN-GB>
Following dialysis, a 5 to 10&nbsp;mg/kg (0.05 to 0.10&nbsp;ml/kg) supplemental
dose is recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Hepatic impairment </span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No dose adjustment is needed in patients
with mild to moderate hepatic impairment. In patients with severe hepatic
impairment, the creatinine clearance may underestimate the renal insufficiency.
Therefore a 50&nbsp;% reduction of the daily maintenance dose is recommended
when the creatinine clearance is &lt;&nbsp;60&nbsp;ml/min/1.73 m<sup>2</sup>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The physician should prescribe the most appropriate pharmaceutical
form, presentation and strength according to age, weight and dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The tablet formulation is not adapted for
use in infants and children under the age of 6 years. Keppra oral solution is
the preferred formulation for use in this population. In addition, the
available dose strengths of the tablets are not appropriate for initial
treatment in children weighing less than 25 kg, for patients unable to swallow
tablets or for the administration of doses below 250 mg. In all of the above
cases Keppra oral solution should be used.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Monotherapy</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The safety
and efficacy of Keppra in children and adolescents below 16 years as
monotherapy treatment have not been established.</span></p>

<p class=MsoNormal style='page-break-after:avoid'>No data are available.</p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i>Adolescents (16 and 17 years of age) weighing 50 kg or
more with partial onset seizures with or without secondary generalisation with
newly diagnosed epilepsy</i></p>

<p class=MsoNormal>Please refer to the above section on <i>Adults (&#8805;18 years)
and adolescents (12 to 17 years) weighing 50 kg or more</i>. </p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Add-on
therapy for infants aged 6 to 23 months, children (2 to 11 years) and
adolescents (12 to 17 years) weighing less than 50 kg</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Keppra oral
solution is the preferred formulation for use in infants and children under the
age of 6 years. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For children
6 years and above, Keppra oral solution should be used for doses under 250 mg,
for doses not multiple of 250 mg when dosing recommendation is not achievable
by taking multiple tablets and for patients unable to swallow tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>The lowest effective dose should be used
for all indications. The starting dose for a child or adolescent of 25kg should
be 250mg twice daily with a maximum dose of 750mg twice daily. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Dose in children 50&nbsp;kg or greater is
the same as in adults for all indications.</span></p>

<p class=MsoNormal>Please refer to the above section on <i>Adults (&#8805;18
years) and adolescents (12 to 17 years) weighing 50 kg or more </i>for all
indications.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Add-on therapy for infants aged from 1
month to less than 6 months</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The oral solution is the formulation to use in infants.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The film-coated tablets must be taken
orally, swallowed with a sufficient quantity of liquid and may be taken with or
without food. </span><span lang=EN-GB>After oral administration the bitter
taste of levetiracetam may be experienced. </span><span lang=EN-GB>The daily
dose is administered in two equally divided doses.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to the active substance or
other pyrrolidone derivatives or to any of the excipients</span><span
lang=EN-GB> listed in section 6.1</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.4 Special warnings and precautions
for use</span></b></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Renal impairment</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The administration of levetiracetam to
patients with renal impairment may require dose adjustment. In patients with
severely impaired hepatic function, assessment of renal function is recommended
before dose selection (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Acute Kidney injury</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The use of levetiracetam has been very
rarely associated with acute kidney injury, with a time to onset ranging from a
few days to several months.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Blood cell counts</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rare cases of decreased blood cell counts
(neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia)
have been described in association with levetiracetam administration, generally
at the beginning of the treatment. Complete blood cell counts are advised in
patients experiencing important weakness, pyrexia, recurrent infections or
coagulation disorders (section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u>Suicide</u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Suicide,
suicide attempt, <span lang=EN-GB>suicidal ideation and behaviour have been
reported in patients treated with anti-epileptic agents (including
levetiracetam). A meta-analysis of randomized placebo-controlled trials of
anti-epileptic medicinal products has shown a small increased risk of suicidal
thoughts and behaviour. The mechanism of this risk is not known. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Therefore, patients should be monitored for
signs of depression and/or suicidal ideation and behaviours and appropriate
treatment should be considered. Patients (and caregivers of patients) should be
advised to seek medical advice should signs of depression and/or suicidal
ideation or behaviour emerge.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Abnormal and aggressive behaviours </span></u></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam may cause psychotic symptoms
and behavioural abnormalities including irritability and aggressiveness.
Patients treated with levetiracetam should be monitored for developing
psychiatric signs suggesting important mood and/or personality changes. If such
behaviours are noticed, treatment adaptation or gradual discontinuation should
be considered. If discontinuation is considered, please refer to section 4.2.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u>Worsening of seizures</u></p>

<p class=MsoNormal>As with other types of antiepileptic drugs, levetiracetam
may rarely exacerbate seizure frequency or severity. This paradoxical effect
was mostly reported within the first month after levetiracetam initiation or
increase of the dose, and was reversible upon drug discontinuation or dose decrease.
Patients should be advised to consult their physician immediately in case of
aggravation of epilepsy.</p>

<p class=MsoNormal><u><span style='font-size:12.0pt'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Electrocardiogram QT interval
prolongation</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rare cases of ECG QT interval prolongation
have been observed during the post-marketing surveillance. Levetiracetam should
be used with caution in patients with QTc-interval prolongation, in patients
concomitantly treated with drugs affecting the QTc-interval, or in patients
with relevant pre-existing cardiac disease or electrolyte disturbances.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The tablet formulation is not adapted for
use in infants and children under the age of 6 years. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Available data in children did not suggest
impact on growth and puberty. However, long term effects on learning,
intelligence, growth, endocrine function, puberty and childbearing potential in
children remain unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipients</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 750 mg film-coated tablets contain
E110 colouring agent which may cause allergic reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.5 Interaction with other medicinal
products and other forms of interaction</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Antiepileptic medicinal products</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Pre-marketing data from clinical studies
conducted in adults indicate that levetiracetam did not influence the serum
concentrations of existing antiepileptic medicinal products (phenytoin,
carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and
primidone) and that these antiepileptic medicinal products did not influence
the pharmacokinetics of levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-AU style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>As in adults,
there is no evidence of clinically significant medicinal product interactions
in paediatric patients receiving up to 60</span><span lang=EN-GB>&nbsp;<span
style='layout-grid-mode:line'>mg/kg/day levetiracetam.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>A
retrospective assessment of pharmacokinetic interactions in children and
adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy
with orally administered levetiracetam did not influence the steady-state serum
concentrations of concomitantly administered carbamazepine and valproate.
However, data suggested </span><span lang=EN-GB>a 20</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% higher levetiracetam clearance in children taking</span><span
lang=EN-GB style='layout-grid-mode:line'> enzyme-inducing antiepileptic
medicinal products. Dose adjustment is not required. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Probenecid</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Probenecid (500&nbsp;mg four times daily),
a renal tubular secretion blocking agent, has been shown to inhibit the renal
clearance of the primary metabolite, but not of levetiracetam. Nevertheless,
the concentration of this metabolite remains low. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Methotrexate</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Concomitant administration of levetiracetam
and methotrexate has been reported to decrease methotrexate clearance,
resulting in increased/prolonged blood methotrexate concentration to
potentially toxic levels. Blood methotrexate and levetiracetam levels should be
carefully monitored in patients treated concomitantly with the two drugs.</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-AU style='layout-grid-mode:line'>Oral
contraceptives and other pharmacokinetics interactions</span></u></p>

<p class=MsoNormal><span lang=EN-AU style='layout-grid-mode:line'>Levetiracetam
1,000&nbsp;mg daily did not influence the pharmacokinetics of oral
contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters
(luteinizing hormone and progesterone) were not modified. Levetiracetam
2,000&nbsp;mg daily did not influence the pharmacokinetics of digoxin and
warfarin; prothrombin times were not modified. Co-administration with digoxin,
oral contraceptives and warfarin did not influence the pharmacokinetics of
levetiracetam.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Laxatives</u></p>

<p class=MsoNormal><span lang=EN-GB>There have been isolated reports of
decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly
administered with oral levetiracetam. Therefore, macrogol should not be taken
orally for one hour before and for one hour after taking levetiracetam.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Food and alcohol</u></p>

<p class=MsoNormal style='page-break-after:avoid'>The extent of absorption of
levetiracetam was not altered by food, but the rate of absorption was slightly
reduced.</p>

<p class=MsoNormal style='page-break-after:avoid'>No data on the interaction of
levetiracetam with alcohol are available.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.6 Fertility,
pregnancy and lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Women of
child bearing potential </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Specialist
advice should be given to women who are of childbearing potential. Treatment
with levetiracetam should be reviewed when a woman is planning to become
pregnant. As with all antiepileptic medicines, sudden discontinuation of
levetiracetam should be avoided as this may lead to breakthrough seizures that
could have serious consequences for the woman and the unborn child. Monotherapy
should be preferred whenever possible because therapy with multiple
antiepileptic medicines AEDs could be associated with a higher risk of
congenital malformations than monotherapy, depending on the associated
antiepileptics.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><span lang=EN-GB>A large amount of postmarketing data on
pregnant women exposed to levetiracetam monotherapy (more than 1800, among
which in more than 1500 exposure occurred during the 1<sup>st</sup> trimester)
do not suggest an increase in the risk for major congenital malformations. Only
limited evidence is available on the neurodevelopment of children exposed to
Keppra monotherapy in utero. However, current epidemiological studies (on about
100 children) do not suggest an increased risk of neurodevelopmental disorders
or delays. </span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam can be used during pregnancy,
if after careful assessment it is considered clinically needed. In such case,
the lowest effective dose is recommended.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Physiological
changes during pregnancy may affect levetiracetam concentration. D</span>ecrease
in levetiracetam plasma concentrations has been observed during pregnancy. This
decrease is more pronounced during the third trimester (up to 60% of baseline
concentration before pregnancy). Appropriate clinical management of pregnant
women treated with levetiracetam should be ensured. </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Breastfeeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam is excreted in human breast
milk. Therefore, breast-feeding is not recommended. </span></p>

<p class=MsoNormal style='line-height:normal'>However, if levetiracetam
treatment is needed during breastfeeding, the benefit/risk of the treatment
should be weighed considering the importance of breastfeeding.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><u>Fertility</u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No impact on
fertility was detected in animal studies (see section 5.3). No clinical data
are available, potential risk for human is unknown.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b><span lang=EN-GB>4.7 Effects on ability to drive and
use machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam has minor or moderate
influence on the ability to drive and use machines.</span><span lang=EN-GB> Due
to possible different individual sensitivity, some patients might experience
somnolence or other central nervous system related symptoms, </span><span
lang=EN-GB>especially</span><span lang=EN-GB> </span><span lang=EN-GB>at the
beginning of treatment or following a dose increase. Therefore, caution is
recommended in those patients when performing skilled tasks, <i>e.g</i>.
driving vehicles or operating machinery. Patients are advised not to drive or use
machines until it is established that </span><span lang=EN-GB>their</span><span
lang=EN-GB> ability to perform such activities is not affected.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Summary of the safety profile</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The most frequently reported adverse
reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness.
The adverse reaction profile presented below is based on the analysis of pooled
placebo-controlled clinical trials with all indications studied, with a total
of 3,416 patients treated with levetiracetam. These data are supplemented with
the use of levetiracetam in corresponding open-label extension studies, as well
as post-marketing experience. The safety profile of levetiracetam is generally
similar across age groups (adult and paediatric patients) and across the
approved epilepsy indications. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Tabulated list of adverse
reactions</u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Adverse
reactions reported in clinical studies (adults, adolescents, children and
infants &gt; 1&nbsp;month) and from post-marketing experience are listed in the
following table per System Organ Class and per frequency. Adverse reactions are
presented in the order of decreasing seriousness and their frequency is defined
as follows: very common (&#8805;1/10); common (&#8805;1/100 to &lt;1/10);
uncommon (&#8805;1/1,000 to &lt;1/100); rare (&#8805;1/10,000 to &lt;1/1,000) and
very rare (&lt;1/10,000).</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="97%"
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="20%" rowspan=2 style='width:20.34%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>MedDRA SOC</span></u></p>
   </td>
   <td width="79%" colspan=4 valign=top style='width:79.66%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center'><u><span
   lang=EN-GB style='font-size:10.0pt'>Frequency category</span></u></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width="20%" valign=top style='width:20.3%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Very common</span></u></p>
   </td>
   <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Common</span></u></p>
   </td>
   <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Uncommon </span></u></p>
   </td>
   <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Rare</span></u></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Infections
  and infestations</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Nasopharyngitis </span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Infection</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Blood and
  lymphatic system disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>Thrombocytopenia,
  leukopenia</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>Pancytopenia,<sup>
  </sup>neutropenia, agranulocytosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Immune system
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>Drug reaction
  with eosinophilia and systemic symptoms (DRESS),</span></p>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>Hypersensitivity
  (including angioedema and anaphylaxis)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Metabolism
  and nutrition disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Anorexia</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Weight
  decreased, weight increase</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Hyponatraemia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Psychiatric
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Depression,
  hostility/ aggression, anxiety, <br>
  insomnia, nervousness/irritability</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Suicide attempt,
  suicidal ideation</span><span lang=EN-AU style='font-size:10.0pt'>,<sup> </sup></span><span
  lang=EN-GB style='font-size:10.0pt'>psychotic disorder</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>abnormal behaviour, hallucination</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>anger, confusional state, panic attack, affect
  lability/mood swings, agitation</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Completed
  suicide</span><span lang=EN-AU style='font-size:10.0pt'>, </span><span
  lang=EN-GB style='font-size:10.0pt'>personality disorder, thinking abnormal,
  delirium</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Nervous
  system disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Somnolence,
  headache</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Convulsion,
  balance disorder, dizziness, lethargy, tremor</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Amnesia, memory
  impairment, coordination abnormal/ataxia, paraesthesia</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>disturbance in attention</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Choreoathetosis,
  dyskinesia, hyperkinesia, gait disturbance, encephalopathy, seizures
  aggravated</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Eye disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Diplopia, vision
  blurred</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Ear and
  labyrinth disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Vertigo</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Cardiac
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>Electrocardiogram
  QT prolonged</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Respiratory,
  thoracic and mediastinal disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Cough</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Gastrointestinal
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT style='font-size:10.0pt'>Abdominal pain,
  diarrhoea, dyspepsia, vomiting, nausea</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Pancreatitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-AU style='font-size:10.0pt'>Hepatobiliary
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Liver function
  test abnormal</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Hepatic failure,
  hepatitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Renal and
  Urinary Disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Acute Kidney
  injury</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Skin and
  subcutaneous tissue disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Rash</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Alopecia</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>eczema, pruritus, </span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Toxic epidermal
  necrolysis, Stevens-Johnson syndrome, erythema multiforme</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Musculoskeletal
  and connective tissue disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Muscular
  weakness, myalgia</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Rhabdomyolysis
  and blood creatine phosphokinase increased*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>General
  disorders and administration site conditions</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Asthenia/fatigue</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Injury,
  poisoning and procedural complications</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Injury</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>* Prevalence is significantly higher in
Japanese patients when compared to non-Japanese patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Description of selected adverse
reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU>The risk of
anorexia is higher when levetiracetam is coadministered with topiramate.</span></p>

<p class=MsoNormal><span lang=EN-AU>In several cases of alopecia, recovery was
observed when levetiracetam was discontinued.</span></p>

<p class=MsoNormal><span style='font-family:"TimesNewRomanPSMT",serif'>Bone
marrow suppression was identified in some of the cases of pancytopenia.</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cases of encephalopathy generally occurred
at the beginning of the treatment (few days to a few months) and were
reversible after treatment discontinuation.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In patients
aged 1 month to less than 4 years, a total of 190 patients have been treated
with levetiracetam in placebo-controlled and open label extension studies.
Sixty of these patients were treated with levetiracetam in placebo-controlled
studies. In patients aged 4-16 years, a total of 645 patients have been
treated with levetiracetam in placebo-controlled and open label extension
studies. 233 of these patients were treated with levetiracetam in
placebo-controlled studies. In both these paediatric age ranges, these data are
supplemented with the post-marketing experience of the use of levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In addition, 101 infants aged less than 12
months have been exposed in a post authorization safety study. No new safety
concerns for levetiracetam were identified for infants less than 12 months of
age with epilepsy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The adverse reaction profile of
levetiracetam is generally similar across age groups and across the approved
epilepsy indications. Safety results in paediatric patients in
placebo-controlled clinical studies were consistent with the safety profile of
levetiracetam in adults except for behavioural and psychiatric adverse
reactions which were more common in children than in adults. In children and
adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation
(common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%),
aggression (common, 8.2%), abnormal behaviour (common, 5.6%), and lethargy
(common, 3.9%) were reported more frequently than in other age ranges or in the
overall safety profile. In infants and children aged 1 month to less than 4
years, irritability (very common, 11.7%) and coordination abnormal (common,
3.3%) were reported more frequently than in other age groups or in the overall
safety profile. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>A double-blind,
placebo-controlled paediatric safety study with a non-inferiority design has
assessed the cognitive and neuropsychological effects of </span><span
lang=EN-GB>levetiracetam</span><span lang=EN-GB> in children 4 to 16 years of
age with partial onset seizures. It was concluded that Keppra was not different
(non inferior) from placebo with regard to the change from baseline of the
Leiter-R Attention and Memory, Memory Screen Composite score in the
per-protocol population. Results related to behavioural and emotional
functioning indicated a worsening in </span><span lang=EN-GB>levetiracetam</span><span
lang=EN-GB> treated patients on aggressive behaviour as measured in a
standardised and systematic way using a validated instrument (CBCL  Achenbach
Child Behavior Checklist). However, subjects, who took </span><span lang=EN-GB>levetiracetam</span><span
lang=EN-GB> in the long-term open label follow-up study, did not experience a
worsening, on average, in their behavioural and emotional functioning; in
particular measures of aggressive behaviour were not worse than baseline.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Reporting of
suspected adverse reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:silver'>the national reporting
system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a></span>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Symptoms</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Somnolence, agitation, aggression,
depressed level of consciousness, respiratory depression and coma were observed
with Keppra overdoses.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Management of overdose</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>After an acute overdose, the stomach may be
emptied by gastric lavage or by induction of emesis. There is no specific
antidote for levetiracetam. Treatment of an overdose will be symptomatic and
may include haemodialysis. The dialyser extraction efficiency is 60&nbsp;% for
levetiracetam and 74&nbsp;% for the primary metabolite.</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='text-transform:uppercase'>5. </span><span lang=EN-GB>PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.1 Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic group: antiepileptics,
other antiepileptics, ATC code: N03AX14. </span></p>

<p class=MsoNormal><span lang=EN-GB>The active substance, levetiracetam, is a
pyrrolidone derivative (S-enantiomer of </span><span lang=EN-GB
style='font-family:Symbol'>a</span><span lang=EN-GB>-ethyl-2-oxo-1-pyrrolidine
acetamide), chemically unrelated to existing antiepileptic active substances.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Mechanism of action</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The mechanism of action of levetiracetam
still remains to be fully elucidated. <i>In vitro</i> and <i>in vivo</i>
experiments suggest that levetiracetam does not alter basic cell
characteristics and normal neurotransmission. </span></p>

<p class=MsoNormal><i><span lang=EN-GB>In vitro</span></i><span lang=EN-GB>
studies show that levetiracetam affects intraneuronal Ca<sup>2+</sup> levels by
partial inhibition of N-type Ca<sup>2+</sup> currents and by reducing the
release of Ca<sup>2+</sup> from intraneuronal stores. In addition, it partially
reverses the reductions in GABA- and glycine-gated currents induced by zinc and
</span><span lang=EN-GB style='font-family:Symbol'>b</span><span lang=EN-GB>-carbolines.
Furthermore, levetiracetam has been shown in <i>in vitro</i> studies to bind to
a specific site in rodent brain tissue. This binding site is the synaptic
vesicle protein 2A, believed to be involved in vesicle fusion and
neurotransmitter exocytosis. Levetiracetam and related analogs show a rank order
of affinity for binding to the synaptic vesicle protein 2A which correlates
with the potency of their anti-seizure protection in the mouse audiogenic model
of epilepsy. This finding suggests that the interaction between levetiracetam
and the synaptic vesicle protein 2A seems to contribute to the antiepileptic
mechanism of action of the medicinal product.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Pharmacodynamic effects</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam induces seizure protection in
a broad range of animal models of partial and primary generalised seizures
without having a pro-convulsant effect. The primary metabolite is inactive.</span></p>

<p class=MsoNormal><span lang=EN-GB>In man, an activity in both partial and
generalised epilepsy conditions (epileptiform discharge/photoparoxysmal
response) has confirmed the broad spectrum pharmacological profile of levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adjunctive therapy in the treatment of
partial onset seizures with or without secondary generalisation in adults,
adolescents, children and infants from 1 month of age with epilepsy.</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In adults, levetiracetam efficacy has been
demonstrated in 3 double-blind, placebo-controlled studies at 1000</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg, 2000</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>mg, or 3000</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg/day,
given in 2 divided doses, with a treatment duration of up to 18</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>weeks. In a pooled analysis, the
percentage of patients who achieved 50</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% or greater reduction from baseline in the partial onset seizure
frequency per week at stable dose (12/14</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>weeks) was of 27.7</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>%, 31.6</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>% and
41.3</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>% for patients on
1000, 2000 or 3000</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg
levetiracetam respectively and of 12.6</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% for patients on placebo. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Paediatric population</u></p>

<p class=MsoNormal style='page-break-after:avoid'><b>&nbsp;</b></p>

<p class=MsoNormal style='page-break-after:avoid'>In paediatric patients (4 to
16 years of age), levetiracetam efficacy was established in a double-blind,
placebo-controlled study, which included 198 patients and had a treatment
duration of 14 weeks. In this study, the patients received levetiracetam as a
fixed dose of 60<span lang=EN-GB>&nbsp;</span>mg/kg/day (with twice a day
dosing).</p>

<p class=MsoNormal><span lang=EN-GB>44.6</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% of the levetiracetam treated patients and 19.6</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% of the patients on placebo had a 50</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% or greater reduction from baseline
in the partial onset seizure frequency per week.</span><span lang=EN-GB> </span><span
lang=EN-GB>With continued long-term treatment, 11.4</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% of the patients were seizure-free for at least 6 months and 7.2</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% were seizure-free for at least 1
year.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>In<span lang=EN-GB> paediatric</span> patients (1 month to
less than 4 years of age), levetiracetam efficacy was established in a
double-blind, placebo-controlled study, which included 116 patients and had a
treatment duration of 5<span lang=EN-GB>&nbsp;</span>days. In this study,
patients were prescribed 20<span lang=EN-GB>&nbsp;</span>mg/kg, 25<span
lang=EN-GB>&nbsp;</span>mg/kg, 40<span lang=EN-GB>&nbsp;</span>mg/kg or 50<span
lang=EN-GB>&nbsp;</span>mg/kg daily dose of oral solution based on their age
titration schedule. A dose of 20<span lang=EN-GB>&nbsp;</span>mg/kg/day
titrating to 40<span lang=EN-GB>&nbsp;</span>mg/kg/day for infants one month to
less than six months and a dose of 25<span lang=EN-GB>&nbsp;</span>mg/kg/day
titrating to 50<span lang=EN-GB>&nbsp;</span>mg/kg/day for infants and children
6 months to less than 4 years old, was use in this study. The total daily dose
was administered twice daily.</p>

<p class=MsoNormal><span lang=EN-GB>The primary measure of effectiveness was
the responder rate (percent of patients with &#8805; 50&nbsp;% reduction from
baseline in average daily partial onset seizure frequency) assessed by a
blinded central reader using a 48-hour video EEG.&nbsp; The efficacy analysis
consisted of 109 patients who had at least 24&nbsp;hours of video EEG in both
baseline and evaluation periods. <span class=msoins0>43.6</span>&nbsp;<span
class=msoins0>% of the levetiracetam treated patients and 19.6</span>&nbsp;<span
class=msoins0>% of the patients on placebo were considered as
responders.&nbsp;The results are consistent across age group.</span></span><span
lang=EN-GB> With continued long-term treatment, 8.6</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% of the patients were seizure-free for at least 6</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>months and 7.8</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% were seizure-free for at least 1</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>year.</span></p>

<p class=MsoNormal><span lang=EN-GB>35 infants aged less than 1 year with
partial onset seizures have been exposed in placebo-control clinical studies of
which only 13 were aged &lt; 6 months.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Monotherapy
in the treatment of partial onset seizures with or without secondary
generalisation in patients from 16 years of age with newly diagnosed epilepsy. </span></i></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>Efficacy of levetiracetam as monotherapy
was established in a double-blind, parallel group, non-inferiority comparison
to carbamazepine-controlled release (CR) in 576 patients 16 years of age or
older with newly or recently diagnosed epilepsy. The patients had to present
with unprovoked partial seizures or with generalized tonic-clonic seizures
only. The patients were randomized to carbamazepine CR 400  1200<span
lang=EN-GB>&nbsp;</span>mg/day or levetiracetam 1000  3000<span lang=EN-GB>&nbsp;</span>mg/day,
the duration of the treatment was up to 121 weeks depending on the response. </p>

<p class=MsoNormal style='page-break-after:avoid'>Six-month seizure freedom was
achieved in 73.0<span lang=EN-GB>&nbsp;</span>% of levetiracetam-treated
patients and 72.8<span lang=EN-GB>&nbsp;</span>% of carbamazepine-CR treated
patients; the adjusted absolute difference between treatments was 0.2<span
lang=EN-GB>&nbsp;</span>% (95<span lang=EN-GB>&nbsp;</span>% CI: -7.8 8.2).
More than half of the subjects remained seizure free for 12 months (56.6<span
lang=EN-GB>&nbsp;</span>% and 58.5<span lang=EN-GB>&nbsp;</span>% of subjects
on levetiracetam and on carbamazepine CR respectively).</p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>In a study
reflecting clinical practice, the concomitant antiepileptic medication could be
withdrawn in a limited number of patients who responded to levetiracetam
adjunctive therapy (36 adult patients out of 69). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adjunctive therapy in the treatment of
myoclonic seizures in adults and adolescents from 12 years of age with Juvenile
Myoclonic Epilepsy.</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Levetiracetam efficacy was established in a double-blind,
placebo-controlled study of 16 weeks duration, in patients 12 years of age and
older suffering from idiopathic generalized epilepsy with myoclonic seizures in
different syndromes. The majority of patients presented with juvenile myoclonic
epilepsy.</p>

<p class=MsoNormal>In this study, levetiracetam, dose was 3000<span lang=EN-GB>&nbsp;</span>mg/day
given in 2 divided doses. </p>

<p class=MsoNormal>58.3<span lang=EN-GB>&nbsp;</span>% of the levetiracetam
treated patients and 23.3<span lang=EN-GB>&nbsp;</span>% of the patients on
placebo had at least a 50<span lang=EN-GB>&nbsp;</span>% reduction in myoclonic
seizure days per week. With continued long-term treatment, 28.6<span
lang=EN-GB>&nbsp;</span>% of the patients were free of myoclonic seizures for
at least 6 months and 21.0<span lang=EN-GB>&nbsp;</span>% were free of
myoclonic seizures for at least 1 year.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adjunctive therapy in the treatment of
primary generalised tonic-clonic seizures in adults and adolescents from 12
years of age with idiopathic generalised epilepsy.</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Levetiracetam efficacy was established in a 24-week
double-blind, placebo-controlled study, which included adults, adolescents and
a limited number of children suffering from idiopathic generalized epilepsy
with primary generalized tonic-clonic (PGTC) seizures in different syndromes
(juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence
epilepsy, or epilepsy with Grand Mal seizures on awakening). In this study,
levetiracetam dose was 3000<span lang=EN-GB>&nbsp;</span>mg/day for adults and
adolescents or 60<span lang=EN-GB>&nbsp;</span>mg/kg/day for children, given in
2 divided doses.</p>

<p class=MsoNormal>72.2<span lang=EN-GB>&nbsp;</span>% of the levetiracetam
treated patients and 45.2<span lang=EN-GB>&nbsp;</span>% of the patients on
placebo had a 50<span lang=EN-GB>&nbsp;</span>% or greater decrease in the
frequency of PGTC seizures per week. With continued long-term treatment, 47.4<span
lang=EN-GB>&nbsp;</span>% of the patients were free of tonic-clonic seizures
for at least 6 months and 31.5<span lang=EN-GB>&nbsp;</span>% were free of
tonic-clonic seizures for at least 1 year.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>5.2 Pharmacokinetic properties</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam is a highly soluble and
permeable compound. The pharmacokinetic profile is linear with low intra- and
inter-subject variability. There is no modification of the clearance after
repeated administration. There is no evidence for any relevant gender, race or
circadian variability. The pharmacokinetic profile is comparable in healthy
volunteers and in patients with epilepsy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Due to its complete and linear absorption,
plasma levels can be predicted from the oral dose of levetiracetam expressed as
mg/kg bodyweight. Therefore, there is no need for plasma level monitoring of
levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A significant correlation between saliva
and plasma concentrations has been shown in adults and children (ratio of
saliva/plasma concentrations ranged from </span>1 to 1.7 for oral tablet
formulation and after 4 hours post-dose for oral solution formulation<span
lang=EN-GB>).</span></p>

<p class=MsoEndnoteText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoEndnoteText><u><span lang=EN-GB>Adults and adolescents</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam is rapidly absorbed after
oral administration. Oral absolute bioavailability is close to 100&nbsp;%. </span></p>

<p class=MsoNormal><span lang=EN-GB>Peak plasma concentrations (C<sub>max</sub>)
are achieved at 1.3&nbsp;hours after dosing. Steady-state is achieved after two
days of a twice daily administration schedule.</span></p>

<p class=MsoNormal><span lang=EN-GB>Peak concentrations (C<sub>max</sub>) are
typically 31 and 43&nbsp;g/ml following a single 1,000&nbsp;mg dose and
repeated 1,000&nbsp;mg twice daily dose, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>The extent of absorption is
dose-independent and is not altered by food.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No tissue distribution data are available
in humans.</span></p>

<p class=MsoNormal><span lang=EN-GB>Neither levetiracetam nor its primary
metabolite are significantly bound to plasma proteins (</span><span lang=EN-GB
style='font-family:Symbol'>&lt;</span><span lang=EN-GB>&nbsp;10&nbsp;%).</span></p>

<p class=MsoNormal><span lang=EN-GB>The volume of distribution of levetiracetam
is approximately 0.5 to 0.7&nbsp;l/kg, a value close to the total body water
volume.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Levetiracetam
is not extensively metabolised in humans. The major metabolic pathway
(24&nbsp;% of the dose) is an enzymatic hydrolysis of the acetamide group.
Production of the primary metabolite, ucb&nbsp;L057, is not supported by liver
cytochrome P<sub>450</sub> isoforms. Hydrolysis of the acetamide group was
measurable in a large number of tissues including blood cells. The metabolite
ucb&nbsp;L057 is pharmacologically inactive.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Two minor metabolites were also identified.
One was obtained by hydroxylation of the pyrrolidone ring (1.6&nbsp;% of the
dose) and the other one by opening of the pyrrolidone ring (0.9&nbsp;% of the
dose). </span></p>

<p class=MsoNormal><span lang=EN-GB>Other unidentified components accounted
only for 0.6&nbsp;% of the dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No enantiomeric interconversion was
evidenced <i>in vivo</i> for either levetiracetam or its primary metabolite.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i>In vitro</i><span lang=EN-GB>, levetiracetam and its
primary metabolite have been shown not to inhibit the major human liver
cytochrome P<sub>450</sub> isoforms (CYP3A4, 2A6, </span>2C9<span lang=EN-GB>,
2C19, 2D6, 2E1 and 1A2), glucuronyl transferase<span style='text-transform:
uppercase'> (</span></span><span style='text-transform:uppercase'>UGT1A1 </span>and<span
style='text-transform:uppercase'> UGT1A6</span><span lang=EN-GB
style='text-transform:uppercase'>)</span><span lang=EN-GB> and epoxide
hydroxylase activities. In addition, levetiracetam does not affect the <i>in
vitro</i> glucuronidation of valproic acid. </span></p>

<p class=MsoNormal><span lang=EN-GB>In human hepatocytes in culture,
levetiracetam </span>had little or no effect on CYP1A2, SULT1E1 or UGT1A1.
Levetiracetam caused mild induction of CYP2B6 and CYP3A4. The in vitro data and
<i>in vivo</i> interaction data on oral contraceptives, digoxin and warfarin
indicate that no significant enzyme induction is expected <i>in vivo</i><span
lang=EN-GB>. Therefore, the interaction of Keppra with other substances, or <i>vice
versa,</i> is unlikely.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The plasma half-life in adults was 7</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>1&nbsp;hours and
did not vary either with dose, route of administration or repeated administration.
The mean total body clearance was 0.96&nbsp;ml/min/kg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The major route of excretion was via urine,
accounting for a mean 95&nbsp;% of the dose (approximately 93&nbsp;% of the
dose was excreted within 48&nbsp;hours). Excretion <i>via</i> faeces accounted
for only 0.3&nbsp;% of the dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>The cumulative urinary excretion of
levetiracetam and its primary metabolite accounted for 66&nbsp;% and 24&nbsp;%
of the dose, respectively during the first 48&nbsp;hours.</span></p>

<p class=MsoNormal><span lang=EN-GB>The renal clearance of levetiracetam and
ucb&nbsp;L057 is 0.6 and 4.2&nbsp;ml/min/kg respectively indicating that
levetiracetam is excreted by glomerular filtration with subsequent tubular
reabsorption and that the primary metabolite is also excreted by active tubular
secretion in addition to glomerular filtration. Levetiracetam elimination is
correlated to creatinine clearance.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Elderly</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the elderly, the half-life is increased
by about 40&nbsp;% (10 to 11&nbsp;hours). This is related to the decrease in
renal function in this population (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Renal impairment</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The apparent body clearance of both
levetiracetam and of its primary metabolite is correlated to the creatinine
clearance. It is therefore recommended to adjust the maintenance daily dose of
Keppra, based on creatinine clearance in patients with moderate and severe
renal impairment (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In anuric end-stage renal disease adult
subjects the half-life was approximately 25 and 3.1&nbsp;hours during
interdialytic and intradialytic periods, respectively. </span></p>

<p class=MsoNormal><span lang=EN-GB>The fractional removal of levetiracetam was
51&nbsp;% during a typical 4-hour dialysis session.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hepatic
impairment</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In subjects
with mild and moderate hepatic impairment, there was no relevant modification
of the clearance of levetiracetam. In most subjects with severe hepatic
impairment, the clearance of levetiracetam was reduced by more than 50&nbsp;%
due to a concomitant renal impairment (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Children
(4 to 12 years)</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Following single oral dose administration
(20&nbsp;mg/kg) to epileptic children (6 to 12&nbsp;years), the half-life of
levetiracetam was 6.0&nbsp;hours. The apparent body weight adjusted clearance
was approximately 30&nbsp;% higher than in epileptic adults.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Following repeated oral dose administration
(20 to 60</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg/kg/day) to
epileptic children (4 to 12</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>years), levetiracetam was rapidly absorbed. Peak plasma concentration
was observed 0.5 to 1.0</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>hour
after dosing. Linear and dose proportional increases were observed for peak
plasma concentrations and area under the curve. The elimination half-life was
approximately 5</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>hours. The
apparent body clearance was 1.1</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>ml/min/kg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Infants and children (1 month to 4
years)</span></i></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Following single dose administration (20</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg/kg) of a 100 mg/ml oral solution to
epileptic children (1&nbsp;month to 4</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>years), levetiracetam was rapidly absorbed and peak plasma
concentrations were observed approximately 1 hour after dosing. The
pharmacokinetic results indicated that half-life was shorter (5.3&nbsp;h) than
for adults (7.2&nbsp;h) and apparent clearance was faster (1.5&nbsp;ml/min/kg)
than for adults (0.96&nbsp;ml/min/kg).</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>In the population pharmacokinetic
analysis conducted in patients from 1 month to 16 years of age, body weight was
significantly correlated to apparent clearance (clearance increased with an
increase in body weight) and apparent volume of distribution. Age also had an
influence on both parameters. This effect was pronounced for the younger
infants, and subsided as age increased, to become negligible around 4 years of
age.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>In both population
pharmacokinetic analyses, there was about a 20<span lang=EN-GB>&nbsp;</span>%
increase of apparent clearance of levetiracetam when it was co-administered
with an enzyme-inducing antiepileptic medicinal product.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b><span lang=EN-GB>5.3 Preclinical safety data</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Non-clinical data reveal no special hazard
for humans based on conventional studies of safety pharmacology, genotoxicity
and carcinogenic potential. </span></p>

<p class=MsoNormal><span lang=EN-GB>Adverse effects not observed in clinical
studies but seen in the rat and to a lesser extent in the mouse at exposure
levels similar to human exposure levels and with possible relevance for
clinical use were liver changes, indicating an adaptive response such as
increased weight and centrilobular hypertrophy, fatty infiltration and
increased liver enzymes in plasma.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No adverse reactions on male or female
fertility or reproduction performance were observed in rats at doses up to 1800</span>&nbsp;mg/kg/day
(x 6 the MRHD on a mg/m2 or exposure basis) in parents and F1 generation.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>Two embryo&#8209;foetal
development (EFD) studies were performed in rats at 400, 1200 and
3600&nbsp;mg/kg/day. At 3600&nbsp;mg/kg/day, in only one of the 2 EFD studies,
there was a slight decrease in foetal weight associated with a marginal
increase in skeletal variations/minor anomalies. There was no effect on
embryomortality and no increased incidence of malformations. The NOAEL (No
Observed Adverse Effect Level) was 3600&nbsp;mg/kg/day for pregnant female rats
(x 12 the MRHD on a mg/m2 basis) and 1200&nbsp;mg/kg/day for fetuses. </p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'>Four embryo&#8209;foetal
development studies were performed in rabbits covering doses of 200, 600, 800,
1200 and 1800&nbsp;mg/kg/day. The dose level of 1800&nbsp;mg/kg/day induced a
marked maternal toxicity and a decrease in foetal weight associated with
increased incidence of fetuses with cardiovascular/skeletal anomalies. The
NOAEL was &lt;200&nbsp;mg/kg/day for the dams and 200&nbsp;mg/kg/day for the
fetuses (equal to the MRHD on a mg/m2 basis). </p>

<p class=MsoNormal>A peri- and post-natal development study was performed in
rats with levetiracetam doses of 70, 350 and 1800&nbsp;mg/kg/day. The NOAEL was
&#8805;&nbsp;1800&nbsp;mg/kg/day for the F0 females, and for the survival,
growth and development of the F1 offspring up to weaning (x 6 the MRHD on a
mg/m2 basis). </p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Neonatal and
juvenile animal studies in rats and dogs demonstrated that there were no
adverse effects seen in any of the standard developmental or maturation
endpoints at doses up to 1800&nbsp;mg/kg/day </span>(x 6-17 the MRHD on a mg/m2
basis) </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='text-transform:uppercase'>6. PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.1 List
of excipients</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Tablet core:</u></p>

<p class=MsoNormal style='page-break-after:avoid'>Croscarmellose sodium</p>

<p class=MsoNormal>Macrogol 6000</p>

<p class=MsoNormal>Silica colloidal anhydrous.</p>

<p class=MsoNormal>Magnesium stearate</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoBodyText><span style='font-size:11.0pt'>Film-coating:</span></p>

<p class=MsoNormal>Polyvinyl alcohol-part. hydrolyzed</p>

<p class=MsoNormal>Titanium dioxide (E171)</p>

<p class=MsoNormal>Macrogol 3350</p>

<p class=MsoNormal>Talc </p>

<p class=MsoNormal>Sunset yellow FCF<span lang=EN-GB> aluminium</span> lake
(E110)</p>

<p class=MsoNormal>Iron oxide red (E172)</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>3 years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.4 Special precautions for storage</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product does not require any
special storage conditions</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.5 Nature and contents of container</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Aluminium/PVC blisters placed into
cardboard boxes containing 20, 30, 50, 60, 80, 100 film-coated tablets and
multipacks containing 200 (2 packs of 100) film-coated tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aluminium/PVC
perforated unit dose blisters placed into cardboard boxes containing 100 x 1 film-coated
tablet. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.6 Special precautions for disposal
</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=FR>7. MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR-BE>UCB Pharma SA </span></p>

<p class=MsoNormal><span lang=FR-BE>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=DE>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>8. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=PT-BR>EU/1/00/146/014</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/015</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/016</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/017</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/018</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/00/146/019</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/00/146/028</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/00/146/036</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>9. DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Date of first authorisation: 29 September 2000</p>

<p class=MsoNormal>Date of latest renewal: 20 August 2015</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>10. DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=Default style='line-height:13.0pt;page-break-after:avoid;text-autospace:
ideograph-numeric ideograph-other'><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicinal
product is available on the website of the European Medicines Agency http://www.ema.europa.eu
<br clear=all style='page-break-before:always'>
</span><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 1000&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains
1,000&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see
section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>3. PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Film-coated tablet.</span></p>

<p class=MsoNormal><span lang=EN-GB>White, 19 mm oblong, scored and debossed
with the code ucb and 1000 on one side.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The score line
is only to facilitate breaking for ease of swallowing and not to divide into
equal doses. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4. CLINICAL PARTICULARS</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra is indicated as monotherapy in the
treatment of partial onset seizures with or without secondary generalisation in
adults and adolescents from 16 years of age with newly diagnosed epilepsy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra is indicated as adjunctive therapy</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the treatment of partial onset seizures with
or without secondary generalisation in adults, adolescents, children and
infants from 1 month of age with epilepsy.</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the treatment of </span>myoclonic seizures in
adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.</p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the treatment of primary generalised
tonic-clonic seizures in adults and adolescents from 12 years of age with
Idiopathic Generalised Epilepsy.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.2 Posology and method of administration</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Partial onset seizures</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dosing for monotherapy
(from 16 years of age) and adjunctive therapy is the same; as outlined below.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>All indications</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adults (&#8805;18 years) and adolescents
(12 to 17 years) weighing 50 kg or more</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The initial therapeutic dose is 500&nbsp;mg
twice daily. This dose can be started on the first day of treatment. <span
style='color:black'>However, a lower initial dose of 250</span>&nbsp;<span
style='color:black'>mg twice daily may be given based on physician assessment
of seizure reduction versus potential side effects. This can be increased to
500</span>&nbsp;<span style='color:black'>mg twice daily after two weeks.</span></span></p>

<p class=MsoNormal><span lang=EN-GB>Depending upon the clinical response and
tolerability, the daily dose can be increased up to 1,500&nbsp;mg twice daily.
Dose changes can be made in 250 mg or 500&nbsp;mg twice daily increases or
decreases every two to four weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adolescents (12 to 17 years) weighing
below 50 kg and children from 1 month of age</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The physician should prescribe the most
appropriate pharmaceutical form, presentation and strength according to weight,
age and dose. Refer to <i>Paediatric population</i> section for dosing
adjustments based on weight.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Discontinuation</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If
levetiracetam has to be discontinued it is recommended to withdraw it gradually
(<i>e.g</i>. in adults and adolescents weighing more than 50&nbsp;kg:
500&nbsp;mg decreases twice daily every two to four weeks; in infants older
than 6 months, children and adolescents weighing less than 50&nbsp;kg: dose
decrease should not exceed 10&nbsp;mg/kg twice daily every two weeks; in
infants (less than 6 months): dose decrease should not exceed 7&nbsp;mg/kg
twice daily every two weeks). </span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly
(65 years and older)</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Adjustment
of the dose is recommended in elderly patients with compromised renal function
(see Renal impairment below).</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i><span lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The daily dose must be individualised
according to renal function. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For adult patients, refer to the following
table and adjust the dose as indicated. To use this dosing table, an estimate
of the patient's creatinine clearance (CL<sub>cr</sub>) in ml/min is needed.
The CL<sub>cr</sub> in ml/min may be estimated from serum creatinine (mg/dl)
determination, for adults and adolescents weighing 50&nbsp;kg or more, the
following formula:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB> [140-age(
years)] x weight (kg)</span></p>

<p class=MsoNormal><span lang=EN-GB>CL<sub>cr</sub> </span>(ml/min)<span
lang=EN-GB> = ----------------------------------------- (x 0.85 for women)</span></p>

<p class=MsoNormal><span lang=EN-GB> 72 x serum
creatinine (mg/dl)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Then <span lang=EN-GB>CL<sub>cr</sub></span> is adjusted for
body surface area (BSA) as follows:</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>  <span
lang=DE>CL<sub>cr</sub> (ml/min)</span></p>

<p class=MsoNormal><span lang=DE>CL<sub>cr</sub> (ml/min/1.73 m<sup>2</sup>) =
---------------------------- x 1.73 </span></p>

<p class=MsoNormal><span lang=DE>  </span><span
lang=FR-BE>BSA subject (m<sup>2</sup>)</span></p>

<p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Dosing adjustment for adult and adolescent
patients weighing more than 50&nbsp;kg with impaired renal function:</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Group</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Creatinine clearance (ml/min</span>/1.73m<sup>2</sup><span
  lang=EN-GB>)</span></p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Dose and frequency</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Normal</span></p>
  <p class=MsoNormal><span lang=EN-GB>Mild</span></p>
  <p class=MsoNormal><span lang=EN-GB>Moderate</span></p>
  <p class=MsoNormal><span lang=EN-GB>Severe</span></p>
  <p class=MsoNormal><span lang=EN-GB>End-stage renal disease patients</span></p>
  <p class=MsoNormal><span lang=EN-GB>undergoing dialysis <sup>(1)</sup></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;</span><span lang=EN-GB>&nbsp;80</span></p>
  <p class=MsoNormal><span lang=EN-GB>50-79</span></p>
  <p class=MsoNormal><span lang=EN-GB>30-49</span></p>
  <p class=MsoNormal><span lang=EN-GB>&lt;&nbsp;30</span></p>
  <p class=MsoNormal><span lang=EN-GB>-</span></p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>500 to 1,500&nbsp;mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>500 to 1,000 mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>250 to 750&nbsp;mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>250 to 500&nbsp;mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>500 to 1,000&nbsp;mg once daily <sup>(2)</sup></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><sup><span lang=EN-GB>(1)</span></sup><span lang=EN-GB> A
750&nbsp;mg loading dose is recommended on the first day of treatment with
levetiracetam.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(2)</span></sup><span lang=EN-GB>
Following dialysis, a 250 to 500&nbsp;mg supplemental dose is recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For children with renal impairment,
levetiracetam dose needs to be adjusted based on the renal function as
levetiracetam clearance is related to renal function. This recommendation is
based on a study in adult renally impaired patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The CL<sub>cr</sub> in ml/min</span>/1.73<span
lang=EN-GB>&nbsp;</span>m<sup>2</sup><span lang=EN-GB> may be estimated from
serum creatinine (mg/dl) determination, for young adolescents, children and
infants, using the following formula (Schwartz formula): </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'> 
Height (cm) x ks</p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>CL<sub>cr</sub></span>
(ml/min/1.73 m<sup>2</sup>) = -------------------------------------</p>

<p class=MsoNormal style='page-break-after:avoid'> 
Serum Creatinine (mg/dl)</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>ks= 0.45 in Term infants to 1 year old; ks=
0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in
adolescent male</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Dosing
adjustment for infants, children and adolescent patients weighing less than 50
kg with impaired renal function:</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=621
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=130 rowspan=2 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Group</span></p>
  </td>
  <td width=113 rowspan=2 valign=top style='width:85.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Creatinine
  clearance (ml/min</span>/1.73m<sup>2</sup><span lang=EN-GB>)</span></p>
  </td>
  <td width=378 colspan=2 valign=top style='width:283.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Dose and frequency <sup>(1)</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infants 1
  to less than 6 months</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Infants 6 to 23 months,
  children and adolescents weighing less than 50 kg </p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Normal</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&#8805;</span><span
  lang=EN-GB>&nbsp;80</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>7 to
  21&nbsp;mg/kg (0.07 to 0.21&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>10 to
  30&nbsp;mg/kg (0.10 to 0.30&nbsp;ml/kg) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Mild</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>50-79</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>7 to
  14&nbsp;mg/kg (0.07 to 0.14&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>10 to
  20&nbsp;mg/kg (0.10 to 0.20&nbsp;ml/kg) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Moderate</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>30-49</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>3.5 to
  10.5&nbsp;mg/kg (0.035 to 0.105&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>5 to
  15&nbsp;mg/kg (0.05 to 0.15&nbsp;ml/kg) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Severe</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&lt;&nbsp;30</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>3.5 to
  7&nbsp;mg/kg (0.035 to 0.07&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>5 to
  10&nbsp;mg/kg (0.05 to 0.10&nbsp;ml/kg) twice daily </span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>End-stage
  renal disease patients</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>undergoing
  dialysis </span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>--</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>7 to
  14&nbsp;mg/kg (0.07 to 0.14&nbsp;ml/kg) once daily <sup>(2) (4)</sup></span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>10 to
  20&nbsp;mg/kg (0.10 to 0.20&nbsp;ml/kg) once daily <sup>(3) (5)</sup></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB>(1)</span></sup><span
lang=EN-GB> Keppra oral solution should be used for doses under 250 mg, for
doses not multiple of 250 mg when dosing recommendation is not achievable by
taking multiple tablets and for patients unable to swallow tablets. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB>(2)</span></sup><span
lang=EN-GB> A 10.5&nbsp;mg/kg (0.105&nbsp;ml/kg) loading dose is recommended on
the first day of treatment with levetiracetam.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(3)</span></sup><span lang=EN-GB> A
15&nbsp;mg/kg (0.15&nbsp;ml/kg) loading dose is recommended on the first day of
treatment with levetiracetam.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(4)</span></sup><span lang=EN-GB>
Following dialysis, a 3.5 to 7&nbsp;mg/kg (0.035 to 0.07&nbsp;ml/kg)
supplemental dose is recommended.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(5)</span></sup><span lang=EN-GB>
Following dialysis, a 5 to 10&nbsp;mg/kg (0.05 to 0.10&nbsp;ml/kg) supplemental
dose is recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Hepatic impairment </span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No dose adjustment is needed in patients
with mild to moderate hepatic impairment. In patients with severe hepatic
impairment, the creatinine clearance may underestimate the renal insufficiency.
Therefore a 50&nbsp;% reduction of the daily maintenance dose is recommended
when the creatinine clearance is &lt;&nbsp;60&nbsp;ml/min</span>/1.73<span
lang=EN-GB>&nbsp;</span>m<sup>2</sup><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The physician should prescribe the most appropriate pharmaceutical
form, presentation and strength according to age, weight and dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The tablet formulation is not adapted for
use in infants and children under the age of 6 years. Keppra oral solution is
the preferred formulation for use in this population. In addition, the
available dose strengths of the tablets are not appropriate for initial
treatment in children weighing less than 25 kg, for patients unable to swallow
tablets or for the administration of doses below 250 mg. In all of the above
cases Keppra oral solution should be used.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Monotherapy</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The safety
and efficacy of Keppra in children and adolescents below 16 years as
monotherapy treatment have not been established.</span></p>

<p class=MsoNormal style='page-break-after:avoid'>No data are available.</p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i>Adolescents (16 and 17 years of age) weighing 50 kg or
more with partial onset seizures with or without secondary generalisation with
newly diagnosed epilepsy</i></p>

<p class=MsoNormal>Please refer to the above section on <i>Adults (&#8805;18
years) and adolescents (12 to 17 years) weighing 50 kg or more</i>. </p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Add-on
therapy for infants aged 6 to 23 months, children (2 to 11 years) and
adolescents (12 to 17 years) weighing less than 50 kg</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Keppra oral
solution is the preferred formulation for use in infants and children under the
age of 6 years. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For children
6 years and above, Keppra oral solution should be used for doses under 250 mg,
for doses not multiple of 250 mg when dosing recommendation is not achievable
by taking multiple tablets and for patients unable to swallow tablets</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The lowest effective dose should be used
for all indications. The starting dose for a child or adolescent of 25kg should
be 250mg twice daily with a maximum dose of 750mg twice daily. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Dose in children 50&nbsp;kg or greater is
the same as in adults for all indications.</span></p>

<p class=MsoNormal>Please refer to the above section on <i>Adults (&#8805;18
years) and adolescents (12 to 17 years) weighing 50 kg or more </i>for all
indications.</p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Add-on therapy for infants aged from 1
month to less than 6 months</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The oral solution is the formulation to use in infants.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The film-coated tablets must be taken
orally, swallowed with a sufficient quantity of liquid and may be taken with or
without food. After oral administration the bitter taste of levetiracetam may
be experienced. The daily dose is administered in two equally divided doses.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to the active substance or
other pyrrolidone derivatives or to any of the excipients</span><span
lang=EN-GB> listed in section 6.1</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.4 Special warnings and precautions
for use</span></b></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Renal impairment</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The administration of levetiracetam to
patients with renal impairment may require dose adjustment. In patients with
severely impaired hepatic function, assessment of renal function is recommended
before dose selection (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u>Acute Kidney injury</u></p>

<p class=MsoNormal>The use of levetiracetam has been very rarely associated
with acute kidney injury, with a time to onset ranging from a few days to
several months.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Blood cell counts</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rare cases of decreased blood cell counts
(neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia)
have been described in association with levetiracetam administration, generally
at the beginning of the treatment. Complete blood cell counts are advised in
patients experiencing important weakness, pyrexia, recurrent infections or
coagulation disorders (section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u>Suicide</u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Suicide, suicide attempt, <span lang=EN-GB>suicidal ideation and
behaviour have been reported in patients treated with anti-epileptic agents
(including levetiracetam). A meta-analysis of randomized placebo-controlled
trials of anti-epileptic medicinal products has shown a small increased risk of
suicidal thoughts and behaviour. The mechanism of this risk is not known. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Therefore, patients should be monitored for
signs of depression and/or suicidal ideation and behaviours and appropriate
treatment should be considered. Patients (and caregivers of patients) should be
advised to seek medical advice should signs of depression and/or suicidal
ideation or behaviour emerge.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Abnormal and aggressive behaviours </span></u></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam may cause psychotic symptoms
and behavioural abnormalities including irritability and aggressiveness.
Patients treated with levetiracetam should be monitored for developing
psychiatric signs suggesting important mood and/or personality changes. If such
behaviours are noticed, treatment adaptation or gradual discontinuation should
be considered. If discontinuation is considered, please refer to section 4.2.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u>Worsening of seizures</u></p>

<p class=MsoNormal>As with other types of antiepileptic drugs, levetiracetam may
rarely exacerbate seizure frequency or severity. This paradoxical effect was
mostly reported within the first month after levetiracetam initiation or
increase of the dose, and was reversible upon drug discontinuation or dose
decrease. Patients should be advised to consult their physician immediately in
case of aggravation of epilepsy.</p>

<p class=MsoNormal><u><span style='font-size:12.0pt'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Electrocardiogram QT interval
prolongation</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rare cases of ECG QT interval prolongation
have been observed during the post-marketing surveillance. Levetiracetam should
be used with caution in patients with QTc-interval prolongation, in patients
concomitantly treated with drugs affecting the QTc-interval, or in patients
with relevant pre-existing cardiac disease or electrolyte disturbances.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The tablet formulation is not adapted for
use in infants and children under the age of 6 years. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Available data in children did not suggest
impact on growth and puberty. However, long term effects on learning,
intelligence, growth, endocrine function, puberty and childbearing potential in
children remain unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.5 Interaction with other medicinal
products and other forms of interaction</span></b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Antiepileptic medicinal products</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Pre-marketing data from clinical studies
conducted in adults indicate that levetiracetam did not influence the serum
concentrations of existing antiepileptic medicinal products (phenytoin,
carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and
primidone) and that these antiepileptic medicinal products did not influence
the pharmacokinetics of levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-AU style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>As in adults,
there is no evidence of clinically significant medicinal product interactions
in paediatric patients receiving up to 60</span><span lang=EN-GB>&nbsp;<span
style='layout-grid-mode:line'>mg/kg/day levetiracetam.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>A
retrospective assessment of pharmacokinetic interactions in children and
adolescents with epilepsy (4 to 17</span><span lang=EN-GB>&nbsp;<span
style='layout-grid-mode:line'>years) confirmed that adjunctive therapy with
orally administered levetiracetam did not influence the steady-state serum
concentrations of concomitantly administered carbamazepine and valproate.
However, data suggested </span></span><span lang=EN-GB>a 20</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% higher levetiracetam clearance in
children taking</span><span lang=EN-GB style='layout-grid-mode:line'>
enzyme-inducing antiepileptic medicinal products. Dose adjustment is not
required. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Probenecid</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Probenecid (500&nbsp;mg four times daily),
a renal tubular secretion blocking agent, has been shown to inhibit the renal
clearance of the primary metabolite, but not of levetiracetam. Nevertheless,
the concentration of this metabolite remains low. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Methotrexate</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Concomitant administration of levetiracetam
and methotrexate has been reported to decrease methotrexate clearance,
resulting in increased/prolonged blood methotrexate concentration to
potentially toxic levels. Blood methotrexate and levetiracetam levels should be
carefully monitored in patients treated concomitantly with the two drugs.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-AU style='layout-grid-mode:line'>Oral
contraceptives and other pharmacokinetics interactions</span></u></p>

<p class=MsoNormal><span lang=EN-AU style='layout-grid-mode:line'>Levetiracetam
1,000&nbsp;mg daily did not influence the pharmacokinetics of oral
contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters
(luteinizing hormone and progesterone) were not modified. Levetiracetam
2,000&nbsp;mg daily did not influence the pharmacokinetics of digoxin and
warfarin; prothrombin times were not modified. Co-administration with digoxin,
oral contraceptives and warfarin did not influence the pharmacokinetics of
levetiracetam.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Laxatives</u></p>

<p class=MsoNormal><span lang=EN-GB>There have been isolated reports of
decreased levetiracetam efficacy when the osmotic laxative macrogol has been
concomitantly administered with oral levetiracetam. Therefore, macrogol should
not be taken orally for one hour before and for one hour after taking
levetiracetam.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u>Food and alcohol</u></p>

<p class=MsoNormal>The extent of absorption of levetiracetam was not altered by
food, but the rate of absorption was slightly reduced.</p>

<p class=MsoNormal>No data on the interaction of levetiracetam with alcohol are
available.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.6 Fertility,
pregnancy and lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Women of
child bearing potential </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Specialist
advice should be given to women who are of childbearing potential. Treatment
with levetiracetam should be reviewed when a woman is planning to become
pregnant. As with all antiepileptic medicines, sudden discontinuation of
levetiracetam should be avoided as this may lead to breakthrough seizures that
could have serious consequences for the woman and the unborn child. Monotherapy
should be preferred whenever possible because therapy with multiple
antiepileptic medicines AEDs could be associated with a higher risk of
congenital malformations than monotherapy, depending on the associated
antiepileptics.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>A large
amount of postmarketing data on pregnant women exposed to levetiracetam monotherapy
(more than 1800, among which in more than 1500 exposure occurred during the 1<sup>st</sup>
trimester) do not suggest an increase in the risk for major congenital
malformations. Only limited evidence is available on the neurodevelopment of
children exposed to Keppra monotherapy in utero. However, current
epidemiological studies (on about 100 children) do not suggest an increased
risk of neurodevelopmental disorders or delays. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Levetiracetam
can be used during pregnancy, if after careful assessment it is considered
clinically needed. In such case, the lowest effective dose is recommended.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Physiological
changes during pregnancy may affect levetiracetam concentration. D</span>ecrease
in levetiracetam plasma concentrations has been observed during pregnancy. This
decrease is more pronounced during the third trimester (up to 60% of baseline
concentration before pregnancy). Appropriate clinical management of pregnant
women treated with levetiracetam should be ensured. </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Breastfeeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam is excreted in human breast milk.
Therefore, breast-feeding is not recommended. </span></p>

<p class=MsoNormal style='line-height:normal'>However, if levetiracetam
treatment is needed during breastfeeding, the benefit/risk of the treatment
should be weighed considering the importance of breastfeeding.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><u>Fertility</u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No impact on
fertility was detected in animal studies (see section 5.3). No clinical data
are available, potential risk for human is unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.7 Effects on ability to drive and
use machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam has minor or moderate
influence on the ability to drive and use machines</span><span lang=EN-GB>. Due
to possible different individual sensitivity, some patients might experience
somnolence or other central nervous system related symptoms, </span><span
lang=EN-GB>especially</span><span lang=EN-GB> </span><span lang=EN-GB>at the
beginning of treatment or following a dose increase. Therefore, caution is
recommended in those patients when performing skilled tasks, <i>e.g</i>.
driving vehicles or operating machinery. Patients are advised not to drive or
use machines until it is established that </span><span lang=EN-GB>their</span><span
lang=EN-GB> ability to perform such activities is not affected.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Summary of the safety profile</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The most frequently reported adverse
reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness. The
adverse reaction profile presented below is based on the analysis of pooled
placebo-controlled clinical trials with all indications studied, with a total
of 3,416 patients treated with levetiracetam. These data are supplemented with
the use of levetiracetam in corresponding open-label extension studies, as well
as post-marketing experience. The safety profile of levetiracetam is generally
similar across age groups (adult and paediatric patients) and across the
approved epilepsy indications. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Tabulated list of adverse
reactions</u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Adverse
reactions reported in clinical studies (adults, adolescents, children and
infants &gt; 1&nbsp;month) and from post-marketing experience are listed in the
following table per System Organ Class and per frequency. Adverse reactions
are presented in the order of decreasing seriousness and their frequency is
defined as follows: very common (&#8805;1/10); common (&#8805;1/100 to
&lt;1/10); uncommon (&#8805;1/1,000 to &lt;1/100); rare (&#8805;1/10,000 to
&lt;1/1,000) and very rare (&lt;1/10,000).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="97%"
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="20%" rowspan=2 style='width:20.26%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
   style='font-size:10.0pt'>MedDRA SOC</span></u></p>
   </td>
   <td width="79%" colspan=4 valign=top style='width:79.74%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><u><span lang=EN-GB style='font-size:10.0pt'>Frequency category</span></u></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:7.45pt'>
   <td width="20%" valign=top style='width:20.26%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
   <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
   style='font-size:10.0pt'>Very common</span></u></p>
   </td>
   <td width="17%" valign=top style='width:17.16%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
   <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
   style='font-size:10.0pt'>Common</span></u></p>
   </td>
   <td width="20%" valign=top style='width:20.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
   <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
   style='font-size:10.0pt'>Uncommon </span></u></p>
   </td>
   <td width="21%" valign=top style='width:21.76%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
   <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
   style='font-size:10.0pt'>Rare</span></u></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
  style='font-size:10.0pt'>Infections and infestations</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Nasopharyngitis </span></p>
  </td>
  <td width="17%" valign=top style='width:17.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Infection</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
  style='font-size:10.0pt'>Blood and lymphatic system disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-AU
  style='font-size:10.0pt'>Thrombocytopenia, leukopenia</span></p>
  </td>
  <td width="21%" valign=top style='width:21.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-AU
  style='font-size:10.0pt'>Pancytopenia, neutropenia, agranulocytosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
  style='font-size:10.0pt'>Immune system disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-AU
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-AU
  style='font-size:10.0pt'>Drug reaction with eosinophilia and systemic
  symptoms (DRESS),</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-AU
  style='font-size:10.0pt'>Hypersensitivity (including angioedema and
  anaphylaxis)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Metabolism
  and nutrition disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Anorexia</span></p>
  </td>
  <td width="20%" valign=top style='width:20.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Weight
  decreased, weight increase</span></p>
  </td>
  <td width="21%" valign=top style='width:21.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Hyponatraemia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Psychiatric
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Depression,
  hostility/ aggression, anxiety, <br>
  insomnia, nervousness/irritability</span></p>
  </td>
  <td width="20%" valign=top style='width:20.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Suicide attempt,
  suicidal ideation</span><span lang=EN-AU style='font-size:10.0pt'>,<sup> </sup></span><span
  lang=EN-GB style='font-size:10.0pt'>psychotic disorder</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>abnormal behaviour, hallucination</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>anger, confusional state</span><sup><span
  lang=EN-GB style='font-size:10.0pt'> </span></sup><span lang=EN-GB
  style='font-size:10.0pt'>, panic attack, affect lability/mood swings,
  agitation, </span></p>
  </td>
  <td width="21%" valign=top style='width:21.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Completed
  suicide</span><span lang=EN-AU style='font-size:10.0pt'>, </span><span
  lang=EN-GB style='font-size:10.0pt'>personality disorder, thinking abnormal,
  delirium</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Nervous
  system disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-before:always'><span lang=EN-GB
  style='font-size:10.0pt'>Somnolence, headache</span></p>
  </td>
  <td width="17%" valign=top style='width:17.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-before:always'><span lang=EN-GB
  style='font-size:10.0pt'>Convulsion, balance disorder, dizziness, lethargy,
  tremor</span></p>
  </td>
  <td width="20%" valign=top style='width:20.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-before:always'><span lang=EN-GB
  style='font-size:10.0pt'>Amnesia, memory impairment, coordination
  abnormal/ataxia, paraesthesia</span><span lang=EN-AU style='font-size:10.0pt'>,
  </span><span lang=EN-GB style='font-size:10.0pt'>disturbance in attention</span></p>
  </td>
  <td width="21%" valign=top style='width:21.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-before:always'><span lang=EN-GB
  style='font-size:10.0pt'>Choreoathetosis, dyskinesia, hyperkinesia, gait
  disturbance, encephalopathy, seizures aggravated</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Eye disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Diplopia, vision
  blurred</span></p>
  </td>
  <td width="21%" valign=top style='width:21.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Ear and
  labyrinth disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Vertigo</span></p>
  </td>
  <td width="20%" valign=top style='width:20.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Cardiac
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>Electrocardiogram
  QT prolonged</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Respiratory,
  thoracic and mediastinal disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Cough</span></p>
  </td>
  <td width="20%" valign=top style='width:20.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Gastrointestinal
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT style='font-size:10.0pt'>Abdominal pain,
  diarrhoea, dyspepsia, vomiting, nausea</span></p>
  </td>
  <td width="20%" valign=top style='width:20.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Pancreatitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-AU style='font-size:10.0pt'>Hepatobiliary
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Liver function
  test abnormal</span></p>
  </td>
  <td width="21%" valign=top style='width:21.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Hepatic failure,
  hepatitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Renal and
  Urinary Disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Acute Kidney
  injury</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Skin and
  subcutaneous tissue disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Rash</span></p>
  </td>
  <td width="20%" valign=top style='width:20.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Alopecia</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>eczema, pruritus, </span></p>
  </td>
  <td width="21%" valign=top style='width:21.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Toxic epidermal
  necrolysis, Stevens-Johnson syndrome, erythema multiforme</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Musculoskeletal
  and connective tissue disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Muscular
  weakness, myalgia</span></p>
  </td>
  <td width="21%" valign=top style='width:21.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Rhabdomyolysis
  and blood creatine phosphokinase increased*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>General
  disorders and administration site conditions</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Asthenia/</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>fatigue</span></p>
  </td>
  <td width="20%" valign=top style='width:20.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Injury,
  poisoning and procedural complications</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Injury</span></p>
  </td>
  <td width="21%" valign=top style='width:21.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>* Prevalence is significantly higher in
Japanese patients when compared to non-Japanese patients. </span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Description of selected adverse
reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU>The risk of
anorexia is higher when levetiracetam is coadministered with topiramate.</span></p>

<p class=MsoNormal><span lang=EN-AU>In several cases of alopecia, recovery was
observed when levetiracetam was discontinued.</span></p>

<p class=MsoNormal><span style='font-family:"TimesNewRomanPSMT",serif'>Bone
marrow suppression was identified in some of the cases of pancytopenia.</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>Cases of encephalopathy generally occurred
at the beginning of the treatment (few days to a few months) and were
reversible after treatment discontinuation.</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In patients
aged 1 month to less than 4 years, a total of 190 patients have been treated
with levetiracetam in placebo-controlled and open label extension studies.
Sixty of these patients were treated with levetiracetam in placebo-controlled
studies. In patients aged 4-16 years, a total of 645 patients have been
treated with levetiracetam in placebo-controlled and open label extension
studies. 233 of these patients were treated with levetiracetam in
placebo-controlled studies. In both these paediatric age ranges, these data
are supplemented with the post-marketing experience of the use of
levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In addition, 101 infants aged less than 12
months have been exposed in a post authorization safety study. No new safety
concerns for levetiracetam were identified for infants less than 12 months of
age with epilepsy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The adverse reaction profile of
levetiracetam is generally similar across age groups and across the approved
epilepsy indications. Safety results in paediatric patients in
placebo-controlled clinical studies were consistent with the safety profile of
levetiracetam in adults except for behavioural and psychiatric adverse
reactions which were more common in children than in adults. In children and
adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation
(common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%),
aggression (common, 8.2%), abnormal behaviour (common, 5.6%), and lethargy
(common, 3.9%) were reported more frequently than in other age ranges or in the
overall safety profile. In infants and children aged 1 month to less than 4
years, irritability (very common, 11.7%) and coordination abnormal (common,
3.3%) were reported more frequently than in other age groups or in the overall
safety profile. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>A double-blind,
placebo-controlled paediatric safety study with a non-inferiority design has
assessed the cognitive and neuropsychological effects of </span><span
lang=EN-GB>levetiracetam</span><span lang=EN-GB> in children 4 to 16</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>years of age with partial onset
seizures. It was concluded that Keppra was not different (non inferior) from
placebo with regard to the change from baseline of the Leiter-R Attention and
Memory, Memory Screen Composite score in the per-protocol population. Results
related to behavioural and emotional functioning indicated a worsening in </span><span
lang=EN-GB>levetiracetam</span><span lang=EN-GB> treated patients on aggressive
behaviour as measured in a standardised and systematic way using a validated
instrument (CBCL  Achenbach Child Behavior Checklist). However, subjects, who
took </span><span lang=EN-GB>levetiracetam</span><span lang=EN-GB> in the
long-term open label follow-up study, did not experience a worsening, on
average, in their behavioural and emotional functioning; in particular measures
of aggressive behaviour were not worse than baseline.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Reporting of
suspected adverse reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:silver'>the national reporting
system listed in Appendix V</span>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Symptoms</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Somnolence, agitation, aggression,
depressed level of consciousness, respiratory depression and coma were observed
with Keppra overdoses.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Management
of overdose</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>After an
acute overdose, the stomach may be emptied by gastric lavage or by induction of
emesis. There is no specific antidote for levetiracetam. Treatment of an
overdose will be symptomatic and may include haemodialysis. The dialyser
extraction efficiency is 60&nbsp;% for levetiracetam and 74&nbsp;% for the
primary metabolite.</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='text-transform:uppercase'>5. </span><span lang=EN-GB>PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.1 Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic group: antiepileptics,
other antiepileptics, ATC code: N03AX14.</span></p>

<p class=MsoNormal><span lang=EN-GB>The active substance, levetiracetam, is a
pyrrolidone derivative (S-enantiomer of </span><span lang=EN-GB
style='font-family:Symbol'>a</span><span lang=EN-GB>-ethyl-2-oxo-1-pyrrolidine
acetamide), chemically unrelated to existing antiepileptic active substances.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Mechanism
of action</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The
mechanism of action of levetiracetam still remains to be fully elucidated. <i>In
vitro </i>and <i>in vivo</i> experiments suggest that levetiracetam does not
alter basic cell characteristics and normal neurotransmission. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>In vitro</span></i><span
lang=EN-GB> studies show that levetiracetam affects intraneuronal Ca<sup>2+</sup>
levels by partial inhibition of N-type Ca<sup>2+</sup> currents and by reducing
the release of Ca<sup>2+</sup> from intraneuronal stores. In addition, it
partially reverses the reductions in GABA- and glycine-gated currents induced
by zinc and </span><span lang=EN-GB style='font-family:Symbol'>b</span><span
lang=EN-GB>-carbolines. Furthermore, levetiracetam has been shown in <i>in
vitro</i> studies to bind to a specific site in rodent brain tissue. This
binding site is the synaptic vesicle protein 2A, believed to be involved in
vesicle fusion and neurotransmitter exocytosis. Levetiracetam and related
analogs show a rank order of affinity for binding to the synaptic vesicle
protein 2A which correlates with the potency of their anti-seizure protection
in the mouse audiogenic model of epilepsy. This finding suggests that the
interaction between levetiracetam and the synaptic vesicle protein 2A seems to
contribute to the antiepileptic mechanism of action of the medicinal product.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Pharmacodynamic effects</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam induces seizure protection in
a broad range of animal models of partial and primary generalised seizures
without having a pro-convulsant effect. The primary metabolite is inactive.</span></p>

<p class=MsoNormal><span lang=EN-GB>In man, an activity in both partial and
generalised epilepsy conditions (epileptiform discharge/photoparoxysmal
response) has confirmed the broad spectrum pharmacological profile of
levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adjunctive therapy in the treatment of
partial onset seizures with or without secondary generalisation in adults,
adolescents, children and infants from 1 month of age with epilepsy.</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In adults, levetiracetam efficacy has been
demonstrated in 3 double-blind, placebo-controlled studies at 1000</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg, 2000</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>mg, or 3000</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg/day,
given in 2 divided doses, with a treatment duration of up to 18</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>weeks. In a pooled analysis, the
percentage of patients who achieved 50</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% or greater reduction from baseline in the partial onset seizure
frequency per week at stable dose (12/14</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>weeks) was of 27.7</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>%, 31.6</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>% and
41.3</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>% for patients on
1000, 2000 or 3000</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg
levetiracetam respectively and of 12.6</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% for patients on placebo. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Paediatric population</u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'>In paediatric patients (4 to
16<span lang=EN-GB>&nbsp;</span>years of age), levetiracetam efficacy was
established in a double-blind, placebo-controlled study, which included 198
patients and had a treatment duration of 14 weeks. In this study, the patients
received levetiracetam as a fixed dose of 60<span lang=EN-GB>&nbsp;</span>mg/kg/day
(with twice a day dosing).</p>

<p class=MsoNormal><span lang=EN-GB>44.6</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% of the levetiracetam treated patients and 19.6</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% of the patients on placebo had a 50</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% or greater reduction from baseline
in the partial onset seizure frequency per week.</span><span lang=EN-GB> </span><span
lang=EN-GB>With continued long-term treatment, 11.4</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% of the patients were seizure-free for at least 6 months and 7.2</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% were seizure-free for at least 1
year.</span></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal>In paediatric patients (1 month to less than 4 years of
age), levetiracetam efficacy was established in a double-blind,
placebo-controlled study, which included 116 patients and had a treatment
duration of 5<span lang=EN-GB>&nbsp;</span>days. In this study, patients were
prescribed 20<span lang=EN-GB>&nbsp;</span>mg/kg, 25<span lang=EN-GB>&nbsp;</span>mg/kg,
40<span lang=EN-GB>&nbsp;</span>mg/kg or 50<span lang=EN-GB>&nbsp;</span>mg/kg
daily dose of oral solution based on their age titration schedule. A dose of 20<span
lang=EN-GB>&nbsp;</span>mg/kg/day titrating to 40<span lang=EN-GB>&nbsp;</span>mg/kg/day
for infants one month to less than six months and a dose of 25<span lang=EN-GB>&nbsp;</span>mg/kg/day
titrating to 50<span lang=EN-GB>&nbsp;</span>mg/kg/day for infants and children
6 months to less than 4 years old, was use in this study. The total daily dose
was administered twice daily.</p>

<p class=MsoNormal><span lang=EN-GB>The primary measure of effectiveness was
the responder rate (percent of patients with &#8805; 50&nbsp;% reduction from
baseline in average daily partial onset seizure frequency) assessed by a
blinded central reader using a 48-hour video EEG. The efficacy analysis
consisted of 109 patients who had at least 24&nbsp;hours of video EEG in both
baseline and evaluation periods. <span class=msoins0>43.6</span>&nbsp;<span
class=msoins0>% of the levetiracetam treated patients and 19.6</span>&nbsp;<span
class=msoins0>% of the patients on placebo were considered as
responders.&nbsp;The results are consistent across age group.</span></span><span
lang=EN-GB> With continued long-term treatment, 8.6</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% of the patients were seizure-free for at least 6 months and 7.8</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% were seizure-free for at least 1
year.</span></p>

<p class=MsoNormal><span lang=EN-GB>35 infants aged less than 1 year with
partial onset seizures have been exposed in placebo-control clinical studies of
which only 13 were aged &lt; 6 months.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Monotherapy
in the treatment of partial onset seizures with or without secondary
generalisation in patients from 16 years of age with newly diagnosed epilepsy. </span></i></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>Efficacy of levetiracetam as
monotherapy was established in a double-blind, parallel group, non-inferiority
comparison to carbamazepine-controlled release (CR) in 576 patients 16<span
lang=EN-GB>&nbsp;</span>years of age or older with newly or recently diagnosed
epilepsy. The patients had to present with unprovoked partial seizures or with
generalized tonic-clonic seizures only. The patients were randomized to
carbamazepine CR 400  1200<span lang=EN-GB>&nbsp;</span>mg/day or
levetiracetam 1000  3000<span lang=EN-GB>&nbsp;</span>mg/day, the duration of
the treatment was up to 121 weeks depending on the response. </p>

<p class=MsoNormal>Six-month seizure freedom was achieved in 73.0<span
lang=EN-GB>&nbsp;</span>% of levetiracetam-treated patients and 72.8<span
lang=EN-GB>&nbsp;</span>% of carbamazepine-CR treated patients; the adjusted
absolute difference between treatments was 0.2<span lang=EN-GB>&nbsp;</span>%
(95<span lang=EN-GB>&nbsp;</span>% CI: -7.8 8.2). More than half of the
subjects remained seizure free for 12 months (56.6<span lang=EN-GB>&nbsp;</span>%
and 58.5<span lang=EN-GB>&nbsp;</span>% of subjects on levetiracetam and on
carbamazepine CR respectively).</p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>In a study
reflecting clinical practice, the concomitant antiepileptic medication could be
withdrawn in a limited number of patients who responded to levetiracetam
adjunctive therapy (36 adult patients out of 69). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adjunctive therapy in the treatment of
myoclonic seizures in adults and adolescents from 12 years of age with Juvenile
Myoclonic Epilepsy.</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Levetiracetam efficacy was established in a double-blind,
placebo-controlled study of 16<span lang=EN-GB>&nbsp;</span>weeks duration, in
patients 12 years of age and older suffering from idiopathic generalized
epilepsy with myoclonic seizures in different syndromes. The majority of
patients presented with juvenile myoclonic epilepsy.</p>

<p class=MsoNormal>In this study, levetiracetam, dose was 3000<span lang=EN-GB>&nbsp;</span>mg/day
given in 2 divided doses. </p>

<p class=MsoNormal>58.3<span lang=EN-GB>&nbsp;</span>% of the levetiracetam
treated patients and 23.3<span lang=EN-GB>&nbsp;</span>% of the patients on
placebo had at least a 50<span lang=EN-GB>&nbsp;</span>% reduction in myoclonic
seizure days per week. With continued long-term treatment, 28.6<span
lang=EN-GB>&nbsp;</span>% of the patients were free of myoclonic seizures for
at least 6 months and 21.0<span lang=EN-GB>&nbsp;</span>% were free of
myoclonic seizures for at least 1 year.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adjunctive therapy in the treatment of
primary generalised tonic-clonic seizures in adults and adolescents from 12
years of age with idiopathic generalised epilepsy.</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Levetiracetam efficacy was established in a 24-week
double-blind, placebo-controlled study which included adults, adolescents and a
limited number of children suffering from idiopathic generalized epilepsy with
primary generalized tonic-clonic (PGTC) seizures in different syndromes
(juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence
epilepsy, or epilepsy with Grand Mal seizures on awakening). In this study,
levetiracetam dose was 3000<span lang=EN-GB>&nbsp;</span>mg/day for adults and
adolescents or 60<span lang=EN-GB>&nbsp;</span>mg/kg/day for children, given in
2 divided doses.</p>

<p class=MsoNormal>72.2<span lang=EN-GB>&nbsp;</span>% of the levetiracetam
treated patients and 45.2<span lang=EN-GB>&nbsp;</span>% of the patients on
placebo had a 50<span lang=EN-GB>&nbsp;</span>% or greater decrease in the
frequency of PGTC seizures per week. With continued long-term treatment, 47.4<span
lang=EN-GB>&nbsp;</span>% of the patients were free of tonic-clonic seizures
for at least 6 months and 31.5<span lang=EN-GB>&nbsp;</span>% were free of
tonic-clonic seizures for at least 1 year.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.2 Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam is a highly soluble and
permeable compound. The pharmacokinetic profile is linear with low intra- and
inter-subject variability. There is no modification of the clearance after
repeated administration. There is no evidence for any relevant gender, race or
circadian variability. The pharmacokinetic profile is comparable in healthy
volunteers and in patients with epilepsy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Due to its complete and linear absorption,
plasma levels can be predicted from the oral dose of levetiracetam expressed as
mg/kg bodyweight. Therefore, there is no need for plasma level monitoring of
levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A significant correlation between saliva
and plasma concentrations has been shown in adults and children (ratio of
saliva/plasma concentrations ranged from </span>1 to 1.7 for oral tablet formulation
and after 4<span lang=EN-GB>&nbsp;</span>hours post-dose for oral solution
formulation<span lang=EN-GB>).</span></p>

<p class=MsoEndnoteText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoEndnoteText><u><span lang=EN-GB>Adults and adolescents</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam is rapidly absorbed after
oral administration. Oral absolute bioavailability is close to 100&nbsp;%. </span></p>

<p class=MsoNormal><span lang=EN-GB>Peak plasma concentrations (C<sub>max</sub>)
are achieved at 1.3&nbsp;hours after dosing. Steady-state is achieved after two
days of a twice daily administration schedule.</span></p>

<p class=MsoNormal><span lang=EN-GB>Peak concentrations (C<sub>max</sub>) are
typically 31 and 43&nbsp;g/ml following a single 1,000&nbsp;mg dose and
repeated 1,000&nbsp;mg twice daily dose, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>The extent of absorption is
dose-independent and is not altered by food.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No tissue distribution data are available
in humans.</span></p>

<p class=MsoNormal><span lang=EN-GB>Neither levetiracetam nor its primary
metabolite are significantly bound to plasma proteins (</span><span lang=EN-GB
style='font-family:Symbol'>&lt;</span><span lang=EN-GB>&nbsp;10&nbsp;%).</span></p>

<p class=MsoNormal><span lang=EN-GB>The volume of distribution of levetiracetam
is approximately 0.5 to 0.7&nbsp;l/kg, a value close to the total body water
volume.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Levetiracetam
is not extensively metabolised in humans. The major metabolic pathway
(24&nbsp;% of the dose) is an enzymatic hydrolysis of the acetamide group.
Production of the primary metabolite, ucb&nbsp;L057, is not supported by liver
cytochrome P<sub>450</sub> isoforms. Hydrolysis of the acetamide group was
measurable in a large number of tissues including blood cells. The metabolite
ucb&nbsp;L057 is pharmacologically inactive.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Two minor metabolites were also identified.
One was obtained by hydroxylation of the pyrrolidone ring (1.6&nbsp;% of the
dose) and the other one by opening of the pyrrolidone ring (0.9&nbsp;% of the
dose). </span></p>

<p class=MsoNormal><span lang=EN-GB>Other unidentified components accounted
only for 0.6&nbsp;% of the dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No enantiomeric interconversion was
evidenced <i>in vivo</i> for either levetiracetam or its primary metabolite.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>In vitro</i><span lang=EN-GB>, levetiracetam and its
primary metabolite have been shown not to inhibit the major human liver
cytochrome P<sub>450</sub> isoforms (CYP3A4, 2A6, </span>2C9<span lang=EN-GB>,
2C19, 2D6, 2E1 and 1A2), glucuronyl transferase<span style='text-transform:
uppercase'> (</span></span><span style='text-transform:uppercase'>UGT1A1 </span>and<span
style='text-transform:uppercase'> UGT1A6</span><span lang=EN-GB
style='text-transform:uppercase'>)</span><span lang=EN-GB> and epoxide
hydroxylase activities. In addition, levetiracetam does not affect the <i>in
vitro</i> glucuronidation of valproic acid.</span></p>

<p class=MsoNormal><span lang=EN-GB>In human hepatocytes in culture,
levetiracetam </span>had little or no effect on CYP1A2, SULT1E1 or UGT1A1.
Levetiracetam caused mild induction of CYP2B6 and CYP3A4. The in vitro data and
<i>in vivo</i> interaction data on oral contraceptives, digoxin and warfarin
indicate that no significant enzyme induction is expected <i>in vivo</i><span
lang=EN-GB>. Therefore, the interaction of Keppra with other substances, or <i>vice
versa,</i> is unlikely.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The plasma half-life in adults was 7</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>1&nbsp;hours and
did not vary either with dose, route of administration or repeated
administration. The mean total body clearance was 0.96&nbsp;ml/min/kg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The major route of excretion was via urine,
accounting for a mean 95&nbsp;% of the dose (approximately 93&nbsp;% of the
dose was excreted within 48&nbsp;hours). Excretion <i>via</i> faeces accounted
for only 0.3&nbsp;% of the dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>The cumulative urinary excretion of
levetiracetam and its primary metabolite accounted for 66&nbsp;% and 24&nbsp;%
of the dose, respectively during the first 48&nbsp;hours.</span></p>

<p class=MsoNormal><span lang=EN-GB>The renal clearance of levetiracetam and
ucb&nbsp;L057 is 0.6 and 4.2&nbsp;ml/min/kg respectively indicating that
levetiracetam is excreted by glomerular filtration with subsequent tubular
reabsorption and that the primary metabolite is also excreted by active tubular
secretion in addition to glomerular filtration. Levetiracetam elimination is
correlated to creatinine clearance.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Elderly</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the elderly, the half-life is increased
by about 40&nbsp;% (10 to 11&nbsp;hours). This is related to the decrease in
renal function in this population (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Renal
impairment</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The apparent body clearance of both
levetiracetam and of its primary metabolite is correlated to the creatinine
clearance. It is therefore recommended to adjust the maintenance daily dose of
Keppra, based on creatinine clearance in patients with moderate and severe
renal impairment (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In anuric end-stage renal disease adult
subjects the half-life was approximately 25 and 3.1&nbsp;hours during
interdialytic and intradialytic periods, respectively. </span></p>

<p class=MsoNormal><span lang=EN-GB>The fractional removal of levetiracetam was
51&nbsp;% during a typical 4-hour dialysis session.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hepatic
impairment</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In subjects
with mild and moderate hepatic impairment, there was no relevant modification
of the clearance of levetiracetam. In most subjects with severe hepatic
impairment, the clearance of levetiracetam was reduced by more than 50&nbsp;%
due to a concomitant renal impairment (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Children
(4 to 12 years)</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Following single oral dose administration
(20&nbsp;mg/kg) to epileptic children (6 to 12&nbsp;years), the half-life of
levetiracetam was 6.0&nbsp;hours. The apparent body weight adjusted clearance
was approximately 30&nbsp;% higher than in epileptic adults.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Following repeated oral dose administration
(20 to 60</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg/kg/day) to
epileptic children (4 to 12</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>years), levetiracetam was rapidly absorbed. Peak plasma
concentration was observed 0.5 to 1.0</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>hour after dosing. Linear and dose proportional increases were
observed for peak plasma concentration and area under the curve. The
elimination half-life was approximately 5</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>hours. The apparent body clearance was 1.1</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>ml/min/kg.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Infants
and children (1 month to 4 years)</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Following
single dose administration (20</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>mg/kg) of a 100</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>mg/ml oral solution to epileptic children (1&nbsp;month to 4</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>years), levetiracetam was rapidly
absorbed and peak plasma concentrations were observed approximately 1</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>hour after dosing. The
pharmacokinetic results indicated that half-life was shorter (5.3&nbsp;h) than
for adults (7.2&nbsp;h) and apparent clearance was faster (1.5&nbsp;ml/min/kg)
than for adults (0.96&nbsp;ml/min/kg). </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>In the population pharmacokinetic
analysis conducted in patients from 1 month to 16 years of age, body weight was
significantly correlated to apparent clearance (clearance increased with an
increase in body weight) and apparent volume of distribution. Age also had an
influence on both parameters. This effect was pronounced for the younger
infants, and subsided as age increased, to become negligible around 4 years of
age.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>In both population
pharmacokinetic analyses, there was about a 20<span lang=EN-GB>&nbsp;</span>%
increase of apparent clearance of levetiracetam when it was co-administered
with an enzyme-inducing antiepileptic medicinal product.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b><span lang=EN-GB>5.3 Preclinical safety data</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Non-clinical data reveal no special hazard
for humans based on conventional studies of safety pharmacology, genotoxicity
and carcinogenic potential. </span></p>

<p class=MsoNormal><span lang=EN-GB>Adverse effects not observed in clinical
studies but seen in the rat and to a lesser extent in the mouse at exposure
levels similar to human exposure levels and with possible relevance for
clinical use were liver changes, indicating an adaptive response such as
increased weight and centrilobular hypertrophy, fatty infiltration and
increased liver enzymes in plasma.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No adverse reactions on male or female
fertility or reproduction performance were observed in rats at doses up to 1800</span>&nbsp;mg/kg/day
(x 6 the MRHD on a mg/m2 or exposure basis) in parents and F1 generation.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>Two embryo&#8209;foetal
development (EFD) studies were performed in rats at 400, 1200 and
3600&nbsp;mg/kg/day. At 3600&nbsp;mg/kg/day, in only one of the 2 EFD studies,
there was a slight decrease in foetal weight associated with a marginal
increase in skeletal variations/minor anomalies. There was no effect on
embryomortality and no increased incidence of malformations. The NOAEL (No
Observed Adverse Effect Level) was 3600&nbsp;mg/kg/day for pregnant female rats
(x 12 the MRHD on a mg/m2 basis) and 1200&nbsp;mg/kg/day for fetuses. </p>

<p class=MsoNormal style='line-height:13.0pt'>Four embryo&#8209;foetal
development studies were performed in rabbits covering doses of 200, 600, 800,
1200 and 1800&nbsp;mg/kg/day. The dose level of 1800&nbsp;mg/kg/day induced a
marked maternal toxicity and a decrease in foetal weight associated with
increased incidence of fetuses with cardiovascular/skeletal anomalies. The
NOAEL was &lt;200&nbsp;mg/kg/day for the dams and 200&nbsp;mg/kg/day for the
fetuses (equal to the MRHD on a mg/m2 basis). </p>

<p class=MsoNormal style='line-height:13.0pt'>A peri- and post-natal
development study was performed in rats with levetiracetam doses of 70, 350 and
1800&nbsp;mg/kg/day. The NOAEL was &#8805;&nbsp;1800&nbsp;mg/kg/day for the F0
females, and for the survival, growth and development of the F1 offspring up to
weaning (x 6 the MRHD on a mg/m2 basis). </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Neonatal and
juvenile animal studies in rats and dogs demonstrated that there were no
adverse effects seen in any of the standard developmental or maturation
endpoints at doses up to 1800&nbsp;mg/kg/day </span>(x 6-17 the MRHD on a mg/m2
basis)</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='text-transform:uppercase'>6. PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.1 List
of excipients</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Tablet core:</u></p>

<p class=MsoNormal style='page-break-after:avoid'>Croscarmellose sodium</p>

<p class=MsoNormal style='page-break-after:avoid'>Macrogol 6000</p>

<p class=MsoNormal style='page-break-after:avoid'>Silica colloidal anhydrous </p>

<p class=MsoNormal style='page-break-after:avoid'>Magnesium stearate</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoBodyText><u><span style='font-size:11.0pt'>Film-coating</span></u><span
style='font-size:11.0pt'>:</span></p>

<p class=MsoNormal>Polyvinyl alcohol-part. Hydrolyzed</p>

<p class=MsoNormal><span lang=IT>Titanium dioxide (E171)</span></p>

<p class=MsoNormal><span lang=IT>Macrogol 3350</span></p>

<p class=MsoNormal><span lang=IT>Talc</span></p>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=IT>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Not
applicable.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>3 years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.4 Special
precautions for storage</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product does not require any
special storage conditions</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.5 Nature and contents of container</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Aluminium/PVC blisters placed into
cardboard boxes containing 10, 20, 30, 50, 60, 100 film-coated tablets and
multipacks containing 200 (2 packs of 100) film-coated tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aluminium/PVC
perforated unit dose blisters placed into cardboard boxes containing 100 x 1
film-coated tablet. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.6 Special precautions for disposal
</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=FR>7. MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=FR-BE>UCB Pharma
SA </span></p>

<p class=MsoNormal><span lang=FR-BE>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=DE>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>8. MARKETING AUTHORISATION
NUMBER(S)</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/020</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/021</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/022</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/023</span></p>

<p class=MsoNormal><span lang=PT-BR>EU/1/00/146/024</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/00/146/025</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/00/146/026</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/00/146/037</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>9. DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'>Date of first authorisation:
29 September 2000</p>

<p class=MsoNormal>Date of latest renewal: 20 August 2015</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>10. DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=Default style='line-height:13.0pt;page-break-after:avoid;text-autospace:
ideograph-numeric ideograph-other'><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
color:windowtext'>Detailed information on this medicinal product is available
on the website of the European Medicines Agency http://www.ema.europa.eu </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 100&nbsp;mg/ml oral solution</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each ml contains 100&nbsp;mg levetiracetam</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipients with known effect</span></u><span
lang=EN-GB>: </span></p>

<p class=MsoNormal><span lang=EN-GB>Each ml contains 2.7&nbsp;mg of methyl
parahydroxybenzoate (E218), 0.3&nbsp;mg of propyl parahydroxybenzoate (E216)
and 300&nbsp;mg of maltitol liquid.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see
section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>3. PHARMACEUTICAL <span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral solution.</span></p>

<p class=MsoNormal><span lang=EN-GB>Clear liquid.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='text-transform:uppercase'>4. Clinical particulars</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra is indicated as monotherapy in the
treatment of partial onset seizures with or without secondary generalisation in
adults and adolescents from 16 years of age with newly diagnosed epilepsy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra is indicated as adjunctive therapy</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the treatment of partial onset seizures with
or without secondary generalisation in adults, adolescents, children and
infants from 1 month of age with epilepsy.</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the treatment of </span>myoclonic seizures in
adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.</p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the treatment of primary generalised tonic-clonic
seizures in adults and adolescents from 12 years of age with Idiopathic
Generalised Epilepsy.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.2 Posology and method of administration</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Partial onset seizures</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dosing for monotherapy
(from 16 years of age) and adjunctive therapy is the same; as outlined below.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>All indications</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Adults (&#8805;18 years) and adolescents
(12 to 17 years) weighing 50 kg or more</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The initial therapeutic dose is 500&nbsp;mg
twice daily. This dose can be started on the first day of treatment. <span
style='color:black'>However, a lower initial dose of 250</span>&nbsp;<span
style='color:black'>mg twice daily may be given based on physician assessment
of seizure reduction versus potential side effects. This can be increased to
500 mg twice daily after two weeks.</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Depending upon the clinical response and
tolerability, the daily dose can be increased up to 1,500&nbsp;mg twice daily.
Dose changes can be made in 250 mg or 500&nbsp;mg twice daily increases or
decreases every two to four weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adolescents (12 to 17 years) weighing
below 50 kg and children from 1 month of age</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The physician should prescribe the most
appropriate pharmaceutical form, presentation and strength according to weight,
age and dose. Refer to <i>Paediatric population</i> section for dosing
adjustments based on weight.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Discontinuation</span></u></p>

<p class=MsoNormal><span lang=EN-GB>If levetiracetam has to be discontinued it
is recommended to withdraw it gradually (<i>e.g</i>. in adults and adolescents
weighing more than 50&nbsp;kg: 500&nbsp;mg decreases twice daily every two to
four weeks; in infants older than 6 months, children and adolescents weighing
less than 50&nbsp;kg: dose decrease should not exceed 10&nbsp;mg/kg twice daily
every two weeks; in infants (less than 6&nbsp;months): dose decrease should not
exceed 7&nbsp;mg/ kg twice daily every two weeks). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Elderly (65 years and older)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Adjustment of the dose is recommended in elderly
patients with compromised renal function (see Renal impairment below).</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i><span lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The daily dose must be individualised
according to renal function. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For adult patients, refer to the following
table and adjust the dose as indicated. To use this dosing table, an estimate
of the patients creatinine clearance (CL<sub>cr</sub>) in ml/min is needed.
The CL<sub>cr</sub> in ml/min may be estimated from serum creatinine (mg/dl)
determination, for adults and adolescents weighing 50&nbsp;kg or more, the
following formula:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB> [140-age
(years)] x weight (kg)</span></p>

<p class=MsoNormal><span lang=EN-GB>CL<sub>cr</sub> </span>(ml/min)<span
lang=EN-GB> = ----------------------------------------- (x 0.85 for women)</span></p>

<p class=MsoNormal><span lang=EN-GB> 72 x serum
creatinine (mg/dl)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Then <span lang=EN-GB>CL<sub>cr</sub></span> is adjusted for
body surface area (BSA) as follows:</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>  <span lang=DE>CL<sub>cr</sub>
(ml/min)</span></p>

<p class=MsoNormal><span lang=DE>CL<sub>cr</sub> (ml/min/1.73 m<sup>2</sup>) =
---------------------------- x 1.73 </span></p>

<p class=MsoNormal><span lang=DE>  </span><span
lang=FR-BE>BSA subject (m<sup>2</sup>)</span></p>

<p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Dosing adjustment for adult and adolescent
patients weighing more than 50&nbsp;kg with impaired renal function:</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Group</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Creatinine clearance (ml/min</span>/1.73m<sup>2</sup><span
  lang=EN-GB>)</span></p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Dose and frequency</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Normal</span></p>
  <p class=MsoNormal><span lang=EN-GB>Mild</span></p>
  <p class=MsoNormal><span lang=EN-GB>Moderate</span></p>
  <p class=MsoNormal><span lang=EN-GB>Severe</span></p>
  <p class=MsoNormal><span lang=EN-GB>End-stage renal disease patients</span></p>
  <p class=MsoNormal><span lang=EN-GB>undergoing dialysis <sup>(1)</sup></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;</span><span lang=EN-GB>&nbsp;80</span></p>
  <p class=MsoNormal><span lang=EN-GB>50-79</span></p>
  <p class=MsoNormal><span lang=EN-GB>30-49</span></p>
  <p class=MsoNormal><span lang=EN-GB>&lt;&nbsp;30</span></p>
  <p class=MsoNormal><span lang=EN-GB>-</span></p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>500 to 1,500&nbsp;mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>500 to 1,000 mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>250 to 750&nbsp;mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>250 to 500&nbsp;mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>500 to 1,000&nbsp;mg once daily <sup>(2)</sup></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><sup><span lang=EN-GB>(1)</span></sup><span lang=EN-GB> A
750&nbsp;mg loading dose is recommended on the first day of treatment with
levetiracetam.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(2)</span></sup><span lang=EN-GB>
Following dialysis, a 250 to 500&nbsp;mg supplemental dose is recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For children with renal impairment,
levetiracetam dose needs to be adjusted based on the renal function as
levetiracetam clearance is related to renal function. This recommendation is
based on a study in adult renally impaired patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The CL<sub>cr</sub> in ml/min</span>/1.73 m<sup>2</sup><span
lang=EN-GB> may be estimated from serum creatinine (mg/dl) determination, for
young adolescents, children and infants, using the following formula (Schwartz
formula): </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'> 
Height (cm) x ks</p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>CL<sub>cr</sub></span>
(ml/min/1.73 m<sup>2</sup>) = ------------------------------------</p>

<p class=MsoNormal style='page-break-after:avoid'> 
Serum Creatinine (mg/dl)</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>ks= 0.45 in Term infants to 1 year old; ks=
0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in
adolescent male</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Dosing
adjustment for infants, children and adolescent patients weighing less than 50
kg with impaired renal function:</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=621
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=130 rowspan=2 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Group</span></p>
  </td>
  <td width=113 rowspan=2 valign=top style='width:85.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Creatinine
  clearance (ml/min</span>/1.73m<sup>2</sup><span lang=EN-GB>)</span></p>
  </td>
  <td width=378 colspan=2 valign=top style='width:283.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Dose and frequency <sup>(1)</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infants 1
  to less than 6 months</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Infants 6 to 23<span
  lang=EN-GB>&nbsp;</span>months, children and adolescents weighing less than
  50<span lang=EN-GB>&nbsp;</span>kg </p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Normal</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span><span
  lang=EN-GB>&#8805;</span><span lang=EN-GB>80</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>7 to
  21&nbsp;mg/kg (0.07 to 0.21&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>10 to
  30&nbsp;mg/kg (0.10 to 0.30&nbsp;ml/kg) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Mild</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>50-79</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>7 to
  14&nbsp;mg/kg (0.07 to 0.14&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>10 to
  20&nbsp;mg/kg (0.10 to 0.20&nbsp;ml/kg) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Moderate</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>30-49</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>3.5 to
  10.5&nbsp;mg/kg (0.035 to 0.105&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>5 to
  15&nbsp;mg/kg (0.05 to 0.15&nbsp;ml/kg) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Severe</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&lt;&nbsp;30</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>3.5 to
  7&nbsp;mg/kg (0.035 to 0.07&nbsp;ml/kg) twice daily </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>5 to
  10&nbsp;mg/kg (0.05 to 0.10&nbsp;ml/kg) twice daily </span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>End-stage
  renal disease patients</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>undergoing
  dialysis </span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>--</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>7 to
  14&nbsp;mg/kg (0.07 to 0.14&nbsp;ml/kg) once daily <sup>(2) (4)</sup></span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>10
  to&nbsp;20 mg/kg (0.10 to 0.20&nbsp;ml/kg) once daily <sup>(3) (5)</sup></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB>(1)</span></sup><span
lang=EN-GB> Keppra oral solution should be used for doses under 250 mg, for
doses not multiple of 250 mg when dosing recommendation is not achievable by
taking multiple tablets and for patients unable to swallow tablets. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB>(2)</span></sup><span
lang=EN-GB> A 10.5&nbsp;mg/kg (0.105&nbsp;ml/kg) loading dose is recommended on
the first day of treatment with levetiracetam.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(3)</span></sup><span lang=EN-GB> A
15&nbsp;mg/kg (0.15&nbsp;ml/kg) loading dose is recommended on the first day of
treatment with levetiracetam.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(4)</span></sup><span lang=EN-GB>
Following dialysis, a 3.5 to 7&nbsp;mg/kg (0.035 to 0.07&nbsp;ml/kg)
supplemental dose is recommended.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(5)</span></sup><span lang=EN-GB>
Following dialysis, a 5 to 10&nbsp;mg/kg (0.05 to 0.10&nbsp;ml/kg) supplemental
dose is recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Hepatic impairment </span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No dose adjustment is needed in patients
with mild to moderate hepatic impairment. In patients with severe hepatic
impairment, the creatinine clearance may underestimate the renal insufficiency.
Therefore a 50&nbsp;% reduction of the daily maintenance dose is recommended
when the creatinine clearance is &lt;&nbsp;60&nbsp;ml/min/1.73 m<sup>2</sup>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The physician should prescribe the most appropriate pharmaceutical
form, presentation and strength according to age, weight and dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra oral solution is the preferred
formulation for use in infants and children under the age of 6 years. In
addition, the available dose strengths of the tablets are not appropriate for initial
treatment in children weighing less than 25 kg, for patients unable to swallow
tablets or for the administration of doses below 250 mg. In all of the above
cases Keppra oral solution should be used.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Monotherapy</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The safety
and efficacy of Keppra in children and adolescents below 16 years as
monotherapy treatment have not been established.</span></p>

<p class=MsoNormal style='page-break-after:avoid'>No data are available.</p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i>Adolescents (16 and 17 years of age) weighing 50 kg or
more with partial onset seizures with or without secondary generalisation </i>w<i>ith
newly diagnosed epilepsy</i></p>

<p class=MsoNormal>Please refer to the above section on <i>Adults (&#8805;18
years) and adolescents (12 to 17 years) weighing 50 kg or more</i>. </p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Add-on
therapy for infants aged 6 to 23 months, children (2 to 11 years) and
adolescents (12 to 17 years) weighing less than 50 kg</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The initial
therapeutic dose is 10&nbsp;mg/kg twice daily. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Depending
upon the clinical response and tolerability, the dose can be increased by 10
mg/kg twice daily every 2 weeks up to 30&nbsp;mg/kg twice daily. Dose changes
should not exceed increases or decreases of 10&nbsp;mg/kg twice daily every two
weeks. The lowest effective dose should be used for all indications.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Dose in children 50&nbsp;kg or greater is
the same as in adults for all indications. </span></p>

<p class=MsoNormal>Please refer to the above section on <i>Adults (&#8805;18
years) and adolescents (12 to 17 years) weighing 50 kg or more </i>for all
indications.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Dose
recommendations for infants from 6 months of age, children and adolescents:</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Weight</span></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Starting
  dose: </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>10&nbsp;mg/kg
  twice daily</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Maximum
  dose: </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>30&nbsp;mg/kg
  twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>6 kg </span><sup><span
  lang=EN-GB>(1)</span></sup></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>60 mg (0.6
  ml) twice daily</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>180 mg
  (1.8 ml) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>10 kg </span><sup><span
  lang=EN-GB>(1)</span></sup></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>100 mg (1
  ml) twice daily</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>300 mg (3
  ml) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>15 kg </span><sup><span
  lang=EN-GB>(1)</span></sup></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>150 mg
  (1.5 ml) twice daily</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>450 mg
  (4.5 ml) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>20 kg </span><sup><span
  lang=EN-GB>(1)</span></sup></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>200 mg (2
  ml) twice daily</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>600 mg (6
  ml) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>25 kg</span></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>250 mg twice
  daily</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>750 mg
  twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>From 50 kg
  </span><sup><span lang=EN-GB>(2)</span></sup></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>500 mg
  twice daily</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>1,500 mg
  twice daily</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB>(1) </span></sup><span
lang=EN-GB>Children 25&nbsp;kg or less should preferably start the treatment
with Keppra 100&nbsp;mg/ml oral solution.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB>(2) </span></sup><span
lang=EN-GB>Dose in children and adolescents 50&nbsp;kg or more is the same as
in adults.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Add-on therapy for infants aged from 1
month to less than 6 months</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The initial therapeutic dose is
7&nbsp;mg/kg twice daily. </span></p>

<p class=MsoNormal><span lang=EN-GB>Depending upon the clinical response and
tolerability, the dose can be increased by 7 mg/kg twice daily every 2 weeks up
to recommended dose of 21&nbsp;mg/kg twice daily. Dose changes should not
exceed increases or decreases of 7&nbsp;mg/kg twice daily every two weeks. The
lowest effective dose should be used.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Infants should start the treatment with Keppra 100&nbsp;mg/ml oral
solution.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Dose recommendations for infants aged <u>from
1 month to less than 6 months:</u></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Weight</span></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Starting dose: </span></p>
  <p class=MsoNormal><span lang=EN-GB>7&nbsp;mg/kg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=254 valign=top style='width:190.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Maximum dose: </span></p>
  <p class=MsoNormal><span lang=EN-GB>21&nbsp;mg/kg twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>4 kg</span></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>28&nbsp;mg (0.3&nbsp;ml) twice daily</span></p>
  </td>
  <td width=254 valign=top style='width:190.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>84&nbsp;mg (0.85&nbsp;ml) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>5 kg</span></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>35&nbsp;mg (0.35&nbsp;ml) twice daily</span></p>
  </td>
  <td width=254 valign=top style='width:190.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>105&nbsp;mg (1.05&nbsp;ml) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>7 kg</span></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>49&nbsp;mg (0.5&nbsp;ml)twice daily</span></p>
  </td>
  <td width=254 valign=top style='width:190.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>147&nbsp;mg (1.5&nbsp;ml) twice daily</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Three presentations are
available: </p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;line-height:normal'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>A 300&nbsp;ml bottle with a 10&nbsp;ml oral syringe (delivering up to
1000&nbsp;mg levetiracetam) graduated every 0.25&nbsp;ml (corresponding to
25&nbsp;mg). </p>

<p class=MsoNormal style='margin-left:35.45pt;line-height:normal'>This presentation
should be prescribed for children aged <u>4 years and older</u>, adolescents
and adults.</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;line-height:normal'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>A 150<span lang=EN-GB>&nbsp;</span>ml bottle with a 3&nbsp;ml oral
syringe (delivering up to 300<span lang=EN-GB>&nbsp;</span>mg levetiracetam)
graduated every 0.1<span lang=EN-GB>&nbsp;</span>ml (corresponding to 10<span
lang=EN-GB>&nbsp;</span>mg)</p>

<p class=MsoNormal style='margin-left:35.45pt;line-height:normal;text-autospace:
none'>In order to ensure the accuracy of the dosing, this presentation should
be prescribed for infants and young children aged <u>from </u><u><span
lang=EN-GB>6 months</span></u><u> to less than 4 years</u>. </p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;line-height:normal'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>A 150<span lang=EN-GB>&nbsp;</span>ml bottle with a 1&nbsp;ml oral
syringe (delivering up to 100<span lang=EN-GB>&nbsp;</span>mg levetiracetam)
graduated every 0.05<span lang=EN-GB>&nbsp;</span>ml (corresponding to 5<span
lang=EN-GB>&nbsp;</span>mg)</p>

<p class=MsoNormal style='margin-left:35.45pt;line-height:normal;text-autospace:
none'>In order to ensure the accuracy of the dosing, this presentation should
be prescribed for infants aged <u>1 month to less than </u><u><span lang=EN-GB>6
months</span></u>. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The oral solution may be diluted in a glass
of water or babys bottle and may be taken with or without food. After oral
administration the bitter taste of levetiracetam may be experienced.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
to the active substance or other pyrrolidone derivatives or to any of the
excipients</span><span lang=EN-GB> listed in section 6.1</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.4 Special warnings and precautions for use</span></b></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Renal impairment</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The administration of levetiracetam to
patients with renal impairment may require dose adjustment. In patients with
severely impaired hepatic function, assessment of renal function is recommended
before dose selection (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u>Acute Kidney injury</u></p>

<p class=MsoNormal>The use of levetiracetam has been very rarely associated
with acute kidney injury, with a time to onset ranging from a few days to
several months.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Blood cell counts</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rare cases of decreased blood cell counts
(neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia)
have been described in association with levetiracetam administration, generally
at the beginning of the treatment. Complete blood cell counts are advised in
patients experiencing important weakness, pyrexia, recurrent infections or
coagulation disorders (section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u>Suicide</u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Suicide,
suicide attempt, <span lang=EN-GB>suicidal ideation and behaviour have been
reported in patients treated with anti-epileptic agents (including
levetiracetam). A meta-analysis of randomized placebo-controlled trials of
anti-epileptic medicinal products has shown a small increased risk of suicidal
thoughts and behaviour. The mechanism of this risk is not known. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Therefore, patients should be monitored for
signs of depression and/or suicidal ideation and behaviours and appropriate
treatment should be considered. Patients (and caregivers of patients) should be
advised to seek medical advice should signs of depression and/or suicidal
ideation or behaviour emerge.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Abnormal and aggressive behaviours </span></u></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam may cause psychotic symptoms
and behavioural abnormalities including irritability and aggressiveness.
Patients treated with levetiracetam should be monitored for developing
psychiatric signs suggesting important mood and/or personality changes. If such
behaviours are noticed, treatment adaptation or gradual discontinuation should
be considered. If discontinuation is considered, please refer to section 4.2.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u>Worsening of seizures</u></p>

<p class=MsoNormal>As with other types of antiepileptic drugs, levetiracetam
may rarely exacerbate seizure frequency or severity. This paradoxical effect
was mostly reported within the first month after levetiracetam initiation or
increase of the dose, and was reversible upon drug discontinuation or dose decrease.
Patients should be advised to consult their physician immediately in case of
aggravation of epilepsy.</p>

<p class=MsoNormal><u><span style='font-size:12.0pt'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Electrocardiogram QT interval
prolongation</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rare cases of ECG QT interval prolongation
have been observed during the post-marketing surveillance. Levetiracetam should
be used with caution in patients with QTc-interval prolongation, in patients
concomitantly treated with drugs affecting the QTc-interval, or in patients
with relevant pre-existing cardiac disease or electrolyte disturbances.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Available data in children did not suggest
impact on growth and puberty. However, long term effects on learning,
intelligence, growth, endocrine function, puberty and childbearing potential in
children remain unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipients</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 100&nbsp;mg/ml oral solution
contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate
(E216) which may cause allergic reactions (possibly delayed).</span></p>

<p class=MsoNormal><span lang=EN-GB>It also contains maltitol liquid; patients
with rare hereditary problems of fructose intolerance should not take this
medicinal product.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.5 Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Antiepileptic
medicinal products</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Pre-marketing
data from clinical studies conducted in adults indicate that levetiracetam did
not influence the serum concentrations of existing antiepileptic medicinal
products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine,
gabapentin and primidone) and that these antiepileptic medicinal products did
not influence the pharmacokinetics of levetiracetam.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-AU
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>As in adults,
there is no evidence of clinically significant medicinal product interactions
in paediatric patients receiving up to 60</span><span lang=EN-GB>&nbsp;<span
style='layout-grid-mode:line'>mg/kg/day levetiracetam.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>A
retrospective assessment of pharmacokinetic interactions in children and
adolescents with epilepsy (4 to 17</span><span lang=EN-GB>&nbsp;<span
style='layout-grid-mode:line'>years) confirmed that adjunctive therapy with
orally administered levetiracetam did not influence the steady-state serum
concentrations of concomitantly administered carbamazepine and valproate.
However, data suggested </span></span><span lang=EN-GB>a 20</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% higher levetiracetam clearance in
children taking</span><span lang=EN-GB style='layout-grid-mode:line'>
enzyme-inducing antiepileptic medicinal products. Dose adjustment is not
required. </span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Probenecid</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Probenecid (500&nbsp;mg four times daily),
a renal tubular secretion blocking agent, has been shown to inhibit the renal
clearance of the primary metabolite, but not of levetiracetam. Nevertheless,
the concentration of this metabolite remains low. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Methotrexate</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Concomitant administration of levetiracetam
and methotrexate has been reported to decrease methotrexate clearance,
resulting in increased/prolonged blood methotrexate concentration to
potentially toxic levels. Blood methotrexate and levetiracetam levels should be
carefully monitored in patients treated concomitantly with the two drugs.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-AU style='layout-grid-mode:line'>Oral
contraceptives and other pharmacokinetics interactions</span></u></p>

<p class=MsoNormal><span lang=EN-AU style='layout-grid-mode:line'>Levetiracetam
1,000&nbsp;mg daily did not influence the pharmacokinetics of oral
contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters
(luteinizing hormone and progesterone) were not modified. Levetiracetam 2,000&nbsp;mg
daily did not influence the pharmacokinetics of digoxin and warfarin;
prothrombin times were not modified. Co-administration with digoxin, oral
contraceptives and warfarin did not influence the pharmacokinetics of
levetiracetam.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Laxatives</u></p>

<p class=MsoNormal><span lang=EN-GB>There have been isolated reports of
decreased levetiracetam efficacy when the osmotic laxative macrogol has been
concomitantly administered with oral levetiracetam. Therefore, macrogol should
not be taken orally for one hour before and for one hour after taking levetiracetam.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u>Food and alcohol</u></p>

<p class=MsoNormal>The extent of absorption of levetiracetam was not altered by
food, but the rate of absorption was slightly reduced.</p>

<p class=MsoNormal>No data on the interaction of levetiracetam with alcohol are
available.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.6 Fertility, pregnancy and lactation</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Women of child bearing potential </span></u></p>

<p class=MsoNormal><span lang=EN-GB>Specialist advice should be given to women
who are of childbearing potential. Treatment with levetiracetam should be
reviewed when a woman is planning to become pregnant. As with all antiepileptic
medicines, sudden discontinuation of levetiracetam should be avoided as this
may lead to breakthrough seizures that could have serious consequences for the
woman and the unborn child. Monotherapy should be preferred whenever possible
because therapy with multiple antiepileptic medicines AEDs could be associated
with a higher risk of congenital malformations than monotherapy, depending on
the associated antiepileptics.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><span lang=EN-GB>A large amount of postmarketing data on
pregnant women exposed to levetiracetam monotherapy (more than 1800, among
which in more than 1500 exposure occurred during the 1st trimester) do not
suggest an increase in the risk for major congenital malformations. Only
limited evidence is available on the neurodevelopment of children exposed to
Keppra monotherapy in utero. However, current epidemiological studies (on about
100 children) do not suggest an increased risk of neurodevelopmental disorders
or delays. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Levetiracetam
can be used during pregnancy, if after careful assessment it is considered
clinically needed. In such case, the lowest effective dose is recommended.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Physiological
changes during pregnancy may affect levetiracetam concentration. D</span>ecrease
in levetiracetam plasma concentrations has been observed during pregnancy. This
decrease is more pronounced during the third trimester (up to 60% of baseline
concentration before pregnancy). Appropriate clinical management of pregnant
women treated with levetiracetam should be ensured. </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Breastfeeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam is excreted in human breast
milk. Therefore, breast-feeding is not recommended. </span></p>

<p class=MsoNormal style='line-height:normal'>However, if levetiracetam
treatment is needed during breastfeeding, the benefit/risk of the treatment
should be weighed considering the importance of breastfeeding.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u>Fertility</u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>No impact on fertility was detected in animal studies (see section
5.3). No clinical data are available, potential risk for human is unknown.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.7 Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam has minor or moderate
influence on the ability to drive and use machines.</span><span lang=EN-GB> Due
to possible different individual sensitivity, some patients might experience
somnolence or other central nervous system related symptoms, </span><span
lang=EN-GB>especially</span><span lang=EN-GB> </span><span lang=EN-GB>at the
beginning of treatment or following a dose increase. Therefore, caution is
recommended in those patients when performing skilled tasks, <i>e.g</i>.
driving vehicles or operating machinery. Patients are advised not to drive or
use machines until it is established that </span><span lang=EN-GB>their</span><span
lang=EN-GB> ability to perform such activities is not affected.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Summary
of the safety profile</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The most frequently reported adverse
reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness. The
adverse reaction profile presented below is based on the analysis of pooled
placebo-controlled clinical trials with all indications studied, with a total
of 3,416 patients treated with levetiracetam. These data are supplemented with
the use of levetiracetam in corresponding open-label extension studies, as well
as post-marketing experience. The safety profile of levetiracetam is generally
similar across age groups (adult and paediatric patients) and across the
approved epilepsy indications. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Tabulated list of adverse
reactions</u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Adverse
reactions reported in clinical studies (adults, adolescents, children and
infants &gt; 1&nbsp;month) and from post-marketing experience are listed in the
following table per System Organ Class and per frequency. Adverse reactions
are presented in the order of decreasing seriousness and their frequency is
defined as follows: very common (&#8805;1/10); common (&#8805;1/100 to
&lt;1/10); uncommon (&#8805;1/1,000 to &lt;1/100); rare (&#8805;1/10,000 to
&lt;1/1,000) and very rare (&lt;1/10,000).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="96%"
 style='margin-left:9.9pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="19%" rowspan=2 style='width:19.56%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>MedDRA SOC</span></u></p>
   </td>
   <td width="80%" colspan=4 valign=top style='width:80.44%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center'><u><span
   lang=EN-GB style='font-size:10.0pt'>Frequency category</span></u></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width="20%" valign=top style='width:20.5%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Very common</span></u></p>
   </td>
   <td width="17%" valign=top style='width:17.36%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Common</span></u></p>
   </td>
   <td width="20%" valign=top style='width:20.76%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Uncommon </span></u></p>
   </td>
   <td width="21%" valign=top style='width:21.84%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Rare</span></u></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Infections
  and infestations</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Nasopharyngitis </span></p>
  </td>
  <td width="17%" valign=top style='width:17.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Infection</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Blood and
  lymphatic system disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>Thrombocytopenia,
  leukopenia</span></p>
  </td>
  <td width="21%" valign=top style='width:21.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>Pancytopenia,<sup>
  </sup>neutropenia, agranulocytosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Immune system
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>Drug reaction
  with eosinophilia and systemic symptoms (DRESS),</span></p>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>Hypersensitivity
  (including angioedema and anaphylaxis)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Metabolism
  and nutrition disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Anorexia</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Weight decreased
  , weight increase</span></p>
  </td>
  <td width="21%" valign=top style='width:21.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Hyponatraemia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Psychiatric
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Depression,
  hostility/ aggression, anxiety, <br>
  insomnia, nervousness/ irritability</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Suicide attempt,
  suicidal ideation</span><span lang=EN-AU style='font-size:10.0pt'>,<sup> </sup></span><span
  lang=EN-GB style='font-size:10.0pt'>psychotic disorder</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>abnormal behaviour, hallucination</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>anger, confusional state</span><sup><span
  lang=EN-GB style='font-size:10.0pt'> </span></sup><span lang=EN-GB
  style='font-size:10.0pt'>, panic attack, affect lability/mood swings,
  agitation</span></p>
  </td>
  <td width="21%" valign=top style='width:21.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Completed
  suicide</span><span lang=EN-AU style='font-size:10.0pt'>, </span><span
  lang=EN-GB style='font-size:10.0pt'>personality disorder, thinking abnormal,
  delirium</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Nervous
  system disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Somnolence,
  headache</span></p>
  </td>
  <td width="17%" valign=top style='width:17.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Convulsion,
  balance disorder, dizziness, lethargy, tremor</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Amnesia, memory
  impairment, coordination abnormal/ataxia, paraesthesia</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>disturbance in attention</span></p>
  </td>
  <td width="21%" valign=top style='width:21.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Choreoathetosis,
  dyskinesia, hyperkinesia, gait disturbance, encephalopathy, seizures
  aggravated</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Eye disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Diplopia, vision
  blurred</span></p>
  </td>
  <td width="21%" valign=top style='width:21.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Ear and
  labyrinth disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Vertigo</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Cardiac
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>Electrocardiogram
  QT prolonged</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Respiratory,
  thoracic and mediastinal disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Cough</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Gastrointestinal
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT style='font-size:10.0pt'>Abdominal pain,
  diarrhoea, dyspepsia, vomiting, nausea</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Pancreatitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-AU style='font-size:10.0pt'>Hepatobiliary
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Liver function
  test abnormal</span></p>
  </td>
  <td width="21%" valign=top style='width:21.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Hepatic failure,
  hepatitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Renal and
  Urinary Disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Acute Kidney
  injury</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Skin and
  subcutaneous tissue disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Rash</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Alopecia</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>eczema, pruritus, </span></p>
  </td>
  <td width="21%" valign=top style='width:21.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Toxic epidermal
  necrolysis, Stevens-Johnson syndrome, erythema multiforme</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Musculoskeletal
  and connective tissue disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Muscular
  weakness, myalgia</span></p>
  </td>
  <td width="21%" valign=top style='width:21.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Rhabdomyolysis
  and blood creatine phosphokinase increased*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>General
  disorders and administration site conditions</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Asthenia/</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>fatigue</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Injury,
  poisoning and procedural complications</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Injury</span></p>
  </td>
  <td width="21%" valign=top style='width:21.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>* Prevalence is significantly higher in
Japanese patients when compared to non-Japanese patients. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Description of selected adverse
reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU>The risk of
anorexia is higher when levetiracetam is coadministered with topiramate.</span></p>

<p class=MsoNormal><span lang=EN-GB>In several cases of alopecia, recovery was
observed when levetiracetam was discontinued.</span></p>

<p class=MsoNormal><span style='font-family:"TimesNewRomanPSMT",serif'>Bone
marrow suppression was identified in some of the cases of pancytopenia.</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cases of encephalopathy generally occurred
at the beginning of the treatment (few days to a few months) and were
reversible after treatment discontinuation.</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients aged 1 month to less than 4
years, a total of 190 patients have been treated with levetiracetam in
placebo-controlled and open label extension studies. Sixty of these patients
were treated with levetiracetam in placebo-controlled studies. In patients
aged 4-16 years, a total of 645 patients have been treated with levetiracetam
in placebo-controlled and open label extension studies. 233 of these patients
were treated with levetiracetam in placebo-controlled studies. In both these
paediatric age ranges, these data are supplemented with the post-marketing
experience of the use of levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In addition, 101 infants aged less than 12
months have been exposed in a post authorization safety study. No new safety
concerns for levetiracetam were identified for infants less than 12 months of
age with epilepsy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The adverse reaction profile of
levetiracetam is generally similar across age groups and across the approved
epilepsy indications. Safety results in paediatric patients in
placebo-controlled clinical studies were consistent with the safety profile of
levetiracetam in adults except for behavioural and psychiatric adverse
reactions which were more common in children than in adults. In children and
adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation
(common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%),
aggression (common, 8.2%), abnormal behaviour (common, 5.6%), and lethargy
(common, 3.9%) were reported more frequently than in other age ranges or in the
overall safety profile. In infants and children aged 1 month to less than 4
years, irritability (very common, 11.7%) and coordination abnormal (common,
3.3%) were reported more frequently than in other age groups or in the overall
safety profile. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>A double-blind,
placebo-controlled paediatric safety study with a non-inferiority design has
assessed the cognitive and neuropsychological effects of </span><span
lang=EN-GB>levetiracetam</span><span lang=EN-GB> in children 4 to 16 years of
age with partial onset seizures. It was concluded that Keppra was not different
(non inferior) from placebo with regard to the change from baseline of the
Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol
population. Results related to behavioural and emotional functioning indicated
a worsening in </span><span lang=EN-GB>levetiracetam</span><span lang=EN-GB>
treated patients on aggressive behaviour as measured in a standardised and
systematic way using a validated instrument (CBCL  Achenbach Child Behavior
Checklist). However, subjects, who took </span><span lang=EN-GB>levetiracetam</span><span
lang=EN-GB> in the long-term open label follow-up study, did not experience a
worsening, on average, in their behavioural and emotional functioning; in
particular measures of aggressive behaviour were not worse than baseline.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Reporting of
suspected adverse reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:silver'>the national reporting
system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a></span>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Symptoms</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Somnolence, agitation, aggression,
depressed level of consciousness, respiratory depression and coma were observed
with Keppra overdoses.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Management of overdose</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After an acute overdose, the stomach may be
emptied by gastric lavage or by induction of emesis. There is no specific
antidote for levetiracetam. Treatment of an overdose will be symptomatic and
may include haemodialysis. The dialyser extraction efficiency is 60&nbsp;% for
levetiracetam and 74&nbsp;% for the primary metabolite.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5. PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.1  Pharmacodynamic properties</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic group: antiepileptics,
other antiepileptics, ATC code: N03AX14</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The active substance, levetiracetam, is a
pyrrolidone derivative (S-enantiomer of </span><span lang=EN-GB
style='font-family:Symbol'>a</span><span lang=EN-GB>-ethyl-2-oxo-1-pyrrolidine
acetamide), chemically unrelated to existing antiepileptic active substances.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Mechanism of action</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The mechanism of action of levetiracetam
still remains to be fully elucidated. <i>In vitro</i> and <i>in vivo</i>
experiments suggest that levetiracetam does not alter basic cell
characteristics and normal neurotransmission. </span></p>

<p class=MsoNormal><i><span lang=EN-GB>In vitro</span></i><span lang=EN-GB>
studies show that levetiracetam affects intraneuronal Ca<sup>2+</sup> levels by
partial inhibition of N-type Ca<sup>2+</sup> currents and by reducing the
release of Ca<sup>2+</sup> from intraneuronal stores. In addition it partially
reverses the reductions in GABA- and glycine-gated currents induced by zinc and
</span><span lang=EN-GB style='font-family:Symbol'>b</span><span lang=EN-GB>-carbolines.
Furthermore, levetiracetam has been shown in <i>in vitro</i> studies to bind to
a specific site in rodent brain tissue. This binding site is the synaptic
vesicle protein 2A, believed to be involved in vesicle fusion and
neurotransmitter exocytosis. Levetiracetam and related analogs show a rank
order of affinity for binding to the synaptic vesicle protein 2A which
correlates with the potency of their anti-seizure protection in the mouse audiogenic
model of epilepsy. This finding suggests that the interaction between
levetiracetam and the synaptic vesicle protein 2A seems to contribute to the
antiepileptic mechanism of action of the medicinal product.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Pharmacodynamic effects</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam induces seizure protection in
a broad range of animal models of partial and primary generalised seizures
without having a pro-convulsant effect. The primary metabolite is inactive.</span></p>

<p class=MsoNormal><span lang=EN-GB>In man, an activity in both partial and
generalised epilepsy conditions (epileptiform discharge/photoparoxysmal
response) has confirmed the broad spectrum pharmacological profile of
levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adjunctive therapy in the treatment of
partial onset seizures with or without secondary generalisation in adults,
adolescents, children and infants from 1 month of age with epilepsy.</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In adults, levetiracetam efficacy has been
demonstrated in 3 double-blind, placebo-controlled studies at 1000</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg, 2000</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>mg, or 3000</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg/day,
given in 2 divided doses, with a treatment duration of up to 18</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>weeks. In a pooled analysis, the
percentage of patients who achieved 50% or greater reduction from baseline in
the partial onset seizure frequency per week at stable dose (12/14</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>weeks) was of 27.7</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>%, 31.6</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% and 41.3</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>%
for patients on 1000, 2000 or 3000</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>mg levetiracetam respectively and of 12.6</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% for patients on placebo. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Paediatric population</u></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal>In paediatric patients (4 to 16<span lang=EN-GB>&nbsp;</span>years
of age), levetiracetam efficacy was established in a double-blind,
placebo-controlled study, which included 198 patients and had a treatment
duration of 14<span lang=EN-GB>&nbsp;</span>weeks. In this study, the patients
received levetiracetam as a fixed dose of 60<span lang=EN-GB>&nbsp;</span>mg/kg/day
(with twice a day dosing).</p>

<p class=MsoNormal><span lang=EN-GB>44.6</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% of the levetiracetam treated patients and 19.6</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% of the patients on placebo had a 50</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% or greater reduction from baseline
in the partial onset seizure frequency per week.</span><span lang=EN-GB> </span><span
lang=EN-GB>With continued long-term treatment, 11.4</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% of the patients were seizure-free for at least 6 months and 7.2</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% were seizure-free for at least 1</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>year.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In paediatric patients (1<span lang=EN-GB>&nbsp;</span>month
to less than 4<span lang=EN-GB>&nbsp;</span>years of age), levetiracetam
efficacy was established in a double-blind, placebo-controlled study, which
included 116 patients and had a treatment duration of 5<span lang=EN-GB>&nbsp;</span>days.
In this study, patients were prescribed 20<span lang=EN-GB>&nbsp;</span>mg/kg,
25<span lang=EN-GB>&nbsp;</span>mg/kg, 40<span lang=EN-GB>&nbsp;</span>mg/kg or
50<span lang=EN-GB>&nbsp;</span>mg/kg daily dose of oral solution based on
their age titration schedule. A dose of 20<span lang=EN-GB>&nbsp;</span>mg/kg/day
titrating to 40<span lang=EN-GB>&nbsp;</span>mg/kg/day for infants one month to
less than six months and a dose of 25 mg/kg/day titrating to 50<span
lang=EN-GB>&nbsp;</span>mg/kg/day for infants and children 6 months to less
than 4<span lang=EN-GB>&nbsp;</span>years old, was use in this study. The total
daily dose was administered twice daily.</p>

<p class=MsoNormal><span lang=EN-GB>The primary measure of effectiveness was
the responder rate (percent of patients with &#8805;&nbsp;50% reduction from
baseline in average daily partial onset seizure frequency) assessed by a
blinded central reader using a 48-hour video EEG.&nbsp; The efficacy analysis
consisted of 109 patients who had at least 24&nbsp;hours of video EEG in both
baseline and evaluation periods. <span class=msoins0>43.6</span>&nbsp;<span
class=msoins0>% of the levetiracetam treated patients and 19.6</span>&nbsp;<span
class=msoins0>% of the patients on placebo were considered as
responders.&nbsp;The results are consistent across age group.</span></span><span
lang=EN-GB> With continued long-term treatment, 8.6</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% of the patients were seizure-free for at least 6 months and 7.8</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% were seizure-free for at least 1</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>year.</span></p>

<p class=MsoNormal>35 infants aged less than 1 year with partial onset seizures
have been exposed in placebo-control clinical studies of which only 13 were
aged &lt; 6 months.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i><span lang=EN-GB>Monotherapy in the treatment of partial
onset seizures with or without secondary generalisation in patients from 16
years of age with newly diagnosed epilepsy. </span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Efficacy of levetiracetam as monotherapy was established in
a double-blind, parallel group, non-inferiority comparison to carbamazepine-controlled
release (CR) in 576 patients 16 years of age or older with newly or recently
diagnosed epilepsy. The patients had to present with unprovoked partial
seizures or with generalized tonic-clonic seizures only. The patients were
randomized to carbamazepine CR 400  1200<span lang=EN-GB>&nbsp;</span>mg/day
or levetiracetam 1000  3000<span lang=EN-GB>&nbsp;</span>mg/day, the duration
of the treatment was up to 121<span lang=EN-GB>&nbsp;</span>weeks depending on
the response. </p>

<p class=MsoNormal>Six-month seizure freedom was achieved in 73.0<span
lang=EN-GB>&nbsp;</span>% of levetiracetam-treated patients and 72.8<span
lang=EN-GB>&nbsp;</span>% of carbamazepine-CR treated patients; the adjusted
absolute difference between treatments was 0.2% (95<span lang=EN-GB>&nbsp;</span>%
CI: -7.8 8.2). More than half of the subjects remained seizure free for 12
months (56.6<span lang=EN-GB>&nbsp;</span>% and 58.5<span lang=EN-GB>&nbsp;</span>%
of subjects on levetiracetam and on carbamazepine CR respectively).</p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>In a study
reflecting clinical practice, the concomitant antiepileptic medication could be
withdrawn in a limited number of patients who responded to levetiracetam
adjunctive therapy (36 adult patients out of 69). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adjunctive therapy in the treatment of
myoclonic seizures in adults and adolescents from 12 years of age with Juvenile
Myoclonic Epilepsy.</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Levetiracetam efficacy was established in a double-blind,
placebo-controlled study of 16 weeks duration, in patients 12<span lang=EN-GB>&nbsp;</span>years
of age and older suffering from idiopathic generalized epilepsy with myoclonic
seizures in different syndromes. The majority of patients presented with
juvenile myoclonic epilepsy.</p>

<p class=MsoNormal>In this study, levetiracetam, dose was 3000<span lang=EN-GB>&nbsp;</span>mg/day
given in 2 divided doses. </p>

<p class=MsoNormal>58.3<span lang=EN-GB>&nbsp;</span>% of the levetiracetam
treated patients and 23.3<span lang=EN-GB>&nbsp;</span>% of the patients on
placebo had at least a 50<span lang=EN-GB>&nbsp;</span>% reduction in myoclonic
seizure days per week. With continued long-term treatment, 28.6<span
lang=EN-GB>&nbsp;</span>% of the patients were free of myoclonic seizures for
at least 6 months and 21.0<span lang=EN-GB>&nbsp;</span>% were free of
myoclonic seizures for at least 1<span lang=EN-GB>&nbsp;</span>year.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adjunctive therapy in the treatment of
primary generalised tonic-clonic seizures in adults and adolescents from 12
years of age with idiopathic generalised epilepsy.</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Levetiracetam efficacy was established in a 24-week
double-blind, placebo-controlled study which included adults, adolescents and a
limited number of children suffering from idiopathic generalized epilepsy with
primary generalized tonic-clonic (PGTC) seizures in different syndromes
(juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence
epilepsy, or epilepsy with Grand Mal seizures on awakening). In this study,
levetiracetam dose was 3000<span lang=EN-GB>&nbsp;</span>mg/day for adults and
adolescents or 60<span lang=EN-GB>&nbsp;</span>mg/kg/day for children, given in
2 divided doses.</p>

<p class=MsoNormal>72.2<span lang=EN-GB>&nbsp;</span>% of the levetiracetam
treated patients and 45.2<span lang=EN-GB>&nbsp;</span>% of the patients on
placebo had a 50<span lang=EN-GB>&nbsp;</span>% or greater decrease in the
frequency of PGTC seizures per week. With continued long-term treatment, 47.4<span
lang=EN-GB>&nbsp;</span>% of the patients were free of tonic-clonic seizures
for at least 6 months and 31.5<span lang=EN-GB>&nbsp;</span>% were free of tonic-clonic
seizures for at least 1<span lang=EN-GB>&nbsp;</span>year.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.2 Pharmacokinetic properties</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam is a highly soluble and
permeable compound. The pharmacokinetic profile is linear with low intra- and
inter-subject variability. There is no modification of the clearance after
repeated administration. There is no evidence for any relevant gender, race or
circadian variability. The pharmacokinetic profile is comparable in healthy
volunteers and in patients with epilepsy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Due to its complete and linear absorption,
plasma levels can be predicted from the oral dose of levetiracetam expressed as
mg/kg bodyweight. Therefore, there is no need for plasma level monitoring of
levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A significant correlation between saliva
and plasma concentrations has been shown in adults and children (ratio of
saliva/plasma concentrations ranged from </span>1 to 1.7 for oral tablet
formulation and after 4<span lang=EN-GB>&nbsp;</span>hours post-dose for oral
solution formulation<span lang=EN-GB>).</span></p>

<p class=MsoEndnoteText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoEndnoteText style='page-break-after:avoid'><u><span lang=EN-GB>Adults
and adolescents</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Levetiracetam
is rapidly absorbed after oral administration. Oral absolute bioavailability is
close to 100&nbsp;%. </span></p>

<p class=MsoNormal><span lang=EN-GB>Peak plasma concentrations (C<sub>max</sub>)
are achieved at 1.3&nbsp;hours after dosing. Steady-state is achieved after two
days of a twice daily administration schedule.</span></p>

<p class=MsoNormal><span lang=EN-GB>Peak concentrations (C<sub>max</sub>) are
typically 31 and 43&nbsp;g/ml following a single 1,000&nbsp;mg dose and
repeated 1,000&nbsp;mg twice daily dose, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>The extent of absorption is
dose-independent and is not altered by food.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No tissue distribution data are available
in humans.</span></p>

<p class=MsoNormal><span lang=EN-GB>Neither levetiracetam nor its primary
metabolite are significantly bound to plasma proteins (</span><span lang=EN-GB
style='font-family:Symbol'>&lt;</span><span lang=EN-GB>&nbsp;10&nbsp;%).</span></p>

<p class=MsoNormal><span lang=EN-GB>The volume of distribution of levetiracetam
is approximately 0.5 to 0.7&nbsp;l/kg, a value close to the total body water
volume.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam is not extensively
metabolised in humans. The major metabolic pathway (24&nbsp;% of the dose) is
an enzymatic hydrolysis of the acetamide group. Production of the primary
metabolite, ucb&nbsp;L057, is not supported by liver cytochrome P<sub>450</sub>
isoforms. Hydrolysis of the acetamide group was measurable in a large number of
tissues including blood cells. The metabolite ucb&nbsp;L057 is
pharmacologically inactive.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Two minor metabolites were also identified.
One was obtained by hydroxylation of the pyrrolidone ring (1.6&nbsp;% of the
dose) and the other one by opening of the pyrrolidone ring (0.9&nbsp;% of the
dose). </span></p>

<p class=MsoNormal><span lang=EN-GB>Other unidentified components accounted
only for 0.6&nbsp;% of the dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No enantiomeric interconversion was
evidenced <i>in vivo</i> for either levetiracetam or its primary metabolite.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i>In vitro</i><span lang=EN-GB>, levetiracetam and its
primary metabolite have been shown not to inhibit the major human liver
cytochrome P<sub>450</sub> isoforms (CYP3A4, 2A6, </span>2C9<span lang=EN-GB>,
2C19, 2D6, 2E1 and 1A2), glucuronyl transferase<span style='text-transform:
uppercase'> (</span></span><span style='text-transform:uppercase'>UGT1A1 </span>and<span
style='text-transform:uppercase'> UGT1A6</span><span lang=EN-GB
style='text-transform:uppercase'>)</span><span lang=EN-GB> and epoxide
hydroxylase activities. In addition, levetiracetam does not affect the <i>in
vitro</i> glucuronidation of valproic acid.</span></p>

<p class=MsoNormal><span lang=EN-GB>In human hepatocytes in culture,
levetiracetam </span>had little or no effect on CYP1A2, SULT1E1 or UGT1A1.
Levetiracetam caused mild induction of CYP2B6 and CYP3A4. The in vitro data and
<i>in vivo</i> interaction data on oral contraceptives, digoxin and warfarin
indicate that no significant enzyme induction is expected <i>in vivo</i><span
lang=EN-GB>. Therefore, the interaction of Keppra with other substances, or <i>vice
versa,</i> is unlikely.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The plasma half-life in adults was 7</span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB>1&nbsp;hours and did not
vary either with dose, route of administration or repeated administration. The
mean total body clearance was 0.96&nbsp;ml/min/kg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The major route of excretion was via urine,
accounting for a mean 95&nbsp;% of the dose (approximately 93&nbsp;% of the
dose was excreted within 48&nbsp;hours). Excretion <i>via</i> faeces accounted
for only 0.3&nbsp;% of the dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>The cumulative urinary excretion of
levetiracetam and its primary metabolite accounted for 66&nbsp;% and 24&nbsp;%
of the dose, respectively during the first 48&nbsp;hours.</span></p>

<p class=MsoNormal><span lang=EN-GB>The renal clearance of levetiracetam and
ucb&nbsp;L057 is 0.6 and 4.2&nbsp;ml/min/kg respectively indicating that
levetiracetam is excreted by glomerular filtration with subsequent tubular
reabsorption and that the primary metabolite is also excreted by active tubular
secretion in addition to glomerular filtration. Levetiracetam elimination is
correlated to creatinine clearance.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Elderly</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the elderly, the half-life is increased
by about 40&nbsp;% (10 to 11&nbsp;hours). This is related to the decrease in
renal function in this population (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Renal impairment</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The apparent body clearance of both
levetiracetam and of its primary metabolite is correlated to the creatinine
clearance. It is therefore recommended to adjust the maintenance daily dose of
Keppra, based on creatinine clearance in patients with moderate and severe
renal impairment (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In anuric end-stage renal disease adult
subjects the half-life was approximately 25 and 3.1&nbsp;hours during
interdialytic and intradialytic periods, respectively. </span></p>

<p class=MsoNormal><span lang=EN-GB>The fractional removal of levetiracetam was
51&nbsp;% during a typical 4-hour dialysis session.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Hepatic impairment</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In subjects with mild and moderate hepatic
impairment, there was no relevant modification of the clearance of levetiracetam.
In most subjects with severe hepatic impairment, the clearance of levetiracetam
was reduced by more than 50&nbsp;% due to a concomitant renal impairment (see
section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Children (4 to 12 years)</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Following single oral dose administration
(20&nbsp;mg/kg) to epileptic children (6 to 12&nbsp;years), the half-life of
levetiracetam was 6.0&nbsp;hours. The apparent body weight adjusted clearance
was approximately 30&nbsp;% higher than in epileptic adults.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Following repeated oral dose administration
(20 to 60</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg/kg/day) to
epileptic children (4 to 12</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>years), levetiracetam was rapidly absorbed. Peak plasma
concentration was observed 0.5 to 1.0</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>hour after dosing. Linear and dose proportional increases were
observed for peak plasma concentrations and area under the curve. The
elimination half-life was approximately 5</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB> hours. The apparent body clearance was 1.1</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>ml/min/kg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Infants and children (1 month to 4
years)</span></i></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Following single dose administration (20</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg/kg) of a 100</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg/ml oral solution to epileptic
children (1&nbsp;month to 4</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>years), levetiracetam was rapidly absorbed and peak plasma
concentrations were observed approximately 1 hour after dosing. The
pharmacokinetic results indicated that half-life was shorter (5.3&nbsp;h) than
for adults (7.2&nbsp;h) and apparent clearance was faster (1.5&nbsp;ml/min/kg)
than for adults (0.96&nbsp;ml/min/kg).</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>In the population pharmacokinetic
analysis conducted in patients from 1 month to 16 years of age, body weight was
significantly correlated to apparent clearance (clearance increased with an increase
in body weight) and apparent volume of distribution. Age also had an influence
on both parameters. This effect was pronounced for the younger infants, and
subsided as age increased, to become negligible around 4 years of age.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>In both population pharmacokinetic
analyses, there was about a 20<span lang=EN-GB>&nbsp;</span>% increase of
apparent clearance of levetiracetam when it was co-administered with an
enzyme-inducing antiepileptic medicinal product.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.3 Preclinical safety data</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Non-clinical data reveal no special hazard
for humans based on conventional studies of safety pharmacology, genotoxicity
and carcinogenic potential. </span></p>

<p class=MsoNormal><span lang=EN-GB>Adverse effects not observed in clinical
studies but seen in the rat and to a lesser extent in the mouse at exposure
levels similar to human exposure levels and with possible relevance for
clinical use were liver changes, indicating an adaptive response such as
increased weight and centrilobular hypertrophy, fatty infiltration and
increased liver enzymes in plasma.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No adverse reactions on male or female fertility
or reproduction performance were observed in rats at doses up to 1800</span>&nbsp;mg/kg/day
(x 6 the MRHD on a mg/m2 or exposure basis) in parents and F1 generation.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>Two embryo&#8209;foetal
development (EFD) studies were performed in rats at 400, 1200 and 3600&nbsp;mg/kg/day.
At 3600&nbsp;mg/kg/day, in only one of the 2 EFD studies, there was a slight
decrease in foetal weight associated with a marginal increase in skeletal
variations/minor anomalies. There was no effect on embryomortality and no
increased incidence of malformations. The NOAEL (No Observed Adverse Effect
Level) was 3600&nbsp;mg/kg/day for pregnant female rats (x 12 the MRHD on a
mg/m2 basis) and 1200&nbsp;mg/kg/day for fetuses. </p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'>Four embryo&#8209;foetal
development studies were performed in rabbits covering doses of 200, 600, 800,
1200 and 1800&nbsp;mg/kg/day. The dose level of 1800&nbsp;mg/kg/day induced a
marked maternal toxicity and a decrease in foetal weight associated with
increased incidence of fetuses with cardiovascular/skeletal anomalies. The
NOAEL was &lt;200&nbsp;mg/kg/day for the dams and 200&nbsp;mg/kg/day for the
fetuses (equal to the MRHD on a mg/m2 basis). </p>

<p class=MsoNormal style='line-height:13.0pt'><b>&nbsp;</b></p>

<p class=MsoNormal>A peri- and post-natal development study was performed in
rats with levetiracetam doses of 70, 350 and 1800&nbsp;mg/kg/day. The NOAEL was
&#8805;&nbsp;1800&nbsp;mg/kg/day for the F0 females, and for the survival,
growth and development of the F1 offspring up to weaning (x 6 the MRHD on a
mg/m2 basis). </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Neonatal and
juvenile animal studies in rats and dogs demonstrated that there were no
adverse effects seen in any of the standard developmental or maturation
endpoints at doses up to 1800&nbsp;mg/kg/day </span>(x 6- 17 the MRHD on a
mg/m2 basis) </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6. PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Sodium citrate </span></p>

<p class=MsoNormal><span lang=EN-GB>Citric acid monohydrate</span></p>

<p class=MsoNormal><span lang=EN-GB>Methyl parahydroxybenzoate (E218)</span></p>

<p class=MsoNormal><span lang=EN-GB>Propyl parahydroxybenzoate (E216)</span></p>

<p class=MsoNormal><span lang=EN-GB>Ammonium glycyrrhizate</span></p>

<p class=MsoNormal><span lang=EN-GB>Glycerol (E422)</span></p>

<p class=MsoNormal><span lang=EN-GB>Maltitol liquid (E965)</span></p>

<p class=MsoNormal><span lang=EN-GB>Acesulfame potassium (E950)</span></p>

<p class=MsoNormal>Grape flavour</p>

<p class=MsoNormal>Purified water</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Not
applicable.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>3 years.</span></p>

<p class=MsoNormal><span lang=EN-GB>After first opening: 7 months</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.4 Special precautions for storage</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in the original bottle in order to
protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.5 Nature and contents of container</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>300 ml amber
glass bottle</span><span lang=EN-GB> (type III) with a w</span><span
lang=EN-AU style='layout-grid-mode:line'>hite child resistant closure
(polypropylene)</span><span lang=EN-GB style='layout-grid-mode:line'> in a
cardboard box also containing a 10 ml graduated oral syringe (polypropylene,
polyethylene)</span><span lang=EN-GB> and an adaptor for the syringe <span
style='layout-grid-mode:line'>(polyethylene).</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>150 ml amber
glass bottle</span><span lang=EN-GB> (type III) with a w</span><span
lang=EN-AU style='layout-grid-mode:line'>hite child resistant closure
(polypropylene)</span><span lang=EN-GB style='layout-grid-mode:line'> in a
cardboard box also containing a 3 ml graduated oral syringe (polypropylene,
polyethylene)</span><span lang=EN-GB> and an adaptor for the syringe <span
style='layout-grid-mode:line'>(polyethylene).</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>150 ml amber
glass bottle</span><span lang=EN-GB> (type III) with a w</span><span
lang=EN-AU style='layout-grid-mode:line'>hite child resistant closure
(polypropylene)</span><span lang=EN-GB style='layout-grid-mode:line'> in a
cardboard box also containing a 1 ml graduated oral syringe (polypropylene,
polyethylene) and</span><span lang=EN-GB> an adaptor for the syringe <span
style='layout-grid-mode:line'>(polyethylene).</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.6 Special precautions for disposal </span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=FR>7. MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR-BE>UCB Pharma SA </span></p>

<p class=MsoNormal><span lang=FR>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=DE>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>8. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>EU/1/00/146/027</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>EU/1/00/146/031</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>EU/1/00/146/032</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Date of first authorisation: 29 September 2000</p>

<p class=MsoNormal>Date of latest renewal: 20 August 2015</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>10. DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt;line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
color:windowtext'>Detailed information on this medicinal product is available
on the website of the European Medicines Agency http://www.ema.europa.eu </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>1. NAME OF THE MEDICINAL PRODUCT</b></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>Keppra 100&nbsp;mg/ml concentrate
for solution for infusion</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>2. QUALITATIVE AND QUANTITATIVE COMPOSITION</b></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Each ml contains
100&nbsp;mg of levetiracetam<span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'>Each 5&nbsp;ml <span lang=EN-GB>vial
contains 500</span>&nbsp;<span lang=EN-GB>mg of </span>levetiracetam.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><u>Excipient with known effect</u>:</p>

<p class=MsoNormal style='line-height:normal'>Each vial contains 19<span
lang=EN-GB>&nbsp;</span>mg of sodium.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>For <span lang=EN-GB>the full
list of </span>excipients, <span lang=EN-GB>see section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>3. PHARMACEUTICAL FORM</b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Concentrate for solution for infusion
(sterile concentrate).<br>
<br>
</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Clear,
colourless, liquid.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>4. CLINICAL PARTICULARS</b></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra is indicated as monotherapy in the
treatment of partial onset seizures with or without secondary generalisation in
adults and adolescents from 16 years of age with newly diagnosed epilepsy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra is indicated as adjunctive therapy</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the treatment of partial onset seizures with
or without secondary generalisation in adults, adolescents and children from 4
years of age with epilepsy.</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the treatment of </span>myoclonic seizures in
adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.</p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the treatment of primary generalised
tonic-clonic seizures in adults and adolescents from 12 years of age with
Idiopathic Generalised Epilepsy.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Keppra concentrate is an alternative for patients when oral
administration is temporarily not feasible.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.2 Posology and method of administration</span></b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra therapy can be initiated with either
intravenous or oral administration.</span></p>

<p class=MsoNormal><span lang=EN-GB>Conversion to or from oral to intravenous
administration can be done directly without titration. The total daily dose and
frequency of administration should be maintained.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Partial onset seizures</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dosing for monotherapy
(from 16 years of age) and adjunctive therapy is the same; as outlined below.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>All indications</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i>Adults <span lang=EN-GB>(&#8805;18 years) and adolescents
(12 to 17 years) weighing 50 kg or more</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The initial therapeutic dose is 500&nbsp;mg twice daily.
This dose can be started on the first day of treatment. <span lang=EN-GB
style='color:black'>However, a lower initial dose of 250</span><span
lang=EN-GB>&nbsp;<span style='color:black'>mg twice daily may be given based on
physician assessment of seizure reduction versus potential side effects. This
can be increased to 500</span>&nbsp;<span style='color:black'>mg twice daily
after two weeks.</span></span></p>

<p class=MsoNormal>Depending upon the clinical response and tolerability, the
daily dose can be increased up to 1,500&nbsp;mg twice daily. Dose changes can
be made in <span lang=EN-GB>250 mg or </span>500&nbsp;mg twice daily increases
or decreases every two to four weeks.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i><span lang=EN-GB>Adolescents (12 to 17 years) weighing
below 50 kg and children from 1 month of age</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The physician should prescribe the most
appropriate pharmaceutical form, presentation and strength according to weight,
age and dose. Refer to <i>Paediatric population</i> section for dosing
adjustments based on weight.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Duration of treatment</span></u></p>

<p class=MsoNormal><span lang=EN-GB>There is no experience with administration
of intravenous levetiracetam for longer period than 4 days.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Discontinuation</span></u></p>

<p class=MsoNormal><span lang=EN-GB>If levetiracetam has to be discontinued it
is recommended to withdraw it gradually (<i>e.g</i>. in adults and adolescents
weighing more than 50&nbsp;kg: 500&nbsp;mg decreases twice daily every two to
four weeks; in children and adolescents weighing less than 50&nbsp;kg: dose
decrease should not exceed 10&nbsp;mg/kg twice daily every two weeks). </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Special populations</u></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Elderly (65 years and older)</i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Adjustment of the dose is recommended in elderly patients
with compromised renal function (see Renal impairment below).</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i>Renal impairment</i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The daily dose must be individualised according to renal
function. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>For adult patients, r</span><span
lang=EN-GB>efer</span> to the following table and adjust the dose as indicated.
To use this dosing table, an estimate of the patient's creatinine clearance (<span
lang=EN-GB>CL<sub>cr</sub></span>) in ml/min is needed. The <span lang=EN-GB>CL<sub>cr</sub></span>
in ml/min may be estimated from serum creatinine (mg/dl) determination, <span
lang=EN-GB>for adults and adolescents weighing 50 kg or more,</span> the
following formula:</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal> [140-age (years)] x weight (kg)</p>

<p class=MsoNormal><span lang=EN-GB>CL<sub>cr</sub></span> (ml/min) =
----------------------------------------- (x 0.85 for women)</p>

<p class=MsoNormal> 72 x serum creatinine (mg/dl)</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Then <span lang=EN-GB>CL<sub>cr</sub></span> is adjusted for
body surface area (BSA) as follows:</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal> <span
lang=DE>CL<sub>cr</sub> (ml/min)</span></p>

<p class=MsoNormal><span lang=DE>CL<sub>cr</sub> (ml/min/1.73 m<sup>2</sup>)
= ---------------------------- x 1.73 </span></p>

<p class=MsoNormal><span lang=DE> 
</span><span lang=FR-BE>BSA subject (m<sup>2</sup>)</span></p>

<p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>

<p class=MsoNormal>Dosing adjustment for <span lang=EN-GB>adult<i> </i>and
adolescent </span>patients <span lang=EN-GB>weighing more than 50&nbsp;kg </span>with
impaired renal function<span lang=EN-GB>:</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Group</p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Creatinine clearance (ml/min/1.73m<sup>2</sup>)</p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Dose and frequency</p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Normal</p>
  <p class=MsoNormal>Mild</p>
  <p class=MsoNormal>Moderate</p>
  <p class=MsoNormal>Severe</p>
  <p class=MsoNormal>End-stage renal disease patients</p>
  <p class=MsoNormal>undergoing dialysis <sup>(1)</sup></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;</span>&nbsp;80</p>
  <p class=MsoNormal>50-79</p>
  <p class=MsoNormal>30-49</p>
  <p class=MsoNormal>&lt;&nbsp;30</p>
  <p class=MsoNormal>-</p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>500 to 1,500&nbsp;mg twice daily</p>
  <p class=MsoNormal>500 to 1,000 mg twice daily</p>
  <p class=MsoNormal>250 to 750&nbsp;mg twice daily</p>
  <p class=MsoNormal>250 to 500&nbsp;mg twice daily</p>
  <p class=MsoNormal>500 to 1,000&nbsp;mg once daily <sup>(2)</sup></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><sup>(1)</sup> A 750&nbsp;mg loading dose is recommended on
the first day of treatment with levetiracetam.</p>

<p class=MsoNormal><sup>(2)</sup> Following dialysis, a 250 to 500&nbsp;mg
supplemental dose is recommended.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For children
with renal impairment, levetiracetam dose needs to be adjusted based on the
renal function as levetiracetam clearance is related to renal function. This
recommendation is based on a study in adult renally impaired patients.</span></p>

<p class=MsoCaption><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The CL<sub>cr</sub>
in ml/min/1.73&nbsp;m2 may be estimated from serum creatinine (mg/dl)
determination, for young adolescents and children using the following formula
(Schwartz formula): </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>  Height (cm)
x ks</p>

<p class=MsoNormal><span lang=EN-GB>CL<sub>cr</sub></span> (ml/min/1.73 m<sup>2</sup>)
= ------------------------------------</p>

<p class=MsoNormal>  Serum Creatinine
(mg/dl)</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>ks= 0.55 in Children to less than 13 years
and in adolescent female; ks= 0.7 in adolescent male</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Dosing adjustment for children </span>and
adolescent <span lang=EN-GB>patients weighing less than 50 kg with impaired
renal function:</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=603
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=130 rowspan=2 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Group</span></p>
  </td>
  <td width=113 rowspan=2 valign=top style='width:85.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Creatinine clearance (ml/min</span>/1.73m<sup>2</sup><span
  lang=EN-GB>)</span></p>
  </td>
  <td width=359 valign=top style='width:269.35pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Dose
  and frequency</span></p>
  </td>
 </tr>
 <tr>
  <td width=359 valign=top style='width:269.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Children from 4 years and adolescents weighing less than
  50 kg</p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Normal</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;</span><span lang=EN-GB>&nbsp;80</span></p>
  </td>
  <td width=359 valign=top style='width:269.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>10 to 30&nbsp;mg/kg (0.10 to
  0.30&nbsp;ml/kg) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Mild</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>50-79</span></p>
  </td>
  <td width=359 valign=top style='width:269.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>10 to 20&nbsp;mg/kg (0.10 to
  0.20&nbsp;ml/kg) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Moderate</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>30-49</span></p>
  </td>
  <td width=359 valign=top style='width:269.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>5 to 15&nbsp;mg/kg (0.05 to
  0.15&nbsp;ml/kg) twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Severe</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&lt;&nbsp;30</span></p>
  </td>
  <td width=359 valign=top style='width:269.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>5 to 10&nbsp;mg/kg (0.05 to
  0.10&nbsp;ml/kg) twice daily </span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>End-stage renal disease patients
  undergoing dialysis </span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>--</span></p>
  </td>
  <td width=359 valign=top style='width:269.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>10 to 20&nbsp;mg/kg (0.10 to
  0.20&nbsp;ml/kg) once daily <sup>(1) (2)</sup></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><sup><span lang=EN-GB>(1)</span></sup><span lang=EN-GB> A
15&nbsp;mg/kg (0.15&nbsp;ml/kg) loading dose is recommended on the first day of
treatment with levetiracetam.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>(2)</span></sup><span lang=EN-GB>
Following dialysis, a 5 to 10&nbsp;mg/kg (0.05 to 0.10&nbsp;ml/kg) supplemental
dose is recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i>Hepatic impairment </i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>No dose adjustment is needed in patients with mild to
moderate hepatic impairment. In patients with severe hepatic impairment, the creatinine
clearance may underestimate the renal insufficiency. Therefore a 50&nbsp;%
reduction of the daily maintenance dose is recommended when the creatinine
clearance is &lt;&nbsp;60&nbsp;ml/min/1.73 m<sup>2</sup>.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The physician should prescribe the most appropriate pharmaceutical
form, presentation and strength according to age, weight and dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Monotherapy</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of Keppra in
children and adolescents 16 years as monotherapy treatment have not been
established.</span></p>

<p class=MsoNormal>No data are available.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Adolescents (16 and 17 years of age) weighing 50 kg or
more with partial onset seizures with or without secondary generalisation with
newly diagnosed epilepsy</i></p>

<p class=MsoNormal>Please refer to the above section on <i>Adults (&#8805;18
years) and adolescents (12 to 17 years) weighing 50 kg or more</i>. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i><span lang=EN-GB>Add-on therapy for children aged 4 to 11
years and adolescents (12 to 17 years) weighing less than 50 kg</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The initial therapeutic dose is
10&nbsp;mg/kg twice daily. </span></p>

<p class=MsoNormal><span lang=EN-GB>Depending upon the clinical response and
tolerability, the dose can be increased up to 30&nbsp;mg/kg twice daily. Dose
changes should not exceed increases or decreases of 10&nbsp;mg/kg twice daily
every two weeks. The lowest effective dose should be used for all indications.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Dose in children 50&nbsp;kg or greater is
the same as in adults for all indications.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal>Please refer to the above section on <i>Adults (&#8805;18
years) and adolescents (12 to 17 years) weighing 50 kg or more </i>for all
indications.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Dose
recommendations for children and adolescents:</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Weight</span></p>
  </td>
  <td width=228 valign=top style='width:170.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Starting
  dose: </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>10&nbsp;mg/kg
  twice daily</span></p>
  </td>
  <td width=228 valign=top style='width:170.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Maximum
  dose: </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>30&nbsp;mg/kg
  twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>15 kg </span><sup><span
  lang=EN-GB>(1)</span></sup></p>
  </td>
  <td width=228 valign=top style='width:170.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>150 mg
  twice daily</span></p>
  </td>
  <td width=228 valign=top style='width:170.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>450 mg
  twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>20 kg </span><sup><span
  lang=EN-GB>(1)</span></sup></p>
  </td>
  <td width=228 valign=top style='width:170.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>200 mg
  twice daily</span></p>
  </td>
  <td width=228 valign=top style='width:170.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>600 mg
  twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>25 kg</span></p>
  </td>
  <td width=228 valign=top style='width:170.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>250 mg
  twice daily</span></p>
  </td>
  <td width=228 valign=top style='width:170.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>750 mg
  twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>From 50 kg
  </span><sup><span lang=EN-GB>(2)</span></sup></p>
  </td>
  <td width=228 valign=top style='width:170.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>500 mg
  twice daily</span></p>
  </td>
  <td width=228 valign=top style='width:170.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>1500 mg
  twice daily</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB>(1) </span></sup><span
lang=EN-GB>Children 25&nbsp;kg or less should preferably start the treatment
with Keppra 100&nbsp;mg/ml oral solution.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB>(2) </span></sup><span
lang=EN-GB>Dose in children and adolescents 50&nbsp;kg or more is the same as
in adults.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Add-on therapy for infants and children
less than 4 years </span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of Keppra </span>concentrate
for solution for infusion<span lang=EN-GB> in infants and children less than 4</span><span
lang=EN-GB>&nbsp;years have not been established.</span></p>

<p class=MsoNormal><span lang=EN-GB>Currently available data are described in
sections 4.8, 5.1, and 5.2 but no recommendation on a posology can be made.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u>Method of
administration</u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Keppra
concentrate is for intravenous use only and <span lang=EN-GB>the recommended
dose</span> must be diluted in at least 100<span lang=EN-GB>&nbsp;</span>ml of
a compatible diluent and administered intravenously as a 15-minute intravenous
infusion (see section 6.6).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>4.3 Contraindications</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Hypersensitivity to the active substance or other
pyrrolidone derivatives or to any of the excipients<span lang=EN-GB> listed in
section 6.1</span>.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>4.4 Special warnings and precautions for use</b></p>

<p class=MsoBodyText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u>Renal i<span lang=EN-GB>mpairment</span></u></p>

<p class=MsoNormal>The administration of <span lang=EN-GB>levetiracetam</span>
to patients with renal impairment may require dose adjustment. In patients with
severely impaired hepatic function, assessment of renal function is recommended
before dose selection (see section 4.2).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Acute Kidney injury</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The use of levetiracetam has been very
rarely associated with acute kidney injury, with a time to onset ranging from a
few days to several months.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Blood cell counts</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rare cases of decreased blood cell counts
(neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia)
have been described in association with levetiracetam administration, generally
at the beginning of the treatment. Complete blood cell counts are advised in
patients experiencing important weakness, pyrexia, recurrent infections or
coagulation disorders (section 4.8).</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u>Suicide</u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Suicide,
suicide attempt, <span lang=EN-GB>suicidal ideation and behaviour have been
reported in patients treated with anti-epileptic agents (including
levetiracetam. A meta-analysis of randomized placebo-controlled trials of
anti-epileptic medicinal products has shown a small increased risk of suicidal
thoughts and behaviour. The mechanism of this risk is not known. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Therefore patients should be monitored for
signs of depression and/or suicidal ideation and behaviours and appropriate
treatment should be considered. Patients (and caregivers of patients) should be
advised to seek medical advice should signs of depression and/or suicidal
ideation or behaviour emerge.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Abnormal and aggressive behaviours </span></u></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam may cause psychotic symptoms
and behavioural abnormalities including irritability and aggressiveness.
Patients treated with levetiracetam should be monitored for developing
psychiatric signs suggesting important mood and/or personality changes. If such
behaviours are noticed, treatment adaptation or gradual discontinuation should
be considered. If discontinuation is considered, please refer to section 4.2.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><u>Worsening of seizures</u></p>

<p class=MsoNormal>As with other types of antiepileptic drugs, levetiracetam
may rarely exacerbate seizure frequency or severity. This paradoxical effect
was mostly reported within the first month after levetiracetam initiation or
increase of the dose, and was reversible upon drug discontinuation or dose
decrease. Patients should be advised to consult their physician immediately in
case of aggravation of epilepsy.</p>

<p class=MsoNormal><u><span style='font-size:12.0pt'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Electrocardiogram QT interval
prolongation</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rare cases of ECG QT interval prolongation
have been observed during the post-marketing surveillance. Levetiracetam should
be used with caution in patients with QTc-interval prolongation, in patients
concomitantly treated with drugs affecting the QTc-interval, or in patients
with relevant pre-existing cardiac disease or electrolyte disturbances.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Available
data in children did not suggest impact on growth and puberty. However, long
term effects on learning, intelligence, growth, endocrine function, puberty and
childbearing potential in children remain unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipients</span></u></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains 2.5</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>mmol (or 57</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>mg) sodium per maximum single dose (0.8 mmol (or 19&nbsp;mg) per
vial). To be taken into consideration by patients on a controlled sodium diet.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>4.5 Interaction with other medicinal products and other forms of
interaction</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Antiepileptic medicinal products</u></p>

<p class=MsoNormal>Pre-marketing data from clinical studies <span lang=EN-GB>conducted
in adults </span>indicate that <span lang=EN-GB>levetiracetam</span> did not
influence the serum concentrations of existing antiepileptic medicinal products
(phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine,
gabapentin and primidone) and that these antiepileptic medicinal products did
not influence the pharmacokinetics of <span lang=EN-GB>levetiracetam</span>.</p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>As in adults,
there is no evidence of clinically significant medicinal product interactions
in paediatric patients receiving up to 60</span><span lang=EN-GB>&nbsp;<span
style='layout-grid-mode:line'>mg/kg/day levetiracetam.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>A
retrospective assessment of pharmacokinetic interactions in children and
adolescents with epilepsy (4 to 17</span><span lang=EN-GB>&nbsp;<span
style='layout-grid-mode:line'>years) confirmed that adjunctive therapy with </span></span><span
lang=EN-GB>orally administered</span><span lang=EN-GB style='layout-grid-mode:
line'> levetiracetam did not influence the steady-state serum concentrations of
concomitantly administered carbamazepine and valproate. However, data suggested
</span><span lang=EN-GB>a 20</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% higher levetiracetam clearance in children taking</span><span
lang=EN-GB style='layout-grid-mode:line'> enzyme-inducing antiepileptic
medicinal products. Dose adjustment is not required. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Probenecid</u></p>

<p class=MsoNormal>Probenecid (500<span lang=EN-GB>&nbsp;</span>mg four times
daily), a renal tubular secretion blocking agent, has been shown to inhibit the
renal clearance of the primary metabolite, but not of levetiracetam.
Nevertheless, the concentration of this metabolite remains low. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Methotrexate</u></p>

<p class=MsoNormal><span lang=EN-GB>Concomitant administration of levetiracetam
and methotrexate has been reported to decrease methotrexate clearance,
resulting in increased/prolonged blood methotrexate concentration to
potentially toxic levels. Blood methotrexate and levetiracetam levels should be
carefully monitored in patients treated concomitantly with the two drugs</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-AU style='layout-grid-mode:line'>Oral
contraceptives and other pharmacokinetics interactions</span></u></p>

<p class=MsoNormal><span style='layout-grid-mode:line'>Levetiracetam
1,000&nbsp;mg daily did not influence the pharmacokinetics of oral
contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters
(luteinizing hormone and progesterone) were not modified. Levetiracetam
2,000&nbsp;mg daily did not influence the pharmacokinetics of digoxin and
warfarin; prothrombin times were not modified. Co-administration with digoxin,
oral contraceptives and warfarin did not influence the pharmacokinetics of
levetiracetam.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Alcohol</u></p>

<p class=MsoNormal>No data on the interaction of levetiracetam with alcohol are
available.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>4.6 <span lang=EN-GB>Fertility, </span></b><b>pregnancy and
lactation</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Women of child bearing potential </span></u></p>

<p class=MsoNormal><span lang=EN-GB>Specialist advice should be given to women
who are of childbearing potential. Treatment with levetiracetam should be
reviewed when a woman is planning to become pregnant. As with all antiepileptic
medicines, sudden discontinuation of levetiracetam should be avoided as this
may lead to breakthrough seizures that could have serious consequences for the
woman and the unborn child. Monotherapy should be preferred whenever possible
because therapy with multiple antiepileptic medicines AEDs could be associated
with a higher risk of congenital malformations than monotherapy, depending on
the associated antiepileptics.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><span lang=EN-GB>A large amount of postmarketing data on
pregnant women exposed to levetiracetam monotherapy (more than 1800, among
which in more than 1500 exposure occurred during the 1<sup>st</sup> trimester)
do not suggest an increase in the risk for major congenital malformations. Only
limited evidence is available on the neurodevelopment of children exposed to
Keppra monotherapy in utero. However, current epidemiological studies (on about
100 children) do not suggest an increased risk of neurodevelopmental disorders
or delays. </span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam can be used during pregnancy,
if after careful assessment it is considered clinically needed. In such case,
the lowest effective dose is recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Physiological
changes during pregnancy may affect levetiracetam concentration. D</span>ecrease
in levetiracetam plasma concentrations has been observed during pregnancy. This
decrease is more pronounced during the third trimester (up to 60% of baseline
concentration before pregnancy). Appropriate clinical management of pregnant
women treated with levetiracetam should be ensured. </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Breastfeeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam is excreted in human breast
milk. Therefore, breast-feeding is not recommended. </span></p>

<p class=MsoNormal style='line-height:normal'>However, if levetiracetam
treatment is needed during breastfeeding, the benefit/risk of the treatment
should be weighed considering the importance of breastfeeding.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><u>Fertility</u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No impact on
fertility was detected in animal studies (see section 5.3). No clinical data
are available, potential risk for human is unknown.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>4.7 Effects on ability to drive and use machines</b></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam has minor or moderate
influence on the ability to drive and use machines.</span><span lang=EN-GB> </span>Due
to possible different individual sensitivity, some patients might experience
somnolence or other central nervous system related symptoms, <span lang=EN-GB>especially</span>
at the beginning of treatment or following a dose increase. Therefore, caution
is recommended in those patients when performing skilled tasks, <i>e.g</i>.
driving vehicles or operating machinery<span lang=EN-GB>. Patients are advised
not to drive or use machines until it is established that </span><span
lang=EN-GB>their</span><span lang=EN-GB> ability to perform such activities is
not affected.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>4.8 Undesirable
effects</b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u>Summary of
the safety profile</u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>The most frequently reported adverse
reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness.
The adverse reaction profile presented below is based on the analysis of pooled
placebo-controlled clinical trials with all indications studied, with a total
of 3,416 patients treated with levetiracetam. These data are supplemented with
the use of levetiracetam in corresponding open-label extension studies, as well
as post-marketing experience. The safety profile of levetiracetam is generally
similar across age groups (adult and paediatric patients) and across the
approved epilepsy indications. Since there was limited exposure for Keppra
intravenous use and since oral and intravenous formulations are bioequivalent,
the safety information of Keppra intravenous will rely on Keppra oral use.</span></p>

<p class=MsoNormal><span style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Tabulated list of adverse
reactions</u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Adverse reactions reported in clinical
studies (adults, adolescents, children and infants &gt; 1&nbsp;month) and from
post-marketing experience are listed in the following table per System Organ
Class and per frequency. Adverse reactions are presented in the order of
decreasing seriousness and their frequency is defined as follows: very common
(&#8805;1/10); common (&#8805;1/100 to &lt;1/10); uncommon (&#8805;1/1,000 to
&lt;1/100); rare (&#8805;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="97%"
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="20%" rowspan=2 style='width:20.32%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>MedDRA SOC</span></u></p>
   </td>
   <td width="79%" colspan=4 valign=top style='width:79.68%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center'><u><span
   lang=EN-GB style='font-size:10.0pt'>Frequency category</span></u></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Very common</span></u></p>
   </td>
   <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Common</span></u></p>
   </td>
   <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Uncommon </span></u></p>
   </td>
   <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Rare</span></u></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Infections
  and infestations</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Nasopharyngitis </span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Infection</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Blood and
  lymphatic system disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>Thrombocytopenia,
  leukopenia</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>Pancytopenia,
  neutropenia, agranulocytosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Immune system
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>Drug reaction
  with eosinophilia and systemic symptoms (DRESS), Hypersensitivity (including
  angioedema and anaphylaxis)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Metabolism
  and nutrition disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Anorexia</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Weight
  decreased, weight increase</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Hyponatraemia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Psychiatric
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Depression,
  hostility/ aggression, anxiety, <br>
  insomnia, nervousness/irritability</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Suicide attempt,
  suicidal ideation</span><span lang=EN-AU style='font-size:10.0pt'>,<sup> </sup></span><span
  lang=EN-GB style='font-size:10.0pt'>psychotic disorder</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>abnormal behaviour, hallucination</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>anger, confusional state</span><sup><span
  lang=EN-GB style='font-size:10.0pt'> </span></sup><span lang=EN-GB
  style='font-size:10.0pt'>, panic attack, affect lability/mood swings,
  agitation</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Completed
  suicide</span><span lang=EN-AU style='font-size:10.0pt'>, </span><span
  lang=EN-GB style='font-size:10.0pt'>personality disorder, thinking abnormal,
  delirium</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Nervous
  system disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Somnolence,
  headache</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Convulsion,
  balance disorder, dizziness, lethargy, tremor</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Amnesia, memory
  impairment, coordination abnormal/ataxia, paraesthesia</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>disturbance in attention</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Choreoathetosis,
  dyskinesia, hyperkinesia, gait disturbance, encephalopathy, seizures
  aggravated</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Eye disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Diplopia, vision
  blurred</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Ear and
  labyrinth disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Vertigo</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Cardiac
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-AU style='font-size:10.0pt'>Electrocardiogram
  QT prolonged</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Respiratory,
  thoracic and mediastinal disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Cough</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Gastrointestinal
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT style='font-size:10.0pt'>Abdominal pain,
  diarrhoea, dyspepsia, vomiting, nausea</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Pancreatitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-AU style='font-size:10.0pt'>Hepatobiliary
  disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Liver function
  test abnormal</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Hepatic failure,
  hepatitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Renal and
  Urinary Disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Acute Kidney
  injury</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Skin and
  subcutaneous tissue disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Rash</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Alopecia</span><span
  lang=EN-AU style='font-size:10.0pt'>, </span><span lang=EN-GB
  style='font-size:10.0pt'>eczema, pruritus, </span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Toxic epidermal
  necrolysis, Stevens-Johnson syndrome, erythema multiforme</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Musculoskeletal
  and connective tissue disorders</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Muscular
  weakness, myalgia</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Rhabdomyolysis
  and blood creatine phosphokinase increased*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>General
  disorders and administration site conditions</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Asthenia/</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>fatigue</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.32%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:10.0pt'>Injury,
  poisoning and procedural complications</span></u></p>
  </td>
  <td width="20%" valign=top style='width:20.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Injury</span></p>
  </td>
  <td width="21%" valign=top style='width:21.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>* Prevalence is significantly higher in
Japanese patients when compared to non-Japanese patients. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Description of selected adverse
reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU>The risk of
anorexia is higher when levetiracetam is coadministered with topiramate.</span></p>

<p class=MsoNormal><span lang=EN-GB>In several cases of alopecia, recovery was
observed when levetiracetam was discontinued.</span></p>

<p class=MsoNormal><span style='font-family:"TimesNewRomanPSMT",serif'>Bone
marrow suppression was identified in some of the cases of pancytopenia.</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cases of encephalopathy generally occurred
at the beginning of the treatment (few days to a few months) and were
reversible after treatment discontinuation.</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients aged 1 month to less than 4
years, a total of 190 patients have been treated with levetiracetam in
placebo-controlled and open label extension studies. Sixty of these patients
were treated with levetiracetam in placebo-controlled studies. In patients
aged 4-16 years, a total of 645 patients have been treated with levetiracetam
in placebo-controlled and open label extension studies. 233 of these patients
were treated with levetiracetam in placebo-controlled studies. In both these
paediatric age ranges, these data are supplemented with the post-marketing
experience of the use of levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In addition, 101 infants aged less than 12
months have been exposed in a post authorization safety study. No new safety
concerns for levetiracetam were identified for infants less than 12 months of
age with epilepsy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The adverse reaction profile of
levetiracetam is generally similar across age groups and across the approved
epilepsy indications. Safety results in paediatric patients in
placebo-controlled clinical studies were consistent with the safety profile of
levetiracetam in adults except for behavioural and psychiatric adverse
reactions which were more common in children than in adults. In children and
adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation
(common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%),
aggression (common, 8.2%), abnormal behaviour (common, 5.6%), and lethargy
(common, 3.9%) were reported more frequently than in other age ranges or in the
overall safety profile. In infants and children aged 1 month to less than 4
years, irritability (very common, 11.7%) and coordination abnormal (common,
3.3%) were reported more frequently than in other age groups or in the overall
safety profile. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>A double-blind,
placebo-controlled paediatric safety study with a non-inferiority design has
assessed the cognitive and neuropsychological effects of </span><span
lang=EN-GB>levetiracetam</span><span lang=EN-GB> in children 4 to 16 years of
age with partial onset seizures. It was concluded that Keppra was not different
(non inferior) from placebo with regard to the change from baseline of the
Leiter-R Attention and Memory, Memory Screen Composite score in the
per-protocol population. Results related to behavioural and emotional
functioning indicated a worsening in </span><span lang=EN-GB>levetiracetam </span><span
lang=EN-GB>treated patients on aggressive behaviour as measured in a
standardised and systematic way using a validated instrument (CBCL  Achenbach
Child Behavior Checklist). However, subjects, who took </span><span lang=EN-GB>levetiracetam</span><span
lang=EN-GB> in the long-term open label follow-up study, did not experience a
worsening, on average, in their behavioural and emotional functioning; in
particular measures of aggressive behaviour were not worse than baseline.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Reporting of
suspected adverse reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:silver'>the national reporting
system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a></span>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>4.9 Overdose</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Symptoms</u></p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal>Somnolence, agitation, aggression, depressed level of
consciousness, respiratory depression and coma were observed with Keppra
overdoses.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Management of overdose</u></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>There is no specific antidote for levetiracetam. Treatment
of an overdose will be symptomatic and may include haemodialysis. The dialyser
extraction efficiency is 60&nbsp;% for levetiracetam and 74&nbsp;% for the
primary metabolite.</p>

<p class=MsoNormal><span style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b><span style='text-transform:
uppercase'>5. </span></b><b>PHARMACOLOGICAL PROPERTIES</b></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>5.1 Pharmacodynamic
properties</b></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>Pharmacotherapeutic group:
antiepileptics, other antiepileptics, ATC code: N03AX14.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The active substance, levetiracetam, is a pyrrolidone
derivative (S-enantiomer of <span style='font-family:Symbol'>a</span>-ethyl-2-oxo-1-pyrrolidine
acetamide), chemically unrelated to existing antiepileptic active substances.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Mechanism of action</u></p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal>The mechanism of action of levetiracetam still remains to be
fully elucidated. <i>In vitro</i> and <i>in vivo</i> experiments suggest that
levetiracetam does not alter basic cell characteristics and normal
neurotransmission.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>In vitro</i> studies show that levetiracetam affects
intraneuronal Ca<sup>2+</sup> levels by partial inhibition of N-type Ca<sup>2+</sup>
currents and by reducing the release of Ca<sup>2+</sup> from intraneuronal
stores. In addition, it partially reverses the reductions in GABA- and
glycine-gated currents induced by zinc and &#946;-carbolines. Furthermore,
levetiracetam has been shown in <i>in vitro</i> studies to bind to a specific
site in rodent brain tissue. This binding site is the synaptic vesicle protein
2A, believed to be involved in vesicle fusion and neurotransmitter exocytosis.
Levetiracetam and related analogues show a rank order of affinity for binding
to the synaptic vesicle protein 2A which correlates with the potency of their
anti-seizure protection in the mouse audiogenic model of epilepsy. This
finding suggests that the interaction between levetiracetam and the synaptic
vesicle protein 2A seems to contribute to the antiepileptic mechanism of action
of the <span lang=EN-GB>medicinal product</span>.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Pharmacodynamic effects</u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'>Levetiracetam induces seizure
protection in a broad range of animal models of partial and primary generalised
seizures without having a pro-convulsant effect. The primary metabolite is
inactive.</p>

<p class=MsoNormal>In man, an activity in both partial and generalised epilepsy
conditions (epileptiform discharge/photoparoxysmal response) has confirmed the
broad spectrum pharmacological profile of levetiracetam.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adjunctive therapy in the treatment of
partial onset seizures with or without secondary generalisation in adults,
adolescents and children from 4 years of age with epilepsy.</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In adults, levetiracetam efficacy has been
demonstrated in 3 double-blind, placebo-controlled studies at 1000</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg, 2000</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>mg, or 3000</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg/day,
given in 2 divided doses, with a treatment duration of up to 18</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>weeks. In a pooled analysis, the
percentage of patients who achieved 50</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% or greater reduction from baseline in the partial onset seizure
frequency per week at stable dose (12/14</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>weeks) was of 27.7</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>%, 31.6</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>% and
41.3</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>% for patients on
1000, 2000 or 3000</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg
levetiracetam respectively and of 12.6</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% for patients on placebo. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Paediatric population</u></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal>In paediatric patients (4 to 16 years of age), levetiracetam
efficacy was established in a double-blind, placebo-controlled study, which
included 198 patients and had a treatment duration of 14 weeks. In this study,
the patients received levetiracetam as a fixed dose of 60<span lang=EN-GB>&nbsp;</span>mg/kg/day
(with twice a day dosing).</p>

<p class=MsoNormal><span lang=EN-GB>44.6</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% of the levetiracetam treated patients and 19.6</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% of the patients on placebo had a 50</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% or greater reduction from baseline
in the partial onset seizure frequency per week.</span><span lang=EN-GB> </span><span
lang=EN-GB>With continued long-term treatment, 11.4</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>% of the patients were seizure-free for at least 6 months and 7.2</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>% were seizure-free for at least 1</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>year.</span></p>

<p class=MsoNormal>35 infants aged less than 1 year with partial onset seizures
have been exposed in placebo-control clinical studies of which only 13 were
aged &lt; 6 months.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i><span lang=EN-GB>Monotherapy in the treatment of partial
onset seizures with or without secondary generalisation in patients from 16
years of age with newly diagnosed epilepsy. </span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Efficacy of levetiracetam as monotherapy was established in
a double-blind, parallel group, non-inferiority comparison to carbamazepine-controlled
release (CR) in 576 patients 16 years of age or older with newly or recently
diagnosed epilepsy. The patients had to present with unprovoked partial
seizures or with generalized tonic-clonic seizures only. The patients were
randomized to carbamazepine CR 400  1200<span lang=EN-GB>&nbsp;</span>mg/day
or levetiracetam 1000  3000<span lang=EN-GB>&nbsp;</span>mg/day, the duration
of the treatment was up to 121<span lang=EN-GB>&nbsp;</span>weeks depending on
the response. </p>

<p class=MsoNormal>Six-month seizure freedom was achieved in 73.0<span
lang=EN-GB>&nbsp;</span>% of levetiracetam-treated patients and 72.8<span
lang=EN-GB>&nbsp;</span>% of carbamazepine-CR treated patients; the adjusted
absolute difference between treatments was 0.2% (95<span lang=EN-GB>&nbsp;</span>%
CI: -7.8 8.2). More than half of the subjects remained seizure free for 12<span
lang=EN-GB>&nbsp;</span>months (56.6<span lang=EN-GB>&nbsp;</span>% and 58.5<span
lang=EN-GB>&nbsp;</span>% of subjects on levetiracetam and on carbamazepine CR
respectively).</p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>In a study
reflecting clinical practice, the concomitant antiepileptic medication could be
withdrawn in a limited number of patients who responded to levetiracetam
adjunctive therapy (36 adult patients out of 69). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adjunctive therapy in the treatment of
myoclonic seizures in adults and adolescents from 12 years of age with Juvenile
Myoclonic Epilepsy.</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Levetiracetam efficacy was established in a double-blind,
placebo-controlled study of 16 weeks duration, in patients 12 years of age and
older suffering from idiopathic generalized epilepsy with myoclonic seizures in
different syndromes. The majority of patients presented with juvenile myoclonic
epilepsy.</p>

<p class=MsoNormal>In this study, levetiracetam, dose was 3000<span lang=EN-GB>&nbsp;</span>mg/day
given in 2 divided doses. </p>

<p class=MsoNormal>58.3<span lang=EN-GB>&nbsp;</span>% of the levetiracetam
treated patients and 23.3<span lang=EN-GB>&nbsp;</span>% of the patients on
placebo had at least a 50<span lang=EN-GB>&nbsp;</span>% reduction in myoclonic
seizure days per week. With continued long-term treatment, 28.6<span
lang=EN-GB>&nbsp;</span>% of the patients were free of myoclonic seizures for
at least 6 months and 21.0<span lang=EN-GB>&nbsp;</span>% were free of
myoclonic seizures for at least 1<span lang=EN-GB>&nbsp;</span>year.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adjunctive therapy in the treatment of
primary generalised tonic-clonic seizures in adults and adolescents from 12
years of age with idiopathic generalised epilepsy.</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Levetiracetam efficacy was established in a 24-week
double-blind, placebo-controlled study which included adults, adolescents and a
limited number of children suffering from idiopathic generalized epilepsy with
primary generalized tonic-clonic (PGTC) seizures in different syndromes
(juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence
epilepsy, or epilepsy with Grand Mal seizures on awakening). In this study,
levetiracetam dose was 3000<span lang=EN-GB>&nbsp;</span>mg/day for adults and
adolescents or 60<span lang=EN-GB>&nbsp;</span>mg/kg/day for children, given in
2 divided doses.</p>

<p class=MsoNormal>72.2<span lang=EN-GB>&nbsp;</span>% of the levetiracetam
treated patients and 45.2<span lang=EN-GB>&nbsp;</span>% of the patients on
placebo had a 50<span lang=EN-GB>&nbsp;</span>% or greater decrease in the
frequency of PGTC seizures per week. With continued long-term treatment, 47.4<span
lang=EN-GB>&nbsp;</span>% of the patients were free of tonic-clonic seizures
for at least 6 months and 31.5<span lang=EN-GB>&nbsp;</span>% were free of
tonic-clonic seizures for at least 1<span lang=EN-GB>&nbsp;</span>year.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>5.2 Pharmacokinetic properties</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>The
pharmacokinetic profile has been characterized following oral administration. A
single dose of 1500&nbsp;mg levetiracetam diluted in 100&nbsp;ml of a
compatible diluent and infused intravenously over 15&nbsp;minutes is
bioequivalent to 1500&nbsp;mg levetiracetam oral intake, given as three 500<span
lang=EN-GB>&nbsp;</span>mg tablets.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>The
intravenous administration of doses up to 4000&nbsp;mg diluted in 100&nbsp;ml
of 0.9<span lang=EN-GB>&nbsp;</span>% sodium chloride infused over
15&nbsp;minutes and doses up to 2500&nbsp;mg diluted in 100&nbsp;ml of 0.9<span
lang=EN-GB>&nbsp;</span>% sodium chloride infused over 5&nbsp;minutes was
evaluated. The pharmacokinetic and safety profiles did not identify any safety
concerns.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal>Levetiracetam is a highly soluble and permeable compound.
The pharmacokinetic profile is linear with low intra- and inter-subject
variability. There is no modification of the clearance after repeated administration.
The time independent pharmacokinetic profile of levetiracetam was also
confirmed following 1500&nbsp;mg intravenous infusion for 4 days with twice
daily dosing. </p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>There is no
evidence for any relevant gender, race or circadian variability. The pharmacokinetic
profile is comparable in healthy volunteers and in patients with epilepsy.</p>

<p class=MsoEndnoteText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoEndnoteText style='page-break-after:avoid'><u><span lang=EN-GB>Adults
and adolescents</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Distribution</u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>Peak plasma concentration
(Cmax) observed in 17 subjects following a single intravenous dose of 1500<span
lang=EN-GB>&nbsp;</span>mg infused over 15<span lang=EN-GB>&nbsp;</span>minutes
was 51  19<span lang=EN-GB>&nbsp;</span>g/ml (arithmetic average  standard
deviation).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>No tissue distribution data are available in humans.</p>

<p class=MsoNormal>Neither levetiracetam nor its primary metabolite are
significantly bound to plasma proteins (<span style='font-family:Symbol'>&lt;</span>&nbsp;10&nbsp;%).</p>

<p class=MsoNormal>The volume of distribution of levetiracetam is approximately
0.5 to 0.7&nbsp;l/kg, a value close to the total body water volume.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Biotransformation</u></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Levetiracetam is not extensively metabolised in humans. The
major metabolic pathway (24&nbsp;% of the dose) is an enzymatic hydrolysis of
the acetamide group. Production of the primary metabolite, ucb&nbsp;L057, is
not supported by liver cytochrome P<sub>450</sub> isoforms. Hydrolysis of the
acetamide group was measurable in a large number of tissues including blood
cells. The metabolite ucb&nbsp;L057 is pharmacologically inactive.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Two minor metabolites were also identified. One was obtained
by hydroxylation of the pyrrolidone ring (1.6&nbsp;% of the dose) and the other
one by opening of the pyrrolidone ring (0.9&nbsp;% of the dose). </p>

<p class=MsoNormal>Other unidentified components accounted only for 0.6&nbsp;% of
the dose.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>No enantiomeric interconversion was evidenced <i>in vivo</i>
for either levetiracetam or its primary metabolite.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>In vitro</i>, levetiracetam and its primary metabolite
have been shown not to inhibit the major human liver cytochrome P<sub>450</sub>
isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase<span
style='text-transform:uppercase'> (</span><span style='text-transform:uppercase'>UGT1A1
</span>and<span style='text-transform:uppercase'> UGT1A6</span><span
style='text-transform:uppercase'>)</span> and epoxide hydroxylase activities.
In addition, levetiracetam does not affect the <i>in vitro</i> glucuronidation
of valproic acid.</p>

<p class=MsoNormal>In human hepatocytes in culture, levetiracetam had little or
no effect on CYP1A2, SULT1E1 or UGT1A1. Levetiracetam caused mild induction of
CYP2B6 and CYP3A4. The in vitro data and <i>in vivo</i> interaction data on
oral contraceptives, digoxin and warfarin indicate that no significant enzyme
induction is expected <i>in vivo</i>. Therefore, the interaction of Keppra with
other substances, or <i>vice versa,</i> is unlikely.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Elimination</u></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The plasma half-life in adults was 7<span style='font-family:
Symbol'></span>1&nbsp;hours and did not vary either with dose, route of
administration or repeated administration. The mean total body clearance was
0.96&nbsp;ml/min/kg.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The major route of excretion was via urine, accounting for a
mean 95&nbsp;% of the dose (approximately 93&nbsp;% of the dose was excreted
within 48&nbsp;hours). Excretion <i>via</i> faeces accounted for only
0.3&nbsp;% of the dose.</p>

<p class=MsoNormal>The cumulative urinary excretion of levetiracetam and its
primary metabolite accounted for 66&nbsp;% and 24&nbsp;% of the dose,
respectively during the first 48&nbsp;hours.</p>

<p class=MsoNormal>The renal clearance of levetiracetam and ucb&nbsp;L057 is
0.6 and 4.2&nbsp;ml/min/kg respectively indicating that levetiracetam is
excreted by glomerular filtration with subsequent tubular reabsorption and that
the primary metabolite is also excreted by active tubular secretion in addition
to glomerular filtration. Levetiracetam elimination is correlated to creatinine
clearance.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Elderly</u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>In the elderly, the half-life
is increased by about 40&nbsp;% (10 to 11&nbsp;hours). This is related to the
decrease in renal function in this population (see section 4.2).</p>

<p class=MsoNormal><span style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><u>Renal impairment</u></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The apparent body clearance of both levetiracetam and of its
primary metabolite is correlated to the creatinine clearance. It is therefore
recommended to adjust the maintenance daily dose of Keppra, based on creatinine
clearance in patients with moderate and severe renal impairment (see section
4.2).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In anuric end-stage renal disease adult<i> </i>subjects the
half-life was approximately 25 and 3.1&nbsp;hours during interdialytic and
intradialytic periods, respectively. </p>

<p class=MsoNormal>The fractional removal of levetiracetam was 51&nbsp;% during
a typical 4-hour dialysis session.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Hepatic impairment</u></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In subjects with mild and moderate hepatic impairment, there
was no relevant modification of the clearance of levetiracetam. In most
subjects with severe hepatic impairment, the clearance of levetiracetam was
reduced by more than 50&nbsp;% due to a concomitant renal impairment (see
section 4.2).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Children (4 to 12 years)</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><a name="OLE_LINK4"><span lang=EN-GB>The pharmacokinetics in
paediatric patients has not been investigated after intravenous administration.
However, based on the pharmacokinetic characteristics of</span></a><span
lang=EN-GB> levetiracetam, the pharmacokinetics in adults after intravenous
administration and the pharmacokinetics in children after oral administration,
the exposure (AUC) of levetiracetam is expected to be similar in paediatric
patients aged 4 to 12</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>years
after intravenous and oral administration.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Following single oral dose administration
(20&nbsp;mg/kg) to epileptic children (6 to 12&nbsp;years), the half-life of
levetiracetam was 6.0&nbsp;hours. The apparent body weight adjusted clearance
was approximately 30&nbsp;% higher than in epileptic adults.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Following repeated oral dose administration
(20 to 60</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg/kg/day) to
epileptic children (4 to 12</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>years), levetiracetam was rapidly absorbed. Peak plasma
concentration was observed 0.5 to 1.0</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>hour after dosing. Linear and dose proportional increases were
observed for peak plasma concentrations and area under the curve. The
elimination half-life was approximately 5</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>hours. The apparent body clearance was 1.1</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>ml/min/kg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>5.3 Preclinical safety data</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Non-clinical data reveal no special hazard for humans based
on conventional studies of safety pharmacology, genotoxicity and <span
lang=EN-GB>carcinogenic potential</span>. </p>

<p class=MsoNormal>Adverse effects not observed in clinical studies but seen in
the rat and to a lesser extent in the mouse at exposure levels similar to human
exposure levels and with possible relevance for clinical use were liver
changes, indicating an adaptive response such as increased weight and
centrilobular hypertrophy, fatty infiltration and increased liver enzymes in
plasma.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>No adverse reactions on male or female
fertility or reproduction performance were observed in rats at doses up to 1800</span>&nbsp;mg/kg/day
(x 6 the MRHD on a mg/m2 or exposure basis) in parents and F1 generation.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>Two embryo&#8209;foetal
development (EFD) studies were performed in rats at 400, 1200 and 3600&nbsp;mg/kg/day.
At 3600&nbsp;mg/kg/day, in only one of the 2 EFD studies, there was a slight
decrease in foetal weight associated with a marginal increase in skeletal
variations/minor anomalies. There was no effect on embryomortality and no
increased incidence of malformations. The NOAEL (No Observed Adverse Effect
Level) was 3600&nbsp;mg/kg/day for pregnant female rats (x 12 the MRHD on a
mg/m2 basis) and 1200&nbsp;mg/kg/day for fetuses. </p>

<p class=MsoNormal style='line-height:13.0pt'>Four embryo&#8209;foetal
development studies were performed in rabbits covering doses of 200, 600, 800,
1200 and 1800&nbsp;mg/kg/day. The dose level of 1800&nbsp;mg/kg/day induced a
marked maternal toxicity and a decrease in foetal weight associated with
increased incidence of fetuses with cardiovascular/skeletal anomalies. The
NOAEL was &lt;200&nbsp;mg/kg/day for the dams and 200&nbsp;mg/kg/day for the
fetuses (equal to the MRHD on a mg/m2 basis). </p>

<p class=MsoNormal>A peri- and post-natal development study was performed in
rats with levetiracetam doses of 70, 350 and 1800&nbsp;mg/kg/day. The NOAEL was
&#8805;&nbsp;1800&nbsp;mg/kg/day for the F0 females, and for the survival,
growth and development of the F1 offspring up to weaning.(x 6 the MRHD on a
mg/m2 basis).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Neonatal and
juvenile animal studies in rats and dogs demonstrated that there were no
adverse effects seen in any of the standard developmental or maturation
endpoints at doses up to 1800&nbsp;mg/kg/day </span>(x 6-17 the MRHD on a mg/m2
basis) </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span style='text-transform:uppercase'>6. PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>6.1 List of excipients</b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Sodium acetate</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Glacial acetic acid</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Sodium chloride</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Water for injections</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>6.2 Incompatibilities</b></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>This
medicinal product must not be mixed with other medicinal products except those
mentioned in section 6.6. </p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>6.3 Shelf life</b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'>&nbsp;</p>

<p class=MsoNormal>3 years.</p>

<p class=MsoNormal>F<span lang=EN-GB>rom a microbiological point of view, the
product should be used immediately after dilution. If not used immediately,
in-use storage time and conditions prior to use are the responsibility of the
user and would normally not be longer than 24 hours at 2 to 8C, unless
dilution has taken place in controlled and validated aseptic conditions.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal><b>6.4 Special precautions for storage</b></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>This
medicinal product does not require any special storage conditions. </p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>For storage conditions of the diluted medicinal product, see section
6.3.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b>6.5 Nature and contents of container</b></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>5<span lang=EN-GB>&nbsp;</span>ml
glass vial (<span lang=EN-GB>type I) closed by a polytetrafluoroethylene </span><span
lang=EN-GB>grey chlorobutyl rubber stopper</span><span lang=EN-GB> or an
uncoated grey bromobutyl rubber stopper and sealed with an
aluminium/polypropylene flip cap. </span></p>

<p class=MsoNormal>Each carton contains 10 vials.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b>6.6 <span lang=EN-GB>Special precautions
for disposal</span></b><b> and other handling</b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>See Table 1 for the recommended preparation and administration of Keppra concentrate
for solution for infusion to achieve a total daily dose of 500<span lang=EN-GB>&nbsp;</span>mg,
1,000<span lang=EN-GB>&nbsp;</span>mg, 2,000<span lang=EN-GB>&nbsp;</span>mg,
or 3,000<span lang=EN-GB>&nbsp;</span>mg in two divided doses.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Table 1. Preparation and administration of Keppra concentrate for
solution for infusion</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:1.9pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=71 valign=top style='width:53.15pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b>Dose</b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b>Withdrawal Volume</b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b>Volume of</b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b>Diluent</b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b>Infusion</b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b>Time</b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b>Frequency of</b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b>Administration</b></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b>Total Daily</b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b>Dose</b></p>
  </td>
 </tr>
 <tr>
  <td width=71 valign=top style='width:53.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR-BE>250 mg</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR-BE>2.5 ml (half 5 ml vial)</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR-BE>100 ml</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR-BE>15 minutes</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR-BE>Twice daily</span></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR-BE>500 mg/day</span></p>
  </td>
 </tr>
 <tr>
  <td width=71 valign=top style='width:53.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>500 mg</p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>5 ml (one 5
  ml vial)</p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>100 ml</p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>15 minutes</p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>Twice daily</p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>1000 mg/day</p>
  </td>
 </tr>
 <tr>
  <td width=71 valign=top style='width:53.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>1000 mg </p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>10 ml (two 5 ml vials) </p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>100 ml </p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>15 minutes </p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Twice daily </p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>2000 mg/day</p>
  </td>
 </tr>
 <tr>
  <td width=71 valign=top style='width:53.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>1500 mg</p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>15 ml (three 5 ml vials) </p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>100 ml </p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>15 minutes </p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Twice daily </p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>3000 mg/day</p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product is for single use
only, any unused solution should be discarded.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Keppra
concentrate for solution for infusion was found to be physically compatible and
chemically stable for at least 24 hours when mixed with the following diluents
and stored in PVC bags at controlled room temperature 15&#8209;25&nbsp;C.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Diluents:</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>  Sodium chloride <span lang=EN-GB>9&nbsp;mg/ml (0.9%) solution
for injection</span> </p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>  Lactated Ringers solution for injection</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>  Dextrose 50 mg/ml (5%) solution for
injection</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Medicinal
product with particulate matter or discoloration should not be used.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Any unused
medicinal product or waste material should be disposed of in accordance with
local requirements.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=FR>7. MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>UCB Pharma SA </span></p>

<p class=MsoNormal><span lang=FR-BE>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=DE>B-1070 Brussels</span></p>

<p class=MsoNormal>Belgium</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>8. MARKETING AUTHORISATION NUMBER(S)</b></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>EU/1/00/146/030</p>

<p class=MsoNormal style='line-height:normal'>EU/1/00/146/033</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b>9. DATE OF FIRST AUTHORISATION/RENEWAL
OF THE AUTHORISATION</b></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal>Date of first authorisation: 29 September 2000</p>

<p class=MsoNormal>Date of latest renewal: 20 August 2015</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>10. DATE OF REVISION
OF THE TEXT</b></p>

<p class=Default style='line-height:13.0pt;page-break-after:avoid;text-autospace:
ideograph-numeric ideograph-other'><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='line-height:13.0pt;page-break-after:avoid;text-autospace:
ideograph-numeric ideograph-other'><span style='font-size:11.0pt;color:windowtext'>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency http://www.ema.europa.eu </span></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:57.2pt;
margin-bottom:0in;margin-left:85.05pt;margin-bottom:.0001pt;text-align:center;
text-indent:-35.4pt'><b><span lang=EN-GB>ANNEX II</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:57.2pt;
margin-bottom:0in;margin-left:85.05pt;margin-bottom:.0001pt;text-align:center;
text-indent:-35.4pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoBlockText style='margin-left:85.05pt;text-indent:-35.4pt'><span
lang=EN-GB>A.  MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:57.2pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>B.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>CONDITIONS </span></b><b><span
lang=EN-GB>OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-right:70.8pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.5pt;margin-bottom:.0001pt;text-indent:-.5in'><b><span
lang=EN-GB>C.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>OTHER CONDITIONS AND REQUIREMENTS OF THE
MARKETING AUTHORISATION</span></b></p>

<p class=MsoListParagraph><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.5pt;margin-bottom:.0001pt;text-indent:-.5in'><b><span
lang=EN-GB>D.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>CONDITIONS </span></b><b><span
lang=EN-GB style='text-transform:uppercase'>or restrictions with regard to the
safe and effective use of the medicinal product</span></b></p>

<p class=MsoNormal style='margin-right:70.8pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:57.2pt;text-indent:.45pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB><span lang=EN-GB>A. MANUFACTURER(S) RESPONSIBLE FOR BATCH
RELEASE</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-AU style='layout-grid-mode:line'>Name and
address of the manufacturers responsible for batch release</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='layout-grid-mode:line'>Film-coated
tablets</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>UCB Pharma SA </span><span
lang=EN-GB>or </span><span lang=EN-GB>Aesica</span><span
lang=EN-GB> </span><span lang=EN-GB>Pharmaceuticals</span><span lang=EN-GB> </span><span
lang=EN-GB>S</span><span lang=BG>.</span><span lang=EN-GB>r</span><span
lang=BG>.</span><span lang=EN-GB>l</span><span lang=BG>.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span lang=IT>Chemin
du Foriest </span><span
lang=IT>Via Praglia, 15</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span lang=IT>B-1420
Braine<a name="_Hlk21065518">-</a>lAlleud </span><span
lang=IT>I-10044 Pianezza</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span lang=IT>Belgium </span><span
lang=IT>Italy</span></p>

<p class=MsoNormal><u><span lang=IT><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=IT>Concentrate for solution for infusion</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=IT
style='layout-grid-mode:line'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span lang=IT>UCB
Pharma SA </span><span
lang=IT>or Aesica</span><span lang=IT> </span><span lang=IT>Pharmaceuticals</span><span
lang=IT> </span><span lang=IT>S</span><span lang=BG>.</span><span lang=IT>r</span><span
lang=BG>.</span><span lang=IT>l</span><span lang=BG>.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span lang=IT>Chemin
du Foriest Via
Praglia, 15</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span lang=IT>B-1420
Braine-lAlleud I-10044
Pianezza</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'>Belgium Italy</p>

<p class=MsoNormal style='line-height:normal'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<h3><u><span lang=FR-BE style='font-size:11.0pt;font-weight:normal'>Oral
solution</span></u></h3>

<p class=MsoNormal><u><span lang=FR-BE><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=FR-BE>NextPharma SAS </span><span
lang=IT>or  UCB Pharma SA </span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span lang=FR>17,
Route de Meulan Chemin
du Foriest </span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>F-78520 Limay B-1420
Braine-lAlleud </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='layout-grid-mode:line'>France     Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU style='layout-grid-mode:line'>The printed
package leaflet of the medicinal product must state the name and address of the
manufacturer responsible for the release of the concerned batch.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>B. </span><span lang=EN-AU
style='layout-grid-mode:line'>CONDITIONS </span><span lang=EN-GB
style='font-family:"Times New Roman Bold"'>OR RESTRICTIONS REGARDING SUPPLY AND
USE</span></p>

<p class=MsoNormal><span lang=EN-AU style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU style='layout-grid-mode:line'>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=TitleB style='margin-left:28.2pt;text-indent:-28.2pt'><span
lang=EN-GB>C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic Safety Update Reports</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>The marketing authorisation holder shall submit periodic safety
update reports for this product in accordance with the requirements set out in
the list of Union reference dates (EURD list) provided for under Article
107c(7) of Directive 2001/83/EC and published on the European medicines web&#8209;portal.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=TitleB style='margin-left:28.2pt;text-indent:-28.2pt'><span
lang=EN-GB>D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND
EFFECTIVE USE OF THE MEDICINAL PRODUCT </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='margin-left:31.5pt;text-indent:-31.5pt;line-height:
normal;text-autospace:none'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b>Risk Management Plan (RMP)</b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>The MAH shall
perform the required pharmacovigilance activities and interventions detailed in
the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any
agreed subsequent updates of the RMP. </p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>An updated
RMP should be submitted: </p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;
</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever </span><span lang=EN-GB>the risk
management system is modified, especially as the result of </span><span
lang=EN-GB>new information being received that may lead to a </span><span
lang=EN-GB>significant change to the benefit/risk profile or as the result </span><span
lang=EN-GB>of an important (pharmacovigilance or risk minimisation) milestone
being reached.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>If the dates
for submission of a PSUR and the update of a RMP coincide, they can be
submitted at the same time.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
III</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>LABELLING
AND PACKAGE LEAFLET</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>Box of 20, 30, 50, 60, 100, 100 (100 x 1)</span></b></p>

</div>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 250&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains
250&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>20 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>30 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>50 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>60 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>100 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:333.05pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>100 x 1 film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>UCB Pharma SA</span></p>

<p class=MsoNormal><span lang=FR-BE>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=EN-GB>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>BELGIUM</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR-BE>EU/1/00/146/001 <i><span style='color:black;
background:#D9D9D9'>20 tablets</span></i></span></p>

<p class=MsoNormal><span lang=FR-BE style='color:black;background:#D9D9D9'>EU/1/00/146/002<i>
30 tablets</i></span></p>

<p class=MsoNormal><span lang=FR-BE style='color:black;background:#D9D9D9'>EU/1/00/146/003<i>
50 tablets</i></span></p>

<p class=MsoNormal><span lang=FR-BE style='color:black;background:#D9D9D9'>EU/1/00/146/004<i>
60 tablets</i></span></p>

<p class=MsoNormal><span lang=FR-BE style='color:black;background:#D9D9D9'>EU/1/00/146/005<i>
100 tablets</i></span></p>

<p class=MsoNormal><span lang=FR-BE style='color:black;background:#D9D9D9'>EU/1/00/146/029<i>
200 tablets (2 packs of 100)</i></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#D9D9D9'>EU/1/00/146/034
<i>100 x 1 tablets</i></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB>16. INFORMATION IN BRAILLE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keppra 250 mg</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
background:#D9D9D9'>Justification for not including Braille accepted <i>100 x 1
tablets</i></span></p>

<p class=MsoNormal style='line-height:normal'><i><span style='background:#D9D9D9'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
background:#D9D9D9'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>PC: </p>

<p class=MsoNormal>SN: </p>

<p class=MsoNormal>NN:</p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
background:#D9D9D9'><br clear=all style='page-break-before:always'>
</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>Box of 200 (2 x 100) containing blue box</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 250&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains
250&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:198.4pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>Multipack: 200 (2 packs of 100) film-coated
tablets </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>UCB Pharma SA</span></p>

<p class=MsoNormal><span lang=FR-BE>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=EN-GB>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>BELGIUM</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR-BE>EU/1/00/146/001 <i><span style='color:black;
background:#D9D9D9'>20 tablets</span></i></span></p>

<p class=MsoNormal><span lang=FR-BE style='color:black;background:#D9D9D9'>EU/1/00/146/002<i>
30 tablets</i></span></p>

<p class=MsoNormal><span lang=FR-BE style='color:black;background:#D9D9D9'>EU/1/00/146/003<i>
50 tablets</i></span></p>

<p class=MsoNormal><span lang=FR-BE style='color:black;background:#D9D9D9'>EU/1/00/146/004<i>
60 tablets</i></span></p>

<p class=MsoNormal><span lang=FR-BE style='color:black;background:#D9D9D9'>EU/1/00/146/005<i>
100 tablets</i></span></p>

<p class=MsoNormal><span lang=FR-BE style='color:black;background:#D9D9D9'>EU/1/00/146/029<i>
200 tablets (2 packs of 100)</i></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#D9D9D9'>EU/1/00/146/034
<i>100 x 1 tablets</i></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>keppra 250 mg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='margin-right:198.4pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>2D barcode carrying the unique identifier
included</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>PC: </p>

<p class=MsoNormal>SN: </p>

<p class=MsoNormal>NN:</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB></span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Intermediate
packaging containing 100 tablets for box of 200 (2 x 100) tablets without blue
box</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 250&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains
250&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>100 film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Component of a multipack, cant be sold
separately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT  OF THE SIGHT AND REACH
OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS  OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF  APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>UCB Pharma SA</span></p>

<p class=MsoNormal><span lang=FR-BE>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=EN-GB>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>BELGIUM</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>keppra 250 mg</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='margin-right:198.4pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>Not applicable</span></p>

<p class=MsoNormal style='margin-right:198.4pt;background:#D9D9D9'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:198.4pt;background:#D9D9D9'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='margin-right:198.4pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>Not applicable</span></p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black;
background:#D9D9D9'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>Aluminium/PVC blister</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 250&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>UCB logo.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Box of 10,
20, 30, 50, 60, 100, 100 (100 x 1), 120</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 500&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains
500&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>10 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>20 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>30 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>50 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>60 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>100 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:333.05pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>100 x 1 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>120 film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS  OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF  APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>UCB Pharma SA</span></p>

<p class=MsoNormal><span lang=FR-BE>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=EN-GB>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>BELGIUM</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>EU/1/00/146/006 <i><span style='color:black;
background:#D9D9D9'>10 tablets</span></i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/007<i>
20 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/008<i>
30 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/009<i>
50 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/010<i>
60 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/011
<i>100 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/012<i>
120 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/013<i>
200 tablets (2 packs of 100)</i></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#D9D9D9'>EU/1/00/146/035
<i>100 x 1 tablets</i></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>keppra 500 mg</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
background:#D9D9D9'>Justification for not including Braille accepted <i>100 x 1
tablets</i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
background:#D9D9D9'>2D barcode carrying the unique identifier included.</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal>PC: </p>

<p class=MsoNormal>SN: </p>

<p class=MsoNormal>NN:<br clear=all style='page-break-before:always'>
</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Box of 200
(2 x 100) with blue box</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

</div>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 500&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains
500&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:219.65pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>Multipack: 200 (2 packs of 100) film-coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT  OF THE SIGHT AND REACH
OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-before:
always;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>UCB Pharma SA</span></p>

<p class=MsoNormal><span lang=FR-BE>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=EN-GB>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>BELGIUM</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>EU/1/00/146/006 <i><span style='color:black;
background:#D9D9D9'>10 tablets</span></i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/007<i>
20 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/008<i>
30 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/009<i>
50 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/010<i>
60 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/011
<i>100 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/012<i>
120 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/013<i>
200 tablets (2 packs of 100)</i></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#D9D9D9'>EU/1/00/146/035
<i>100 x 1 tablets</i></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>keppra 500 mg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='margin-right:219.65pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal style='margin-right:219.65pt;background:#D9D9D9'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:219.65pt;background:#D9D9D9'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal>PC: </p>

<p class=MsoNormal>SN: </p>

<p class=MsoNormal>NN:</p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>Intermediate packaging containing 100 tablets for box of 200 (2 x
100) tablets without blue box</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 500&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains
500&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>100 film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Component of a multipack, cant be sold
separately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT  OF THE SIGHT AND REACH
OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>UCB Pharma SA</span></p>

<p class=MsoNormal><span lang=FR-BE>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=EN-GB>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>BELGIUM</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>keppra 500 mg</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='margin-right:198.4pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>Not applicable</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-right:198.4pt;background:#D9D9D9'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:198.4pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>Not applicable</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-before:
always'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>Aluminium/PVC blister</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 500&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>UCB logo.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Box of
20, 30, 50, 60, 80, 100, 100 (100 x 1)</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 750&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains
750&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Contains sunset yellow (E 110). <span
style='background:silver'>See the package leaflet for further information.</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>20 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>30 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>50 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>60 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>80 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>100 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:333.05pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>100 x 1 film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT  OF THE SIGHT AND REACH
OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>UCB Pharma SA</span></p>

<p class=MsoNormal><span lang=FR-BE>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=EN-GB>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>BELGIUM</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>12. MARKETING AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal><span lang=FR>EU/1/00/146/014 <i><span style='color:black;
background:#D9D9D9'>20 tablets</span></i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/015<i>
30 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/016<i>
50 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/017<i>
60 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/018<i>
80 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/019<i>
100 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/028<i>
200 tablets (2 packs of 100)</i></span></p>

<p class=MsoNormal><span lang=FR-BE style='color:black;background:#D9D9D9'>EU/1/00/146/036
<i>100 x 1 tablets</i></span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>keppra 750 mg</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
background:#D9D9D9'>Justification for not including Braille accepted <i>100 x 1
tablets</i></span></p>

<p class=MsoNormal style='line-height:normal'><i><span style='background:#D9D9D9'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span style='background:#D9D9D9'>&nbsp;</span></i></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
background:#D9D9D9'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>PC: </p>

<p class=MsoNormal>SN: </p>

<p class=MsoNormal style='line-height:normal'>NN:</p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Box of
200 (2 x 100) with blue box</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 750&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains
750&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Contains sunset yellow (E 110). <span
style='background:silver'>See the package leaflet for further information.</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:219.65pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>Multipack: 200 (2 packs of 100) film-coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>UCB Pharma SA</span></p>

<p class=MsoNormal><span lang=FR-BE>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=EN-GB>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>BELGIUM</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>EU/1/00/146/014 <i><span style='color:black;
background:#D9D9D9'>20 tablets</span></i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/015<i>
30 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/016<i>
50 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/017<i>
60 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/018<i>
80 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/019<i>
100 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/028<i>
200 tablets (2 packs of 100)</i></span></p>

<p class=MsoNormal><span lang=FR-BE style='color:black;background:#D9D9D9'>EU/1/00/146/036
<i>100 x 1 tablets</i></span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keppra 750 mg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#D9D9D9'>2D
barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>PC: </p>

<p class=MsoNormal>SN: </p>

<p class=MsoNormal>NN:</p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Intermediate
packaging containing 100 tablets for box of 200 (2 x 100) tablets without blue
box</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 750&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains
750&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Contains sunset yellow (E 110). <span
style='background:silver'>See the package leaflet for further information</span>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>100 film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Component of a multipack, cant be sold
separately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>11. NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>UCB Pharma SA</span></p>

<p class=MsoNormal><span lang=FR-BE>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=EN-GB>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>BELGIUM</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>keppra 750 mg</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='margin-right:198.4pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>Not applicable</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#D9D9D9'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:198.4pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>Not applicable</span></p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>Aluminium/PVC blister</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 750&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2. NAME OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>UCB logo.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Box of
10, 20, 30, 50, 60, 100, 100 (100 x 1)</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra&nbsp;1000&nbsp;mg film-coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains
1,000&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>10 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>20 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>30 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>50 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>60 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:347.2pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>100 film-coated tablets</span></p>

<p class=MsoNormal style='margin-right:333.05pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>100 x 1 film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS  OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF  APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>11. NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>UCB Pharma SA</span></p>

<p class=MsoNormal><span lang=FR-BE>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=EN-GB>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>BELGIUM</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>12. MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE>EU/1/00/146/020 <i><span style='color:black;
background:#D9D9D9'>10 tablets</span></i></span></p>

<p class=MsoNormal><span lang=DE style='color:black;background:#D9D9D9'>EU/1/00/146/021
<i>20 tablets</i></span></p>

<p class=MsoNormal><span lang=DE style='color:black;background:#D9D9D9'>EU/1/00/146/022<i>
30 tablets</i></span></p>

<p class=MsoNormal><span lang=DE style='color:black;background:#D9D9D9'>EU/1/00/146/023<i>
50 tablets</i></span></p>

<p class=MsoNormal><span lang=DE style='color:black;background:#D9D9D9'>EU/1/00/146/024<i>
60 tablets</i></span></p>

<p class=MsoNormal><span lang=DE style='color:black;background:#D9D9D9'>EU/1/00/146/025<i>
100 tablets</i></span></p>

<p class=MsoNormal><span lang=FR-BE style='color:black;background:#D9D9D9'>EU/1/00/146/026<i>
200 tablets (2 packs of 100)</i></span></p>

<p class=MsoNormal><span lang=FR-BE style='color:black;background:#D9D9D9'>EU/1/00/146/037
<i>100 x 1 tablets</i></span></p>

<p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>keppra 1000 mg</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
background:#D9D9D9'>Justification for not including Braille accepted <i>100 x 1
tablets</i></span></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span style='background:#D9D9D9'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
background:#D9D9D9'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>PC: </p>

<p class=MsoNormal>SN: </p>

<p class=MsoNormal>NN:<br clear=all style='page-break-before:always'>
</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Box of
200 (2 x 100) with blue box</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra&nbsp;1000&nbsp;mg film-coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains
1,000&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:219.65pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>Multipack: 200 (2 packs of 100) film-coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT  OF THE SIGHT AND REACH
OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>UCB Pharma SA</span></p>

<p class=MsoNormal><span lang=FR-BE>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=EN-GB>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>BELGIUM</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>12. MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>EU/1/00/146/020 <i><span style='color:black;
background:#D9D9D9'>10 tablets</span></i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/021
<i>20 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/022<i>
30 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/023<i>
50 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/024<i>
60 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/025<i>
100 tablets</i></span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:#D9D9D9'>EU/1/00/146/026<i>
200 tablets (2 packs of 100)</i></span></p>

<p class=MsoNormal><span lang=FR-BE style='color:black;background:#D9D9D9'>EU/1/00/146/037
<i>100 x 1 tablets</i></span></p>

<p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>keppra 1000 mg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#D9D9D9'>2D
barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#D9D9D9'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#D9D9D9'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal>PC: </p>

<p class=MsoNormal>SN: </p>

<p class=MsoNormal>NN:</p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING </span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Intermediate
packaging containing 100 tablets for box of 200 (2 x 100) tablets without blue
box</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 1000&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains
1,000&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>100 film-coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Component of a multipack, cant be sold
separately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT  OF THE SIGHT AND REACH
OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>UCB Pharma SA</span></p>

<p class=MsoNormal><span lang=FR-BE>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=EN-GB>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>BELGIUM</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>keppra 1000 mg</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='margin-right:198.4pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>Not applicable</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:198.4pt;background:#D9D9D9'><span
lang=EN-GB style='color:black'>Not applicable</span></p>

<p class=MsoNormal style='line-height:normal;page-break-before:always'><span
lang=EN-GB></span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>Aluminium/PVC blister</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra&nbsp;1000&nbsp;mg film-coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>UCB logo.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>Bottle of
300 ml</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 100&nbsp;mg/ml oral solution</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam </span></p>

<p class=MsoNormal>For adults and children aged 4 years and older.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each ml contains 100&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Contains E216, E218 and maltitol liquid. </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>300 ml <span style='background:silver'>oral
solution</span> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal>Only use the 10&nbsp;ml syringe included in the package.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT  OF THE SIGHT AND REACH
OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>300 ml, 10 ml, 4 years and older</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Do not use
after 7 months of first opening the bottle.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Date of
opening <i><span style='background:silver'>only for the outer carton</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Store in the
original bottle in order to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS  OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF  APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>UCB Pharma SA</span></p>

<p class=MsoNormal><span lang=FR>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=EN-GB>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>BELGIUM</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/00/146/027 </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>keppra 100 mg/ml
<i><span style='background:silver'>only for the outer carton</span></i></span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#D9D9D9'>2D
barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>PC: </p>

<p class=MsoNormal>SN: </p>

<p class=MsoNormal>NN:</p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-before:always'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>Bottle of
150 ml</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 100&nbsp;mg/ml oral solution</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>For children
aged 6 months to less than 4 years.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each ml contains 100&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Contains E216, E218 and maltitol liquid. </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>150 ml <span style='background:silver'>oral
solution</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal>Only use the 3&nbsp;ml syringe included in the package.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT  OF THE SIGHT AND REACH
OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>150 ml, 3 ml, 6 months to less than 4 years</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Do not use
after 7 months of first opening the bottle.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Date of
opening <i><span style='background:silver'>only for the outer carton</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Store in the
original bottle in order to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS  OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF  APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>UCB Pharma SA</span></p>

<p class=MsoNormal><span lang=FR>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=EN-GB>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>BELGIUM</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/00/146/031 </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>keppra 100 mg/ml
<i><span style='background:silver'>only for the outer carton</span></i></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal>PC: </p>

<p class=MsoNormal>SN: </p>

<p class=MsoNormal>NN:</p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
background:#D9D9D9'><br clear=all style='page-break-before:always'>
</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>Bottle of
150 ml</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 100&nbsp;mg/ml oral solution</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam </span></p>

<p class=MsoNormal>For children aged <a name="_Hlk26780742">1 month to less
than 6 months</a>.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each ml contains 100&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Contains E216, E218 and maltitol liquid. </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>150 ml <span style='background:silver'>oral
solution</span> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal>Only use the 1&nbsp;ml syringe included in the package.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT  OF THE SIGHT AND REACH
OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>150 ml, 1 ml, 1 month to less than 6 months</span></p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Do not use
after 7 months of first opening the bottle.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Date of
opening <i><span style='background:silver'>only for the outer carton</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Store in the
original bottle in order to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS  OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF  APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>UCB Pharma SA</span></p>

<p class=MsoNormal><span lang=FR>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=EN-GB>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>BELGIUM</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/00/146/032 </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>keppra 100 mg/ml
<i><span style='background:silver'>only for the outer carton</span></i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal>PC: </p>

<p class=MsoNormal>SN: </p>

<p class=MsoNormal>NN:</p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
background:#D9D9D9'><br clear=all style='page-break-before:always'>
</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b>Box of
10 vials</b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keppra
100&nbsp;mg/ml concentrate for solution for infusion</span></p>

<p class=MsoNormal style='line-height:normal'><a name="OLE_LINK1"><span
lang=EN-GB>Levetiracetam</span></a></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>One vial contains
500&nbsp;mg/5&nbsp;ml levetiracetam.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Each ml contains
100&nbsp;mg levetiracetam.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Other
ingredients include </span><span lang=EN-GB>sodium acetate, glacial acetic
acid, sodium chloride, water for injections. <span style='background:silver'>See
the package leaflet for further information.</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4. PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>500<span lang=EN-GB>&nbsp;mg/5&nbsp;ml</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>10 vials <span style='background:silver'>of concentrate for
solution for infusion</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5. METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED
OUT  OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
after dilution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS  OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF  APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>UCB Pharma SA</span></p>

<p class=MsoNormal><span lang=FR-BE>Alle de la Recherche 60</span></p>

<p class=MsoNormal><span lang=EN-GB>B-1070 Brussels</span></p>

<p class=MsoNormal><span lang=EN-GB>BELGIUM</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12. MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/00/146/030 <span
style='background:silver'>(polytetrafluoroethylene<i> -faced stopper</i>)</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>EU/1/00/146/033 (<i>Uncoated stopper</i>)</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
background:#D9D9D9'>Justification for not including Braille accepted</span><b><u><span
lang=EN-GB> </span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span style='background:#D9D9D9'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
background:#D9D9D9'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>PC: </p>

<p class=MsoNormal>SN: </p>

<p class=MsoNormal>NN:</p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
background:#D9D9D9'><br clear=all style='page-break-before:always'>
</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>Vial of 5 ml</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>Keppra
100&nbsp;mg/ml sterile concentrate</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>Levetiracetam</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IV</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2. METHOD OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP </span></p>

<p class=MsoNormal><span lang=EN-GB>Use immediately after dilution.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>500&nbsp;mg/5&nbsp;ml
</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package Leaflet: Information for the patient</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Keppra
250&nbsp;mg film-coated tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Keppra
500&nbsp;mg film-coated tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Keppra
750&nbsp;mg film-coated tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Keppra
1000&nbsp;mg film-coated tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Levetiracetam</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Read all of
this leaflet carefully before you or your child start taking this medicine
because it contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have </span>any <span lang=EN-GB>further
questions, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet. </span><span lang=EN-GB>See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>What is in
this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>1. What
Keppra is and what it is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>2. What
you need to know before you take Keppra</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>3. How
to take Keppra</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>4. Possible
side effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>5. How
to store Keppra</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>1. What Keppra is and what it is used for</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam is an antiepileptic medicine
(a medicine used to treat seizures in epilepsy).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU style='layout-grid-mode:line'>Keppra is
used: </span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal><a name="OLE_LINK20"></a><a name="OLE_LINK22"><span
     lang=EN-AU style='layout-grid-mode:line'>on its own in adults and adolescents
     from 16 years of age with newly diagnosed epilepsy, to treat </span></a><span
     style='layout-grid-mode:line'>a certain form of epilepsy. Epilepsy is a
     condition where the patients have repeated fits (seizures). Levetiracetam
     is used for the epilepsy form in which the fits initially affect only one
     side of the brain but could thereafter extend to larger areas on both
     sides of the brain (partial onset seizure with or without secondary
     generalisation). Levetiracetam has been given to you by your doctor to
     reduce the number of fits.</span></li>
 <li class=MsoNormal><span lang=EN-GB>as an add-on to other antiepileptic
     medicines to treat:</span></li>
</ul>

<p class=MsoNormal style='margin-left:46.35pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>partial onset seizures with or without
generalisation in adults, adolescents, children and infants from one month of
age;</span></p>

<p class=MsoNormal style='margin-left:46.35pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>myoclonic seizures (short, shock-like jerks of a
muscle or group of muscles) in </span><span lang=EN-AU style='layout-grid-mode:
line'>adults and adolescents</span><span lang=EN-GB> from 12 years of age with
juvenile myoclonic epilepsy;</span></p>

<p class=MsoNormal style='margin-left:46.35pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-AU style='layout-grid-mode:line'>primary
generalised tonic-clonic seizures (</span><span style='layout-grid-mode:line'>major
fits, including loss of consciousness)</span><span lang=EN-AU style='layout-grid-mode:
line'> in adults and adolescents from 12 years of age with idiopathic
generalised epilepsy (the type of epilepsy that is thought to have a genetic
cause).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>2. What
you need to know before you take Keppra</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Do not take
Keppra</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you are allergic to levetiracetam,
pyrrolidone derivatives or any of the other ingredients of this medicine
(listed in Section 6). </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>Talk to your doctor before taking Keppra</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you suffer from kidney problems, follow your
doctors instructions. He/she may decide if your dose should be adjusted.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>If you notice any slowdown in the growth or unexpected puberty
development of your child, please contact your doctor.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A small number of people being treated with
anti-epileptics such as Keppra have had thoughts of harming or killing
themselves.</span><span lang=EN-GB style='font-size:10.0pt'> </span>If you have
any symptoms of depression and/or suicidal ideation, please contact your
doctor.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><a
name="_Hlk54160043"></a><a name="_Hlk49340898"><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>If you have a family or medical history of irregular heart rhythm
(visible on an electrocardiogram), or if you have a disease and/or take a
treatment that make(s) you prone to heartbeat irregularities or salt
imbalances.</a></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Tell your doctor or pharmacist if any of the following side
effects gets serious or last longer than a few days:</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Abnormal thoughts, feeling irritable or reacting more
aggressively than usually, or if you or your family and friends notice
important changes in mood or behaviour.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Aggravation of epilepsy</p>

<p class=MsoNormal style='margin-left:28.35pt'>Your seizures may rarely become
worse or happen more often, mainly during the first month after the start of
the treatment or increase of the dose. If you experience any of these new
symptoms while taking Keppra, see a doctor as soon as possible.</p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'><b>Children and adolescents</b></p>

<p class=MsoNormal style='margin-right:-.1pt'><b>&nbsp;</b></p>

<p style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;margin-left:28.35pt;
text-indent:-28.35pt;line-height:13.0pt'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Keppra is not indicated in
children and adolescents below 16 years on its own (monotherapy). </span></p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'><b>Other medicines and Keppra</b></p>

<p class=MsoNormal style='margin-right:-.1pt'><u>Tell your doctor or pharmacist</u>
if you are taking, have recently taken or might take any other medicines.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not take macrogol (a drug used as
laxative) for one hour before and one hour after taking levetiracetam as this
may results in a loss of its effect. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Pregnancy and breast-feeding</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If you are
pregnant or breastfeeding, think you may be pregnant or are planning to have a
baby, ask your doctor for advice before taking this medicine. Levetiracetam can
be used during pregnancy, only if after careful assessment it is considered
necessary by your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>You should not
stop your treatment without discussing this with your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'>A risk of birth defects for your
unborn child cannot be completely excluded. </p>

<p class=MsoNormal><span lang=EN-GB>Breast-feeding is not recommended during
treatment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Driving and
using machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Keppra may impair your ability to drive or
operate any tools or machinery, as it may make you feel sleepy. This is more
likely at the beginning of treatment or after an increase in the dose. You
should not drive or use machines until it is established that your ability to
perform such activities is not affected.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Keppra 750 mg
tablets contain Sunset Yellow FCF (E110). </span></b></p>

<p class=MsoNormal><span lang=EN-GB>Sunset Yellow FCF (E110) colouring agent
may cause allergic reactions.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>3. How
to take Keppra</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Always take this
medicine exactly as your doctor or pharmacist has told you. Check with your
doctor or pharmacist if you are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Take the number of tablets following your
doctors instructions.</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra must be taken twice a day, once in
the morning and once in the evening, at about the same time each day.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><i><span lang=EN-GB>Adjunctive
Therapy and monotherapy (from 16 years of age)</span></i></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Adults (&#8805;18 years) and adolescents <a
name="_Hlk25736813">(12 to 17 years)</a> weighing 50 kg or more:</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;text-indent:28.35pt'><span
lang=EN-GB>General dose: between 1000&nbsp;mg and 3,000&nbsp;mg each day.</span></p>

<p class=MsoNormal style='margin-left:31.5pt;line-height:normal;text-autospace:
none'>When you will first start taking Keppra, your doctor will prescribe you a
<b>lower dose </b>during 2 weeks before giving you the lowest general dose.</p>

<p class=MsoNormal style='margin-left:31.5pt'><i><span lang=EN-GB>Example: if
your daily dose is intended to be 1000&nbsp;mg, your reduced starting dose is 1
tablet of 250 mg in the morning and 1 tablet of 250 mg in the evening, and the
dose will be gradually incremented to reach 1000 mg daily after 2 weeks.</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Adolescents (12 to 17 years) weighing</span></b><span
lang=EN-GB> <b>50 kg or less:</b></span></p>

<p class=MsoNormal style='margin-left:31.5pt'><span lang=EN-GB>Your doctor will
prescribe the most appropriate pharmaceutical form of Keppra according to
weight and dose. </span></p>

<p class=MsoNormal style='margin-left:27.0pt;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:31.5pt;margin-bottom:.0001pt;text-indent:-31.5pt;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Dose in infants (1 month to 23 months) and
children (2 to 11 years) weighing less than 50 kg:</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:31.5pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>Your
doctor will prescribe the most appropriate pharmaceutical form of Keppra
according to the age, weight and dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:31.5pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>Keppra
100&nbsp;mg/ml oral solution is a formulation more appropriate to infants and
children under the age of 6 years and to children and adolescent (from 6 to 17
years) weighing less than 50kg and when tablets dont allow accurate dosage.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Swallow
Keppra tablets with a sufficient quantity of liquid (<i>e.g</i>. a glass of
water). You may take Keppra with or without food. After oral administration the
bitter taste of levetiracetam may be experienced.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Duration of treatment</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keppra is used as a chronic treatment. You
should continue Keppra treatment for as long as your doctor has told you.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not stop your treatment without your doctors
advice as this could increase your seizures. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>If you take
more Keppra than you should</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The possible side effects of an overdose of
Keppra are sleepiness, agitation, aggression, decrease of alertness, inhibition
of breathing and coma.</span></p>

<p class=MsoNormal><span lang=EN-GB>Contact your doctor if you took more
tablets than you should. Your doctor will establish the best possible treatment
of overdose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>If you forget
to take Keppra:</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Contact your
doctor if you have missed one or more doses. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not take a
double dose to make up for a forgotten tablet. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>If you stop
taking Keppra:</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If stopping
treatment, Keppra should be discontinued gradually to avoid an increase of
seizures. Should your doctor decide to stop your Keppra treatment, he/she will
instruct you about the gradual withdrawal of Keppra.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If you have any
further questions on the use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><a name="_Hlk1556437"><span
lang=EN-GB>&nbsp;</span></a></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>4. Possible
side effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Tell your doctor immediately, or go to
your nearest emergency department, if you experience:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weakness, feel light-headed or dizzy or have
difficulty breathing, as these may be signs of a serious allergic
(anaphylactic) reaction</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of the face, lips, tongue and throat
(Quinckes oedema)</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN>flu&#8209;like symptoms and a rash on the face
followed by an extended rash with a high temperature, increased levels of liver
enzymes seen in blood tests and an increase in a type of white blood cell
(eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and
Systemic Symptoms [DRESS])</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>symptoms such as low urine volume, tiredness,
nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this
may be a sign of sudden decrease of kidney function</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a skin rash which may form blisters and look
like small targets (central dark spots surrounded by a paler area, with a dark
ring around the edge) (<i>erythema multiforme</i>)</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a widespread rash with blisters and peeling
skin, particularly around the mouth, nose, eyes and genitals (<i>Stevens-Johnson
syndrome</i>)</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a more severe form of rash causing skin peeling
in more than 30% of the body surface (<i>toxic epidermal necrolysis</i>)</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>signs of serious mental changes or if someone
around you notices signs of confusion, somnolence (sleepiness), amnesia (loss
of memory), memory impairment (forgetfulness), abnormal behaviour or other
neurological signs including involuntary or uncontrolled movements. These could
be symptoms of an encephalopathy.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The most frequently reported side effects
are nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness.</span><span
lang=EN-GB> At the beginning of the treatment or at dose increase side effects
like sleepiness, tiredness and dizziness may be more common. These effects
should however decrease over time.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>Very common</b>: may affect more than 1 in 10 people</p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nasopharyngitis;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>somnolence (sleepiness), headache.<u><br>
<br>
</u></p>

<p class=MsoNormal><b><span lang=EN-GB>Common</span></b><span lang=EN-GB>: </span>may
affect up to 1 in 10 people</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>anorexia (loss of appetite);</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>depression, hostility or aggression, anxiety, insomnia,
nervousness or irritability;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>convulsion, balance disorder (equilibrium disorder), dizziness
(sensation of unsteadiness), lethargy (lack of energy and enthusiasm), tremor
(involuntary trembling);</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>vertigo (sensation of rotation);</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cough;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abdominal pain, </span>diarrhoea, dyspepsia
(indigestion), vomiting, nausea;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=FR-BE style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=FR-BE>rash;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>asthenia/fatigue (tiredness).</p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal><b><span lang=EN-GB>Uncommon</span></b>: may affect up to 1
in 100 people</p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased number of blood platelets, </span>decreased
number of white blood cells; </p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>weight decrease, weight increase;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-AU>suicide attempt and suicidal ideation</span>,
mental disorder, abnormal behaviour, hallucination, anger, confusion, panic
attack, emotional instability/mood swings, agitation;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>amnesia (loss of memory), memory impairment (forgetfulness),
abnormal coordination/ataxia (impaired coordinated movements), paraesthesia
(tingling), disturbance in attention (loss of concentration);</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>diplopia (double vision)<span lang=EN-GB>, vision blurred;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>elevated/abnormal values in a liver function test; </p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hair loss, </span>eczema, pruritus; </p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>muscle weakness, myalgia (muscle pain);</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>injury.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><a name="_Hlk1556422"><b><span lang=EN-GB>Rare</span></b><span
lang=EN-GB>:<b> </b>may affect up to 1 in 1,000 people</span></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>infection;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>decreased number of all blood cell types; </p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe allergic reactions (DRESS, </span><span
lang=EN-GB>anaphylactic reaction [severe and important allergic reaction],
Quinckes oedema [swelling of the face, lips, tongue and throat]</span><span
lang=EN-GB>);</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-AU>decreased blood sodium concentration;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-AU>suicide, </span><span lang=EN-GB>personality
disorders (behavioural problems), thinking abnormal </span><span lang=EN-GB>(</span>slow
thinking, unable to concentrate);</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><a
name="_Hlk1556461"><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>delirium;</span></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>encephalopathy (see sub-section Tell your
doctor immediately for a detailed description of symptoms);</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>seizures may become worse or happen more often;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>uncontrollable muscle spasms affecting the head, torso and limbs,
difficulty in controlling movements, <span lang=EN-GB>hyperkinesia
(hyperactivity);</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><a
name="_Hlk54160086"></a><a name="_Hlk49340977"><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>change of the heart rhythm (Electrocardiogram);</span></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>pancreatitis;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-AU>liver failure,</span> hepatitis;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>sudden decrease in kidney function;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin rash, which may form blisters and looks
like small targets (central dark spots surrounded by a paler area, with a dark
ring around the edge) (<i>erythema multiforme</i>), a widespread rash with
blisters and peeling skin, particularly around the mouth, nose, eyes and  genitals
(<i>StevensJohnson syndrome), </i>and a more severe form causing skin peeling
in more than 30% of the body surface (<i>toxic epidermal necrolysis</i>);</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rhabdomyolysis (breakdown of muscle tissue) and
associated blood creatine phosphokinase increase. Prevalence is significantly
higher in Japanese patients when compared to non-Japanese patients.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>limp or difficulty walking.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If you get any
side effects talk to your doctor or pharmacist. This includes any possible
side effects not listed in this leaflet.</span><span lang=EN-GB> You can also
report side effects directly via <span style='background:silver'>the national
reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a></span></span><span lang=EN-GB>.
By reporting side effects you can help provide more information on the safety
of this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=X-NONE>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>5. How
to store Keppra</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date stated on the carton
box and blister after EXP.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>The expiry
date refers to the last day of the month.</p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>This medicine
does not require any special storage conditions.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not throw
away any medicines via wastewater or household waste. Ask your pharmacist how
to throw away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>6. </span></b><b><span lang=EN-GB>Contents of the pack and
other information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'><b>What Keppra contains</b></p>

<p class=MsoNormal>The active substance is called levetiracetam. </p>

<p class=MsoNormal>One tablet of Keppra 250 mg contains <span lang=EN-GB>250&nbsp;mg</span>
of levetiracetam.</p>

<p class=MsoNormal>One tablet of Keppra 500&nbsp;mg contains <span lang=EN-GB>500&nbsp;mg</span>
of levetiracetam.</p>

<p class=MsoNormal>One tablet of Keppra 750&nbsp;mg contains <span lang=EN-GB>750&nbsp;mg</span>
of levetiracetam.</p>

<p class=MsoNormal>One tablet of Keppra 1,000&nbsp;mg contains <span
lang=EN-GB>1,000&nbsp;mg</span> of levetiracetam.</p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'>The other ingredients are: <span
lang=EN-GB><br>
</span><i><span lang=EN-GB>Tablet core</span></i><span lang=EN-GB>: </span>croscarmellose
sodium, macrogol 6000, silica colloidal anhydrous, magnesium stearate<span
lang=EN-GB>.<br>
<i>Film-coating</i>: </span><span lang=EN-GB>Polyvinyl alcohol-part.
hydrolyzed, titanium dioxide (E171), macrogol 3350, talc, colourants*</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>* The colourants are:</span></p>

<p class=MsoNormal>250&nbsp;mg tablet: <span lang=EN-GB>indigo carmine
aluminium lake (E132)</span></p>

<p class=MsoNormal>500&nbsp;mg tablet: <span lang=EN-GB>iron oxide yellow
(E172)</span></p>

<p class=MsoNormal>750&nbsp;mg tablet: <span lang=EN-GB>sunset yellow FCF aluminium
lake (E110), iron oxide red (E172)</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Keppra looks like and contents of the pack</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 250&nbsp;mg film-coated tablets are
blue, 13 mm oblong, scored and debossed with the code ucb and 250 on one
side.</span></p>

<p class=MsoNormal>The score line is only to facilitate breaking for ease of
swallowing and not to divide into equal doses. </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 500&nbsp;mg film-coated tablets are
yellow, 16 mm oblong, scored and debossed with the code ucb and 500 on one
side.</span></p>

<p class=MsoNormal>The score line is only to facilitate breaking for ease of
swallowing and not to divide into equal doses. </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keppra 750&nbsp;mg film-coated tablets are
orange, 18 mm oblong, scored and debossed with the code ucb and 750 on one
side.</span></p>

<p class=MsoNormal>The score line is only to facilitate breaking for ease of
swallowing and not to divide into equal doses. </p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keppra
1000&nbsp;mg film-coated tablets are white, 19 mm oblong, scored and debossed
with the code ucb and 1000 on one side.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal>The score line is only to facilitate breaking for ease of
swallowing and not to divide into equal doses. </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='font-family:"TimesNewRomanPSMT",serif'>Keppra tablets are packaged in
blister packs supplied in cardboard boxes containing:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"TimesNewRomanPSMT",serif'>250 mg: </span><span
lang=EN-GB>20, 30, 50, 60, 100 x 1, 100 film-coated tablets and multipacks
containing 200 (2 packs of 100) film-coated tablets</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"TimesNewRomanPSMT",serif'>500 mg: </span><span
lang=EN-GB>10, 20, 30, 50, 60, 100 x 1, 100, 120 film-coated tablets and
multipacks containing 200 (2 packs of 100) film-coated tablets</span></p>

<p class=MsoListParagraph><span style='font-family:"TimesNewRomanPSMT",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"TimesNewRomanPSMT",serif'>750&nbsp;mg: </span><span
lang=EN-GB>20, 30, 50, 60, 80, 100 x 1, 100 film-coated tablets and multipacks
containing 200 (2 packs of 100) film-coated tablets</span></p>

<p class=MsoListParagraph><span style='font-family:"TimesNewRomanPSMT",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"TimesNewRomanPSMT",serif'>1000 mg: </span><span
lang=EN-GB>10, 20, 30, 50, 60, 100 x 1, 100 film-coated tablets and multipacks
containing 200 (2 packs of 100) film-coated tablets</span></p>

<p class=MsoNormal><span style='font-family:"TimesNewRomanPSMT",serif'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The 100 x 1 tablet packs are available in
aluminium/PVC perforated unit dose blisters. All other packs are available in
standard aluminium/PVC blisters. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=FR-BE>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal><span lang=FR-BE>UCB Pharma SA, Alle de la Recherche 60,
B-1070 Brussels, Belgium.</span></p>

<p class=MsoNormal><b><span lang=FR-BE>Manufacturer</span></b></p>

<p class=MsoNormal><span lang=FR-BE></span><span lang=FR-BE> </span><span
lang=FR-BE>UCB Pharma SA, Chemin du Foriest, B-1420 Braine-lAlleud, Belgium.</span></p>

<p class=MsoNormal><span lang=IT style='background:silver'>or </span><span
lang=IT style='background:silver'>Aesica</span><span lang=IT style='background:
silver'> </span><span lang=IT style='background:silver'>Pharmaceuticals</span><span
lang=IT style='background:silver'> </span><span lang=IT style='background:silver'>S</span><span
lang=BG style='background:silver'>.</span><span lang=IT style='background:silver'>r</span><span
lang=BG style='background:silver'>.</span><span lang=IT style='background:silver'>l</span><span
lang=BG style='background:silver'>.</span><span lang=IT style='background:silver'>,
Via Praglia 15, I-10044 Pianezza, Italy</span></p>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>For any
information about this medicine, please contact the local representative of the
Marketing Authorisation Holder.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-BE>Belgi/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR-BE>UCB Pharma SA/NV</span></p>
  <p class=MsoNormal><span lang=FR>Tel/Tl: + 32 / (0)2 559 92 00</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LT>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-right:-22.45pt'><span lang=LT>UCB Pharma Oy
  Finland</span></p>
  <p class=MsoNormal style='margin-right:-22.45pt'><span lang=LT>Tel: </span><span
  lang=FR>+358 9 2514 4231 (Suomija)</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>&#1070;
  &#1057;&#1048; &#1041;&#1048;</span><span lang=BG> </span><span lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal><span lang=IT style='font-family:"TimesNewRoman",serif'>Te</span><span
  lang=BG>&#1083;.</span><span lang=IT>: </span><span lang=BG>+ 359 (0) 2 962 </span><span
  lang=FR-BE>30 49</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>UCB Pharma SA/NV</span></p>
  <p class=MsoNormal><span lang=PT-BR>Tl/Tel: + 32 / (0)2 559 92 00</span></p>
  <p class=MsoNormal><b><span lang=PT-BR>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=HU>&#268;esk
  republika</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=HU>UCB s.r.o.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=HU>Tel: +
  420&nbsp;221 773 411</span></p>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=HU>&nbsp;</span></b></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=HU>Magyarorszg</span></b></p>
  <p class=MsoNormal><span lang=HU>UCB Magyarorszg Kft.</span></p>
  <p class=MsoNormal><span lang=HU>Tel.: + 36-(1) 391 0060</span></p>
  <p class=MsoNormal><b><span lang=HU>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UCB Nordic A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: + 45 / 32 46 24 00</span></p>
  <p class=MsoNormal><span lang=HU>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT>Malta</span></b></p>
  <p class=MsoNormal><span lang=MT>Pharmasud Ltd.</span></p>
  <p class=MsoNormal><span lang=MT>Tel: + 356 / 21 37 64 36</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE>UCB Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: + 49 /(0) 2173 48 4848</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Nederland</span></b></p>
  <p class=MsoNormal><span lang=NL>UCB Pharma B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel.: + 31 / (0)76-573 11 40</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ET>Eesti</span></b></p>
  <p class=MsoNormal><span lang=ET>UCB Pharma Oy Finland </span></p>
  <p class=MsoNormal><span lang=ET>Tel: +358 9 2514 4231</span><span lang=ET> </span><span
  lang=ET>(Soome)</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='layout-grid-mode:line'>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>UCB Nordic
  A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Tlf: + 45 /
  32 46 24 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=ET>UCB </span><span
  lang=EL>&#913;</span><span lang=ET>.</span><span lang=EL>&#917;</span><span
  lang=ET>. </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EL>&#932;&#951;&#955;:
  + 30 / 2109974000</span></p>
  <p class=MsoNormal><span lang=ET>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE>UCB Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: <span style='layout-grid-mode:line'>+
  43 (0)1 291 80 00</span></span><span lang=DE> </span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES-MX>Espaa</span></b></p>
  <p class=MsoNormal><span lang=ES-MX>UCB Pharma, S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: + 34 / 91 570 34 44</span></p>
  <p class=MsoNormal><span lang=EL>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PL>Polska</span></b></p>
  <p class=MsoNormal><span lang=PL>UCB Pharma Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel</span><span lang=EL>: + 48 22 696 99
  20</span></p>
  <p class=MsoNormal><span lang=EL>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.2pt'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt;
  height:44.2pt'>
  <p class=MsoNormal><b><span lang=FR-BE>France</span></b></p>
  <p class=MsoNormal><span lang=FR-BE>UCB Pharma S.A.</span></p>
  <p class=MsoNormal><span lang=FR-BE>Tl: + 33 / (0)1 47 29 44 35</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt;
  height:44.2pt'>
  <p class=MsoNormal><b><span lang=PT-BR>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>UCB Pharma (Produtos Farmacuticos), Lda</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: + 351 / 21 302 5300</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=SV>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=SV>Medis Adria d.o.o.</span></p>
  <p class=MsoNormal><span lang=FR-BE>Tel: +385 (0) 1 230 34 46</span></p>
  <p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-BE>Romnia</span></b></p>
  <p class=MsoNormal><span lang=FR-BE>UCB Pharma Romania S.R.L.</span></p>
  <p class=MsoNormal><span lang=FR-BE>Tel: + 40 21 300 29 04</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK>Ireland</span></b></p>
  <p class=MsoNormal><span lang=SK>UCB (Pharma) Ireland Ltd.</span></p>
  <p class=MsoNormal><span lang=SK>Tel: + 353 / (0)1-46 37 395 </span></p>
  <p class=MsoNormal><b><span lang=IS>&nbsp;</span></b></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SL>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=SL>Medis, d.o.o.</span></p>
  <p class=MsoNormal><span lang=SL>Tel: + 386 1 589 69 00</span></p>
  <p class=MsoNormal><b><span lang=SK>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IS>sland</span></b></p>
  <p class=MsoNormal><span lang=CS>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=IS>Tel: </span><span lang=CS>+ 354 535 7000</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK>Slovensk republika</span></b></p>
  <p class=MsoNormal><span lang=IS>UCB s.r.o.</span><span lang=SK
  style='font-family:"Arial",sans-serif'>, </span><span lang=IS>organiza&#269;n
  zloka</span></p>
  <p class=MsoNormal><span lang=IS>Tel: + 421 (0) </span>2 5920 2020</p>
  <p class=MsoNormal><b><span lang=SK>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR>Italia</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>UCB Pharma S.p.A.</span></p>
  <p class=MsoNormal><span lang=PT-BR>Tel: + 39 / 02 300 791</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=LT>UCB Pharma Oy Finland</span></p>
  <p class=MsoNormal><span lang=EN-GB>Puh/Tel: </span><span lang=PT-BR>+358 9
  2514 4221</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>Lifepharma (Z.A.M.) </span><span lang=EL>Ltd</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;: + 357 22 34 74 40 </span></p>
  <p class=MsoNormal><b><span lang=EL>&nbsp;</span></b></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR>Sverige</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>UCB Nordic A/S</span></p>
  <p class=MsoNormal><span lang=PT-BR>Tel: + 46 / (0) 40 29 49 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV>Latvija</span></b></p>
  <p class=MsoNormal><span lang=LV>UCB Pharma Oy Finland</span></p>
  <p class=MsoNormal><span lang=LV>Tel: </span><span lang=NL>+358 9 2514 4231</span><span
  lang=NL> </span><span lang=NL>(Somija)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UCB Pharma Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Tel: </span><span
  lang=FR-BE style='layout-grid-mode:line'>+ 44 / (0)1753 534 655</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=FI>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>This leaflet
was last revised in {month/YYYY}</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Other sources
of information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency web
site: http://www.ema.europa.eu</span></p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package Leaflet: Information for the patient</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Keppra&nbsp;100&nbsp;mg/ml
oral solution</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Levetiracetam</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Read all of
this leaflet carefully before you or your child start taking this medicine
because it contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have </span>any <span lang=EN-GB>further
questions, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet. </span><span lang=EN-GB>See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>What is in
this leaflet</span></b><span lang=EN-GB>: </span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>1. What
Keppra is and what it is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>2. What
you need to know before you take Keppra</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>3. How
to take Keppra</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>4. Possible
side effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>5. How
to store Keppra</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>1. What Keppra is and what it is used for</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Levetiracetam&nbsp;is an antiepileptic
medicine (a medicine used to treat seizures in epilepsy).</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU style='layout-grid-mode:line'>Keppra is
used: </span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal><span lang=EN-AU style='layout-grid-mode:line'>on its own
     in adults and adolescents from 16 years of age with newly diagnosed
     epilepsy, to treat </span><span style='layout-grid-mode:line'>a certain
     form of epilepsy. Epilepsy is a condition where the patients have repeated
     fits (seizures). Levetiracetam is used for the epilepsy form in which the
     fits initially affect only one side of the brain but could thereafter
     extend to larger areas on both sides of the brain (partial onset seizure
     with or without secondary generalisation). Levetiracetam has been given to
     you by your doctor to reduce the number of fits.</span></li>
 <li class=MsoNormal><span lang=EN-GB>as an add-on to other antiepileptic
     medicines to treat:</span></li>
</ul>

<p class=MsoNormal style='margin-left:46.35pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>partial onset seizures with or without
generalisation in adults, adolescents, children and infants from one month of
age</span></p>

<p class=MsoNormal style='margin-left:46.35pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>myoclonic seizures (short, shock-like jerks of a
muscle or group of muscles) in </span><span lang=EN-AU style='layout-grid-mode:
line'>adults and adolescents</span><span lang=EN-GB> from 12 years of age with
juvenile myoclonic epilepsy</span></p>

<p class=MsoNormal style='margin-left:46.35pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-AU style='layout-grid-mode:line'>primary
generalised tonic-clonic seizures (</span><span style='layout-grid-mode:line'>major
fits, including loss of consciousness)</span><span lang=EN-AU style='layout-grid-mode:
line'> in adults and adolescents from 12 years of age with idiopathic
generalised epilepsy (the type of epilepsy that is thought to have a genetic
cause).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>2. What you need to know before you take Keppra</span></b></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Do not take
Keppra</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you are allergic to levetiracetam,
pyrrolidone derivatives or any of the other ingredients of this medicine
(listed in Section 6). </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Warnings and
precautions</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Talk to your
doctor before taking Keppra</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you suffer from kidney problems, follow your
doctors instructions. He/she may decide if your dose should be adjusted.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>If you notice any slowdown in the growth or unexpected puberty
development of your child, please contact your doctor.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A small number of people being treated with
anti-epileptics such as Keppra have had thoughts of harming or killing themselves.</span><span
lang=EN-GB style='font-size:10.0pt'> </span>If you have any symptoms of
depression and/or suicidal ideation, please contact your doctor.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>If you have a family or medical history of irregular heart rhythm
(visible on an electrocardiogram), or if you have a disease and/or take a
treatment that make(s) you prone to heartbeat irregularities or salt
imbalances.</p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Tell your doctor or pharmacist if any of the following side
effects gets serious or last longer than a few days:</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Abnormal thoughts, feeling irritable or reacting more
aggressively than usually, or if you or your family and friends notice
important changes in mood or behaviour.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Aggravation of epilepsy</p>

<p class=MsoNormal style='margin-left:28.35pt'>Your seizures may rarely become
worse or happen more often, mainly during the first month after the start of
the treatment or increase of the dose. If you experience any of these new
symptoms while taking Keppra, see a doctor as soon as possible.</p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'><b>Children and adolescents</b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keppra is not indicated in children and
adolescents below 16 years on its own (monotherapy)</span></p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'><b>Other medicines and Keppra</b></p>

<p class=MsoNormal style='margin-right:-.1pt'><u>Tell your doctor or pharmacist</u>
if you are taking or have recently taken or might take any other medicines.</p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Do not take macrogol (a drug used as
laxative) for one hour before and one hour after taking levetiracetam as this
may results in a </span><span lang=EN-GB>reduction</span><span
class=MsoCommentReference><span lang=EN-GB style='font-size:8.0pt'> </span></span><span
lang=EN-GB>of its effect. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Pregnancy and breast-feeding</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If you are
pregnant or breastfeeding, think you may be pregnant, or are planning to have a
baby, ask your doctor for advice before taking this medicine. Levetiracetam can
be used during pregnancy, only if after careful assessment it is considered
necessary by your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>You should not
stop your treatment without discussing this with your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'>A risk of birth defects for your
unborn child cannot be completely excluded. </p>

<p class=MsoNormal><span lang=EN-GB>Breast-feeding is not recommended during
treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Driving and
using machines</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>Keppra may
impair your ability to drive or operate any tools or machinery, as it may make
you feel sleepy. This is more likely at the beginning of treatment or after an
increase in the dose. You should not drive or use machines until it is
established that your ability to perform such activities is not affected.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Keppra
contains methyl parahydroxybenzoate, propyl parahydroxybenzoate and maltitol</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Keppra </span>oral solution <span
lang=EN-GB>includes methyl parahydroxybenzoate (E218) and p</span>ropyl
parahydroxybenzoate (E216) which may cause allergic reactions (possibly
delayed). </p>

<p class=MsoNormal><span lang=EN-GB>Keppra oral solution also contains
maltitol. If you have been told by your doctor that you have an intolerance to
some sugars, contact your doctor before taking this medicinal product.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>3. How
to take Keppra</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Always take this
medicine exactly as your doctor or pharmacist has told you. Check with your
doctor or pharmacist if you are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Keppra must be
taken twice a day, once in the morning and once in the evening, at about the same
time each day.</span></p>

<p class=MsoNormal><span lang=EN-GB>Take the oral solution following your
doctors instructions.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><i><span lang=EN-GB>Monotherapy
(from 16 years of age)</span></i></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Adults (&#8805;18 years) and adolescents
(from 16 years of age):</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Measure the appropriate dosage using the 10
ml syringe included in the package for patients 4 years and above.</span></p>

<p class=MsoNormal><u><span lang=EN-GB>General dose</span></u><span lang=EN-GB>:
Keppra is taken twice daily, in two equally divided doses, each individual dose
being measured between 5 ml (500mg) and 15 ml (1500mg).<b> </b></span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>When you will
first start taking Keppra, your doctor will prescribe you a <b>lower dose </b>during
2 weeks before giving you the lowest general dose.</p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><i><span
lang=EN-GB>Add-on therapy</span></i></b></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>Dose in adults and adolescents (12 to 17 years):</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Measure the
appropriate dosage using the 10 ml syringe included in the package for patients
of 4 years and above.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB>General dose</span></u><span
lang=EN-GB>: Keppra is taken twice daily, in two equally divided doses, each
individual dose being measured between 5 ml (500mg) and 15 ml (1500mg). <b>&nbsp;</b></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b>Dose in
children 6 months and older<span lang=EN-GB>:</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Your doctor will prescribe the most appropriate pharmaceutical form
of Keppra according to the age, weight and dose.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>For children 6 months to 4 years, </span></b><span
lang=EN-GB>measure the appropriate dosage using the<b> 3 ml </b>syringe
included in the package. </span></p>

<p class=MsoNormal><b><span lang=EN-GB>For children above 4 years</span></b><span
lang=EN-GB>, measure the appropriate dosage using the<b> 10 ml </b>syringe
included in the package.</span></p>

<p class=MsoNormal><u><span lang=EN-GB>General dose</span></u><span lang=EN-GB>:
Keppra is taken twice daily, in two equally divided doses, each individual dose
being measured between 0.1 ml (10mg) and 0.3 ml (30mg), per kg bodyweight of
the child. (see table below for dose examples). </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b>Dose in
children 6 months and older</b><b><span lang=EN-GB>:</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Weight</span></p>
  </td>
  <td width=295 valign=top style='width:221.6pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Starting dose: 0.1&nbsp;ml/kg twice daily</span></p>
  </td>
  <td width=300 valign=top style='width:225.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Maximum dose: 0.3&nbsp;ml/kg twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>6 kg </span></p>
  </td>
  <td width=295 valign=top style='width:221.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>0.6 ml twice daily</span></p>
  </td>
  <td width=300 valign=top style='width:225.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>1.8 ml twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>8 kg</span></p>
  </td>
  <td width=295 valign=top style='width:221.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>0.8 ml twice daily</span></p>
  </td>
  <td width=300 valign=top style='width:225.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>2.4 ml twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>10 kg </span></p>
  </td>
  <td width=295 valign=top style='width:221.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>1 ml twice daily</span></p>
  </td>
  <td width=300 valign=top style='width:225.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>3 ml twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>15 kg </span></p>
  </td>
  <td width=295 valign=top style='width:221.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>1.5 ml twice daily</span></p>
  </td>
  <td width=300 valign=top style='width:225.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>4.5 ml twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>20 kg </span></p>
  </td>
  <td width=295 valign=top style='width:221.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>2 ml twice daily</span></p>
  </td>
  <td width=300 valign=top style='width:225.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>6 ml twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>25 kg</span></p>
  </td>
  <td width=295 valign=top style='width:221.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>2.5 ml twice daily</span></p>
  </td>
  <td width=300 valign=top style='width:225.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>7.5 ml twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>From 50 kg </span></p>
  </td>
  <td width=295 valign=top style='width:221.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>5 ml twice daily</span></p>
  </td>
  <td width=300 valign=top style='width:225.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>15 ml twice daily</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Dose in infants (1 month to less than 6 months):</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>For infants 1 month to less than 6
months, </span></b><span lang=EN-GB>measure the appropriate dosage using the <b>1
ml</b> syringe included in the package.<b> </b></span></p>

<p class=MsoNormal><u><span lang=EN-GB>General dose</span></u><span lang=EN-GB>:
Keppra is taken twice daily, in two equally divided doses, each individual dose
being measured between 0.07 ml (7mg) and 0.21 ml (21mg), per kg bodyweight of
the infant. (see table below for dose examples). </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Dose in infants (1 month to less than 6 months):</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=161 valign=top style='width:120.4pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Weight</span></p>
  </td>
  <td width=290 valign=top style='width:217.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Starting dose: 0.07&nbsp;ml/kg twice
  daily</span></p>
  </td>
  <td width=304 valign=top style='width:227.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Maximum dose: 0.21&nbsp;ml/kg twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 valign=top style='width:120.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>4 kg</span></p>
  </td>
  <td width=290 valign=top style='width:217.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>0.3&nbsp;ml twice daily</span></p>
  </td>
  <td width=304 valign=top style='width:227.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>0.85&nbsp;ml twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 valign=top style='width:120.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>5 kg</span></p>
  </td>
  <td width=290 valign=top style='width:217.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>0.35&nbsp;ml twice daily</span></p>
  </td>
  <td width=304 valign=top style='width:227.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>1.05&nbsp;ml twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 valign=top style='width:120.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>6 kg</span></p>
  </td>
  <td width=290 valign=top style='width:217.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>0.45 ml twice daily</span></p>
  </td>
  <td width=304 valign=top style='width:227.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>1.25 ml twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 valign=top style='width:120.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>7 kg</span></p>
  </td>
  <td width=290 valign=top style='width:217.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>0.5&nbsp;ml twice daily</span></p>
  </td>
  <td width=304 valign=top style='width:227.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>1.5&nbsp;ml twice daily</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Method of
administration:</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'>After measuring the correct
dosage with an appropriate syringe,<span style='font-family:"Arial",sans-serif'>
</span><span lang=EN-GB>Keppra oral solution may be diluted in a glass of water
or babys bottle. </span>You may take Keppra with or without food.<span
lang=EN-GB> After oral administration the bitter taste of levetiracetam may be
experienced.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Instructions for use:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Open the bottle: press the cap and turn it
anticlockwise (figure 1)</span></p>

<p class=MsoNormal><span style='position:relative;z-index:-1895821824'><span
style='position:absolute;left:35px;top:-94871px;width:86px;height:1px'><img
width=86 height=1 src="Keppra%20-%20EN%20PI%20clea_files/image001.gif"></span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Separate the adaptor from the syringe (figure
2). Insert the adaptor into the bottle neck (figure 3). Ensure it is well
fixed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span style='position:relative;z-index:251652608'><span
style='position:absolute;left:33px;top:-95079px;width:311px;height:1px'>

<table cellpadding=0 cellspacing=0 align=left>
 <tr>
  <td width=0 height=0></td>
  <td width=180></td>
  <td width=13></td>
  <td width=118></td>
 </tr>
 <tr>
  <td height=1></td>
  <td align=left valign=top><img width=180 height=1
  src="Keppra%20-%20EN%20PI%20clea_files/image002.gif"></td>
  <td></td>
  <td align=left valign=top><img width=118 height=1
  src="Keppra%20-%20EN%20PI%20clea_files/image003.gif"></td>
 </tr>
</table>

</span></span><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<br clear=ALL>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take the syringe and put it in the adaptor
opening (figure 4). Turn the bottle upside down (figure 5). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span style='position:relative;z-index:251653632'><span
style='position:absolute;left:18px;top:-95322px;width:279px;height:1px'>

<table cellpadding=0 cellspacing=0 align=left>
 <tr>
  <td width=0 height=0></td>
  <td width=134></td>
  <td width=43></td>
  <td width=102></td>
 </tr>
 <tr>
  <td height=1></td>
  <td align=left valign=top><img width=134 height=1
  src="Keppra%20-%20EN%20PI%20clea_files/image004.gif"></td>
  <td></td>
  <td align=left valign=top><img width=102 height=1
  src="Keppra%20-%20EN%20PI%20clea_files/image005.gif"></td>
 </tr>
</table>

</span></span><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<br clear=ALL>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><a
name="OLE_LINK2"></a><a name="OLE_LINK11"><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fill the syringe with a small amount of solution
by pulling the piston down (figure 5A), then push the piston upward in order to
remove any possible bubble (figure 5B). Pull the piston down to the graduation
mark corresponding to the quantity in milliliters (ml) prescribed by your doctor
(figure 5C). </span></a></p>

<p class=MsoNormal><span style='position:relative;z-index:251655680'><span
style='position:absolute;left:10px;top:-95599px;width:376px;height:1px'>

<table cellpadding=0 cellspacing=0 align=left>
 <tr>
  <td width=0 height=0></td>
  <td width=144></td>
  <td width=19></td>
  <td width=96></td>
  <td width=21></td>
  <td width=96></td>
 </tr>
 <tr>
  <td height=1></td>
  <td align=left valign=top><img width=144 height=1
  src="Keppra%20-%20EN%20PI%20clea_files/image006.gif"></td>
  <td></td>
  <td align=left valign=top><img width=96 height=1
  src="Keppra%20-%20EN%20PI%20clea_files/image007.gif"></td>
  <td></td>
  <td align=left valign=top><img width=96 height=1
  src="Keppra%20-%20EN%20PI%20clea_files/image008.gif"></td>
 </tr>
</table>

</span></span><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<br clear=ALL>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Turn the bottle the right way up (figure 6A).
Remove the syringe from the adaptor (figure 6B).</span></p>

<p class=MsoNormal><span style='position:relative;z-index:251658752'><span
style='position:absolute;left:49px;top:-95755px;width:218px;height:1px'>

<table cellpadding=0 cellspacing=0 align=left>
 <tr>
  <td width=0 height=0></td>
  <td width=66></td>
  <td width=41></td>
  <td width=111></td>
 </tr>
 <tr>
  <td height=1></td>
  <td align=left valign=top><img width=66 height=1
  src="Keppra%20-%20EN%20PI%20clea_files/image009.gif"></td>
  <td></td>
  <td align=left valign=top><img width=111 height=1
  src="Keppra%20-%20EN%20PI%20clea_files/image010.gif"></td>
 </tr>
</table>

</span></span><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<br clear=ALL>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Empty the contents of the syringe in a glass of
water or babys bottle by pushing the piston to the bottom of the syringe
(figure 7). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:28.35pt'><span lang=EN-GB><img border=0
width=107 height=91 src="Keppra%20-%20EN%20PI%20clea_files/image011.gif"></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='position:relative;z-index:251660800'><span
style='left:0px;position:absolute;left:368px;top:-96050px;width:95px;
height:1px'><img width=95 height=1
src="Keppra%20-%20EN%20PI%20clea_files/image012.gif"></span></span><span
lang=EN-GB>Drink the whole contents of the glass/babys bottle.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Close the bottle with the plastic screw cap.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Wash the syringe with water only (figure 8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Duration of
treatment:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keppra is used as a chronic treatment. You
should continue Keppra treatment for as long as your doctor has told you.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><u><span lang=EN-GB>Do not stop your treatment without your
doctors advice as this could increase your seizures</span></u><span
lang=EN-GB>. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>If you take
more Keppra than you should</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The possible side effects of an overdose of
Keppra are sleepiness, agitation, aggression, decrease of alertness, inhibition
of breathing and coma.</span></p>

<p class=MsoNormal><span lang=EN-GB>Contact your doctor if you took more Keppra
than you should. Your doctor will establish the best possible treatment of
overdose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>If you forget
to take Keppra:</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Contact your doctor
if you have missed one or more doses. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not take a
double dose to make up for a forgotten dose. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>If you stop
taking Keppra:</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If stopping
treatment, Keppra should be discontinued gradually to avoid an increase of
seizures. Should your doctor decide to stop your Keppra treatment, he/she will
instruct you about the gradual withdrawal of Keppra.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If you have any
further questions on the use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>4. Possible
side effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Tell your doctor immediately, or go to
your nearest emergency department, if you experience:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weakness, feel light-headed or dizzy or have
difficulty breathing, as these may be signs of a serious allergic
(anaphylactic) reaction</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of the face, lips, tongue and throat
(Quinckes oedema)</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN>flu&#8209;like symptoms and a rash on the face
followed by an extended rash with a high temperature, increased levels of liver
enzymes seen in blood tests and an increase in a type of white blood cell
(eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and
Systemic Symptoms [DRESS]),.</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>symptoms such as low urine volume, tiredness,
nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this
may be a sign of sudden decrease of kidney function</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a skin rash which may form blisters and look
like small targets (central dark spots surrounded by a paler area, with a dark
ring around the edge) (<i>erythema multiforme</i>)</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a widespread rash with blisters and peeling
skin, particularly around the mouth, nose, eyes and genitals (<i>Stevens-Johnson
syndrome</i>)</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a more severe form of rash causing skin peeling
in more than 30% of the body surface (<i>toxic epidermal necrolysis</i>)</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>signs of serious mental changes or if someone
around you notices signs of confusion, somnolence (sleepiness), amnesia (loss
of memory), memory impairment (forgetfulness), abnormal behaviour or other
neurological signs including involuntary or uncontrolled movements. These could
be symptoms of an encephalopathy.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The most frequently reported adverse
reactions were nasopharyngitis, somnolence (sleepiness), headache, fatigue and
dizziness. </span><span lang=EN-GB>At the beginning of the treatment or at dose
increase side effects like sleepiness, tiredness and dizziness may be more
common. These effects should however decrease over time.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>Very common</b>: may affect more than 1 in 10 people</p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nasopharyngitis;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>somnolence (sleepiness), headache.<u><br>
<br>
</u></p>

<p class=MsoNormal><b><span lang=EN-GB>Common</span></b>: may affect up to 1 in
10 people</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>anorexia (loss of appetite);</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>depression, hostility or aggression, anxiety, insomnia,
nervousness or irritability;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>convulsion, balance disorder (equilibrium disorder), dizziness
(sensation of unsteadiness), lethargy (lack of energy and enthusiasm), tremor
(involuntary trembling);</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>vertigo (sensation of rotation);</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cough;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abdominal pain, </span>diarrhoea, dyspepsia
(indigestion), vomiting, nausea;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=FR-BE style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=FR-BE>rash;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>asthenia/fatigue (tiredness).</p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal><b><span lang=EN-GB>Uncommon</span></b>: may affect up to 1
in 100 people</p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased number of blood platelets, </span>decreased
number of white blood cells; </p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>weight decrease, weight increase;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-AU>suicide attempt and suicidal ideation</span>,
mental disorder, abnormal behaviour, hallucination, anger, confusion, panic
attack, emotional instability/mood swings, agitation;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>amnesia (loss of memory), memory impairment (forgetfulness), abnormal
coordination/ataxia (impaired coordinated movements), paraesthesia (tingling),
disturbance in attention (loss of concentration);</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>diplopia (double vision)<span lang=EN-GB>, vision blurred;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>elevated/abnormal values in a liver function test;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hair loss, </span>eczema, pruritus; </p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>muscle weakness, myalgia (muscle pain);</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>injury.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b><span lang=EN-GB>Rare</span></b><span lang=EN-GB>:<b> </b>may
affect up to 1 in 1,000 people</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>infection;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>decreased number of all blood cell types; </p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe allergic reactions (DRESS, </span><span
lang=EN-GB>anaphylactic reaction [severe and important allergic reaction],
Quinckes oedema [swelling of the face, lips, tongue and throat]</span><span
lang=EN-GB>);</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-AU>decreased blood sodium concentration;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-AU>suicide, </span><span lang=EN-GB>personality
disorders (behavioural problems), thinking abnormal </span><span lang=EN-GB>(</span>slow
thinking, unable to concentrate);</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>delirium;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>encephalopathy (see sub-section Tell your
doctor immediately for a detailed description of symptoms);</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>seizures may become worse or happen more often;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>uncontrollable muscle spasms affecting the head, torso and limbs,
difficulty in controlling movements, <span lang=EN-GB>hyperkinesia
(hyperactivity);</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>change of the heart rhythm (Electrocardiogram);</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>pancreatitis;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-AU>liver failure,</span> hepatitis;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-AU style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-AU>sudden decrease in kidney function;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin rash, which may form blisters and looks
like small targets (central dark spots surrounded by a paler area, with a dark
ring around the edge) (<i>erythema multiforme</i>), a widespread rash with
blisters and peeling skin, particularly around the mouth, nose, eyes and
genitals (<i>Stevens-Johnson syndrome</i>), and a more severe form causing skin
peeling in more than 30% of the body surface (<i>toxic epidermal necrolysis</i>);</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rhabdomyolysis (breakdown of muscle tissue) and
associated blood creatine phosphokinase increase. Prevalence is significantly
higher in Japanese patients when compared to non-Japanese patients.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>limp or difficulty walking.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects talk to your
doctor or pharmacist. This includes any possible side effects not listed in
this leaflet.</span><span lang=EN-GB> You can also report side effects directly
via <span style='background:silver'>the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a></span></span><span lang=EN-GB>.
By reporting side effects you can help provide more information on the safety
of this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>5. How
to store Keppra</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>Do not use this medicine after the expiry date stated on the
cardboard box and bottle after EXP:</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>The expiry
date refers to the last day of the month.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>Do not use
after 7 months of first opening the bottle.</p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in the original bottle, in order to
protect from light.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not throw
away any medicines via wastewater or household waste. Ask your pharmacist how
to throw away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>6. Contents
of the pack and other information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'><b>What Keppra contains</b></p>

<p class=MsoNormal>The active substance is called levetiracetam. <span
lang=EN-GB>Each ml contains 100&nbsp;mg of levetiracetam.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>The other ingredients are: s<span lang=EN-GB
style='layout-grid-mode:line'>odium citrate, citric acid monohydrate, methyl
parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), ammonium
glycyrrhizate, glycerol (E422), maltitol liquid (E965), acesulfame potassium
(E950), grape flavour, purified water.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What Keppra looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Keppra&nbsp;100 mg/ml oral solution</span> is a clear<span
lang=EN-GB> liquid.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>The 300 ml
glass bottle of Keppra (for children aged 4 years and above, adolescents and
adults) is packed in a cardboard box containing a 10&nbsp;ml oral syringe
(graduated every 0.25&nbsp;ml) <a name="OLE_LINK21">and an adaptor for the
syringe</a>.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>The 150 ml
glass bottle of Keppra (for infants and young children aged from 6 months to
less than 4 years) is packed in a cardboard box containing a 3&nbsp;ml oral
syringe (graduated every 0.1&nbsp;ml) and an adaptor for the syringe.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>The 150 ml
glass bottle of Keppra (for infants aged 1 month to less than 6 months) is packed
in a cardboard box containing a 1&nbsp;ml oral syringe (graduated every
0.05&nbsp;ml) and an adaptor for the syringe.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=FR>Marketing Authorisation Holder </span></b></p>

<p class=MsoNormal><span lang=FR>UCB Pharma S.A. Alle de la Recherche 60,
B-1070 Brussels, Belgium.</span></p>

<p class=MsoNormal><b><span lang=FR-BE>Manufacturer</span></b></p>

<p class=MsoNormal><span lang=FR-BE>NextPharma SAS, 17 Route de Meulan, F-78520
Limay, France.</span></p>

<p class=MsoNormal><span lang=IT style='background:silver'>or </span><span
lang=FR-BE style='background:silver'>UCB Pharma SA, Chemin du Foriest, B-1420
Braine-lAlleud, Belgium</span><span lang=FR-BE style='background:silver'> </span></p>

<p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>For any
information about this medicine, please contact the local representative of the
Marketing Authorisation Holder.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-BE>Belgi/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR-BE>UCB Pharma SA/NV</span></p>
  <p class=MsoNormal><span lang=FR>Tel/Tl: + 32 / (0)2 559 92 00</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LT>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-right:-22.45pt'><span lang=LT>UCB Pharma Oy
  Finland</span></p>
  <p class=MsoNormal style='margin-right:-22.45pt'><span lang=LT>Tel</span><span
  lang=FR>: +358 9 2514 4231 (Suomija)</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>&#1070;
  &#1057;&#1048; &#1041;&#1048;</span><span lang=BG> </span><span lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal><span lang=IT style='font-family:"TimesNewRoman",serif'>Te</span><span
  lang=BG>&#1083;.</span><span lang=IT>: </span><span lang=BG>+ 359 (0) 2 962 </span><span
  lang=FR-BE>30 49</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>UCB Pharma SA/NV</span></p>
  <p class=MsoNormal><span lang=PT-BR>Tl/Tel: + 32 / (0)2 559 92 00</span></p>
  <p class=MsoNormal><b><span lang=PT-BR>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=HU>&#268;esk
  republika</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=HU>UCB s.r.o.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=HU>Tel: +
  420&nbsp;221 773 411</span></p>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=HU>&nbsp;</span></b></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=HU>Magyarorszg</span></b></p>
  <p class=MsoNormal><span lang=HU>UCB Magyarorszg Kft.</span></p>
  <p class=MsoNormal><span lang=HU>Tel.: + 36-(1) 391 0060</span></p>
  <p class=MsoNormal><b><span lang=HU>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UCB Nordic A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: + 45 / 32 46 24 00</span></p>
  <p class=MsoNormal><span lang=HU>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT>Malta</span></b></p>
  <p class=MsoNormal><span lang=MT>Pharmasud Ltd.</span></p>
  <p class=MsoNormal><span lang=MT>Tel: + 356 / 21 37 64 36</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE>UCB Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: + 49 /(0) 2173 48 4848</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Nederland</span></b></p>
  <p class=MsoNormal><span lang=NL>UCB Pharma B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel.: + 31 / (0)76-573 11 40</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ET>Eesti</span></b></p>
  <p class=MsoNormal><span lang=ET>UCB Pharma Oy Finland </span></p>
  <p class=MsoNormal><span lang=ET>Tel: +358 9 2514 4231 (Soome)</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='layout-grid-mode:line'>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>UCB Nordic
  A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Tlf: + 45 /
  32 46 24 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=ET>UCB </span><span
  lang=EL>&#913;</span><span lang=ET>.</span><span lang=EL>&#917;</span><span
  lang=ET>. </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EL>&#932;&#951;&#955;:
  + 30 / 2109974000</span></p>
  <p class=MsoNormal><span lang=ET>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE>UCB Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: + 43 (0)1 291 80 00</span><span
  lang=DE> </span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES-MX>Espaa</span></b></p>
  <p class=MsoNormal><span lang=ES-MX>UCB Pharma, S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: + 34 / 91 570 34 44</span></p>
  <p class=MsoNormal><span lang=EL>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PL>Polska</span></b></p>
  <p class=MsoNormal><span lang=PL>UCB Pharma Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel</span><span lang=EL>: + 48 22 696 99
  20</span></p>
  <p class=MsoNormal><span lang=EL>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.2pt'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt;
  height:44.2pt'>
  <p class=MsoNormal><b><span lang=FR-BE>France</span></b></p>
  <p class=MsoNormal><span lang=FR-BE>UCB Pharma S.A.</span></p>
  <p class=MsoNormal><span lang=FR-BE>Tl: + 33 / (0)1 47 29 44 35</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt;
  height:44.2pt'>
  <p class=MsoNormal><b><span lang=PT-BR>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>UCB Pharma (Produtos Farmacuticos), Lda</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: + 351 / 21 302 5300</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=SV>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=SV>Medis Adria d.o.o.</span></p>
  <p class=MsoNormal><span lang=FR-BE>Tel: +385 (0) 1 230 34 46</span></p>
  <p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-BE>Romnia</span></b></p>
  <p class=MsoNormal><span lang=FR-BE>UCB Pharma Romania S.R.L.</span></p>
  <p class=MsoNormal><span lang=FR-BE>Tel: + 40 21 300 29 04</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK>Ireland</span></b></p>
  <p class=MsoNormal><span lang=SK>UCB (Pharma) Ireland Ltd.</span></p>
  <p class=MsoNormal><span lang=SK>Tel: + 353 / (0)1-46 37 395 </span></p>
  <p class=MsoNormal><b><span lang=IS>&nbsp;</span></b></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SL>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=SL>Medis, d.o.o.</span></p>
  <p class=MsoNormal><span lang=SL>Tel: + 386 1 589 69 00</span></p>
  <p class=MsoNormal><b><span lang=SK>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IS>sland</span></b></p>
  <p class=MsoNormal><span lang=CS>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=IS>Tel: </span><span lang=CS>+ 354 535 7000</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK>Slovensk republika</span></b></p>
  <p class=MsoNormal><span lang=IS>UCB s.r.o.</span><span lang=SK
  style='font-family:"Arial",sans-serif'>, organiza&#269;n zloka</span></p>
  <p class=MsoNormal><span lang=IS>Tel: + 421 (0) </span>2 5920 2020</p>
  <p class=MsoNormal><b><span lang=SK>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR>Italia</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>UCB Pharma S.p.A.</span></p>
  <p class=MsoNormal><span lang=PT-BR>Tel: + 39 / 02 300 791</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=LT>UCB Pharma Oy Finland</span></p>
  <p class=MsoNormal><span lang=EN-GB>Puh/</span><span lang=IS>Tel: +358 9 2514
  4221</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>Lifepharma (Z.A.M.) </span><span lang=EL>Ltd</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;: + 357 22 34 74 40 </span></p>
  <p class=MsoNormal><b><span lang=EL>&nbsp;</span></b></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR>Sverige</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>UCB Nordic A/S</span></p>
  <p class=MsoNormal><span lang=PT-BR>Tel: + 46 / (0) 40 29 49 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV>Latvija</span></b></p>
  <p class=MsoNormal><span lang=LV>UCB Pharma Oy Finland</span></p>
  <p class=MsoNormal><span lang=NL>Tel: +358 9 2514 4231</span><span lang=NL> </span><span
  lang=NL>(Somija)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UCB Pharma Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Tel: </span><span
  lang=FR-BE style='layout-grid-mode:line'>+ 44 / (0)1753 534 655</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
lang=FR-BE>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>This leaflet
was last revised in {month/YYYY}</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Other sources
of information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency web
site: http://www.ema.europa.eu</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b>&nbsp;</b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package Leaflet: Information for the patient</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b>Keppra 100<span
lang=EN-GB>&nbsp;</span></b><b>mg/ml concentrate for solution for infusion</b></p>

<p class=MsoNormal align=center style='text-align:center'>Levetiracetam</p>

<p class=MsoNormal style='margin-right:-.1pt'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Read all of
this leaflet carefully before you or your child start using this medicine
because it contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have </span>any <span lang=EN-GB>further
questions, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet. </span><span lang=EN-GB>See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>What is in
this leaflet</span></b><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>1. What
Keppra is and what it is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>2. What
you need to know before you are given Keppra</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>3. How
Keppra is given</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>4. Possible
side effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>5. How
to store Keppra</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>1. What Keppra is and what it is used for</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Levetiracetam
<span lang=EN-GB>is an antiepileptic medicine (a medicine used to treat
seizures in epilepsy).</span> </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span style='layout-grid-mode:line'>Keppra is used:</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal><span lang=EN-AU style='layout-grid-mode:line'>on its own
     in adults and adolescents from 16 years of age with newly diagnosed
     epilepsy, to treat </span><span style='layout-grid-mode:line'>a certain
     form of epilepsy. Epilepsy is a condition where the patients have repeated
     fits (seizures). Levetiracetam is used for the epilepsy form in which the
     fits initially affect only one side of the brain but could thereafter
     extend to larger areas on both sides of the brain (partial onset seizure
     with or without secondary generalisation). Levetiracetam has been given to
     you by your doctor to reduce the number of fits.</span></li>
</ul>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>as an add-on to other antiepileptic medicines to
treat:</span></p>

<p class=MsoNormal style='margin-left:46.35pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>partial onset seizures with or without
generalisation in in adults, adolescents and children from 4 years of age</span></p>

<p class=MsoNormal style='margin-left:46.35pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>myoclonic seizures (short, shock-like jerks of a
muscle or group of muscles) in </span><span lang=EN-AU style='layout-grid-mode:
line'>adults and adolescents</span><span lang=EN-GB> from 12 years of age with
juvenile myoclonic epilepsy.</span></p>

<p class=MsoNormal style='margin-left:46.35pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>primary generalised tonic-clonic seizures </span><span
lang=EN-AU style='layout-grid-mode:line'>(</span><span style='layout-grid-mode:
line'>major fits, including loss of consciousness)</span><span lang=EN-GB> in </span><span
lang=EN-AU style='layout-grid-mode:line'>adults and adolescents from 12 years
of age with idiopathic generalised epilepsy (the type of epilepsy that is
thought to have a genetic cause).</span></p>

<p class=MsoNormal style='margin-left:46.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Keppra concentrate for solution for infusion is an
alternative for patients when administration of the antiepileptic oral Keppra&nbsp;medicine
is temporarily not feasible.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What you need to know before you are
given Keppra</span></b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Do not use
Keppra</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you are allergic to levetiracetam,
pyrrolidone derivatives or any of the other ingredients of this medicine
(listed in Section 6). </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>Talk to your doctor before you are given Keppra</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you suffer from kidney problems, follow your
doctors instructions. He/she may decide if your dose should be adjusted.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>If you notice any slowdown in the growth or unexpected puberty
development of your child, please contact your doctor.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A small number of people being treated with
anti-epileptics such as Keppra have had thoughts of harming or killing
themselves.</span><span lang=EN-GB style='font-size:10.0pt'> </span>If you have
any symptoms of depression and/or suicidal ideation, please contact your
doctor.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>If you have a family or medical history of irregular heart rhythm
(visible on an electrocardiogram), or if you have a disease and/or take a
treatment that make(s) you prone to heartbeat irregularities or salt
imbalances.</p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=MsoNormal>Tell your doctor or pharmacist if any of the following side
effects gets serious or last longer than a few days:</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Abnormal thoughts, feeling irritable or reacting more
aggressively than usually, or if you or your family and friends notice
important changes in mood or behaviour.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Aggravation of epilepsy</p>

<p class=MsoNormal style='margin-left:28.35pt'>Your seizures may rarely become
worse or happen more often, mainly during the first month after the start of
the treatment or increase of the dose. If you experience any of these new
symptoms while taking Keppra, see a doctor as soon as possible.</p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'><b>Children and adolescents</b></p>

<p class=MsoNormal style='margin-right:-.1pt'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keppra is not indicated in children and
adolescents below 16 years on its own (monotherapy)</span></p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'><b>Other medicines and Keppra</b></p>

<p class=MsoNormal style='margin-right:-.1pt'>Tell <u>your doctor or pharmacist</u>
if you are taking, have recently taken or might take any other medicines,
including medicines obtained without a prescription.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not take macrogol (a drug used as
laxative) for one hour before and one hour after taking levetiracetam as this
may results in a </span><span lang=EN-GB>reduction</span><span
class=MsoCommentReference><span lang=EN-GB style='font-size:8.0pt'> </span></span><span
lang=EN-GB>of its effect. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b>Pregnancy and breast-feeding</b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If you are
pregnant or breastfeeding, think you may be pregnant or are planning to have a
baby, ask your doctor for advice before taking this medicine. Levetiracetam can
be used during pregnancy, only if after careful assessment it is considered
necessary by your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>You should not
stop your treatment without discussing this with your doctor.</span></p>

<p class=MsoNormal>A risk of birth defects for your unborn child cannot be
completely excluded. </p>

<p class=MsoNormal><span lang=EN-GB>Breast-feeding is not recommended during
treatment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b>Driving and using machines</b></p>

<p class=MsoNormal><span lang=EN-GB>Keppra may impair your ability to</span>
drive or operate any tools or machine<span lang=EN-GB>ry, as</span> it may make
you feel sleepy. This is more likely at the beginning of treatment or after an
increase in the dose.<span lang=EN-GB> You should not drive or use machines
until it is established that your ability to perform such activities is not
affected.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Keppra contains sodium</span></b></p>

<p class=MsoNormal>One maximum single dose of Keppra concentrate<span
lang=EN-GB> contains 2.5 mmol (or 57 mg) of sodium (0.8 mmol (or 19&nbsp;mg) of
sodium per vial). This should be taken into consideration if you are on a
controlled sodium diet.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'><b>3. How Keppra is given</b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>A doctor or a nurse will administer you Keppra as an
intravenous infusion.</p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Keppra must be
administered twice a day, once in the morning and once in the evening, at about
the same time each day.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=MsoNormal>The intravenous formulation is an alternative to your oral
administration. You can switch from the film-coated tablets or from the oral
solution to the intravenous formulation or reverse directly without dose
adaptation. Your total daily dose and frequency of administration remain
identical.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><i><span lang=EN-GB>Adjunctive
therapy and Monotherapy (from 16 years of age). </span></i></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Adults (&#8805;18 years) and adolescents
(12 to 17 years) weighing 50 kg or more:</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>General dose:
between 1000&nbsp;mg and 3,000&nbsp;mg each day.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>When you will
first start taking Keppra, your doctor will prescribe you a <b>lower dose </b>during
2 weeks before giving you the lowest general dose.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Dose in children (4 to 11 years) and adolescents (12 to 17 years)
weighing less than 50 kg:</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>General dose: between 20 mg per kg bodyweight and 60 mg per kg
bodyweight each day.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b>Method and route of
administration:</b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Keppra is for
intravenous use.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>The
recommended dose must be diluted in at least 100 ml of a compatible diluent and
infused over 15-minutes.</p>

<p class=MsoNormal style='margin-right:-.1pt'>F<span lang=EN-GB>or doctors and
nurses, more detailed direction for the proper use of Keppra is provided in
section 6.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b>Duration of treatment:</b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>There is no experience with administration of
intravenous levetiracetam for a longer period than 4 days.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'><b>If you stop using Keppra:</b></p>

<p class=MsoNormal style='margin-right:-.1pt'>If stopping treatment, as with
other antiepileptic medicines, Keppra should be discontinued gradually to avoid
an increase of seizures. <span lang=EN-GB>Should your doctor decide to stop
your Keppra treatment, he/she will instruct you about the gradual withdrawal of
Keppra.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If you have any
further questions on the use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>4. Possible
side effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Tell your doctor immediately, or go to
your nearest emergency department, if you experience:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weakness, feel light-headed or dizzy or have
difficulty breathing, as these may be signs of a serious allergic
(anaphylactic) reaction</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of the face, lips, tongue and throat
(Quinckes oedema)</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN>flu&#8209;like symptoms and a rash on the face
followed by an extended rash with a high temperature, increased levels of liver
enzymes seen in blood tests and an increase in a type of white blood cell
(eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and
Systemic Symptoms [DRESS]).</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>symptoms such as low urine volume, tiredness,
nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this
may be a sign of sudden decrease of kidney function</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a skin rash which may form blisters and look
like small targets (central dark spots surrounded by a paler area, with a dark
ring around the edge) (<i>erythema multiforme</i>)</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a widespread rash with blisters and peeling
skin, particularly around the mouth, nose, eyes and genitals (<i>Stevens-Johnson
syndrome</i>)</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a more severe form of rash causing skin peeling
in more than 30% of the body surface (<i>toxic epidermal necrolysis</i>)</span></p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>signs of serious mental changes or if someone
around you notices signs of confusion, somnolence (sleepiness), amnesia (loss
of memory), memory impairment (forgetfulness), abnormal behaviour or other
neurological signs including involuntary or uncontrolled movements. These could
be symptoms of an encephalopathy.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The most frequently reported adverse
reactions were nasopharyngitis, somnolence (sleepiness), headache, fatigue and
dizziness. At the beginning of the treatment or at dose increase side effects
like sleepiness, tiredness and dizziness may be more common. These effects
should however decrease over time.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>Very common</b>: may affect more than 1 in 10 people</p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nasopharyngitis;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>somnolence (sleepiness), headache.<u><br>
<br>
</u></p>

<p class=MsoNormal><b><span lang=EN-GB>Common</span></b>: may affect up to 1 in
10 people</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>anorexia (loss of appetite);</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>depression, hostility or aggression, anxiety, insomnia,
nervousness or irritability;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>convulsion, balance disorder (equilibrium disorder), dizziness
(sensation of unsteadiness), lethargy (lack of energy and enthusiasm), tremor
(involuntary trembling);</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>vertigo (sensation of rotation);</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cough;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abdominal pain, </span>diarrhoea, dyspepsia
(indigestion), vomiting, nausea;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=FR-BE style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=FR-BE>rash;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>asthenia/fatigue (tiredness).</p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal><b><span lang=EN-GB>Uncommon</span></b>: may affect up to 1
in 100 people</p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased number of blood platelets, </span>decreased
number of white blood cells; </p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>weight decrease, weight increase;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-AU>suicide attempt and suicidal ideation</span>,
mental disorder, abnormal behaviour, hallucination, anger, confusion, panic
attack, emotional instability/mood swings, agitation;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>amnesia (loss of memory), memory impairment (forgetfulness),
abnormal coordination/ataxia (impaired coordinated movements), paraesthesia
(tingling), disturbance in attention (loss of concentration);</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>diplopia (double vision)<span lang=EN-GB>, vision blurred;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>elevated/abnormal values in a liver function test;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hair loss, </span>eczema, pruritus; </p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>muscle weakness, myalgia (muscle pain);</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>injury.</p>

<p class=MsoNormal>. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b><span lang=EN-GB>Rare</span></b><span lang=EN-GB>:<b> </b>may
affect up to 1 in 1,000 people</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>infection;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>decreased number of all blood cell types; </p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe allergic reactions (DRESS, </span><span
lang=EN-GB>anaphylactic reaction [severe and important allergic reaction],
Quinckes oedema [swelling of the face, lips, tongue and throat]</span><span
lang=EN-GB>);</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-AU>decreased blood sodium concentration;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-AU>suicide, </span><span lang=EN-GB>personality
disorders (behavioural problems), thinking abnormal </span><span lang=EN-GB>(</span>slow
thinking, unable to concentrate);</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>delirium;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>encephalopathy (see sub-section Tell your
doctor immediately for a detailed description of symptoms);<a
name="_Hlk30680466"></a></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>seizures may become worse or happen more often;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>uncontrollable muscle spasms affecting the head, torso and limbs,
difficulty in controlling movements, <span lang=EN-GB>hyperkinesia
(hyperactivity);</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>change of the heart rhythm (Electrocardiogram);</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>pancreatitis;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-AU>liver failure,</span> hepatitis;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>sudden decrease in kidney function;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin rash, which may form blisters and looks
like small targets (central dark spots surrounded by a paler area, with a dark
ring around the edge) (<i>erythema multiforme</i>), a widespread rash with
blisters and peeling skin, particularly around the mouth, nose, eyes and
genitals (<i>Stevens-Johnson syndrome</i>), and a more severe form causing skin
peeling in more than 30% of the body surface (<i>toxic epidermal necrolysis</i>);</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rhabdomyolysis (breakdown of muscle tissue) and
associated blood creatine phosphokinase increase. Prevalence is significantly
higher in Japanese patients when compared to non-Japanese patients.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>limp or difficulty walking.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects talk to your
doctor or pharmacist. This includes any possible side effects not listed in
this leaflet.</span><span lang=EN-GB> You can also report side effects directly
via <span style='background:silver'>the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a></span></span><span lang=EN-GB>.
By reporting side effects you can help provide more information on the safety
of this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b>5. <span lang=EN-GB>How
to store Keppra</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not use this
medicine after the expiry date stated on the vial and carton box after EXP</span>:</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>The expiry
date refers to the last day of the month.</p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>This medicine
does not require any special storage conditions.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b>6. Contents
of the pack and other information</b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'><b>What Keppra contains</b></p>

<p class=MsoNormal>The active substance is called levetiracetam. Each ml contains
100 mg of levetiracetam.</p>

<p class=MsoNormal style='line-height:normal'>The other ingredients are: <span
lang=EN-GB>sodium acetate, glacial acetic acid, sodium chloride, water for
injections.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Keppra looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Keppra
concentrate<b> </b>for solution for infusion (sterile concentrate) is a clear,
colourless liquid.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Keppra
concentrate for solution for infusion is packed in a cardboard box containing
10 vials of 5 ml. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=FR-BE>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal><span lang=FR>UCB Pharma SA, Alle de la Recherche 60,
B-1070 Brussels, Belgium.</span></p>

<p class=MsoNormal><b><span lang=FR-BE>Manufacturer</span></b></p>

<p class=MsoNormal><span lang=FR-BE>UCB Pharma </span><span lang=FR>SA, </span><span
lang=FR-BE>Chemin du Foriest, B-1420 Braine-lAlleud, Belgium </span></p>

<p class=MsoNormal><span lang=IT style='background:silver'>or  Aesica</span><span
lang=IT style='background:silver'> </span><span lang=IT style='background:silver'>Pharmaceuticals</span><span
lang=IT style='background:silver'> </span><span lang=IT style='background:silver'>S</span><span
lang=BG style='background:silver'>.</span><span lang=IT style='background:silver'>r</span><span
lang=BG style='background:silver'>.</span><span lang=IT style='background:silver'>l</span><span
lang=BG style='background:silver'>.</span><span lang=IT style='background:silver'>,
Via Praglia, 15, I-10044 Pianezza, Italy.</span></p>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'>For any information about this
medicine, please contact the local representative of the Marketing
Authorisation Holder.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-BE>Belgi/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR-BE>UCB Pharma SA/NV</span></p>
  <p class=MsoNormal><span lang=FR>Tel/Tl: + 32 / (0)2 559 92 00</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LT>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-right:-22.45pt'><span lang=FR>UCB Pharma Oy
  Finland</span></p>
  <p class=MsoNormal style='margin-right:-22.45pt'><span lang=FR>Tel: +358 9
  2514 4231 (Suomija)</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>&#1070;
  &#1057;&#1048; &#1041;&#1048;</span><span lang=BG> </span><span lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal><span lang=IT style='font-family:"TimesNewRoman",serif'>Te</span><span
  lang=BG>&#1083;.</span><span lang=IT>: </span><span lang=BG>+ 359 (0) 2 962 </span><span
  lang=FR-BE>30 49</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>UCB Pharma SA/NV</span></p>
  <p class=MsoNormal><span lang=PT-BR>Tl/Tel: + 32 / (0)2 559 92 00</span></p>
  <p class=MsoNormal><b><span lang=PT-BR>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=HU>&#268;esk
  republika</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=HU>UCB s.r.o.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=HU>Tel: +
  420&nbsp;221 773 411</span></p>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=HU>&nbsp;</span></b></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=HU>Magyarorszg</span></b></p>
  <p class=MsoNormal><span lang=HU>UCB Magyarorszg Kft.</span></p>
  <p class=MsoNormal><span lang=HU>Tel.: + 36-(1) 391 0060</span></p>
  <p class=MsoNormal><b><span lang=HU>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UCB Nordic A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: + 45 / 32 46 24 00</span></p>
  <p class=MsoNormal><span lang=HU>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT>Malta</span></b></p>
  <p class=MsoNormal><span lang=MT>Pharmasud Ltd.</span></p>
  <p class=MsoNormal><span lang=MT>Tel: + 356 / 21 37 64 36</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE>UCB Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: + 49 /(0) 2173 48 4848</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Nederland</span></b></p>
  <p class=MsoNormal><span lang=NL>UCB Pharma B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel.: + 31 / (0)76-573 11 40</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ET>Eesti</span></b></p>
  <p class=MsoNormal><span lang=ET>UCB Pharma Oy Finland </span></p>
  <p class=MsoNormal><span lang=ET>Tel: +358 9 2514 4231 (Soome)</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='layout-grid-mode:line'>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>UCB Nordic
  A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Tlf: + 45 /
  32 46 24 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=ET>UCB </span><span
  lang=EL>&#913;</span><span lang=ET>.</span><span lang=EL>&#917;</span><span
  lang=ET>. </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EL>&#932;&#951;&#955;:
  + 30 / 2109974000</span></p>
  <p class=MsoNormal><span lang=ET>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE>UCB Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: </span><span lang=ET>+ 43 (0)1 291 80
  00 </span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES-MX>Espaa</span></b></p>
  <p class=MsoNormal><span lang=ES-MX>UCB Pharma, S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: + 34 / 91 570 34 44</span></p>
  <p class=MsoNormal><span lang=EL>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PL>Polska</span></b></p>
  <p class=MsoNormal><span lang=PL>UCB Pharma Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel</span><span lang=EL>: + 48 22 696 99
  20</span></p>
  <p class=MsoNormal><span lang=EL>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.2pt'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt;
  height:44.2pt'>
  <p class=MsoNormal><b><span lang=FR-BE>France</span></b></p>
  <p class=MsoNormal><span lang=FR-BE>UCB Pharma S.A.</span></p>
  <p class=MsoNormal><span lang=FR-BE>Tl: + 33 / (0)1 47 29 44 35</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt;
  height:44.2pt'>
  <p class=MsoNormal><b><span lang=PT-BR>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>UCB Pharma (Produtos Farmacuticos), Lda</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: + 351 / 21 302 5300</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=SV>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=SV>Medis Adria d.o.o.</span></p>
  <p class=MsoNormal><span lang=FR-BE>Tel: +385 (0) 1 230 34 46</span></p>
  <p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-BE>Romnia</span></b></p>
  <p class=MsoNormal><span lang=FR-BE>UCB Pharma Romania S.R.L.</span></p>
  <p class=MsoNormal><span lang=FR-BE>Tel: + 40 21 300 29 04</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK>Ireland</span></b></p>
  <p class=MsoNormal><span lang=SK>UCB (Pharma) Ireland Ltd.</span></p>
  <p class=MsoNormal><span lang=SK>Tel: + 353 / (0)1-46 37 395 </span></p>
  <p class=MsoNormal><b><span lang=IS>&nbsp;</span></b></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SL>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=SL>Medis, d.o.o.</span></p>
  <p class=MsoNormal><span lang=SL>Tel: + 386 1 589 69 00</span></p>
  <p class=MsoNormal><b><span lang=SK>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IS>sland</span></b></p>
  <p class=MsoNormal><span lang=CS>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=IS>Tel: </span><span lang=CS>+ 354 535 7000</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK>Slovensk republika</span></b></p>
  <p class=MsoNormal><span lang=IS>UCB s.</span><span lang=SL>r.o.,
  organiza&#269;n zloka</span></p>
  <p class=MsoNormal><span lang=IS>Tel: + 421 (0) </span>2 5920 2020</p>
  <p class=MsoNormal><b><span lang=SK>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR>Italia</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>UCB Pharma S.p.A.</span></p>
  <p class=MsoNormal><span lang=PT-BR>Tel: + 39 / 02 300 791</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=LT>UCB Pharma Oy Finland</span></p>
  <p class=MsoNormal><span lang=LT>Puh/Tel: +358 9 2514 4221</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>Lifepharma (Z.A.M.) </span><span lang=EL>Ltd</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;: + 357 22 34 74 40 </span></p>
  <p class=MsoNormal><b><span lang=EL>&nbsp;</span></b></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR>Sverige</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>UCB Nordic A/S</span></p>
  <p class=MsoNormal><span lang=PT-BR>Tel: + 46 / (0) 40 29 49 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="49%" valign=top style='width:49.82%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV>Latvija</span></b></p>
  <p class=MsoNormal><span lang=LV>UCB Pharma Oy Finland</span></p>
  <p class=MsoNormal><span lang=LV>Tel: </span><span lang=PT-BR>+358 9 2514 4231</span><span
  lang=PT-BR> </span><span lang=NL>(Somija)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
  <td width="50%" valign=top style='width:50.18%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UCB Pharma Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Tel: </span><span
  lang=FR-BE style='layout-grid-mode:line'>+ 44 / (0)1753 534 655</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>This leaflet
was last revised in {month/YYYY}</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Other sources
of information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency web
site: http://www.ema.europa.eu</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>---------------------------------------------------------------------------------------------------------------------------</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>The
following information is intended for healthcare professionals only</span></b><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Directions for
the proper use of Keppra is provided in section 3.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>One vial of
Keppra concentrate contains 500 mg levetiracetam (<span lang=EN-GB>5 ml
concentrate of 100 mg/ml</span>). See Table 1 for the recommended preparation
and administration of Keppra concentrate to achieve a total daily dose of 500
mg, 1000 mg, 2000 mg, or 3000 mg in two divided doses.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u>Table 1.
Preparation and administration of Keppra </u><u>concentrate</u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:1.9pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=71 valign=top style='width:53.15pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b>Dose</b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b>Withdrawal
  Volume</b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b>Volume
  of</b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b>Diluent</b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b>Infusion</b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b>Time</b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b>Frequency
  of</b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b>administration</b></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b>Total
  Daily</b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b>Dose</b></p>
  </td>
 </tr>
 <tr>
  <td width=71 valign=top style='width:53.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR-BE>250 mg</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR-BE>2.5 ml (half 5 ml vial)</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR-BE>100 ml</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR-BE>15 minutes</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR-BE>Twice daily</span></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR-BE>500 mg/day</span></p>
  </td>
 </tr>
 <tr>
  <td width=71 valign=top style='width:53.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>500 mg</p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>5 ml (one 5
  ml vial)</p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>100 ml</p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>15 minutes</p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>Twice daily</p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>1000 mg/day</p>
  </td>
 </tr>
 <tr>
  <td width=71 valign=top style='width:53.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>1000 mg </p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>10 ml (two 5 ml vials) </p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>100 ml </p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>15 minutes </p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Twice daily </p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>2000 mg/day</p>
  </td>
 </tr>
 <tr>
  <td width=71 valign=top style='width:53.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>1500 mg</p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>15 ml (three 5 ml vials) </p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>100 ml </p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>15 minutes </p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Twice daily </p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>3000 mg/day</p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product is for single use
only, any unused solution should be discarded.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In use shelf life:</span> f<span
lang=EN-GB>rom a microbiological point of view, the product should be used
immediately after dilution. If not used immediately, in-use storage time and
conditions prior to use are the responsibility of the user and would normally
not be longer than 24 hours at 2 to 8C, unless <u>dilution</u> has taken place
in controlled and validated aseptic conditions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Keppra
concentrate was found to be physically compatible and chemically stable when
mixed with the following diluents for at least 24 hours and stored in PVC bags
at controlled room temperature 15-25C.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Diluents:</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>  Sodium
chloride <span lang=EN-GB>9&nbsp;mg/ml (0.9%) solution for injection</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>  Lactated
Ringers solution for injection</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>  Dextrose
50 mg/ml (5%) solution for injection</p>

</div>

</body>

</html>
